

ÉCOLE DOCTORALE 414 Science de la Vie et de la Santé

Architecture et Réactivité de l'ARN – IBMC Strasbourg

THÈSE présentée par :

Alessandra MARENNA

soutenue le : **29 septembre 2017**

pour obtenir le grade de : **Docteur de l'université de Strasbourg**
Discipline/ Spécialité : Aspects Moléculaires et Cellulaires de la Biologie

***Staphylococcus aureus* protein S1, an RNA
chaperone involved in translation initiation and
sRNA regulation**

THÈSE dirigée par :

Mr MARZI Stefano

CR1, IBMC, Université de Strasbourg

RAPPORTEURS :

Mme DOCK-BREGÉON Anne-Catherine

Mr REDDER Peter

DR2, LB12M, Station Biologique de Roscoff

Prof., LMGM, Université de Toulouse III

AUTRES MEMBRES DU JURY :

Mme GUILLIER Maude

Mr GIEGE Philippe

CR1, IBPC, Paris

DR2, IBMP, Université de Strasbourg

Acknowledgements

I would like to start by thanking my committee members Anne-Catherine Dock-Bregeon, Maude Guillier, Peter Redder and Philippe Giege for their interest in my work.

I would like to express my special appreciation and thanks to Pascale and Stefano. Pascale, thank you for giving me the opportunity to join your group and to explore the world of science. Thank you for all the scientific discussions, recommendations, constructive criticism and personal understanding. I greatly benefited from your keen scientific insight and your ability to put complex ideas into simple terms.

Stefano, thanks for always being ready to draw an explanation, for insightful comment and always making me focus on the question. Thanks for maintaining a positive spirit, for teaching me how to be critical in science as in life.

During the writing of this thesis, you gave me the support and the energy I needed to move on. You are for me an extremely reliable source of knowledge. Thanks for broadening my horizons.

Thank you to Isabelle, most of the work performed in this thesis would not have succeeded without your guidance and inspiration. Thank you also for your support in my private life.

Anne-Catherine, thank you for your friendship, your persistent encouragement during stormy times and for your precious help in the bench work. I will keep you in my heart. Thank you.

I would like to direct a warm and broad thank you to all the colleagues in “436 lab” Melodie, she is a true friend. Delphine is an amazing person in too many ways. Arnaud, Emma, Lucas, Laura and Maria Rosaria for informal, friendly and helpful working environment.

I've met many people along the way but I've got just few friends that I will love for all my life. My journey was made millions times more enjoyable by you Terry, Zongfu and Simona. Thank you for sharing so many good moments with me.

To my Daddy.

I am indebted to my mother and to my sister. I am very thankful for their thoughtfulness, support and encouragement in any and everything I do. In the last period of my life, I took decisions probably difficult to understand but I always had the feeling to have both of you on my side. Thank you for existing and making my life so special. Thanks for giving me the best advice coming deeply from your hearts. My apologies to both of you for having declined some of our meetings.

Above all, thanks to my amazing boyfriend. Daniele, you have been more than any, the greatest support, suffering with me at times and celebrating at others. Your high expectations continue to push me and you make me feel like I can do anything.

To Ludovica Mariafrancesca, right now, the joys of my life and to whom this thesis is dedicated.

List of abbreviations

Proteins and complexes

30S-PIC 30S pre-initiation complex

30S-IC 30S initiation complex

70S-IC 70S initiation complex

BSA « bovine serum albumin »

IF Initiation factor

OB Oligonucleotide/oligosaccharide binding

ORF Open reading frame

PNPase Polynucleotide phosphorylase

RNase Ribonuclease

RNA

mRNA messenger RNA

sRNA regulatory RNA

tRNA Transfert RNA

itRNA Initiator tRNA

RBS Ribosomal binding site

SD Shine and Dalgarno sequence

UTR Untranslated region

Metabolites/Ions

Ca Calcium

Cl Chlorine

Fe Iron

K Potassium

Mg Magnesium

Na Sodium

Ni Nickel

NH₄ Ammonium

ROS Reactive oxygen species

Bacteria

B. subtilis *Bacillus subtilis*

E. coli *Escherichia coli*

S. aureus *Staphylococcus aureus*

Media and antibiotics

LB Lysogeny broth

BHI Brain heart infusion

NZM Minimal media

Amp Ampicillin

Cam Chloramphenicol

Kan Kanamycin

Chemical reagents

EtBr Ethidium bromide

DTT Dithiothreitol

EDTA Ethylenediaminetetraacetic acid

IPTG Isopropyl β -D-1-thiogalactopyranoside

P32 Phosphorus-32

SDS Sodium dodecyl sulfate

General

Å Angström

°C Celsius degrees

cpm Count per minute

OD Optical density

g grams

K_D Dissociation constant

L Litre

M Molar

mol Mole

nt nucleotide

pb base pair

pI isoelectric point

UV ultraviolet

V volt

vol volume

W watt

WT wild-type

Table des matières

| | |
|-------------------------------------------------------------------------------------------------------|-----|
| Acknowledgements..... | i |
| List of abbreviations..... | iii |
| Synopsis de la thèse en Français..... | 1 |
| I. Introduction..... | 3 |
| II. Résultats..... | 4 |
| II.1. Fonction de <i>SauS1</i> dans la traduction..... | 4 |
| II.2. <i>SauS1</i> est une protéine chaperone de l'ARN..... | 8 |
| III. Discussion et perspectives..... | 10 |
| IV. Bibliographie..... | 13 |
| Introduction..... | 15 |
| I. <i>Staphylococcus aureus</i> is a versatile opportunistic human pathogen..... | 17 |
| II. Virulence determinants in <i>Staphylococcus aureus</i> play central role in its pathogenesis..... | 19 |
| II.1. Tissue colonization..... | 21 |
| II.2. Immune evasion (non CWA or Eap)..... | 22 |
| II.3. Tissue invasion and dissemination..... | 22 |
| III. Regulation of the expression of virulence factors..... | 29 |
| III.1 Regulation of PSM production and other virulence factors by the <i>agr</i> locus..... | 30 |
| III.2. Two component regulatory system SaeRS..... | 33 |
| III.3. The global regulator SarA..... | 33 |
| III.4. <i>S. aureus</i> sigma factors..... | 34 |
| IV. Antibiotic resistances in <i>Staphylococcus aureus</i> | 35 |
| V. Translation and its control in <i>S. aureus</i> | 37 |
| V.1. Translation initiation, a check point for regulation..... | 37 |
| V.2. A view on the Translation Initiation in Gram-negative bacteria..... | 38 |
| V.3. <i>S. aureus</i> ribosome structure and specific features..... | 42 |
| V.4. A glimpse on <i>Staphylococcus aureus</i> translation machinery and its control..... | 45 |
| Objectives and experimental strategies..... | 59 |
| I. How <i>S. aureus</i> ribosome initiates translation of structured mRNAs?..... | 61 |
| I.1. Biological questions and objectives..... | 61 |
| I.2. Main experimental strategies..... | 61 |
| II. Could <i>SauS1</i> be involved in regulatory mechanisms mediated by small non-coding RNAs?..... | 63 |
| II.1. Biological questions and Objectives..... | 63 |
| II.2. Main experimental strategies..... | 64 |
| III. Summary of the main experimental strategies..... | 65 |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Results | 67 |
| I. Result I: translation functions of <i>SauS1</i> | 69 |
| I. Result I: translation functions of <i>SauS1</i> (manuscript ready for submission) | 71 |
| <i>Staphylococcus aureus</i> S1 activates translation initiation of PSM α toxins and stimulates the production of several other secreted virulence factors..... | 71 |
| II. Result II: <i>SauS1</i> is an RNA chaperone involved in different steps of sRNA-dependent regulation and of RNA metabolism in <i>S. aureus</i> | 125 |
| II.1. <i>SauS1</i> helps translation initiation of structured mRNAs | 125 |
| II.2. Phenotypic characterization of <i>rpsA</i> mutants..... | 126 |
| II.3. <i>SauS1</i> and its constellation of RNAs. RIP-seq (co-immunoprecipitation and RNA-seq) analysis | 129 |
| II.4. <i>SauS1</i> forms stable complexes with various sRNAs but does not interact with all of them..... | 133 |
| II.5. <i>SauS1</i> forms a ternary complex with RsaI and RsaG | 134 |
| II.6. RsaI binding site for RsaG is hindered into a pseudoknot structure | 136 |
| II.7. Probing the interaction between RsaI and RsaG by footprinting experiments | 138 |
| II.8. Characterization of RNA annealing and strand displacement activities of S1 by FRET experiments | 139 |
| Discussions and Perspectives..... | 141 |
| I. <i>Staphylococcus aureus</i> S1 as translational activator. Further considerations..... | 143 |
| I.1. General discussion | 143 |
| I.2. Perspectives | 145 |
| II. Involvement of <i>SauS1</i> in sRNAs stabilization..... | 147 |
| II.1. General discussion..... | 147 |
| II.2. Perspectives..... | 148 |
| III. Involvement of <i>SauS1</i> in sRNA-target recognition..... | 149 |
| III.1. General discussion | 149 |
| III.2. Perspectives | 152 |
| IV. Involvement of <i>SauS1</i> in tRNA maturation | 153 |
| IV.I. General statement..... | 153 |
| IV.2. Perspectives | 157 |
| V. Involvement of <i>SauS1</i> in <i>cis-acting</i> regulatory elements..... | 157 |
| VI. General conclusion..... | 159 |
| Materials and Methods | 161 |
| Media and growth of bacteria..... | 163 |
| Purification of <i>SauS1</i> | 163 |
| Sonication..... | 163 |

| | |
|-------------------------------------------------------|-----|
| First Ni-NTa column purification..... | 164 |
| Dialysis..... | 164 |
| Protein concentration..... | 165 |
| Second Ni-Nta column purification..... | 165 |
| FPLC using anion exchange column..... | 165 |
| SDS-PAGE analysis..... | 166 |
| Co-immunoprecipitation assays..... | 167 |
| Deep-sequencing analysis..... | 167 |
| Bandshift on polyacrylamide gel..... | 168 |
| Chemical probing of S. aureus RsaI..... | 168 |
| Enzymatic probing of RsaI..... | 168 |
| Footprinting RsaI*/RsaG..... | 169 |
| FRET..... | 170 |
| Northern Blot..... | 170 |
| In vitro transcription of RNA-DIG probes..... | 170 |
| Migration, transfer, hybridization and detection..... | 171 |
| 30S ribosomal subunits purification..... | 172 |
| Toeprinting assay..... | 172 |
| 5' end Labeling of oligonucleotides..... | 172 |
| Toeprinting..... | 173 |
| Sequences preparation..... | 173 |
| References..... | 175 |

Synopsis de la thèse en Français

La protéine S1 chez *Staphylococcus aureus*, une protéine chaperonne de l'ARN impliquée dans l'initiation de la traduction et la régulation médiée par des ARN non codants

I. Introduction

Staphylococcus aureus est une bactérie pathogène opportuniste à Gram-positif, responsable d'un grand nombre d'infections communautaires et nosocomiales qui peuvent être bénignes comme les furoncles, ou beaucoup plus graves telles que des pneumonies, des ostéomyélites, et des endocardites. Cette bactérie est aussi capable de s'adapter rapidement à divers environnements. Cette adaptation rapide requiert un changement de l'expression de gènes qui s'effectue aussi bien au niveau transcriptionnel, traductionnel que post-traductionnel. Contrôler la traduction a l'avantage d'apporter une réponse rapide nécessaire pour les processus adaptatifs. Les régulations de la traduction s'effectuent majoritairement à l'étape de l'initiation qui est l'étape limitante de la synthèse des protéines, et au cours de laquelle l'ARN messager (ARNm) se lie à l'ARN de transfert (ARNt) initiateur sur la petite sous-unité du ribosome (30S). L'ARNm exerce un rôle clé dans ces mécanismes de régulation, en présentant des structures particulières dans leurs régions 5' non codantes qui peuvent soit directement influencer sur la reconnaissance du ribosome, soit être reconnues par des protéines régulatrices ou des ARN non codants (ARNnc). Ainsi, les ARNm régulés sont souvent fortement structurés. Néanmoins pour être activement traduit, le site de liaison du ribosome sur l'ARNm doit être accessible. Chez *Escherichia coli*, l'initiation de la traduction des ARNm structurés est facilitée par l'action de la protéine ribosomique S1 qui est une protéine chaperonne de l'ARN capable de déstabiliser les structures des ARNm et de favoriser l'adaptation du codon d'initiation sur le canal de décodage du ribosome (Duval *et al.*, 2013). La protéine S1 d'*E. coli* (*EcoS1*) est constituée de six domaines OB-fold et est ancrée à la sous-unité 30S grâce aux deux premiers domaines, alors que la protéine S1 de *S. aureus* (*SauS1*) est plus courte (quatre domaines OB-fold) et ne contient pas le premier domaine qui sert à l'ancrage sur le ribosome. La fonction de cette protéine chez ce pathogène majeur de l'homme n'était pas encore connue au début de ma thèse.

Les objectifs de ma thèse ont été (1) d'élucider les mécanismes moléculaires qui permettent au ribosome de *S. aureus* de reconnaître ces ARNm structurés pour initier leur traduction et (2) de caractériser les fonctions de *SauS1* dans le métabolisme des ARN.

Nous avons récemment démontré que les sous-unités 30S purifiées de *S. aureus* ne contiennent pas S1, et ne sont pas capables de former efficacement des complexes d'initiation avec des ARNm structurés de *S. aureus* (Introduction, §V.4. Article 1 : Khusainov, Marena *et al.*, 2016). Pendant ma thèse, j'ai démontré que la protéine *SauS1* n'interagit pas directement avec la sous-unité 30S mais est capable de stimuler *in vitro* et *in vivo* l'initiation de la traduction de certains ARNm structurés par une interaction directe. Par l'utilisation de diverses approches incluant des études d'interactome, de mutagenèse, de FRET, de cartographie en solution, de toe-printing (pour analyser la formation des complexes ribosomiques) et de retard sur gel, j'ai également montré que *SauS1* agit comme une protéine chaperonne de l'ARN et qu'elle peut former différents complexes cellulaires impliqués dans des régulations dépendantes des ARNnc et dans les processus de maturation/dégradation de l'ARN.

II. Résultats

II.1. Fonction de *SauS1* dans la traduction

Le premier objectif de mon projet de thèse a porté sur la caractérisation de l'impact fonctionnel de la protéine *SauS1* sur l'initiation de la traduction d'ARNm structurés spécifiques. Du fait que j'ai montré que *SauS1* n'est pas strictement une protéine ribosomique, mon objectif a été de caractériser les cibles *in vivo* pour mieux comprendre l'étendue de ses fonctions biologiques. Dans un premier temps, en collaboration avec I. Caldelari, j'ai utilisé l'approche RIP-Seq qui est basé sur l'expression d'une protéine *SauS1* portant à son extrémité C-terminale une étiquette Flag. Après immunoprécipitation, les ARN co-purifiés à *SauS1* ont été identifiés par séquençage haut débit.

Nous avons ainsi identifié plusieurs classes d'ARN enrichis avec *SauS1* dont plusieurs ARNm, ARN régulateurs (ARNnc, « riboswitch ») et ARNt. Les interactions directes entre certains des ARN cibles et *SauS1* ont été validées par des expériences de gel retard et par la détermination de la structure des complexes par cartographie en solution. De manière intéressante, parmi les ARNm, nous avons identifié l'opéron


α psm1-4 qui code pour quatre peptides appelés « Phenol-soluble modulins » ou PSM, qui sont des exo-toxines dont la synthèse est activée par le système de densité cellulaire *agr*. Les PSM (« Phenyl Soluble Modulins ») appartiennent à une famille de peptides amphipathiques composés d'hélices alpha. Cet ARNm est fortement structuré et les quatre sites de reconnaissance du ribosome sont tous engagés dans des structures en tige-boucle. L'analyse du transcriptome comparatif provenant des souches HG001 sauvage et $\Delta rpsA$ montre une régulation négative de l'opéron α psm1-4. Nous avons émis l'hypothèse que la délétion de *SauS1* a entraîné une chute de la traduction de l'ARNm et par conséquent une déstabilisation de l'ARNm. De manière intéressante, d'autres ARNm cibles identifiés codent aussi pour des exo-toxines impliquées dans la virulence et la structure secondaire de leurs ARNm sont prédites pour adopter des structures dans leurs régions 5' non traduites qui pourraient moduler l'accessibilité de la sous-unité 30S.

Dans ce manuscrit, nous avons analysé en détail le mécanisme d'action de *SauS1* sur l'opéron α psm1-4. Nous avons ainsi démontré que *SauS1* active la formation du complexe d'initiation impliquant la sous-unité 30S, l'ARNm α psm1-4, et l'ARNt initiateur. Des expériences *in vivo* ont confirmé le rôle important de *SauS1* pour recruter l'ARNm dans les polysomes. Dans ce travail, j'ai bénéficié de l'expertise de plusieurs membres de l'équipe. Isabelle Caldelari a construit plusieurs souches mutées au niveau du gène *rpsA*, et a introduit l'étiquette Flag au niveau de l'extrémité C-terminale de la protéine pour effectuer les expériences de co-immunoprécipitation. Celle-ci a également mesuré le temps de demie vie de l'ARNm α psm1-4 dans les souches sauvage HG001 et la souche mutant $\Delta rpsA$. Lucas Herrgott a suivi la traduction *in vivo* des ARNm α psm1-4 et *hu* en analysant les profils des polysomes, suivi de l'analyse des ARNm par des expériences de Northern blot. Iskander Khusainov a préparé les sous-unités 30S de *S. aureus*, qui ont été utilisées pour des études structurales (Khusainov *et al.*, 2017). Dans ce qui va suivre, j'ai résumé les résultats que j'ai obtenu et qui ont été décrits dans le manuscrit présenté dans la partie résultat (§ I.1).

II.1.1. SauS1 ne suit pas le profil d'expression des protéines ribosomiques mais est synthétisée dès le milieu de la phase exponentielle de la croissance.

Au cours de la phase exponentielle de la croissance bactérienne, la synthèse des protéines ribosomiques est liée à la transcription des ARN ribosomiques et est régulée selon les changements environnementaux et aux différentes phases de croissance

(Nomura, 1999; Kaczanowska and Rydén-Aulin, 2007). *SauS1*, codée par le gène *rpsA*, a un profil d'expression caractéristique puisque sa synthèse n'est pas stimulée dans les conditions où les autres protéines ribosomiques sont activement produites, par exemple en réponse aux stress antibiotiques, comme il a été récemment démontré par une analyse de spectrométrie de masse (Bonn *et al.*, 2016). Afin de comprendre le mécanisme de régulation, j'ai analysé l'expression de l'ARNm *rpsA* en fonction de la phase de croissance (Figure 1) par des expériences de Northern et suivi la synthèse de la protéine par Western. L'ARNm *rpsA* présente deux isoformes à cause de deux sites d'initiation de la transcription (TSS) (Figure 1a). Le transcrit court est constitutivement exprimé alors que le transcrit long commence à être exprimé à 3 h et s'accumule en fin de croissance (Figure 1b). Un profil de transcription similaire est observé dans d'autres souches de *S. aureus* (Figure 1c) indiquant un mécanisme de régulation conservé. Le profil d'expression de la protéine *SauS1*, analysée par Western, montre que sa synthèse est en phase avec l'expression du transcrit long (Figure 1d).



II.1.2. *SauS1* n'est pas une protéine essentielle mais est liée au métabolisme des ARN

Afin de mieux comprendre la fonction de *SauS1*, j'ai délété le gène *rpsA* par remplacement allélique. Chez *E. coli*, le gène *rpsA* est essentiel et la protéine ribosomique *EcoS1* est requise pour la traduction de la majorité des ARNm (Duval *et al.*, 2013). L'absence de phénotype de croissance observée dans la souche de *S. aureus* mutante dans des conditions de culture optimale de laboratoire indique que *SauS1*, contrairement à *E. coli*, n'est pas essentielle. Toutefois, nous avons effectué une étude comparative des protéomes et des transcriptomes de la souche sauvage (HG001) et de la

souche mutante (HG001 $\Delta rpsA$). Dans la souche mutante, le niveau d'expression de nombreux ARNm et ARNnc est altéré alors qu'un défaut de la maturation de certains ARNt a été détecté. Des expériences de rifampicine ont été réalisées pour suivre la stabilité de l'ARNm $\alpha psm1-4$. Le temps de demie-vie est clairement diminué dans la souche mutante. Ce résultat pourrait suggérer un rôle de *SauS1* dans la traduction (voir manuscrit dans la partie résultat, Figure 13).

II.1.3. SauS1 n'interagit pas avec le ribosome mais active la synthèse des PSM

Pour caractériser l'impact de *SauS1* sur la traduction de l'ARNm *psm* $\alpha psm1-4$, nous avons analysé les profils des polysomes couplés à des expériences de Northern. De cette façon, nous avons évalué le taux de traduction de l'ARNm dans les souches sauvage (WT) et mutante $\Delta rpsA$. Une différence importante est observée dans la quantité de l'ARNm *psm* $\alpha psm1-4$ trouvée dans les polysomes entre les deux souches: en absence de *SauS1*, beaucoup moins d'ARNm (2,5 fois moins) est engagé sur les ribosomes pour être traduit. Ce comportement est spécifique de l'ARNm *psm* $\alpha psm1-4$, puisque l'ARNm *hu* est légèrement mieux traduit (1,78 fois plus) (Figure 2a et b). Pour confirmer l'implication directe de *SauS1* dans la traduction des PSM, j'ai purifié *SauS1* et ai testé son activité sur la formation du complexe d'initiation de la traduction par des expériences de Toe-printing. Les résultats ont montré que l'addition de *SauS1* augmente fortement la formation d'un complexe d'initiation actif sur l'ARNm *psm* $\alpha psm1-4$ (Figure 2c). Cet effet est spécifique puisqu'aucun effet n'a été observé pour un ARNm non structuré tel que l'ARNm *spa* codant pour la protéine A (manuscrit dans partie résultats, Figure S3).




Figure 2 Effet de *SauS1* sur la traduction de l'ARNm *psm*, *hu* et *mgrA*. a) et b), les profils des polysomes sont couplés à une analyse par Northern des ARNm *psm* et *hu* dans les souches WT et $\Delta rpsA$ (a et b, respectivement). L= lysat cellulaire. l'ARN 16S en ligne L est utilisé pour la normalisation. c) et d), effet de la protéine *SauS1* sur la formation des complexes d'initiation impliquant les ARNm de *S. aureus* *psm* c) et *mgrA* d). Les expériences montrent que l'addition de la protéine S1 induit la formation d'un complexe d'initiation actif surtout à des concentrations très faibles de 30S. L'arrêt de la reverse transcriptase en position +16 indique la présence du ribosome fixé à l'ARNm.

II.2. *SauS1* est une protéine chaperone de l'ARN

II.2.1. *SauS1* interagit avec d'autres ARN

Afin d'identifier les partenaires protéiques et les ARN de *SauS1* *in vivo*, nous avons effectué des expériences d'immunoprécipitation suivies par des analyses protéomiques et de séquençage haut débit des ARN. Cela a permis de caractériser les protéines et les ARN qui ont été enrichis avec la protéine étiquetée. Parmi les ARN, nous avons trouvé plusieurs ARNnc dont *RsaI*, *RsaH*, *RsaG*, *RsaE* et *RsaD*, des ARNm hautement structurés comme les *psm*, des éléments régulateurs agissant *in cis* appelés « riboswitch » incluant celui de la flavine mononucléotide (FMN), et de nombreux ARNt.

Pour valider *in vitro* l'interaction directe entre S1 et les ARN, j'ai visualisé la formation des complexes par des expériences de gel retard. Celles-ci montrent que *SauS1* forme un complexe stable avec *RsaI* et *RsaH* (Figure 3a et b), et une interaction faible avec *RsaE* (données non montrées), alors qu'aucune interaction n'a été observée avec les autres ARNnc (*RsaA* et *RsaG* ; partie résultats, Figure 20). J'ai également vérifié l'interaction directe entre S1 et l'ARNm *psm* (Figure 3c).




Figure 3. Analyse de la formation des complexes S1-ARN par gel retard.

Formation du complexe entre les ARNc RsaI (a) et RsaH (b), et l'ARNm *psm* (c). les ARN sont marqués radioactivement en 5' et les concentrations croissantes de S1 ont été ajoutées.

(d) A gauche, la formation du complexe entre RsaI et RsaG en absence de S1. A droite, la même expérience en présence de *SauS1*. Un complexe ternaire entre RsaI, RsaG et S1 est observé.

Parmi les protéines potentiellement partenaires de *SauS1*, nous avons détecté deux machineries cellulaires majeurs, le dégradosome avec tous ses composants hautement enrichis (dont les ribonucléases J1, J2, Y, la PNPase et l'hélicase CshA) et le ribosome.

II.2.2. Quel est le mécanisme d'action de *SauS1*?

Des expériences effectuées par Delphine Bronesky dans notre laboratoire ont démontré une interaction directe entre RsaI et RsaG, et comme nous n'avons pas mis en évidence de formation de complexe entre *SauS1* et RsaG, nous avons vérifié la possible formation d'un complexe ternaire qui pourrait expliquer les résultats de la co-immunoprécipitation. De manière intéressante, des expériences de formation des complexes par gel retard montrent clairement une bande retardée spécifique qui correspondrait au complexe formé entre RsaI, *SauS1* et RsaG (Figure 3d). De plus, la présence de S1 augmente de manière significative l'affinité entre RsaI et RsaG.

J'ai ensuite effectué *in vitro* des expériences d'empreinte en utilisant la cartographie en solution SHAPE qui modifie les riboses, DMS pour modifier les adénines en position N1 et les cytosines en position N3, et diverses ribonucléases qui coupent les régions en simple brin (RNase T1 pour les guanines) et en double brin (RNase V1). De cette façon, j'ai obtenu la structure de RsaI et identifié le site d'interaction avec RsaG. Les résultats sont en faveur de l'existence d'une structure en pseudoknot dans RsaI qui implique deux régions hautement conservées chez tous les staphylocoques: un motif riche en guanines exposé dans une boucle et une séquence interhélicoidale riche en uridines. Le motif riche en guanines se lie à un motif conservé riche en cytosines de RsaG (Geissmann *et al*, 2009). Par des expériences de pontage, j'ai montré une interaction possible entre *SauS1* et la séquence riche en uridines de RsaI. Il est possible que S1

pourrait perturber la structure en pseudoknot de RsaI afin de faciliter l'interaction avec RsaG (Partie résultats, Figure 24).

II.2.3. *SauS1* est une protéine chaperone de l'ARN

SauS1 interagit directement avec ses ARNm et ARNnc cibles et stimule l'interaction ARN-ARN probablement en modifiant leur structure secondaire. Pour vérifier si *SauS1* stimule la cinétique de l'interaction ARN-ARN et fonctionne comme une protéine chaperone de l'ARN, j'ai effectué des expériences préliminaires de « time resolved FRET » avec des oligonucléotides d'ARN modèle couplés à des fluorophores. La présence de *SauS1* accélère la formation des appariements ARN-ARN de 5 fois (Partie résultats, Figure 27).

III. Discussion et perspectives

Malgré le fait que la protéine *SauS1* n'est pas une protéine essentielle, elle est impliquée dans plusieurs processus cellulaires fondamentaux résumés dans la figure 4.




Figure 4. Les différentes fonctions de la protéine *SauS1*: La protéine kinase membranaire AgrC active le régulateur de réponse AgrA lorsque le peptide signal sécrété AIP a atteint une concentration seuil. Les trois locus *PSMs* sont contrôlés à la fois au niveau transcriptionnel par AgrA et au niveau traductionnel par *SauS1*. SarA est un des facteurs activant la synthèse de *rpsA* et des transcrits *psm*. Des expériences de co-immunoprécipitation utilisant une version modifiée de *SauS1* portant une étiquette Flag suivies d'un séquençage des ARN a permis l'identification *in vivo* de différentes cibles ARN incluant divers ARNm, ARN régulateurs, riboswitch et des ARNt dont le CCA est aussi présent dans le gène. Toutes ces ARNs ont un taux affecté dans la souche mutante $\Delta rpsA$. Des exemples de dérégulations pour chaque classe d'ARN sont donnés dans l'encadré de couleur jaune.

Même si elle n'est pas associée directement au ribosome, *SauS1* favorise l'initiation de la traduction d'ARNm structurés. Le mécanisme de cette stimulation n'est pas encore connu mais il est possible que *SauS1*, comme *EcoS1*, puisse fragiliser les structures d'ARNm au niveau des sites d'initiation de la traduction, facilitant l'accès au ribosome. Nous avons démontré que l'ARNm *psm* α psm1-4 nécessite *SauS1* pour faciliter l'initiation de sa traduction. A forte concentration ($> 1 \mu\text{M}$), les PSM α possèdent une activité lytique *in vitro* sur les neutrophiles (Löffler *et al.*, 2010) et sur les érythrocytes (Cheung et Otto, 2012). Ce pouvoir lytique est lié à leur propriété amphipathique. En fait, les PSM α s'agrègent à la surface des membranes pour former des pores transmembranaires. En outre, il a été montré que PSM α 1 et PSM α 2 présentaient une activité bactéricide contre les bactéries d'un genre différent de *Staphylococcus*. Ainsi ces toxines confèreraient à *S. aureus* la capacité d'entrer en compétition avec d'autres espèces bactériennes pour la colonisation de l'hôte (Joo et Otto, 2011).

SauS1 peut-elle moduler la virulence de *S. aureus* en agissant sur la production des PSM? Pour aborder cette question, en collaboration avec l'équipe de François Vandenesch (Lyon), nous caractériserons l'impact fonctionnel de la protéine S1 sur la pathogénicité de *S. aureus*, en utilisant différentes approches *in vivo* et *in vitro*: dosage par spectrométrie de masse des PSM dans les surnageants de culture, infection des cellules immunitaire (macrophages, neutrophiles), analyse de la formation de biofilms entre les souches sauvage et mutante $\Delta rpsA$ et la souche mutante complémentée avec un plasmide qui exprime le gène *rpsA* sous son propre promoteur, et analyse de l'effet de *SauS1* dans divers modèles d'infection chez la souris.

Des résultats plus récents montrent que *SauS1* est aussi requise pour faciliter la traduction de l'ARNIII qui code pour l'hémolysine delta, un autre peptide de type PSM induit par le système *agr*. Il a été suggéré que la traduction de *hld* est retardée de 1h par rapport à la transcription de l'ARNIII. Ce décalage entre transcription et traduction a aussi été observé pour les autres PSM α . Du fait que la protéine *SauS1* est exprimée principalement à haute densité cellulaire, nous proposons que la protéine serait responsable de cet effet de décalage pour activer de manière coordonnée la traduction des PSM. Nous envisageons d'utiliser un promoteur constitutif pour exprimer *SauS1* et analyser si, dans ce contexte, le délai entre la transcription et la traduction des PSM est aboli.

S1 est-elle impliquée dans des processus de régulation des ARNnc? Dans diverses bactéries à Gram-négatif, les protéines chaperones, dont Hfq et ProQ, participent à la régulation des ARNnc en les stabilisant et en facilitant leurs appariements avec leurs ARNm cibles. Chez *S. aureus*, aucune protéine n'a encore été impliquée dans ces mécanismes. ProQ n'est pas présente, et Hfq a une composition en acides aminés différente au niveau du site de liaison de l'ARN, ce qui ne permet pas de former des complexes ARN-ARN. Nous avons trouvé que *SauS1* est directement associée à plusieurs ARNnc et avons montré que cela pourrait, au moins dans un cas, stimuler l'hybridation entre l'ARNnc et sa cible (RsaI-RsaG). Bien que l'activité chaperone à l'ARN de *SauS1* a été démontrée, les mécanismes détaillés par lesquels elle favorise l'interaction ARN-ARN doivent encore être élucidés. Des résultats préliminaires suggèrent que celle-ci favorise la cinétique d'appariement entre deux fragments d'ARN dans un système modèle. Pour montrer que la cinétique de liaison de l'ARNnc aux cibles est stimulée par S1, il sera possible d'utiliser l'appareil SwitchSense disponible dans notre unité. Nous pourrions tester différents systèmes ARNnc-cibles en présence ou en absence de *SauS1*.

Est-ce que S1 est impliquée dans la stabilité et la maturation des ARN? *SauS1* a été retrouvée en association avec le dégradosome, la machinerie responsable pour la dégradation/maturation des ARN. Les nombreux ARNt identifiés dans les expériences de co-immunoprécipitation suggèrent un défaut de maturation qui devra être confirmé par des expériences de Northern.

Ainsi, pour la première fois, l'ensemble de mes résultats ont permis de démontrer le rôle clé d'une protéine fixant l'ARN pour la traduction d'ARNm structuré et pour la régulation de l'expression des gènes. Il sera intéressant de vérifier si ces fonctions sont conservées dans les bactéries de type Gram-positif et qui sont éloignés dans l'évolution telles que *Bacillus subtilis*. L'utilisation d'autres approches telles que le Grad-seq devrait aider à mettre en évidence d'autres protéines impliquées dans la régulation post-transcriptionnelle de l'expression des gènes de *S. aureus* (Smirnov *et al.*, 2016).

IV. Bibliographie

- Cheung G.Y.C., Duong A.C., Otto M. Direct and synergistic hemolysis caused by Staphylococcus phenol-soluble modulins: implications for diagnosis and pathogenesis. *Microbes Infect.* 2012 Apr;14(4):380-6. doi: 10.1016/j.micinf.2011.11.013. Epub 2011 Dec 7.
- Cheung G.Y.C., Otto M. Phenol-soluble modulines-critical determinants of staphylococcal virulence. *FEMS Microbiol Rev.* 2014 Jul;38(4):698-719. doi: 10.1111/1574-6976.12057. Epub 2014 Jan 16
- Duval M., Korepanov A., Fuchsbauer O., Fechter P., Haller A., Fabbretti A., Marzi S. et al. Ribosomal protein S1 unfolds structured mRNAs onto the ribosome for active translation initiation. *PLoS Biol.* 2013 Dec; 11(12): e1001731
- Geissmann T., Chevalier C., Cros M.J., Boisset S., Fechter P., Noirot C., Romby P. et al. A search for small noncoding RNAs in Staphylococcus aureus reveals a conserved sequence motif for regulation. *Nucleic Acids Res.* 2009 Nov;37(21):7239-57. doi: 10.1093/nar/gkp668.
- Green C. J., Vold B. S. Staphylococcus aureus has clustered tRNA genes. , *J Bacteriol.* 1993 Aug;175(16):5091
- Joo H-S, Cheung G.Y.C., Otto M. Antimicrobial activity of community-associated methicillin-resistant Staphylococcus aureus is caused by phenol-soluble modulin derivatives. *J Biol Chem.* 2011 Mar 18;286(11):8933-40. doi: 10.1074/jbc.M111.221382. Epub 2011 Jan 28
- Kaczanowska M. and Rydén-Aulin M.. Ribosome biogenesis and the translation process in Escherichia coli. *Microbiol Mol Biol Rev.* 2007 Sep;71(3):477-94
- Khusainov I., Marena A., Cerciati M., Fechter P., Hashem Y., Marzi S., Romby P., Yusupova G., Yusupov M. A glimpse on Staphylococcus aureus translation machinery and its control. *Mol Biol* 2016 Jul-Aug;50(4):549-557
- Koch G., Yepes A., Forsner K.U., Wermser C., Stengel S.T., Modamio J., Ohlsen K., Foster K.R., Lopez D. Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competition. *Cell* 2014 Aug 28 ; 158(5) :1060-71. doi : 10.1016/j
- Löffler B., Hussain M., Grundmeier M., Brück M., Holzinger D., Varga G., et al. Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. *PLoS Pathog.* 2010 Jan 8;6(1):e1000715. doi: 10.1371/journal.ppat.1000715
- Nomura M. Regulation of Ribosome Biosynthesis in Escherichia coli and Saccharomyces cerevisiae: Diversity and Common Principles *J Bacteriol.* 1999 Nov; 181(22): 6857-6864

Roberts R.J. Staphylococcal transfer ribonucleic acids. *J Biol Chem.* 1974 Aug 10;249(15):4787-96

Smirnov A, Förstner KU, Holmqvist E, Otto A, Günster R, Becher D, Reinhardt R, Vogel J. Grad-seq guides the discovery of ProQ as a major small RNA-binding protein. *Proc Natl Acad Sci U S A.* 2016 Oct 11;113(41):11591-11596.

Introduction

I. *Staphylococcus aureus* is a versatile opportunistic human pathogen

Staphylococcus aureus was discovered in 1880 by Sir Alexander Ogston (Ogston, 1881). He observed grape-like clusters of bacteria when examining a purulent discharge from patients with post-operative wounds and he named them “staphyle”, the greek expression for a bunch of grapes. Few years later, in 1884, Friedrich Julius Rosenbach succeeded in isolating yellow bacterial colonies from abscesses and named them *Staphylococcus aureus*, “aureus” from the latin word referred to golden color caused by the presence of carotenoids (Rosenbach, 1884). 121 years later, this golden pigment staphyloxanthin, has been demonstrated to be one of the many virulence factors produced by *S. aureus*. It shields the microbe from oxidation-based clearance promoted by the neutrophil oxidative burst, thus allowing its survival in blood (Liu et al., 2005).

Among staphylococci, *S. aureus* is the most virulent and pathogenic for humans, being responsible of wide range of diseases from a variety of skin, wound and deep tissue infections to more life-threatening conditions such as pneumonia, endocarditis, septic arthritis and septicemia (**Figure 1**). This bacterium is one of the most common species responsible for nosocomial infections and it might also cause food poisoning, scalded-skin syndrome and toxic shock syndrome, through production of several toxins. Intriguingly, despite its invasive opportunism, *S. aureus* replicates and evolves in a large proportion of the human population as a harmless colonizing organism that might never cause diseases. Approximately 30% of the population is asymptotically colonized by *S. aureus* (Wertheim et al., 2005). The anterior nasal mucosa is the most frequent site for the colonization of healthy human carriers (Kluytmans et al., 1997); other anatomical sites are throat (Mertz et al., 2007), perineum, gastrointestinal tract (Yotis, 1963), axillae, groin (Gordon and Lowy, 2008), and vagina (Bourgeois-Nicolaos et al., 2010). Although humans are the primary natural reservoirs, domestic animals, livestock, and fomites may serve as adjunctive reservoirs.




Figure 1. Sites of colonization and diseases caused by *S. aureus*. *Staphylococcus aureus* can be a human commensal or a potentially lethal opportunistic pathogen. Indeed, it is able to survive and multiply within the human body by creating microenvironments that protect it from host immune attack (Rooijackers et al., 2005). It can cause life-threatening diseases, as well as minor diseases such as soft tissue infections.

S. aureus is a Gram-positive bacterium, has a cell diameter of 0.6 μm , is non-motile, non-spore-forming, and is a facultative anaerobe. It belongs to the genus *Staphylococcus* of the *Micrococcaceae* family. This genus is traditionally divided in two groups based on the bacteria ability to produce coagulase, an enzyme that causes blood clotting. The coagulase-positive staphylococci includes *Staphylococcus aureus*, and the coagulase-negative staphylococci (CoNS) are common commensals of the skin. Both coagulase and staphyloxanthin are contributing to the host immune system evasion strategies, part of *S. aureus* impressive armory which relies on antigens (adhesins and capsule) that facilitate adhesion to host cells, enzymes (coagulases, lipases, hyaluronidases, staphylokinases, nucleases) for tissue degradation and nutrient acquisition, and toxins (α -, β - and δ - haemolysins, P-V leukocidins, enterotoxins, exfoliative toxins, Toxic Shock Syndrome toxin) for the evasion of host defenses. Their production requires the need for *S. aureus* to make physiological adjustments for energy conservation. Thus, the virulence

factors are primarily targets of gene regulation, which reprogram the *S. aureus* lifestyle upon infection.

II. Virulence determinants in *Staphylococcus aureus* play central role in its pathogenesis

S. aureus has a circular chromosome of 2.8 M base pairs (bp) with low G+C composition (32.8%). Its genome has about 2700 coding sequences among which approximately 23% have still unknown functions (data from the most recent annotation of the strain HG001 (Caldelari et al., 2017)). Several virulence factors are chromosomally encoded while others are parts of pathogenicity islands (PIs), which are the repository of many toxins, adherence and invasion factors, superantigens, and secretion systems (Novick et al., 2010; Novick and Ram, 2016; Novick and Subedi, 2007).

The pathogenicity of *S. aureus* is a complex process based on extremely coordinated expression of virulence factors at appropriate time among the different stages of host infection (**Table 1**): colonization, escape host immuno-defense, growth and cell division, and spreading (**Figure 2**). Their expression also responds to a plethora of environmental cues including bacterial cell density, amino acid limitation, metal depletion, decreased pH, and oxidant production. Through integration of these environmental cues, *S. aureus* can simultaneously coordinate expression of the genes coding for surface proteins involved in adhesion and defense against the host immune-system and only later during the post-exponential phase, *S. aureus* starts to secrete toxins able to disrupt host cells and tissues facilitating the spread of the infection (Thammavongsa et al., 2015).

Studying the expression pattern of virulence factors during the infection in the host could be quite difficult (Burian et al., 2010; Cheung et al., 2004; Montgomery et al., 2008; Que et al., 2005) and many factors, including cellular immune factors and nutrient conditions, might add an extra layer of regulation. In a few studies, the use of serum in *S. aureus* cultures to induce the expression of virulence factors (Ishii et al., 2014; Oogai et al., 2011) has produced promising results, but most commonly, bacterial media, such as Trypticase soy broth (TSB), brain heart infusion (BHI) broth, and Luria-Bertani (LB) broth, have been used for *S. aureus* growing. In the following description of several

major virulence factors, their timed expression is referred to different phases of the growth in these media.

| VIRULENCE FACTORS | PUTATIVE FUNCTIONS |
|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cell surface factors | |
| Staphylococcal protein A (SpA) | Bind to IgG, interfering with opsinization and phagocytosis |
| Fibronectin-binding proteins (FnbpA and FnbpB) | Attachment to fibronectin and plasma clot |
| Clumping factor proteins (ClfA and ClfB) | Mediate clumping and adherence to fibrinogen in the presence of fibronectin |
| Capsular polysaccharides | Reduce phagocytosis by neutrophils; enhance bacterial colonization and persistence on mucosal surfaces |
| Staphyloxanthin | Resistance to neutrophil reactive oxidant-based phagocytosis |
| Secreted factors | |
| <u>Superantigens</u> | |
| Staphylococcal enterotoxins (SEA, B, C, D, E, G and Q) | Massive activation of T cells and antibody presenting cells |
| Toxic shock syndrome toxin-1 (TSST-1) | Massive activation of T cells and antibody presenting cells |
| <u>Cytolytic toxins</u> | |
| α -hemolysin | Induce lysis on a wide spectrum of cells, mainly platelets and monocytes |
| β -hemolysin | Hydrolysis of sphingomyelin of the plasmatic membrane of monocytes, erythrocytes, neutrophils and lymphocytes; make cells susceptible to other lytic agents |
| γ -hemolysin | Induce lysis on erythrocytes and leukocytes |
| <u>Leukocidin family</u> | |
| Leukocidins E/D and M/F-PV | Induce lysis on leukocytes |
| Panton-Valentine leukocidin (PVL) | Induce lysis on leukocytes |
| <u>Various exoenzymes</u> | |
| <u>Lipases</u> | Inactivate fatty acids |
| <u>Proteases</u> | |
| Serine (e.g. exfoliative toxins ETA and ETB) | Inactivate neutrophil activity; activate T cells (only ETA and ETB) |
| Cysteine (e.g. staphopain) | Block neutrophil activation and chemotaxis |
| Aureolysin | Inactivate antimicrobial peptides |
| Hyaluronidase | Degrade hyaluronic acid |
| Staphylokinase (SAK) | Activate plasminogen; inactivate antimicrobial peptides |
| <u>Coagulase</u> | |
| CoA | Coagulation promoting virulence factor |
| Miscellaneous proteins | |
| Staphylococcal complement inhibitor (SCIN) | Inhibit complement activation |
| Extracellular fibrinogen binding protein (Efb) | Inhibit complement activation |
| Chemotaxis inhibitory protein of <i>S. aureus</i> (CHIPS) | Inhibit chemotaxis and activation of neutrophils |
| Formyl peptide receptor-like 1 inhibitory protein (FLIPr) | Inhibit chemotaxis of neutrophils |
| Extracellular adherence protein (Eap) | Inhibit neutrophil migration |

Table 1 Major virulence factors involved in the pathogenesis of *Staphylococcus aureus* and respective putative functions.

II.1. Tissue colonization

Interaction with endothelial cells is a critical primordial step of infection and several bacterial proteins have been shown to be involved. They include secreted proteins and Cell Wall Associated proteins (CWA). Hereafter, I provide few examples of different mechanisms with which they promote adhesion and prevent clearance by the host immune system.

The extracellular adherence protein (Eap) of *S. aureus* participates in a wide range of protein-protein interactions that facilitate the initiation and dissemination of *Staphylococcal* disease. Eaps are secreted proteins involved in adherence and internalization of bacteria in eukaryotic cells (Hagggar et al., 2003; Palma et al., 1999). They have strong anti-inflammatory properties resulting in a decreased recruitment of neutrophils at the sites of infection. These immunomodulating proteins are also able to inhibit T and B cells proliferation (Hagggar et al., 2005).

The cell-surface proteins are the frontline of infection, involved in adhesion, internalization, colonization (Malachowa et al., 2011; Sibbald et al., 2006), invasion of non-phagocytic host cells (Foster et al., 2014), and immune evasion. *S. aureus* produces up to 24 CWA, which are covalently anchored to the cell wall peptidoglycan. Among them the most abundant are the protein A (*spa*), Sbi and the fibronectin binding proteins (FnBPs) (Foster et al., 2014). *Spa* is expressed during the exponential growth phase (Gao and Stewart, 2004). It is involved both in adhesion to host cells and in evading innate immune responses mediated by immunoglobulins binding, bacterial opsonisation and stimulation of TNF- α pro-inflammatory response (Atkins et al., 2008; DeDent et al., 2007; Gonzalez et al., 2015; Thammavongsa et al., 2015; Zecconi and Scali, 2013). Protein A also impacts the normal function of B-cells and induces their apoptosis, thus preventing the host from developing immunological memory (Goodyear and Silverman, 2004). Staphylococcal binder of immunoglobulin (Sbi) is both a secreted and CWA protein that, as protein A, binds to IgG (Smith et al., 2011). Both forms of the proteins participate in immune evasion whereas only the secreted form triggers the activation of the complement (Smith et al., 2012). Indeed, the secreted form of Sbi interacts with the antigen recognition of B-cells, rendering the pathogen undetectable and as a result, opsonins are not released and the immune response is not triggered (Markiewski and Lambris, 2007; Smith et al., 2012; Toapanta and Ross, 2006). Binding to the IgGs

contained in the human serum stimulates its expression, this is why in laboratory growth conditions, Sbi expression is very low. Fibronectin binding proteins (Fnbps) are adhesins, which as other cell wall-associated proteins, are expressed during the exponential phase of bacterial growth (Fitzgerald et al., 2012). They form fibronectin bridges required to stabilize the adhesion of the pathogen to host tissues (Martin et al., 2012; Piroth et al., 2008). Moreover, FnbpA and FnbpB are able to bind platelets whose activation and aggregation promotes thrombus formation (Kerrigan et al., 2002). The formation of platelet-fibrin thrombi protects bacteria from neutrophil recognition (Hartleib et al., 2000).

II.2. Immune evasion (non CWA or Eap)

Normally, the blood coagulation system is a process resulting in the formation of a blood clot, which closes the injured part of the vessel. However, this process can also be activated by the immune system in response to infection. In this case, the bacteria are trapped in a blood coat preventing their dissemination in other sites of the body. Many organisms, including *S. aureus* have developed strategies able to convert the blood coagulation as an advantage to ensure their survival. Indeed, when a clot or eventually an abscess is formed, the bacteria are protected from the host immune attack. Coagulase (Coa) is the main coagulation-promoting factor produced by *S. aureus*. In combination with other proteins, it activates the host prothrombin inducing fibrin formation that protects the pathogen against phagocytosis by immune cells (Friedrich et al., 2003; Kroh et al., 2009) and promotes abscess formation (Cheng et al., 2010; McAdow et al., 2012)).

S. aureus has also other specific proteins that affect the innate and adaptive immune system. The innate immune modulators such as chemotaxis inhibitory protein (CHIPS) and the staphylococcal complement inhibitor (SCIN), are employed in the inactivation of the human complement (van Wamel et al., 2006).

II.3. Tissue invasion and dissemination

S. aureus secreted proteins are involved in host tissue damage, inflammation, invasion and disruption of the host immune system in order to facilitate bacteria dissemination (Foster, 2005; Lin and Peterson, 2010; Malachowa et al., 2011). These secreted factors

can be divided into four groups: superantigens, exoenzymes, miscellaneous proteins and cytolytic (poreforming) toxins.

II.3.1 Superantigens

Superantigens (Sags) are secreted immune-stimulatory low-molecular weight (19,000 to 30,000 Da) enterotoxins involved in many human diseases, including allergy, autoimmune diseases, food poisoning and toxic shock syndrome (TSS) (Chesney et al., 1997; Parrillo, 1993; Reingold et al., 1982). These proteins are exceptionally resistant to heat, to proteolysis and acidic conditions and they are highly resistant to desiccation (Dinges et al., 2000; McCormick et al., 2001). The production of superantigens interferes with antibody production and phagocytic cell chemotaxis. Indeed, irrespective of their antigen specificity and function, Sags induce massive activation of T cells resulting in a cytokine overproduction, aggravation of allergic inflammation and shock (Xu and McCormick, 2012).

II.3.2 Exoenzymes

S. aureus secretes several extracellular enzymes whose principal goal is to disrupt host tissues, to inactivate host antimicrobial mechanisms (e.g. antibodies and complement mediators), and to produce nutrients for bacterial growth and facilitate dissemination. In the large group of exoenzymes are included lipases, proteases and staphylokinase (SAK).

Lipases are deoxyribonuclease (DNase) and fatty acid modifying enzymes that catalyze the hydrolysis of the ester bonds between glycerol and fatty acids to form triglycerides and this is believed to aid the bacteria to breakdown host tissue resulting in nutrients availability (Lu et al., 2012). Among the proteolytic enzymes produced by *S. aureus* there are the metalloproteinase (aureolysin, Aur), the serine glutamyl endopeptidase referred to as the V8 protease (serine protease, SspA) and two related cysteine proteinases, the staphopain (ScpA) and the cysteine protease (SspB) (Arvidson et al., 2000). Their deletion resulted in increased abundance of secreted and surface-associated virulence factors. Indeed, these proteases work to degrade indiscriminately both "self" and "host" proteins.

The metalloprotease, Aureolysin (Aur) is responsible for the proteolytic cleavage and activation of SspA (Drapeau, 1978) as well as for the cleavage of the surface-associated clumping factor ClfB, which protects the bacteria from phagocytosis (McAleese et al., 2001). The SspA protease, produced from a polycistronic operon with *sspB* (Reed et al., 2001), was shown to induce the cleavage of fibrinogen-binding protein (McGavin et al., 1997), of surface protein A (Spa) (Karlsson et al., 2001), and host proteins such as the heavy chain of all human immunoglobulin classes (Prokesova et al., 1992).

The secreted cysteines Staphopain A (ScpA) and Staphopain B (SspB) are known to induce cleavage of different host substrates including fibrinogen, collagen and elastin (Potempa et al., 1988). ScpA degrades fibers composed of elastin in the connective tissues, and both ScpA and SspB contribute to the turnover of collagen, the main component of the connective tissue (Potempa et al., 1988). In the bloodstream, fibrinogen cleavage by ScpA and SspB interferes with plasma clotability, resulting in a tendency to induce bleeding (Ohbayashi et al., 2011). ScpA can also inhibit neutrophil activation and chemotaxis (Laarman et al., 2012). The proteolytic susceptibility of cell-wall associated proteins such as FnBP and Protein A, both involved in adherence to host cells, could suggest that these extracellular proteases are important for the release of *S. aureus* from colonization sites to other sites of the human body. It has also been proposed that the degradation of toxins, such as α -haemolysin, induced by the proteases may downregulate *in vivo*, the virulence of *S. aureus* (Shaw et al., 2004).

Staphylokinases (SAKs) are potent extracellular prothrombin activators (Osamu Matsuo, Masashi Sakai, 2017 - (Dinges et al., 2000) able to convert human plasminogen (plg) to active plasmin (Kwiecinski et al., 2010), a serine protease with a broad-spectrum of substrates such as fibrin, collagen and elastin. Plasmin-mediated proteolysis of different extracellular substrates potentially contributes to bacterial virulence by facilitating staphylococci entry into the deeper host tissues (Bergmann and Hammerschmidt, 2007; Bhattacharya et al., 2012; Sanderson-Smith et al., 2012). The role of this factor in virulence is however controversial. Indeed, Jin *et al.* showed that staphylokinase-deficient *S. aureus* strain is more virulent compared to wild-type strain, whereas Piechowicz *et al.* did not find such a phenotype (Jin et al., 2003; Piechowicz et al., 2010).

II.3.3. Cytolytic (poreforming) toxins

Immune evasion is, to a large extent, due to cytolytic toxins which are secreted to kill immune cells, among which the most important are the bi-component leukotoxin family, α -toxin and the phenolsoluble modulins (PSM) peptides (Otto, 2014).

II 3.3.1 Leukotoxins

S. aureus strains associated with human infections produce four types of leukotoxins: the Pantone-Valentine Leukocidin (PVL), gamma (γ)-haemolysin (HlgACB), Leukotoxin ED (LukED), and Leukotoxin AB/GH (LukAB/GH). They are bi-component proteins composed of two subunits secreted separately and then assembled in hexameric or heptameric oligomers having high affinity for leukocytes. They mainly act by forming pores in the membranes of leukocytes leading to their lysis, all four leukotoxins have also been demonstrated to kill human neutrophils (Löffler et al., 2010). Moreover, the γ -haemolysin can cause the lysis of red blood cells thus promoting the survival of *S. aureus* in bloodstream (Kaneko et al., 1997; Malachowa et al., 2011).

II.3.3.2 α -haemolysin

S. aureus α -toxin (α -haemolysin, Hla) is the prototype for the class of small β -barrel pore-forming cytotoxins (PFTs) (Parker and Feil, 2005). For many years, *Staphylococcus aureus* α -toxin has been considered as the major virulence factor. Indeed, this peptide is secreted as a water soluble monomer and then oligomerized into a heptameric structure on the host cell membrane to introduce pores and to cause host cell lysis (Berube and Bubeck-Wardenburg, 2013). Following the recent identification of multiple toxin receptors, it is now understood that PFTs exert subtle changes in cell activity and host physiology even at sub-lytic concentrations. Exposure to α -toxin can cause cellular death by necrosis, apoptosis, or pyroptosis, through activation of different cellular pathways (Craven et al., 2009; Essmann et al., 2003).




Figure 2 Mechanisms by which *S. aureus* escape host innate immune defense and virulence factors regulation. The synthesis of virulence factors is under the control of sophisticated mechanisms of regulation. Two component system (green), global transcriptional regulator (black) and the Sigma B factor (Blue). Golden carotenoid pigment provides an antioxidant shield whereas catalase detoxifies hydrogen peroxide. Resistance to cationic antimicrobial peptides is afforded by positive charge modifications of the cell wall, aureolysin-mediated proteolysis, and binding/inactivation by staphylokinase. Protein A binds Fc domains of Igs in a nonopsonic manner. The pore-forming toxins g-haemolysin and Panton-Valentine leukocidin preferentially target leukocyte membranes causing their lysis. The plasminogen (PG) binding protein staphylokinase (SAK) activates the zymogen to the active protease plasmin, which can degrade complement opsonin C3b and the immunoglobulin Fc domain. (Adapted from (Nizet, 2007).

II.2.3.3 PSMs

PSMs are virtually produced by all staphylococcal species and given their crucial role in *S. aureus* pathogenicity, they have recently received large interest. In *S. aureus*, PSMs constitute a group of seven different peptides that are encoded by three different loci in the bacterial genome (Cheung et al., 2014; Wang et al., 2007) (**Figure 3**).




Figure 3 Phenol soluble modulins are small peptides expressed from three loci of the *S. aureus* genome. Phenol soluble modulins (PSMs) are encoded in two operons, the alpha (α PSM1 to 4) and beta (β PSM1 to 2) operons, and δ -toxin is embedded within the regulatory RNAIII (*hld*). (Figure adapted from (Schwartz et al., 2012).

Their coding sequences are small enough to have eluded detection by conventional gene annotation programs, and they are still poorly annotated in public databases (Wang et al., 2007). We have recently sequenced and annotated the genome of the strain HG001, a derivative of RN1 (NCT8325) strain with restored *rbsU* (a positive activator of SigB). Prokka software (Seemann, 2014), used to predict coding sequences (CDS), has failed to include the *psma* locus which has been manually added (Caldelari et al., 2017). The α -type peptides are ~20 to 25 amino acids in size and, in *S. aureus*, comprise PSM α 1-4 and the δ -toxin, which are encoded by the *psma* and *hld* loci, respectively. *S. aureus* PSM β 1 and PSM β 2 are members of the larger (~45-amino-acid) β -type PSMs and are encoded by the *psm β* locus. The *hld* gene is embedded within RNAIII, the intracellular effector of the accessory gene regulator (*agr*) system ((Novick et al., 1993), see § III). In *S. aureus*, PSM α peptides and δ -toxin are highly abundant, with δ -toxin usually more strongly expressed than PSM α probably to compensate its only moderate cytolytic capacities. Only small amounts of PSM β peptides are produced under common laboratory conditions (Cheung et al., 2010).

PSMs are responsible for the development of *S. aureus* infections, particularly in highly virulent strains. The secretion of these peptides does not occur via canonical system, such as Sec-dependent transport, but requires dedicated secretion mechanisms. The Phenol-soluble modulins transporter (Pmt), present in all staphylococcal species, was recently identified as specific PSM exporter. Pmt consists of four genes (*pmtA*, *pmtB*,

pmtC, *pmtD*), encoding an ABC transporter with two separate membrane parts (PmtB, PmtD) and two separate ATPases (PmtA, PmtC). It assists PSM transport in a specific and energy-dependent fashion (Chatterjee et al., 2013). Interestingly, the ABC is essential for bacterial survival. Indeed, its deletion leads to an abnormal accumulation of PSM toxins in the cytoplasm, resulting in growth deficiency, cellular defect and autolysis (Chatterjee and Otto, 2013). Pmt is ubiquitously present among all *Staphylococcus* species and is responsible of exporting all types of PSM peptides. Upstream of the *pmtA-D* genes is a gene predicted to encode a transcriptional regulator named PmtR. Binding of PmtR to the operator of the *pmt* promoter causes repression of the *pmt* cluster. PSMs bind to PmtR and disrupt the PmtR-*pmt* promoter complex, which enables *pmt* transcription. Thus, PSMs positively influence the expression of *pmt* to facilitate their own export (Joo et al., 2016; Joo and Otto, 2016). Moreover, Pmt act to protect *S. aureus* from the antimicrobial activity of the PSM secreted by other co-colonizing staphylococcal bacteria (Cogen et al., 2010).

Despite the fact that these toxins have different structures and different target specificity, their mechanism of action is quite similar. At low doses (nanomolar concentration), they form β -barrel pores in the cytoplasmic membranes of target cells and cause leakage of the cell's content while, when present at high doses (micromolar concentration), they have cytolytic activity. In contrast to α -toxins and bi-component leukotoxins that induce membrane pore formation by binding to specific receptors, the PSMs are believed to induce the disruption of cytoplasmic membrane in a less specific manner without receptor recognition. Most probably, the phospholipid composition and membrane charge are important for cell susceptibility to PSMs (Otto, 2015).

PSM α of *S. aureus* and *S. epidermidis*, are able to lyse human white and red blood cells (Otto, 2012). Additionally, as soluble molecules they also contribute to biofilm detachment/dissemination acting as surfactant-like peptides (Kong et al., 2006; Periasamy et al., 2012; Tsompanidou et al., 2011). This process allows the spread of the infection in other parts of the body (Periasamy et al., 2012). In contrast to this activity, it has been also demonstrated that, when polymerized into amyloid fibers, some PSMs promote biofilm stability (Schwartz et al., 2012). These PSM fibers share morphological and biophysical characteristics with functional bacterial amyloids such as curli in *Escherichia coli*, TsaA of *Bacillus subtilis*, and the Fap fimbriae in *Pseudomonas*

aeruginosa (Chapman et al., 2002; Dueholm et al., 2013; Romero et al., 2010). In this regard, the recent solved crystal structure of full-length PSM α 3 peptide, revealed a distinctive “cross- α ” amyloid-like architecture of the molecules, in which amphipathic α helices stacked perpendicular to the fibril axis into tight self-associating sheets. It was shown that the “cross- α ” fibrillation of PSM α 3 is responsible for cytotoxicity, confirming that this mode of assembly has specific functions in *S. aureus* (Tayeb-Fligelman and Landau, 2017).

In addition to chromosomally encoded PSM peptides, *S. aureus* secretes PSM-mec toxins belonging to the PSM α -type. They are encoded on a mobile antibiotic resistance cassette (SCC Staphylococcal cassette chromosome) (Chatterjee et al., 2011; Kaito et al., 2011) that influences cytolytic ability, methicillin resistance, biofilm formation, cell spreading, and the expression of other virulence factors such as other PSMs, resulting in a significant impact on *S. aureus* pathogenicity (Qin et al., 2016). The amount of secreted Psm-mec is highly variable among different MRSA strains and is strongly correlated to the level of synthesis of PSM α peptides (Chatterjee et al., 2011). The *psm-mec* RNA has been shown to alter the stability of *agrA* mRNA most probably through basepairings (Kaito et al., 2013) although these data have not been reproduced in another strain background (Cheung et al., 2014). These data suggested that *psm-mec* RNA has a dual function, acting as an antisense RNA and coding a PSM peptide. Such a dual activity has been well recognized for RNAlII, the intracellular effector of quorum sensing system, which also encodes a PSM (see § III).

III. Regulation of the expression of virulence factors

To regulate this coordinated expression of virulence factors, multiple trans-acting modulators, including regulatory proteins, secondary metabolites, small peptides, and RNAs, are brought into play (Novick and Geisinger, 2008; Wyatt et al., 2010). I will thereafter describe only several of these regulators to illustrate the complexity of the regulatory networks, which are aimed to fine tune the expression of the virulence factors in a dynamic manner according to various external and internal stimuli.

III.1 Regulation of PSM production and other virulence factors by the *agr* locus

Timing and fine regulation of virulence determinants during infection and development of acute staphylococcal disease might be achieved by putting genes involved in pathogenicity under the control of common regulators such as *agr* quorum sensing system. The *agr* locus is comprised of two adjacent units, RNAII and RNAIII (transcribed in opposite directions) that are under the control of P2 and P3 promoters, respectively. RNAII codes for a cell-density cassette, *agrD* and *agrB*, and for the bacterial two-component signal transduction system (TCS), composed of the sensor histidine kinase AgrC and its response regulator AgrA. The processing of the precursor peptide AgrD by the protease AgrB, produce an autoinducing thiolactone peptide (AIP), which is continuously released in the extracellular environment. AgrA is activated by AgrC through phosphorylation in response to a threshold concentration of the secreted AIP. In turn, the phosphorylated form of AgrA directly enhances the transcription of RNAII and RNAIII by binding to its promoter regions (Queck et al., 2008) (**Figure 4**).




Figure 4. Schematic representation of *S. aureus agr* regulatory system. The *agr* operon consists of two transcriptional units RNAII and RNAIII, driven by the promoters P2 and P3, respectively. RNAII is an operon of four genes, *agr BDCA*, encoding AgrB responsible for processing and exporting AgrD, the AIP precursor. At threshold levels of AIP, AgrC will be autophosphorylated, leading to the phosphorylation of

AgrA. AgrA activates RNAIII expression. Many RNAIII-dependent agr targets contain a series of key virulence factors such as proteases and toxins while the PSMs are regulated *via* AgrA in an RNAIII-independent way (adapted from Queck et al., 2008).

RNAIII and AgrA are the two main intracellular effectors of the *agr* system. RNAIII is composed of 14 hairpin structures, which are organized in different functional modules (Benito et al., 2000). The RNA is responsible for the regulation of the synthesis of many virulence factors. It positively affects the synthesis of several exoproteins including α -toxin, β -haemolysin, TSST-1 and leukotoxins (Morfeldt et al., 1995; Novick and Geisinger, 2008; Novick et al., 1993; Oscarsson et al., 2006), while it negatively controls the expression of several cell wall-associated proteins including protein A, coagulase (*coa*) and fibronectin binding proteins (**Figure 5**). The 5' end of RNAIII, activates the translation of α -haemolysin by disrupting the intramolecular RNA secondary structure sequestering the *hla* ribosomal binding site (Morfeldt et al., 1995; Novick et al., 1993). The RNAIII 3' domain represses the translation of several virulence factors including protein A and of the global regulator of toxins Rot through direct binding to the Shine and Dalgarno (SD) sequence of the mRNAs. The resulting complexes are composed of an imperfect duplex sequestering the SD sequence of mRNAs, and in turn prevent the formation of initiation complexes. The mRNAs bound to RNAIII are then rapidly degraded by the double-strand-specific endoribonuclease III (RNase III) (Chevalier et al., 2010). It was also demonstrated that both the 3' and 5' ends of RNAIII interact with the 5' UTR of *mgrA* mRNA preventing its degradation (Bronesky et al., 2016) (**Figure 5**).




Figure 5: Mechanism of action of RNAIII on its target mRNAs. Genomic organization of the quorum-sensing *agr* system is given at top. The schematic secondary structure of RNAIII (red) is from Benito *et al.* The *hld* gene encoding δ -haemolysin is yellow. The various C-rich sequence motifs of RNAIII are the seed sequences that bind to the Shine and Dalgarno (SD) sequence of mRNA targets (gray). Various topologies

of RNAIII-mRNA are given. Binding of RNAIII to several mRNAs (*spa*, *coa*) can prevent binding of the 30S small ribosomal subunit, and in several cases this step is followed by rapid degradation initiated by the double strand-specific endoribonuclease III (gray circle). Binding of RNAIII to target mRNAs can also activate synthesis of exotoxins. For *hla* mRNA, interaction with RNAIII prevents the formation of an inhibitory structure sequestering the SD, whereas for *mgrA* mRNA, binding of RNAIII stabilizes the mRNA against an RNase attack. In these latter cases, the seed sequences initiating basepairings between RNAIII and mRNA targets (*hla*, *mgrA*) have not yet been demonstrated. Abbreviation: AIP, autoinducing thiolactone peptide. Adapted from (Bronesky et al., 2016).

Embedded in RNAIII, there is the *hld* gene coding for the PSM δ -toxin, the haemolysin delta. In 1995, Novick and Balaban have shown that RNAIII is transcribed at the mid-exponential phase of bacterial growth, while the PSM δ -toxin starts to be synthesized during the post-exponential phase. The delay of 1 hour, between the transcription of the RNAIII and the appearance of the PSM δ -toxin, was eliminated by the deletion of the 3' non coding part of RNAIII. These data suggested the existence of unknown *trans*-acting factor that would control the expression of δ -toxin during the bacterial growth. Moreover, the RNAIII secondary structure showed basepairings between the 3' and the 5' ends of the molecule, suggesting that a conformational rearrangement is required for *hld* translation (**Figure 5**).

AgrA not only activates its own operon and RNAIII, but also the transcription of the *PSM α* , *PSM β* , and *psm-mec* (Chatterjee et al., 2011; Chatterjee et al., 2013; Queck et al., 2008). Based on these data, Queck *et al.* (2008) have suggested that the RNAIII-dependent regulatory circuits and the *agrA* quorum-sensing system have been combined during evolution in order to synchronize the cell density changes to virulence gene expression during infection. Although the regulation of PSM transcription is clearly linked to AgrA, other mechanisms for their regulation also existed.

PSMs are produced at extremely high levels in response to specific external stimuli that could be independent of the cell density, reaching ~ 60% of the total secreted protein mass in *S. aureus* (Chatterjee and Otto, 2013). The quorum-sensing system is activated only in response to sufficient concentration of AIP, however, there is faster regulation of PSM expression via intracellular signaling molecules. When internalized by leukocytes or neutrophils, *S. aureus* produces high level of (p)ppGpp which quickly activate PSM production by a non yet characterized mechanism (Geiger et al., 2012). This data suggested that both *agr*-dependent (Surewaard et al., 2012) and *agr*-independent (Geiger et al., 2012) responses co-exist to ensure immediate and continued production of PSMs, allowing *S. aureus* to escape host immune-response and to induce cell lysis. The

production of the PSM α is also positively modulated by SarA. Indeed, by down-regulating the expression of aureolysin (Aur), SarA decreases the rate of PSM degradation (Antignac et al., 2007; Zielinska et al., 2011).

III.2. Two component regulatory system SaeRS

The *sae* locus codified for SaeRS TCS regulates the expression of many virulence factors: it up-regulates α -, β - and γ - haemolysins (Goerke et al., 2005; Liang et al., 2006) and down-regulates Protein A (Giraud et al., 1997). As other typical TCSs, the signaling cascade in the SaeRS TCS starts when the histidine kinase SaeS detects environmental signals coming from human neutrophils or peptides (Geiger et al., 2008). As the consequence, SaeS autophosphorylates and transfer its phosphoryl group to SaeR that binds to SaeR binding sequence (SBS) and, in most cases, activates the transcription of the target genes (Liu et al., 2016).

III.3. The global regulator SarA

Among the global regulatory systems identified in *S. aureus*, the staphylococcal accessory regulator A (*sarA*) and its several homologues, are the most well characterized. The *sar* locus is composed of three overlapping transcripts *sarA*, *sarC*, and *sarB* originating from the P1, P3, and P2 promoters, respectively. The promoters P1 and P2 are SigA dependent, while the P3 promoter is dependent on SigB. SarA is constitutively expressed and it regulates several genes (Manna et al., 1998). By binding to a consensus motif rich in AT in the promoter regions of target genes (Novick and Jiang, 2003), SarA up-regulates the expression of some virulence factors including Fnbps (for adhesion to the host cells), α - and β -haemolysins (for tissue spread) and down-regulates other genes encoding Protein A and proteases (Chan and Foster, 1998; Cheung et al., 1994).

Several SarA homologues have been identified, and all of them contribute to modulate the *agr* system (**Figure 2**; (Cheung et al., 2008)). SarR is involved in the inhibition of SarA and in the regulation of several virulence factors during the exponential and stationary phases of growth (Manna and Cheung, 2001; Manna and Cheung, 2006). SarS

is a DNA binding protein involved in the activation of transcription of *spa* during the exponential phase of bacterial growth (Cheung et al., 2004). SarT activates the expression of SarS while it inhibits the α -haemolysin. The transcription of this factor is also repressed by SarA and AgrA (Cheung et al., 2001). SarU is repressed by SarT, it activates the *agr* operon. In contrast, SarX represses the *agr* operon when activated by MgrA (Manna and Cheung, 2006). MgrA, which activates the *agr* operon, is repressed by SarS. MgrA works as a multiple gene regulator, which inhibits the synthesis of several secreted proteases (Ingavale et al., 2005; Luong et al., 2003). SarZ activates the *agr* operon and the expression of SspA, while it represses SarS. Upon its MgrA-dependent activation, it regulates important genes involved in biofilm formation (Tamber and Cheung, 2009). Finally, the global regulator Rot negatively affects the transcription of numerous factors including lipase, haemolysins, proteases, while positively regulates many other genes including cell surface adhesins. It acts as an antagonist of *agr* which represses its synthesis during the stationary phase of bacterial growth (McNamara et al., 2000; Said-Salim et al., 2003).

III.4. *S. aureus* sigma factors

The regulation of virulence factors is also mediated by sigma factors (σ), which bind to the core RNA polymerase to form the holoenzyme able to recognize specific promoters (Palma and Cheung, 2001). *S. aureus* have four sigma factors (σ^A , σ^B , σ^S , σ^H). σ^A is responsible for the expression of housekeeping genes essential for growth (Deora et al., 1997). σ^B regulates the expression of genes involved in several cellular functions such as stress responses (Deora and Misra, 1996) and in virulence (Bischoff et al., 2001; Horsburgh et al., 2002). It up-regulates FnbpA and the coagulase (CoA), and downregulates haemolysins and serine protease A (Bischoff et al., 2004; Entenza et al., 2005). However, the effect of σ^B on virulence might result via the regulation of transcriptional factors such as *sarA*, *sarS*, and *rot*. It has also been shown to be involved in antibiotic resistance, biofilm formation and in bacterial internalization into host cells (Nair et al., 2003; Rachid et al., 2000). σ^H has been demonstrated as a key actor for competence development (Morikawa et al., 2012). The factor also modulates prophage integration and excision through the regulation of the integrase expression (Tao et al.,

2010). For the last Sigma factor σ^S , its regulon is still not yet defined but high levels of the factor were observed in cells grown in the presence of serum. Its inactivation decreased the fitness of *S. aureus* at high temperature, and the infectivity of the mutant strain was altered in a murine model of septic arthritis (Miller et al., 2012; Peton et al., 2016).

IV. Antibiotic resistances in *Staphylococcus aureus*

S. aureus is able to invade and survive within neutrophils and macrophages, leading to its incomplete clearance even in the presence of high levels of antibiotics. The introduction of penicillin in the early 1940s positively influenced the prognosis of patients with staphylococcal infections. However, few years later, penicillin-resistant staphylococci were recognized, first in the hospitals and then in the community. The resistance to penicillin is mediated by *blaZ*, the gene that encodes β -lactamase. This predominantly extracellular enzyme, synthesized when staphylococci are exposed to β -lactam antibiotics, hydrolyzes the β -lactam ring of penicillin deactivating the antibacterial properties of the molecule (Chambers and Deleo, 2009; Lowy, 2003). With the emergence of resistance to the penicillins, a semi-synthetic antibiotic methicillin, which is derived from penicillin but resistant to β -lactamase inactivation, became the molecule of choice for the treatment *S. aureus* infections. However, immediately after its introduction, methicillin-resistant (MRSA) bacteria were isolated (Jevons, 1961). The gene responsible for methicillin resistance is named *mecA*, it is located on a mobile genetic element known as *mec* element (SSCmec) (Chambers, H. F. 1997) that serves as a vehicle for gene exchange among staphylococcal species (Hacker et al., 2004). *MecA* is responsible for synthesis of the penicillin-binding protein 2a (PBP2a), a membrane-bound enzyme located at the membrane-cell wall interface and involved in the peptidoglycan synthesis (Ghuysen, 1994). PBP2a substitutes for other PBSPs and, given its low affinity for all β -lactam antibiotics, allows staphylococci to survive even in the presence of high concentrations of this drug. Under the pressure of intensive emerging antibiotic resistant strains, the last remaining antibiotic to which MRSA strains were susceptible was the vancomycin, able to inhibit *S. aureus* cell wall. The reduced susceptibility to vancomycin was due to the synthesis of an unusually cell wall containing dipeptides (D-Ala-D-Ala) capable of binding the antibiotic, sequestering it

and thereby reducing availability of the drug for intracellular target molecules. Fortunately, these resistant strains did not spread substantially, possibly due to increased fitness cost. The ability of *S. aureus* to develop resistance to antibiotic treatments is dynamic and has changed significantly over the years. It could virtually acquire resistance against all antimicrobial agents available in hospitals and communities (DeLeo et al., 2010). Hence, the reengineering of existing antibiotics and the synthesis of new therapeutic alternatives are urgently needed.

V. Translation and its control in *S. aureus*

V.1. Translation initiation, a check point for regulation

The above described orchestration of *S. aureus* virulence demonstrates the ability that bacteria have to rapidly sense their environment and constantly adapt their physiology in response to its variations. Several extracellular and intracellular signals (e.g. the quorum sensing peptide described for the *agr* system) are detected and associated to multi-step regulations at the transcriptional and post-transcriptional levels, which contribute to reprogramming the bacterial proteome. Among the different regulatory mechanisms, translational control can ensure a rapid and transient. The RNAIII-directed translational silencing or activation mechanisms represent a typical example of how protein synthesis could be regulated. In the vast majority of the cases, changes in translational efficiency are the result of a modulation of its initiation process (Romby, 2007) during which the ribosome assembles on the mRNA in the order of seconds (Gold, 1988; Kennell and Riezman, 1977). This slow, rate-limiting step of protein synthesis provides the time window necessary for regulation between mRNA transcription and active translation or mRNA degradation. Even if in bacteria, transcription, translation and mRNA degradation are interconnected processes and often coupled (Burmann et al., 2010; Campos and Jacobs-Wagner, 2013; Das et al., 1967; Mehdi and Yudkin, 1967; Proshkin et al., 2010; Shin and Moldave, 1966; Stent, 1964), large 5' and 3' Untranslated Regions (5'UTR, 3'UTR) which are often structured, strongly impact translation initiation and are therefore target of several regulatory mechanisms (Geissmann et al., 2009b; Marzi et al., 2008a; Ruiz de los Mozos et al., 2013). Bacterial translation initiation is a highly conserved process, but some differences and specific features among distant bacteria have been observed. This is the case of the Gram-negative bacterium *Escherichia coli* and the Gram-positive low G+C content *S. aureus* which have diverged more than 10 million years ago.

I will thereafter describe the details of the bacterial initiation process mainly derived from studies on Gram-negative bacteria and will illustrate some structural differences between *E. coli* and *S. aureus* ribosomes. The description of the main functional differences between the initiation processes is included in the joined review "A glimpse on *Staphylococcus aureus* translation machinery and its control" (Khusainov et al., 2016) where I am second author.

V.2. A view on the Translation Initiation in Gram-negative bacteria

In contrast to eukaryotes and archaea (for reviews see (Londei, 2005; Pestova et al., 2007)), the initiation process in bacteria involves a rather low number of *trans*-acting factors. Three initiation factors (IF1, IF2, IF3) kinetically assist the formation of the translation initiation complex, with the 30S small ribosomal subunit, the aminoacylated and formylated initiator tRNA (fMet-tRNA^{fMet}) and the mRNA (**Figure 6**; (Simonetti et al., 2008)). The three factors have no direct influence on the recruitment of the mRNA (Milon et al., 2012) but exert specific functions. IF3 acts as “fidelity factor”. It helps in the selection of initiator tRNA (fMet-tRNA^{fMet}) by destabilizing the binding of other tRNAs in the P site of the ribosome (Hartz et al., 1990; Milon et al., 2012). It is also known to strongly anchor the 30S subunit preventing the association with the large ribosomal subunit so to maintain a cellular pool of 30S for translation initiation (Grigoriadou et al., 2007). IF2 is a GTPase factor that binds specifically to fMet-tRNA^{fMet} and correctly positions it on the 30S to favour the 50S joining (Simonetti et al., 2013; Simonetti et al., 2008). IF1, the smallest of the three initiation factors, binds to the A site of the 30S ribosomal subunit (Carter et al., 2001) where physically it prevents tRNA binding and prepares the P site for fMet-tRNA^{fMet} binding. The formation of the “30S initiation complex” (30SIC) takes place at the Ribosome Binding Site (RBS) of the mRNA. The mRNA stably binds the 30S *via* its Shine-Dalgarno sequence (SD) complementary to the anti SD (aSD) sequence at the 3’ end of the 16S rRNA (Hui and de Boer, 1987; Jacob et al., 1987; Shine and Dalgarno, 1974). For many bacterial mRNAs, the selection of the correct start codon (usually AUG) depends largely on the formation of this short SD-aSD helix. Once the 30SIC complex is formed, the translational reading frame is set and protein synthesis can start. During the following steps of translation initiation, the joining of the large ribosomal subunit (50S) to the 30SIC leads to the formation of the “70S initiation complex” (70SIC; made by the small and the large ribosomal subunits, the fMet-tRNA^{fMet} and the mRNA), ready for the first peptide bond formation. During this transition, the adjustment of fMet-tRNA^{fMet} in the ribosomal P-site and the release of all factors are coupled with the hydrolysis of the GTP molecule bound to IF2 (Allen et al., 2005; Myasnikov et al., 2005; Simonetti et al., 2008). The formation of the correct 70SIC marks the irreversible transition to the elongation phase.

The binding of the mRNA to the 30S subunit is one of the most critical steps of translation initiation and the target of the majority of known translation regulations. It takes place into two sequential steps, first the localization on the platform of the 30S to form the 30S pre-initiation complex, and then the accommodation into the mRNA channel (Figure 6).




Figure 6. A schematic view of the initiation process of translation and its regulation in *Escherichia coli*. Three initiation factors (IF3 in light blue, IF1 in blue and IF2 in green) bind to the 30S subunit (in orange). The platform binding center is in red with the anti-SD (aSD) sequence in cyan. Structured mRNA binds to 30S in two distinct steps: the docking of the mRNA on the platform of the 30S subunit is followed by the accommodation of the mRNA into the normal path to promote the codon-anticodon interaction in the P site. These two steps are submitted to tight control, through the alternative competition and entrapment mechanisms. Numbers refer to: 1) the cellular pool of initiating 30S subunits bound to IF3; 2) 30S pre-Initiation Complex refers to the docking step of the structured mRNA; 3) 30S Initiation Complex refers to the active complex in which the mRNA is accommodated into the normal path forming the codon-anticodon interaction; 4) 70S Initiation Complex, the 50S subunit (in brown) joins the 30S Initiation Complex to proceed protein synthesis. The scheme is derived from (Marzi et al., 2008b). At the bottom, the different domains of the 30S subunit, the mRNA channel and the aSD sequence are given.

V.2.1. *E. coli* r-protein S1, an RNA chaperone associated with the ribosome for structured mRNA translation

E. coli S1 is an atypical ribosomal protein: S1 is the largest (61KDa) protein of the 30S subunit, is among the ribosomal proteins with documented high affinity for numerous mRNAs (Draper et al., 1977), is the most acidic (pI= 4.7) r-protein (Kaltschmidt and Wittmann, 1970), it is the last protein to associate on the 30S and its interaction with the 30S is weak and reversible. *EcoS1* is essential for growth and its functional relevance is related to its ability to simultaneously bind mRNAs and the ribosome. Indeed, S1 mediates initiation of translation by binding the 5' UTR of mRNAs, thus increasing their affinity for the ribosome up to 5000 fold (Draper and von Hippel, 1979; Katunin et al., 1980). This is especially evident for weak SD-containing mRNAs, which necessitate S1 to be stabilized on the 30S (Komarova et al., 2005). In *E. coli*, S1 is also responsible of the accommodation of the mRNA in the 30S decoding channel, a slow process essential for the translation of structured mRNAs (Duval et al., 2013b).

EcoS1 is composed of 6 OB fold domains (**Figure 7**): the first two domains, d1 and d2, are essential for 30S subunit binding, while the domains d3 and d4 together with d1 and d2 form the minimal protein that recognize mRNAs and allow their accommodation into the decoding channel (Duval et al., 2013b; Duval et al., 2017). The last two C-terminal domains are dispensable and have regulatory functions related to RNA maturation/degradation (unpublished data from the laboratory).




Figure 7. Modelled structure of *E. coli* S1. Domain 1 in light blue, domain 2 in dark blue, domain 3 in green, domain 4 in yellow, domain 5 in orange and domain 6 in red. Model realized by Stefano Marzi.

To date, X-ray and/or Cryo-EM ribosomal structures of Gram-negative bacteria such as *E. coli* and *Thermus Thermophilus*, have failed to visualize S1. In this regard, it has to be considered that the purification of ribosomes for X-ray studies involves a step of deliberate removal of S1 in order to increase the homogeneity of the ribosomes and to obtain better diffracting crystals (Schuwirth et al., 2005; Yusupov et al., 2001), while Cryo-EM investigations might be not suitable for a highly dynamic protein due to the averaging of different conformations. Recently, the S1 N-terminal domain (d1) was

nevertheless observed by Cryo-EM interacting *via* a zinc binding pocket to the ribosomal protein S2 on the 30S platform (Byrgazov et al., 2015). Crosslinking experiments in combination with high resolution mass spectrometry analysis have also placed S1 in the same region on the ribosome (Lauber et al., 2012). The platform between the head and the body of the 30S (**Figure 8**) is thus formed by S1 and several other r-proteins (S2, S7, S11, S18 and S21) together with two rRNA helices (h26 and h40) that are surrounding the aSD close to one extremity of the decoding channel. Since both r-protein S1 and the aSD are on the platform, we can imagine that several mRNAs would transit on this site before getting into the mRNA decoding channel. A systematic structure and sequence analysis revealed that conserved residues of the r-proteins of the platform form patches of positive charges on its surface that could localize folded mRNA regardless of their specific structure or sequence (Marzi et al., 2007). Interestingly, it has been observed that even sequences that have low propensity to form structures, like poly(A) or poly(U), get folded into compact structures similar to hairpins close to r-protein S2 (Yusupova et al., 2006) (**Figure 8**).





Figure 8. The platform of the 30S. On the left, view of the 30S subunit showing the localization of the platform. On the right, enlarged and rotated view of the platform showing the charge distribution of the r-proteins composing it. S2, S7, S11, S18 and S21 are forming a nest of positive charges (blue surfaces) around the aSD. Negatively charged amino acids are represented in red. The mRNA (green) is shown accommodated into the decoding channel. The model in the figure has been obtained using the coordinates of *E. coli* ribosome (pdb file 4TP8) which contains all the r-proteins of the platform but S1 and the mRNA pathway described in the *T. thermophilus* translation initiation complex (pdb file 4HGR).

V.3. *S. aureus* ribosome structure and specific features

The structures of the bacterial 70S ribosomes have been extensively studied in Gram-negative bacteria such as *E. coli* (e.g. (Schuwirth et al., 2005; Noeske et al., 2015)) and *T. thermophilus* (e.g. (Yusupov et al., 2001; Yusupova et al., 2001)), but have received little attention in Gram-positive bacteria (Beckert et al., 2015; Eyal et al., 2015; Sohmen et al., 2015). Recently, structures of *S. aureus* large ribosomal 50S subunit bound to specific antibiotics (Eyal et al., 2015) and of the whole 70S (Khusainov et al., 2017) have shed light on some features specific to *S. aureus*.

Concerning the 30S platform, two main differences could be spotted. The most evident is the absence of ribosomal protein S1 (**Figure 9**), which slightly changes the charge distribution of the two platforms, making more positive the one from *S. aureus* in the region which is close to the 3' end of the 16S rRNA (aSD) and the h26. The second difference is in the length of h26, which is incremental when going from *T. thermophilus* (19 nt) through *E. coli* (25 nt), *B. subtilis* (26 nt) to *S. aureus* (27 nt). Such variations at a strategic ribosomal region could reflect species-specific involvement of h26 in translation initiation and regulation.



Byrgazov et al., NAR 2015

Khusainov et al., NAR 2017

Figure 9. *E. coli* and *S. aureus* 30S platform. On the left, *E. coli* platform as in figure 10, with the exception that the structure used here contains also d1 (Byrgazov et al., 2015). On the right, charge distribution of the r-proteins from *S. aureus* 70S structure (Khusainov et al., 2017). The charge distribution is similar in the two structures, but the absence of S1 increases even more the positively rich environment surrounding the aSD, which also appears shifted toward h26 in *S. aureus* structure.

V.3.1. *S. aureus* protein S1, a shorter protein not associated with the ribosome

S1 is found in almost all Gram-negative and in several Gram-positive bacteria. A shorter form (45 kDa) exists in chloroplasts, but is absent in eukaryotic cells. Phylogenetic studies have indicated that S1 from low G+C Gram-positive bacteria (Firmicutes), such as *B. subtilis* and *S. aureus*, would not contain the ribosome binding domain d1 (Salah et al., 2009) (**Figure 10**).




Figure 10. Schematic representation of the organization of protein S1 in different bacteria. Colors have been attributed for conserved domains: domain 1 in blue, domain 2 in green, domain 3 in yellow, as domains 4/5 in orange and domain 6 in magenta. The OB fold domains, which could not be assigned to any *E. coli* domain are in white. The domains not identified as OB fold domains are in deep blue. The figure is adapted from (Salah et al., 2009).

Indeed, after purification of *S. aureus* 30S and 70S ribosomes (Fechter et al., 2009), only traces of r-protein S1 were observed by mass spectrometry analysis, suggesting that the protein is not tightly associated with the ribosome (Khusainov et al., 2016). It was

previously demonstrated that *B. subtilis* S1 plays no major role in translation and is not an essential protein (Farwell et al., 1992; Juhas et al., 2014; Vellanoweth and Rabinowitz, 1992). It was thus proposed that Firmicutes obviate the need of S1 acting on the 30S because the majority of mRNAs carry short 5' UTRs with strong SD sequences (Omotajo et al., 2015). However in *S. aureus*, numerous mRNAs carrying long 5' or 3' UTRs have been reported (Anderson et al., 2006; Lasa et al., 2011; Ruiz de los Mozos et al., 2013). They include mRNAs encoding virulence determinants, various transcriptional regulators, and metabolic enzymes. How does *S. aureus* ribosome translate them is one of the key question that I have addressed during my PhD project.

In the following review paper, using toe-printing assays, we have monitored the behavior of isolated *S. aureus* 30S and 70S ribosomes and compared them with *E. coli* ribosomes containing or not S1. Different mRNAs have been used in which the SDs were exposed in loops or shaded into hairpins, demonstrating that *S. aureus* 30S, as the *E. coli* S1-depleted 30S, could not efficiently bind to structured mRNAs.

V.4. A glimpse on Staphylococcus aureus translation machinery and its control

Khusainov Iskander, Marena Alessandra, Cerciat Marie, Fechter Pierre, Hashem Yaser, Marzi Stefano, Romby Pascale, Yusupova Gulnara & Yusupov Marat

My contribution to the work presented in this review was related to the characterization of *S. aureus* ribosome. Mass-spectrometry analysis of purified 70S has shown the absence of *SauS1*. By gel filtration assay I have demonstrated the inability of the protein to assemble on the 30S ribosomal subunit.

I also contributed to the discussion of the results with all the authors and I have participated to the final writing of the manuscript.

REVIEWS

UDC 577.217.34

A Glimpse on *Staphylococcus aureus* Translation Machinery and Its Control¹

I. Khusainov^{a, b}, A. Marennac, M. Cerciat^a, P. Fechter^{c, 2}, Y. Hashem^c,
S. Marzi^{c, *}, P. Romby^{c, **}, G. Yusupova^a, and M. Yusupov^{a, b, **}

^aIGBMC (Institute of Genetics and of Molecular and Cellular Biology), Department of Structural Biology and Genomics, Illkirch, F-67404 France; Inserm, U596, Illkirch, F-67400 France; CNRS, UMR7104, Illkirch, F-67400 France; Université Louis Pasteur, Strasbourg, F-67000 France

^bInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kremlyovskaya St. 18, Kazan, 420008 Russia

^cArchitecture et Réactivité de l'ARN, Université de Strasbourg, CNRS, IBMC, 15 Rue René Descartes, 67084 Strasbourg, France

e-mail: *p.romby@ibmc-cnrs.unistra.fr; **marat@igbmc.fr

Received February 23, 2016; in final form, February 23, 2016

Abstract—*Staphylococcus aureus* is a major opportunistic and versatile pathogen. Because the bacteria rapidly evolve multi-resistances towards antibiotics, there is an urgent need to find novel targets and alternative strategies to cure bacterial infections. Here, we provide a brief overview on the knowledge acquired on *S. aureus* ribosomes, which is one of the major antibiotic targets. We will show that subtle differences exist between the translation at the initiation step of Gram-negative and Gram-positive bacteria although their ribosomes display a remarkable degree of resemblance. In addition, we will illustrate using specific examples the diversity of mechanisms controlling translation initiation in *S. aureus* that contribute to shape the expression of the virulence factors in a temporal and dynamic manner.

Keywords: *Staphylococcus aureus*, quorum sensing, regulatory RNAs, post-transcriptional regulation

DOI: 10.1134/S002689331604004X

INTRODUCTION

Protein synthesis is an essential process across all domains of life, which is carried out by the ribosome. Although the ribosome is universally conserved machinery, significant differences were found in the composition of the ribosomal proteins, in extension/reduction of rRNA regions, and in the associated factors between eubacteria, archaea, eukaryotes and their organelles [1–6]. Due to its essential function, the ribosome represents one of the main antibiotic targets [7, 8]. Extensive biochemical and structural studies have now revealed the molecular mechanisms of numerous antibacterial drugs acting directly on the ribosome functioning [8]. Intriguingly, the vast majority of antibiotics act to interfere with the elongation step of protein synthesis while only a few of them interfere with the initiation step [8]. Because initiation of translation and primarily the mRNA recruitment diverge significantly in the three kingdoms of life (reviewed in [9, 10]), these differences could be potentially exploited for drug design against major human pathogens.

The structures of the bacterial 70S ribosomes have been extensively studied in Gram-negative bacteria such as *Escherichia coli* [11, 12] and *Thermus thermophilus* [13, 14], but have received little attention in Gram-positive bacteria [15–17]. *Staphylococcus aureus* is a Gram-positive bacterium that is recognized as a major human opportunistic and versatile pathogen, which causes a large spectrum of infections [18]. Importantly, methicillin-resistant strains (MRSA) are now widespread and are responsible for severe infections in the community as well as in the hospital [19], and strains resistant to vancomycin have also emerged [20, 21]. A recent study shows that MRSA isolates spontaneously diversify into distinct strains that evolve new antibiotic resistance via competition between bacterial cells within a monoclonal population [22]. A monoclonal population of cells is thus heterogeneous due to the fact that the bacteria should constantly compete for space and acquisition of nutrients [23]. Hence, there is an urgent need to develop alternative anti-bacterial strategies [24–26] but also to better understand the mechanisms leading to the bacterial genetic variation [27].

The recent structure of *S. aureus* large ribosomal 50S subunit bound to specific antibiotics shed light on their mechanism of action and highlight peripheral

¹ The article is published in the original.

² Present address: UMR 7242, 300 boulevard Sébastien Brant, 67412 Illkirch cedex, France.

motifs specific to *S. aureus* [16]. Furthermore, significant differences in ribosome functioning have been described between low GC content Gram-positive and Gram-negative bacteria [28–32]. The present review will be focus on specific characteristics of the translation initiation in *S. aureus*. In addition, we will illustrate the diversity of mechanisms regulating the recruitment of the ribosomes on the mRNAs that have a direct functional impact on bacterial pathogenesis.

REGULATION OF *S. aureus* TRANSLATION INITIATION

S. aureus has developed numerous mechanisms to respond to changing environments and to colonize nearly all niches within a host. Such amazing adaptation is accompanied by a significant remodeling of gene expression and particularly of the virulence determinants mainly driven by transcriptional regulatory proteins [33]. Besides, it is now well admitted that protein-mediated transcriptional control and RNA/protein-mediated translational control are intertwined. Genome-wide studies have discovered a high number of large and small RNAs, which selectively bind to mRNA targets to regulate primarily translation initiation (for reviews [34, 35]). In addition, the discovery of overlapping operons led to the hypothesis that widespread antisense transcription would significantly impact gene regulation at the translational and post-transcriptional levels [36]. Other mRNAs are characterized by large 5' and 3' untranslated regions (UTR) which contain specific structures or sequence signatures that modify the genetic response at the translational level. Hence, a high diversity of mechanisms at the translational level has been evidenced as illustrated by several examples below.

Trans-acting regulatory RNAs. The first *S. aureus* regulatory RNA has been discovered by Novick et al. [37] as the main intracellular effectors of the quorum sensing *agr* system. *S. aureus* produces a battery of virulence factors that are responsible for defense against the host immune response, adhesion, invasion, acquisition of novel nutrients, and dissemination in host tissues [38, 39]. The *agr* system is pivotal for the temporal regulation of two sets of virulence factors, adhesins and exotoxins. It is composed of two divergent transcripts, RNAII encodes a quorum sensing cassette (AgrBD) and a two-component system (AgrAC) while RNAIII is the multifunctional RNA, which encodes a PSM δ -hemolysin (*hld*). Besides its coding capacity, RNAIII promotes the switch between the expression of surface proteins and the synthesis of excreted toxins [35]. These regulatory properties are endowed within the non-coding parts of RNAIII, which primarily act as antisense RNA to activate or repress the translation of target mRNAs. On one hand, its 5'UTR binds to the leader region of *hla* mRNA encoding α -hemolysin to prevent the formation of an inhibitory structure in order to facilitate ribosome recruitment [40] (Fig. 1a).

In addition, the 5' and 3' ends of RNAIII both interact with the leader of *mgrA* mRNA to enhance the mRNA stability [41]. On the other hand, its large 3'UTR is primarily acting as a repressor domain (Fig. 1a). This domain is the most highly conserved domain of RNAIII, which contains four C-rich sequence repeats located in unpaired regions [42]. This sequence motif acts as a seed sequence, which initiates basepairing interactions with the Shine and Dalgarno (SD) sequence of target mRNAs (Fig. 1a). The initial GC-rich pairings confer a fast association rate constant for the formation of the complex, and in general are subsequently propagated either to form long duplexes or are stabilized by additional distant pairings according to the mRNA signals (Fig. 1a) [43]. However, in all cases binding of RNAIII prevents the loading of the ribosome and the formation of the initiation complex. These mRNAs encode virulence factors expressed at the surface of the cell (protein A, coagulase, SA1000, Sbi), and the transcriptional repressor of toxins, Rot [43–47]. Through the inhibition of Rot translation, RNAIII indirectly activates the transcription of exotoxins. Such regulatory circuits create a temporal delay between the repression of adhesin synthesis and the induction of exotoxin production enabling an effective transition of the pathogen for spreading and dissemination [48].

Later on, the search for small non-coding RNAs (sRNAs) has revealed the existence of a class of sRNAs carrying unpaired C-rich sequence motif similar to RNAIII [50, 52, 53]. Determination of the functions of several sRNAs demonstrated that this sequence motif is indeed a characteristic signature for translational repressors. For instance, the SigB-dependent RsaA sRNA represses translation initiation of the global transcriptional regulator MgrA through a sequestration of the SD sequence in a manner similar to RNAIII [49] (Fig. 1a). Through MgrA regulation, RsaA attenuates the severity of systemic infections and enhances chronic infection [49]. Another example is *S. aureus* RsaE which represses at the translational level mRNAs involved in the TCA cycle under specific conditions of stresses, NO induction, and when carbon sources are decreasing [50, 53, 54]. In both cases, an unpaired C-rich motif binds to the SD sequence of the mRNAs. Because many mRNAs in Gram-positive bacteria have a strong SD sequence (AGGAGG) and a rather short 5'UTR, targeting the SD is a rapid way to prevent the recruitment of the ribosome and to arrest translation even during the transcription process. However, these examples also demonstrate that additional basepairing interactions outside the SD region are required to ensure a specific response.

Cis-acting regulatory RNAs. In *S. aureus*, UTRs of mRNAs are generally of small size, but exceptions of mRNAs carrying large 5' or 3'UTRs have been reported [51, 55, 56]. They include mRNAs encoding virulence determinants, various transcriptional regulators, and metabolic enzymes. Large 5'UTRs are




Fig. 1. Mechanisms regulating translation initiation. (a) Examples of *trans*-acting RNAs acting as antisense RNAs. *S. aureus* RNAIII binds to the 5'UTR of *hla* mRNA to prevent the formation of basepairings sequestering the Shine and Dalgarno (SD) sequence, and to favor the ribosome recruitment [40]. Two C-rich motifs of RNAIII bind to two hairpin loops of *rot* mRNA; one of them includes the SD sequence, to form two loop-loop interactions that prevent ribosome binding [43, 45]. The small non coding RNA, RsaA, binds to the SD sequence via its C-rich motif to repress the translation of *mgrA* mRNA. In both cases, the repression of translation is subsequently followed by RNase III degradation [49]. (b) Example of a *cis*-acting regulatory riboswitch responding to flavin mononucleotide (FMN) intracellular concentration. Binding of FMN in the left formed by the compact structure of the aptamer domain led to the stabilization of a hairpin structure sequestering the SD sequence to repress translation initiation of the downstream gene SA1316 [50]. (c) Example of a long-distance interaction affecting in *cis* the translation of *icaR* mRNA. A C-rich motif in the 3'UTR of *icaR* mRNA binds to the SD sequence to prevent translation, and creates a structure suitable for RNase III cleavages [51].

often the reservoirs of regulatory signals such as the riboswitches, which are direct sensors for intracellular metabolite concentrations [57]. Riboswitch consists of a sensor/aptamer domain containing a binding pocket specific for a dedicated metabolite and of an expression platform controlling the downstream transcripts. At least seven *S. aureus* operons are under the control of riboswitches that respond to the intracellular concentrations of S-adenosylmethionine (SAM), thiamine pyrophosphate (TPP), flavin mononucleotide (FMN), lysine, glycine, guanine, 7-aminomethyl-7-deazaguanine (preQ1), and glucosamine-6-phosphate (Glc-6P) [50, 58]. Most of them are regulated through a premature transcription arrest [52], while only one FMN-sensing riboswitch is expected to control the translation of a hypothetical protein. Binding

of FMN to the aptamer domain is predicted to stabilize the formation of a hairpin structure sequestering the SD sequence (Fig. 1b). Because many of these riboswitches regulate the synthesis of essential proteins involved in amino acid biosynthesis, as well as co-factors and nucleotide biosynthesis, they were used as targets for the design of drugs that could constitutively repress the synthesis of essential enzymes [59, 60]. For instance, a pyrimidine derivative compound PC1 binds to the *S. aureus* guanine riboswitch to constitutively repress the expression of *guaA*. This compound showed bactericidal activity against *S. aureus* and significantly reduced mammary gland infection in mice [61]. This compound was more recently assayed to treat bovine intra-mammary infections [62]. Although a significant reduction in bacterial concen-

trations was observed in the milk after PC1 treatment, the clearance of the bacterial was not completely achieved. However, these studies show that ribo-switches are still promising drug targets for the search of novel classes of antibiotics.

In contrast to the 5'UTRs, large 3'UTRs have been underestimated [51, 56, 63]. Recent findings have revealed the importance of a long 3'UTR in *icaR* mRNA, which encodes a transcriptional repressor of biofilm formation. IcaR controls the transcription of the operon *icaADBC* required for the synthesis of the main exopolysaccharidic polymer PIA-PNAG, a major component of the biofilm matrix. Surprisingly, the 390 nt-long 3'UTR of *icaR* appears to be a negative determinant for the translation initiation of its own mRNA (Fig. 1c). The 3'UTR contains a C-rich sequence motif that binds to the SD sequence to prevent ribosome binding, and subsequently recruits RNase III for cleavage [51]. Disrupting this interaction resulted in the accumulation of IcaR and inhibited biofilm formation. This study shows that the 3'UTR can act in *cis* to block the ribosome binding site in the 5'UTR by a mechanism that is reminiscent of RNAIII and other *trans*-acting sRNAs from *S. aureus* (Fig. 1c). A significant number of mRNAs carrying large 3'UTRs have been recently mapped suggesting that the circularization of mRNA is not so uncommon in bacteria. In addition, these regions might also contain specific binding sites for *trans*-acting factors modifying the mRNA stability or translatability, or can also be the reservoir of small regulatory RNAs as recently demonstrated in *Salmonella typhimurium* [64].

These examples demonstrate the importance of the translation regulation for the physiology of *S. aureus*. Analyzing the translational control on a global scale in *S. aureus* in response to the host and *vice versa* [65] will certainly open new horizons and insights into the pathogenesis, persistence of the bacteria within the host, and evolution of the strains.

SPECIFIC FEATURES OF *S. aureus* TRANSLATION INITIATION

Translation initiation is the rate-limiting step of protein synthesis [66]. This is probably why many regulatory events modulate the mRNA binding to the 30S ribosomal subunit [67–69] (Fig. 1). The initiation process of bacteria requires three initiation factors, IF1, IF2 and IF3, which in addition of the mRNA, and the initiator fMet-tRNA^{fMet}, assembled in a multi-step process on 30S to form an active initiation complex [66]. The efficiency of mRNA binding to 30S is independent of the initiation factors and relies solely on specific signatures present on the mRNAs such as the presence of SD sequence (GGAGG), the nature of the initiation codon, the distance between the initiation codon and the SD, the presence or not of structured motif within the mRNA track [70, 71]. Although this process is conserved among bacteria, significant

differences have been observed between Gram-negative bacteria (*E. coli*) and low GC content Gram-positive bacteria such as *Bacillus subtilis* and *S. aureus*. Some of these features are described below.

Different mRNA binding properties of the 30S from low GC content Gram-positive and Gram-negative bacteria. In bacteria, the mRNA is recruited at a strategic position at the exit site of the 30S subunit surrounded by several key ribosomal proteins (r-proteins): S1, S2, S7, S11, S18 and S21 [66, 69]. Among these r-proteins, the largest r-protein S1 in *E. coli* with its six OB-fold (oligonucleotide/oligosaccharide-binding fold) domains confers to the 30S the ability to recognize any type of mRNAs [72–75]. Particularly, S1 has been shown to compensate the lack of a strong SD in many mRNAs, and to confer an RNA chaperone activity to the 30S that is essential for the unfolding of structured mRNAs in order to accommodate the initiation codon into the P-site. In *E. coli*, the essential activity of S1 is linked to its association with the 30S via its N-terminal OB-fold domain [75–77]. A phylogenetic study revealed that S1 from Gram-negative bacteria and high GC content Gram-positive bacteria (*Micrococcus*) contained at least the first four OB-fold domains that retained full 30S and RNA binding capacity, and the RNA chaperone activity [29, 75]. Interestingly, it has been shown that *Micrococcus luteus* S1 was able to substitute *E. coli* S1 on the 30S [28]. In contrast, S1 from low GC content Gram-positive bacteria, which contained only four OB-fold domains, has lost the N-terminal domain that was shown to promote specific binding with S2 on *E. coli* 30S [78]. This probably explained why *B. subtilis* S1 plays no major role in translation [28, 79]. Indeed, *B. subtilis* ribosomes have similar properties than S1-depleted *E. coli* ribosomes which have lost their abilities to translate mRNAs with no or weak SD sequence. Addition of S1 from *E. coli* or from *M. luteus* to the S1-depleted *E. coli* ribosomes restored the 30S properties to translate mRNAs bearing weak SD but these proteins had no effect on *B. subtilis* ribosomes [28, 79]. Another characteristic of *B. subtilis* ribosomes is the greater tolerance for the non-AUG initiation codons than *E. coli* ribosome but the presence of a strong SD significantly enhanced the capacity of *E. coli* ribosomes to utilize non-AUG codons [79]. It was thus proposed that firmicutes obviate the need of S1 acting on the 30S because the majority of mRNAs carry a strong SD sequence [80].

Because S1 is very similar in *B. subtilis* and *S. aureus* [29], we have analyzed the ability of *S. aureus* 30S subunits to form initiation complexes using various *S. aureus* mRNA substrates (Figs. 2, 3).

After purification of the 30S and 70S ribosomes [81], only traces of r-protein S1 were observed by mass spectrometry analysis suggesting that the protein is not tightly associated with the ribosome (results not shown). We then monitored the formation of initiation complexes formed by mRNA, 30S subunit and the ini-




Fig. 2. Formation of simplified initiation ribosomal complex by toeprinting assays involving *coa* mRNA and *spa* mRNA encoding two virulence factors. The mRNAs (12 nM) were incubated with either *E. coli* 30S or *S. aureus* 30S (300 nM), and the initiator tRNA^{fMet} (1 μM). The effect of increasing concentrations of magnesium (8.5 mM to 20 mM) was monitored on the formation of the initiation complex. Lanes G, A, U, C are sequencing ladders. Secondary structure models of *coa* and *spa* mRNAs are shown. SD is for the Shine and Dalgarno sequence (nucleotides in green). The initiation triplet is schematized by a green rectangle. The toeprint at position +16 is shown by an arrow. Experimental conditions were described in Fechter et al. [81]. nts is for nucleotides.

tiator tRNA using toeprinting assays [81, 82]. This approach is based on a premature reverse transcription arrest (called toeprint) caused by the formation of the simplified initiation complex, giving the exact position of the 3' edge of the 30S location on the mRNA. The signature of an active initiation complex is given by the position of the toeprint at position +16 from the AUG codon [82]. We first show that *S. aureus* 30S binds efficiently to *spa* and *coa* mRNAs, which encode two major virulence factors, protein A and coagulase, respectively. These two mRNAs harbor the same structure and sequence signatures, i.e. short 5'UTR,

strong SD sequence present in a hairpin loop, and a rather long unpaired AU rich motif just downstream the initiation codon [44, 46] (Fig. 2). Conversely, two other mRNAs *mgrA* and *icaR*, which encode major transcriptional regulatory proteins, were poorly recognized by *S. aureus* 30S (Fig. 3). These two mRNAs contain a large and structured 5'UTR, in which the SD is embedded into a secondary structure [41, 49, 51]. It remains to be addressed whether these two mRNAs are less well translated in vivo than the virulence factors (protein A and coagulase). However, a comparative analysis performed with the *E. coli* ribo-




Fig. 3. Effect of *E. coli* ribosomal protein S1 on the formation of various initiation complexes involving *S. aureus* *icaR* and *mgrA* mRNAs and *E. coli* *sodB* mRNA. The mRNAs (12 nM) were incubated with *E. coli* 30S (300 nM), or *E. coli* S1-depleted 30S (as prepared in Duval *et al.* [75]), or with *E. coli* S1-depleted 30S pre-incubated with purified r-protein S1 (350 nM) in the presence of the initiator tRNA^{Met} (1 μM) (tRNAⁱ). The same experiments were carried out with either *S. aureus* 70S or 30S (300 nM) either in the absence or in the presence of *E. coli* r-protein S1 (350 nM), and in the presence of the initiator tRNA^{Met} (1 μM). The toeprint at position +16 is shown by an arrow. The experiments show that the addition of *E. coli* S1 to the *E. coli* S1-depleted ribosome restored the formation of the initiation complex as evidenced by the toeprint at +16 while addition of *E. coli* S1 to the *S. aureus* ribosome inhibits the formation of the ternary initiation complex. Secondary structure models of *S. aureus* *icaR* and *mgrA* mRNAs, and of *E. coli* *sodB* mRNA are shown below the autoradiographies. SD is for the Shine and Dalgarno sequence (nucleotides in green). The initiation triplet is schematized by a green rectangle. The toeprint at position +16 is shown by an arrow. Experimental conditions were described in Fechter *et al.* [81].

somes containing S1, showed that the 30S are able to form initiation complexes with both *mgrA* and *icaR* mRNAs (Fig. 3). This efficient recognition was linked to the presence of S1 because S1-depleted *E. coli* 30S were not able to recognize the two structured mRNAs while mRNA binding was restored using S1-depleted 30S saturated with purified *E. coli* S1 added in *trans* (Fig. 3). Hence, these experiments indicate that the *S. aureus* 30S behaves as the *E. coli* S1-depleted 30S for the recognition of structured mRNAs. We finally compared the formation of the initiation complex formed with *E. coli* *sodB* mRNA encoding a superoxide dismutase and the ribosomes of either *E. coli* or of *S. aureus*. This mRNA is recognized by *E. coli* ribosomes in a manner independent of S1 [75]. Indeed,

the toeprinting assays revealed that both *E. coli* and *S. aureus* ribosomes are able to form initiation complexes with *sodB* mRNA in a similar manner (Fig. 3). Surprisingly, the toeprint was strongly decreased if *E. coli* S1 was added to *S. aureus* ribosomes. The same result was also obtained with *icaR* mRNA (Fig. 3). We propose that *E. coli* S1 does not efficiently bind to *S. aureus* ribosome although most of the key residues in *E. coli* S1 are also conserved in *S. aureus* S2 [78]. This probably suggests that the S1 binding site in *E. coli* is more complex than expected [75]. The observed inhibition of the toeprint might result from a direct interaction of S1 with mRNAs outside of the ribosome. For instance *sodB* mRNA presents a large unpaired AU-rich




Fig. 4. Possible mechanisms for the formation of initiation complexes in *S. aureus*. (a) In the one-step pathway, the weakly structured mRNA (such as *spa* mRNA) is directly recruited on the 30S ribosomal subunit through its unpaired Shine and Dalgarno (SD) sequence. Due to the strong SD-antiSD interaction, the unpaired initiation codon will be located directly in the P-site. (b) For mRNAs carrying structures sequestering the SD (such as *mgrA* mRNA), it is expected that the recognition will involve at least two steps pathway where docking will be followed by the accommodation process to promote the correct positioning of the initiation codon. It is not yet known *in vivo* whether the unfolding process of the mRNA structure in *S. aureus* occurs on the ribosome through the action of the initiation factors or of an unknown RNA-binding protein or outside the ribosome possibly through the binding of protein S1. In these particular examples, the ribosome might also recognize the SD during the transcription process of the mRNA, i.e. before the formation of the inhibitory structure.

sequence just upstream the SD, known to be a typical binding site for S1 [75] (Fig. 3).

Taken together, these data show that the presence of a strong and unpaired SD in mRNA is necessary to be recognized by *S. aureus* 30S (Fig. 4a). How do *S. aureus* ribosomes initiate the translation of structured mRNAs is still an open question (Fig. 4b). Do structured mRNAs bind first to the platform of the 30S? Clearly, the melting and chaperone properties of *E. coli* S1 were not able to help *S. aureus* ribosome to unfold mRNA structure and liberate the SD sequence. Many questions remain to be explored. Does the shorter protein S1 in *S. aureus* contribute to the translation of structured mRNAs through direct mRNA binding outside of the ribosome? Do other *trans*-acting factors (RNA chaperone proteins, RNA helicases) act on the ribosome to promote translation of specific structured mRNAs? Does the coupling between transcription and translation provide a window allowing the ribosome to load on mRNA before the formation of structures within the ribosome binding site?

Ribosome hibernation, another mechanism to regulate translation initiation during growth. The formation of inactive ribosomal dimers, also referred to as 100S

ribosomes or as hibernating ribosomes, repress protein synthesis in bacteria [83]. Inactive ribosome dimers are usually formed as a response of bacterial cells to unfavorable conditions and can be rapidly rescued after normalization of environment [84]. Formation of dimers is supposed to increase the survival rate under stress conditions [85]. In *B. subtilis*, a recent study showed that the dimers are formed during the early stationary phase and these dimers are required to facilitate rapid regrowth of cells if they are facing better nutrient conditions [86]. However, unlike in *E. coli* the 100S ribosomes in *S. aureus* were found in all growth phases [30] questioning on their exact roles under rich medium conditions during cell growth.

The mechanism of 100S ribosomes formation also varies between bacterial species. Many γ -proteobacteria (including *E. coli*) express three proteins: hibernation promoting factor (HPF, former name YhbH) [87], ribosome modulation factor (RMF) [85, 88] and protein YfiA (former names RaiA or protein Y) [89]. The formation of 100S ribosomes is driven by the concomitant binding of RMF and HPF proteins [90] while YfiA prevents the recycling of ribosomes and favors the formation of translationally inactive 70S

[89]. Despite of high similarity with HPF (~40%), YfiA occupies partially the RMF binding site [90, 91]. Instead in firmicutes (such as *S. aureus*), only one protein called long HPF has been identified [92]. Its N-terminal domain shares high similarity with short HPF and YfiA, but not with RMF protein (reviewed in [93]). This unique HPF protein can both promote the formation of 100S dimers and of non-functional 70S [30, 92].

Phenotypic analysis revealed that the depletion of RMF in *E. coli* leads to reduced long-term viability and stress tolerance during stationary phase while depletion of short HPF or YfiA do not cause strong cellular defects [93]. In contrast, depletion of the long HPF protein leads to decreased survival of *Lactococcus lactis* under stress conditions [94], decreased pathogenesis in *Listeria monocytogenes* [95], and enhanced sensitivity to prolonged antibiotic exposure [96]. Crystal structure of *E. coli* ribosome bound to YfiA showed that the protein is located close to the region where mRNA, tRNAs and initiation factors bind during protein synthesis [97]. Heterologous crystal structures of *T. thermophilus* 70S ribosome with *E. coli* hibernation factors showed that HPF shares the binding site with YfiA, whereas RMF binds next to the anti-SD region and prevents interaction of 16S rRNA and mRNA during the initiation process [91]. Single particle cryo-electron microscopy and cryo-electron tomography confirmed the presence of *E. coli* ribosome dimers in situ [98]. Ribosomal proteins S2, S9, S10 and helix 39 of 16S rRNA make contacts between two 70S particles but the hibernation factors were not directly involved in the contacts [91, 98]. The authors suggested that the dimerization occurs as a result of structural rearrangement of the head of 30S upon binding of RMF. However, it is still unclear whether the same mechanism and contacts are involved in ribosome dimerization in the long HPF in *S. aureus*. Due to high similarity between the short HPF of *E. coli* and the N-terminal domain of long HPF in *S. aureus*, we propose that these two proteins would share the same binding site on the ribosome, and that the C-terminal domain of long HPF might be directly involved in contacts between the two ribosomes in *S. aureus*. Hence, solving the high-resolution structure of the ribosome dimers from *S. aureus* will shed light on one biological mechanism that might promote successful persistence of this severe pathogen in response to stress conditions or antibiotic treatments.

TOWARDS THE HIGH RESOLUTION OF THE TRANSLATION MACHINERY IN *S. aureus*

Although the core of the bacterial ribosome is very conserved, certain peculiarities existed between the ribosomes of different bacterial species. These differences may determine some specifications for mRNA recognition, regulation of translation, and susceptibil-

ity to antibiotics. Two structures of low GC content Gram-positive ribosomes have been recently solved. The MifM-stalled 70S ribosome from *B. subtilis* was solved at a resolution of 3.5–3.9 Å by cryoelectron microscopy [15, 17] and the crystal structure of *S. aureus* 50S subunit was elucidated at a resolution of 3.5 Å [16]. The majority of the rRNAs of the core of *S. aureus* 50S subunit is structurally highly conserved. However, several helices, primarily located on the periphery of the ribosome, show sequence and length variability among different bacteria [16]. In contrast to the rRNA, more differences were observed for ribosomal proteins. Although the globular domains as well as the structural elements interacting with rRNAs are rather conserved, many of the r-proteins contained specific extensions. This is the case of universal r-protein uL3 and bacteria-specific r-protein bL17, which both carry a loop motif unique to staphylococci extending toward the solvent side at the periphery of the ribosome. Also the extension at the C-terminus of uL16 is located on the solvent side, while the protein is at the interface close to the tRNA binding sites. Interestingly, bL27 also carries an extended N-terminus that should be cleaved by a specific protease before the assembly of the 70S ribosome [32]. Although the N-terminal part of bL27 was only traced from residue 19 due to its high flexibility in the crystal structure [16], this domain is expected to be located in the proximity to the peptidyl-transferase center (PTC) and of the 5'-end of the P-site tRNA [16]. Nevertheless, these structural features alone could neither explain the different activities in protein synthesis and translation initiation as compared to *E. coli* ribosomes, nor the requirement of higher concentration of magnesium to avoid subunit dissociation as reported in earlier studies [99]. The crystal structure of *S. aureus* 50S was also solved in the presence of several antibiotics such as linezolid, telithromycin, and pleuromutilin revealing unexpected features in the orientation of some of the antibiotics specific for *S. aureus* [16].

Clearly, one of the important challenges for the future will be to determine the structure of the full ribosome under physiological conditions and/or trapped by antibiotics. It should better highlight the peculiarities located at strategic positions of the ribosome, such as the PTC, the decoding center, the tRNA binding sites, and the mRNA channel. Furthermore, more knowledge is required for the *trans*-acting factors (initiation factors, S1, RNA-binding proteins, RNA helicases, etc.) that could modulate the functioning of *S. aureus* ribosome at the initiation step. Time is certainly arrived to better understand at the molecular level, the differences observed in protein synthesis and control between Gram-negative bacteria and the low GC content Gram-positive bacteria, which comprise many human pathogens, such as *S. aureus*. These studies should pave the way to identify specific strategies to selectively inhibit *S. aureus* pathogenesis and/or growth with less effect on the

human microbiome and less selective pressure on resistant population.

ACKNOWLEDGMENTS

We thank all the members of our respective teams for helpful discussions. This work was supported by the ‘Centre National de la Recherche Scientifique’ (CNRS), ‘Institut National de la Santé et de la Recherche Médicale’ (INSERM), and the University of Strasbourg. This work benefits from funding from the state managed by the French National Research Agency as part of the Investments for the future program under the framework of the LabEx: ANR-10-LABX-0036_NETRINA (to P.R., Y.H.), from ANR-15-CE11-0021-01 (to G.Y.), from European Research Council advanced grant 294312 (to M.Y.), and from the Russian Government Program of Competitive Growth of Kazan Federal University (to M.Y., I.K. and G.Y.).

REFERENCES

- Klinge S., Voigts-Hoffmann F., Leibundgut M., Ban N. 2012. Atomic structures of the eukaryotic ribosome. *Trends Biochem. Sci.* **37**, 189–198.
- Melnikov S., Ben-Shem A., Garreau de Loubresse N., Jenner L., Yusupova G.Z., Yusupov M.M. 2012. One core, two shells: Bacterial and eukaryotic ribosomes. *Nat. Struct. Mol. Biol.* **19**, 560–567.
- Petrov A.S., Bernier C.R., Hsiao C., Norris A.M., Kovacs N.A., Waterbury C.C., Stepanov V.G., Harvey S.C., Fox G.E., Wartell R.M., Hud N.V., Williams L.D. 2014. Evolution of the ribosome at atomic resolution. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 10251–10256.
- Sharma M.R., Wilson D.N., Datta P.P., Barat C., Schluenzen F., Fucini P., Agrawal R.K. 2007. Cryo-EM study of the spinach chloroplast ribosome reveals the structural and functional roles of plastid-specific ribosomal proteins. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 19315–19320.
- Amunts A., Brown A., Toots J., Scheres S.H., Ramakrishnan V. 2015. Ribosome. The structure of the human mitochondrial ribosome. *Science*. **348**, 95–98.
- Greber B.J., Bieri P., Leibundgut M., Leitner A., Aebersold R., Boehringer D., Ban N. 2015. Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome. *Science*. **348**, 303–308.
- Poehlsgaard J., Douthwaite S. 2005. The bacterial ribosome as a target for antibiotics. *Nat. Rev. Microbiol.* **3**, 870–881.
- Wilson D.N. 2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nat. Rev. Microbiol.* **12**, 35–48.
- Allen G.S., Frank J. 2007. Structural insights on the translation initiation complex: Ghosts of a universal initiation complex. *Mol. Microbiol.* **63**, 941–950.
- Myasnikov A.G., Simonetti A., Marzi S., Kloholz B.P. 2009. Structure–function insights into prokaryotic and eukaryotic translation initiation. *Curr. Opin. Struct. Biol.* **19**, 300–309.
- Schuwirth B.S., Borovinskaya M.A., Hau C.W., Zhang W., Vila-Sanjurjo A., Holton J.M., Cate J.H. 2005. Structures of the bacterial ribosome at 3.5 Å resolution. *Science*. **310**, 827–834.
- Noeske J., Wasserman M.R., Terry D.S., Altman R.B., Blanchard S.C., Cate J.H. 2015. High-resolution structure of the *Escherichia coli* ribosome. *Nat. Struct. Mol. Biol.* **22**, 336–341.
- Yusupov M.M., Yusupova G.Z., Baucom A., Lieberman K., Earnest T.N., Cate J.H., Noller H.F. 2001. Crystal structure of the ribosome at 5.5 Å resolution. *Science*. **292**, 883–896.
- Yusupova G.Z., Yusupov M.M., Cate J.H., Noller H.F. 2001. The path of messenger RNA through the ribosome. *Cell*. **106**, 233–241.
- Beckert B., Kedrov A., Sohmen D., Kempf G., Wild K., Sinning I., Stahlberg H., Wilson D.N., Beckmann R. 2015. Translational arrest by a prokaryotic signal recognition particle is mediated by RNA interactions. *Nat. Struct. Mol. Biol.* **22**, 767–773.
- Eyal Z., Matzov D., Krupkin M., Wekselman I., Paukner S., Zimmermann E., Rozenberg H., Bashan A., Yonath A. 2015. Structural insights into species-specific features of the ribosome from the pathogen *Staphylococcus aureus*. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E5805–E5814.
- Sohmen D., Chiba S., Shimokawa-Chiba N., Innis C.A., Berninghausen O., Beckmann R., Ito K., Wilson D.N. 2015. Structure of the *Bacillus subtilis* 70S ribosome reveals the basis for species-specific stalling. *Nat. Commun.* **6**, 6941.
- Lowy F.D. 1998. *Staphylococcus aureus* infections. *New Engl. J. Med.* **339**, 520–532.
- Kreiswirth B., Kornblum J., Arbeit R.D., Eisner W., Maslow J.N., McGeer A., Low D.E., Novick R.P. 1993. Evidence for a clonal origin of methicillin resistance in *Staphylococcus aureus*. *Science*. **259**, 227–230.
- Pofelski J., Pavese P., Brion J.P., Marrakchi C., Gay E., Recule C., Stahl J.P. 2003. *Staphylococcus aureus* meningitis with intermediate sensitivity to glycopeptides. Therapeutic indications. *Presse Med.* **32**, 217–220.
- Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. 2010. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. *Clin. Microbiol. Rev.* **23**, 99–139.
- Koch G., Yepes A., Forstner K.U., Wermser C., Stengel S.T., Modamio J., Ohlsen K., Foster K.R., Lopez D. 2014. Evolution of resistance to a last-resort antibiotic in *Staphylococcus aureus* via bacterial competition. *Cell*. **158**, 1060–1071.
- Nadell C.D., Xavier J.B., Foster K.R. 2009. The socio-biology of biofilms. *FEMS Microbiol. Rev.* **33**, 206–224.
- Cegelski L., Marshall G.R., Eldridge G.R., Hultgren S.J. 2008. The biology and future prospects of antivirulence therapies. *Nat. Rev. Microbiol.* **6**, 17–27.
- Gordon C.P., Williams P., Chan W.C. 2013. Attenuating *Staphylococcus aureus* virulence gene regulation: A

- medicinal chemistry perspective. *J. Med. Chem.* **56**, 1389–1404.
26. Gray B., Hall P., Gresham H. 2013. Targeting *agr*- and *agr*-like quorum sensing systems for development of common therapeutics to treat multiple gram-positive bacterial infections. *Sensors*. **13**, 5130–5166.
 27. Messina J.A., Thaden J.T., Sharma-Kuinkel B.K., Fowler V.G.J. 2016. Impact of bacterial and human genetic variation on *Staphylococcus aureus* infections. *PLoS Pathog.* **12**, e1005330.
 28. Farwell M.A., Roberts M.W., Rabinowitz J.C. 1992. The effect of ribosomal protein S1 from *Escherichia coli* and *Micrococcus luteus* on protein synthesis in vitro by *E. coli* and *Bacillus subtilis*. *Mol. Microbiol.* **6**, 3375–3383.
 29. Salah P., Bisaglia M., Aliprandi P., Uzan M., Sizun C., Bontems F. 2009. Probing the relationship between Gram-negative and Gram-positive S1 proteins by sequence analysis. *Nucleic Acids Res.* **37**, 5578–5588.
 30. Ueta M., Wada C., Wada A. 2010. Formation of 100S ribosomes in *Staphylococcus aureus* by the hibernation promoting factor homolog SaHPF. *Genes Cells.* **15**, 43–58.
 31. Chirgadze Y.N., Clarke T.E., Romanov V., Kisselman G., Wu-Brown J., Soloveychik M., Chan T.S., Gordon R.D., Battaile K.P., Pai E.F., Chirgadze N.Y. 2015. The structure of SAV1646 from *Staphylococcus aureus* belonging to a new “ribosome-associated” subfamily of bacterial proteins. *Acta Crystallogr. D: Biol. Crystallogr.* **71**, 332–337.
 32. Wall E.A., Caufield J.H., Lyons C.E., Manning K.A., Dokland T., Christie G.E. 2015. Specific N-terminal cleavage of ribosomal protein L27 in *Staphylococcus aureus* and related bacteria. *Mol. Microbiol.* **95**, 258–269.
 33. Ibarra J.A., Perez-Rueda E., Carroll R.K., Shaw L.N. 2013. Global analysis of transcriptional regulators in *Staphylococcus aureus*. *BMC Genomics.* **14**, 126.
 34. Felden B., Vandenesch F., Bouloc P., Romby P. 2011. The *Staphylococcus aureus* RNome and its commitment to virulence. *PLoS Pathog.* **7**, e1002006.
 35. Tomasini A., Francois P., Howden B.P., Fechter P., Romby P., Caldelari I. 2014. The importance of regulatory RNAs in *Staphylococcus aureus*. *Infect. Genet. Evol.* **21**, 616–626.
 36. Lasa I., Toledo-Arana A., Gingeras T.R. 2012. An effort to make sense of antisense transcription in bacteria. *RNA Biol.* **9**, 1039–1044.
 37. Novick R.P., Ross H.F., Projan S.J., Kornblum J., Kreiswirth B., Moghazeh S. 1993. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. *EMBO J.* **12**, 3967–3975.
 38. Novick R.P., Geisinger E. 2008. Quorum sensing in staphylococci. *Annu. Rev. Genet.* **42**, 541–564.
 39. Geisinger E., Muir T.W., Novick R.P. 2009. *agr* receptor mutants reveal distinct modes of inhibition by staphylococcal autoinducing peptides. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 1216–1221.
 40. Morfeldt E., Taylor D., von Gabain A., Arvidson S. 1995. Activation of alpha-toxin translation in *Staphylococcus aureus* by the trans-encoded antisense RNA, RNAIII. *EMBO J.* **14**, 4569–4577.
 41. Gupta R.K., Luong T.T., Lee C.Y. 2015. RNAIII of the *Staphylococcus aureus* agr system activates global regulator MgrA by stabilizing mRNA. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 14036–14041.
 42. Benito Y., Kolb F.A., Romby P., Lina G., Etienne J., Vandenesch F. 2000. Probing the structure of RNAIII, the *Staphylococcus aureus* agr regulatory RNA, and identification of the RNA domain involved in repression of protein A expression. *RNA.* **6**, 668–679.
 43. Boisset S., Geissmann T., Huntzinger E., Fechter P., Bendridi N., Possedko M., Chevalier C., Helfer A.C., Benito Y., Jacquier A., Gaspin C., Vandenesch F., Romby P. 2007. *Staphylococcus aureus* RNAIII coordinately represses the synthesis of virulence factors and the transcription regulator Rot by an antisense mechanism. *Genes Dev.* **21**, 1353–1366.
 44. Huntzinger E., Boisset S., Saveanu C., Benito Y., Geissmann T., Namane A., Lina G., Etienne J., Ehresmann B., Ehresmann C., Jacquier A., Vandenesch F., Romby P. 2005. *Staphylococcus aureus* RNAIII and the endoribonuclease III coordinately regulate *spa* gene expression. *EMBO J.* **24**, 824–835.
 45. Geisinger E., Adhikari R.P., Jin R., Ross H.F., Novick R.P. 2006. Inhibition of rot translation by RNAIII, a key feature of *agr* function. *Mol. Microbiol.* **61**, 1038–1048.
 46. Chevalier C., Boisset S., Romilly C., Masquida B., Fechter P., Geissmann T., Vandenesch F., Romby P. 2010. *Staphylococcus aureus* RNAIII binds to two distant regions of *coa* mRNA to arrest translation and promote mRNA degradation. *PLoS Pathog.* **6**, e1000809.
 47. Chabelskaya S., Bordeau V., Felden B. 2014. Dual RNA regulatory control of a *Staphylococcus aureus* virulence factor. *Nucleic Acids Res.* **42**, 4847–4858.
 48. Nitzan M., Fechter P., Peer A., Altuvia Y., Bronesky D., Vandenesch F., Romby P., Biham O., Margalit H. 2015. A defense-offense multi-layered regulatory switch in a pathogenic bacterium. *Nucleic Acids Res.* **43**, 1357–1369.
 49. Romilly C., Lays C., Tomasini A., Caldelari I., Benito Y., Hammann P., Geissmann T., Boisset S., Romby P., Vandenesch F. 2014. A non-coding RNA promotes bacterial persistence and decreases virulence by regulating a regulator in *Staphylococcus aureus*. *PLoS Pathog.* **10**, e1003979.
 50. Geissmann T., Marzi S., Romby P. 2009. A search for small noncoding RNAs in *Staphylococcus aureus* reveals a conserved sequence motif for regulation. *Nucleic Acids Res.* **37**, 7239–7259.
 51. Ruiz de los Mozos I., Vergara-Irigaray M., Segura V., Villanueva M., Bitarte N., Saramago M., Domingues S., Arraiano C.M., Fechter P., Romby P., Valle J., Solano C., Lasa I., Toledo-Arana A. 2013. Base pairing interaction between 5'- and 3'-UTRs controls *icaR* mRNA translation in *Staphylococcus aureus*. *PLoS Genet.* **9**, e1004001.
 52. Beaume M., Hernandez D., Farinelli L., Deluen C., Linder P., Gaspin C., Romby P., Schrenzel J., Francois P. 2010. Cartography of methicillin-resistant *S. aureus* transcripts: Detection, orientation and temporal expression during growth phase and stress conditions. *PLoS ONE.* **5**, e10725.

53. Bohn C., Rigoulay C., Chabelskaya S., Sharma C.M., Marchais A., Skorski P., Borezee-Durant E., Barbet R., Jacquet E., Jacq A., Gautheret D., Felden B., Vogel J., Bouloc P. 2010. Experimental discovery of small RNAs in *Staphylococcus aureus* reveals a riboregulator of central metabolism. *Nucleic Acids Res.* **38**, 6620–6636.
54. Durand S., Braun F., Lioliou E., Romilly C., Helfer A.C., Kuhn L., Quittot N., Nicolas P., Romby P., Condon C. 2015. A nitric oxide regulated small RNA controls expression of genes involved in redox homeostasis in *Bacillus subtilis*. *PLoS Genet.* **11**, e1004957.
55. Anderson K.L., Roberts C., Disz T., Vonstein V., Hwang K., Overbeek R., Olson P.D., Projan S.J., Dunman P.M. 2006. Characterization of the *Staphylococcus aureus* heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover. *J. Bacteriol.* **188**, 6739–6756.
56. Lasa I., Toledo-Arana A., Dobin A., Villanueva M., de Los Mozos I.R., Vergara-Irigaray M., Segura V., Fagegaltier D., Penades J.R., Valle J., Solano C., Gíngeras T.R. 2011. Genome-wide antisense transcription drives mRNA processing in bacteria. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 20172–20177.
57. Barrick J.E., Breaker R.R. 2007. The distributions, mechanisms, and structures of metabolite-binding riboswitches. *Genome Biol.* **8**, R239.
58. Caldelari I., Fechter P., Lioliou E., Romilly C., Chevalier C., Gaspin C., Romby P. 2011. A current overview of regulatory RNAs in *Staphylococcus aureus*. In: *Regulatory RNAs in Prokaryotes*. Eds. Marchfelder A., Hess W. Wien: Wiley.
59. Mulhbacher J., St-Pierre P., Lafontaine D.A. 2010. Therapeutic applications of ribozymes and riboswitches. *Curr. Opin. Pharmacol.* **10**, 551–556.
60. Breaker R.R. 2011. Prospects for riboswitch discovery and analysis. *Mol. Cell.* **43**, 867–879.
61. Mulhbacher J., Brouillette E., Allard M., Fortier L.C., Malouin F., Lafontaine D.A. 2010. Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. *PLoS Pathog.* **6**, e1000865.
62. Ster C., Allard M., Boulanger S., Lamontagne Boulet M., Mulhbacher J., Lafontaine D.A., Marsault E., Lacasse P., Malouin F. 2013. Experimental treatment of *Staphylococcus aureus* bovine intramammary infection using a guanine riboswitch ligand analog. *J. Dairy Sci.* **96**, 1000–1008.
63. Linder P., Lemeille S., Redder P. 2014. Transcriptome-wide analyses of 5'-ends in RNase J mutants of a gram-positive pathogen reveal a role in RNA maturation, regulation and degradation. *PLoS Genet.* **10**, e1004207.
64. Chao Y., Vogel J. 2016. A 3'UTR-derived small RNA provides the regulatory noncoding arm of the inner membrane stress response. *Mol. Cell.* **61**, 352–363.
65. Westermann A.J., Forstner K.U., Amman F., Barquist L., Chao Y., Schulte L.N., Muller L., Reinhardt R., Stadler P.F., Vogel J. 2016. Dual RNA-seq unveils non-coding RNA functions in host-pathogen interactions. *Nature.* **529**, 496–501.
66. Simonetti A., Marzi S., Jenner L., Myasnikov A., Romby P., Yusupova G., Klaholz B.P., Yusupov M. 2009. A structural view of translation initiation in bacteria. *Cell. Mol. Life Sci.* **66**, 423–436.
67. Romby P., Springer M. 2007. Translational control in prokaryotes. In: *Translational Control in Biology and Medicine*. Eds. Matthews M.B.S.N., Hershey J.W.B. Cold Spring Harbor: Cold Spring Harbor Lab. Press, pp. 803–827.
68. Wagner E.G., Romby P. 2015. Small RNAs in bacteria and archaea: Who they are, what they do, and how they do it. *Adv. Genet.* **90**, 133–208.
69. Duval M., Simonetti A., Caldelari I., Marzi S. 2015. Multiple ways to regulate translation initiation in bacteria: Mechanisms, regulatory circuits, dynamics. *Biochimie.* **114**, 18–29.
70. Studer S.M., Joseph S. 2006. Unfolding of mRNA secondary structure by the bacterial translation initiation complex. *Mol. Cell.* **22**, 105–115.
71. Milon P., Maracci C., Filonava L., Gualerzi C.O., Rodnina M.V. 2012. Real-time assembly landscape of bacterial 30S translation initiation complex. *Nat. Struct. Mol. Biol.* **19**, 609–615.
72. Boni I.V., Isaeva D.M., Musychenko M.L., Tzareva N.V. 1991. Ribosome-messenger recognition: mRNA target sites for ribosomal protein S1. *Nucleic Acids Res.* **19**, 155–162.
73. Tzareva N.V., Makhno V.I., Boni I.V. 1994. Ribosome-messenger recognition in the absence of the Shine-Dalgarno interactions. *FEBS Lett.* **337**, 189–194.
74. Sorensen M.A., Fricke J., Pedersen S. 1998. Ribosomal protein S1 is required for translation of most, if not all, natural mRNAs in *Escherichia coli* in vivo. *J. Mol. Biol.* **280**, 561–569.
75. Duval M., Korepanov A., Fuchsbauer O., Fechter P., Haller A., Fabbretti A., Choulier L., Micura R., Klaholz B.P., Romby P., Springer M., Marzi S. 2013. *Escherichia coli* ribosomal protein S1 unfolds structured mRNAs onto the ribosome for active translation initiation. *PLoS Biol.* **11**, e1001731.
76. Byrgazov K., Manoharadas S., Kaberdina A.C., Vesper O., Moll I. 2012. Direct interaction of the N-terminal domain of ribosomal protein S1 with protein S2 in *Escherichia coli*. *PLoS ONE.* **7**, e32702.
77. Byrgazov K., Vesper O., Moll I. 2013. Ribosome heterogeneity: Another level of complexity in bacterial translation regulation. *Curr. Opin. Microbiol.* **16**, 133–139.
78. Byrgazov K., Grishkovskaya I., Arenz S., Coudevylle N., Temmel H., Wilson D.N., Djinovic-Carugo K., Moll I. 2015. Structural basis for the interaction of protein S1 with the *Escherichia coli* ribosome. *Nucleic Acids Res.* **43**, 661–673.
79. Vellanoweth R.L., Rabinowitz J.C. 1992. The influence of ribosome-binding-site elements on translational efficiency in *Bacillus subtilis* and *Escherichia coli* in vivo. *Mol. Microbiol.* **6**, 1105–1114.
80. Omotajo D., Tate T., Cho H., Choudhary M. 2015. Distribution and diversity of ribosome binding sites in prokaryotic genomes. *BMC Genomics.* **16**, 604–612.
81. Fechter P., Chevalier C., Yusupova G., Yusupov M., Romby P., Marzi S. 2009. Ribosomal initiation complexes probed by toeprinting and effect of trans-acting translational regulators in bacteria. *Methods Mol. Biol.* **540**, 247–263.

82. Hartz D., McPheeters D.S., Traut R., Gold L. 1988. Extension inhibition analysis of translation initiation complexes. *Methods Enzymol.* **164**, 419–425.
83. Yoshida H., Maki Y., Kato H., Fujisawa H., Izutsu K., Wada C., Wada A. 2002. The ribosome modulation factor (RMF) binding site on the 100S ribosome of *Escherichia coli*. *J. Biochem.* **132**, 983–989.
84. Wada A., Yamazaki Y., Fujita N., Ishihama A. 1990. Structure and probable genetic location of a “ribosome modulation factor” associated with 100S ribosomes in stationary-phase *Escherichia coli* cells. *Proc. Natl. Acad. Sci. U. S. A.* **87**, 2657–2661.
85. Yamagishi M., Matsushima H., Wada A., Sakagami M., Fujita N., Ishihama A. 1993. Regulation of the *Escherichia coli* *rmf* gene encoding the ribosome modulation factor: Growth phase- and growth rate-dependent control. *EMBO J.* **12**, 625–630.
86. Akanuma G., Kazo Y., Tagami K., Hiraoka H., Yano K., Suzuki S., Hanai R., Nanamiya H., Kato-Yamada Y., Kawamura F. 2016. Ribosome dimerization is essential for the efficient regrowth of *Bacillus subtilis*. *Microbiology.* **162** (3), 448–458. doi 10.1099/mic.0.000234
87. Maki Y., Yoshida H., Wada A. 2000. Two proteins, YfiA and YhbH, associated with resting ribosomes in stationary phase *Escherichia coli*. *Genes Cells.* **5**, 965–974.
88. Izutsu K., Wada A., Wada C. 2001. Expression of ribosome modulation factor (RMF) in *Escherichia coli* requires ppGpp. *Genes Cells.* **6**, 665–676.
89. Agafonov D.E., Kolb V.A., Nazimov I.V., Spirin A.S. 1999. A protein residing at the subunit interface of the bacterial ribosome. *Proc. Natl. Acad. Sci. U. S. A.* **96**, 12345–12349.
90. Ueta M., Yoshida H., Wada C., Baba T., Mori H., Wada A. 2005. Ribosome binding proteins YhbH and YfiA have opposite functions during 100S formation in the stationary phase of *Escherichia coli*. *Genes Cells.* **10**, 1103–1112.
91. Polikanov Y.S., Blaha G.M., Steitz T.A. 2012. How hibernation factors RMF, HPF, and YfiA turn off protein synthesis. *Science.* **336**, 915–918.
92. Ueta M., Wada C., Daifuku T., Sako Y., Bessho Y., Kitamura A., Ohniwa R.L., Morikawa K., Yoshida H., Kato T., Miyata T., Namba K., Wada A. 2013. Conservation of two distinct types of 100S ribosome in bacteria. *Genes Cells.* **18**, 554–574.
93. Yoshida H., Wada A. 2014. The 100S ribosome: Ribosomal hibernation induced by stress. *Wiley Interdisc. Rev. RNA.* **5**, 723–732.
94. Puri P., Eckhardt T.H., Franken L.E., Fusetti F., Stuart M.C., Boekema E.J., Kuipers O.P., Kok J., Poolman B. 2014. *Lactococcus lactis* YfiA is necessary and sufficient for ribosome dimerization. *Mol. Microbiol.* **91**, 394–407.
95. Kline B.C., McKay S.L., Tang W.W., Portnoy D.A. 2015. The *Listeria monocytogenes* hibernation-promoting factor is required for the formation of 100S ribosomes, optimal fitness, and pathogenesis. *J. Bacteriol.* **197**, 581–591.
96. McKay S.L., Portnoy D.A. 2015. Ribosome hibernation facilitates tolerance of stationary-phase bacteria to aminoglycosides. *Antimicrob. Agents Chemother.* **59**, 6992–6999.
97. Vila-Sanjurjo A., Schuwirth B.S., Hau C.W., Cate J.H. 2004. Structural basis for the control of translation initiation during stress. *Nat. Struct. Mol. Biol.* **11**, 1054–1059.
98. Ortiz J.O., Brandt F., Matias V.R., Sennels L., Rappsilber J., Scheres S.H., Eibauer M., Hartl F.U., Baumeister W. 2010. Structure of hibernating ribosomes studied by cryoelectron tomography in vitro and in situ. *J. Cell Biol.* **190**, 613–621.
99. Mao J.C.H. 1967. Protein synthesis in a cell-free extract from *Staphylococcus aureus*. *J. Bacteriol.* **94**, 80–86.

Objectives and experimental strategies

I. How *S. aureus* ribosome initiates translation of structured mRNAs?

I.1. Biological questions and objectives

As I have mentioned in the introduction, *S. aureus* has evolved sophisticated means to tune the efficiency of translation of different genes in response to the host, stress and various environmental changes. Gene expression regulation is often exerted at the earliest step of protein biosynthesis, the initiation process, when the mRNA is recruited on the 30S ribosomal subunit and accommodated in the decoding channel for the interaction with the initiator tRNA at the P site. Specific features of mRNAs such as the length and the position of the SD sequence (Chen et al., 1994; Vimberg et al., 2007), the «stand-by » site acting as an enhancer sequence preceding the SD (Salis et al., 2009), the type of initiation codon and the secondary structures at the 5' UTR, are all key determinants for translation efficiency. Transcriptomic analysis of *S. aureus* has revealed that numerous mRNAs encoding for virulence factors, stress responses and metabolism, carry large structured 5' and 3' UTR where regulatory domains are potentially embedded (Ruiz de los Mozos et al., 2013). If Gram-negative ribosomes have the ability to deal with a wealth of different structures and different SD strengths thanks to their protein S1 (Duval et al., 2013a), *S. aureus* ribosomes do not carry S1 and did not show the same plasticity in recognizing structured mRNAs (Khusainov et al., 2016). Nevertheless, those structured mRNAs have to be translated, at least in some specific conditions, and translational regulators are expected to compensate for the loss of the associated S1. Alternatively, *SauS1* would still induce the translation of specific mRNAs outside of the 30S, acting as a translational activator. The first aim of my thesis was to understand the impact of *SauS1* on translation initiation of structured mRNAs and on cell physiology.

I.2. Main experimental strategies

In order to decipher the impact that *SauS1* could have on the initiation of translation of specific mRNAs, I have used different experimental approaches. I also have benefit from the expertise of the team members: Isabelle Caldelari designed and performed some experiments, Anne-Catherine Helfer and Lucas Herrgott gave their technical support and

conceptual advice, Melodie Duval, Delphine Bronesky and Emma Desgranges gave me intellectual contribution and have also stimulated scientific discussions.

- First I have followed the expression profiles of the *rpsA* gene (*SauS1*) by Northern blot and Western blot analysis, to understand in which conditions the protein accumulated. Its expression profile has been compared with other r-proteins giving some insights on its regulatory functions.
- Mutagenesis of the *rpsA* gene (complete deletion or intron insertion) has been carried out to better understand its functions. Indeed, I have used the *rpsA* mutant strains to look for phenotypic alteration using different stress conditions. Moreover, comparative transcriptomic and quantitative proteomic analyses of the wild type and mutant $\Delta rpsA$ strains have revealed the genes for which the expression is regulated by *SauS1*, providing some hints on the mRNA targets which would require S1 for their translation.
- Using comparative ($\Delta rpsA$ /WT) polysome profiles coupled with Northern blot analysis, we have monitored the effect of *SauS1* *in vivo* on the level of translation of selected target mRNAs.
- The mRNAs issued from the OMICS analysis and confirmed by the polysome profiles, have been then validated *in vitro* by toe-printing assays to monitor the effect of purified *SauS1* on the formation of initiation complexes using isolated 30S ribosomal subunit. In parallel, I have analyzed the ability of *SauS1* to directly bind the mRNAs and to present them to the ribosomes using gel retardation assays (EMSA) and gel filtration chromatographies, respectively.

In collaboration with F. Vandenesch (Centre International de Recherche en Infectiologie, CIRI, Lyon), the $\Delta rpsA$ mutant strain will be used to monitor the effect of *SauS1* on virulence. Cellular and animal models to check host interaction and infectivity are indeed available in Lyon and can be used to specifically analyze tissue colonization, immune system evasion and dissemination.

II. Could *SauS1* be involved in regulatory mechanisms mediated by small non-coding RNAs?

II.1. Biological questions and Objectives

In Gram-negative bacteria, most if not all of the identified sRNAs, requires the Sm-like protein Hfq for their stability and functional activation (Wagner and Romby, 2015). Hfq forms a ring-shaped homohexamer that binds the U-rich terminator at the 3' end of most sRNAs (Otaka et al., 2011) protecting the Hfq-associated sRNAs from cellular ribonucleases (Brennan and Link, 2007; Valentin-Hansen et al., 2004) and helping them to recognize their target mRNAs (Storz et al., 2011; Updegrove et al., 2016). Several mechanisms of regulation mediated by Hfq have also been described in *E. coli*. In association with sRNAs, Hfq can directly repress or activate the translation of target mRNAs by sequestering/liberating their RBS. Deletion of *E. coli hfq* leads to pleiotropic effects such as growth defect, sensitivity to UV light and increased cell length (Tsui et al., 1994). Mutations in *hfq* also decreased virulence in several pathogens (for review, see Vogel and Papenfort 2006). In contrast to this, the function of Hfq in low G+C Gram-positive bacteria is still unclear and controversial. In *S. aureus*, Hfq has been shown to interact with RNAPIII, but it neither enhance its recognition with target mRNAs (Zheng et al., 2016) and nor affects their stability (Boisset et al., 2007; Preis et al., 2009). Furthermore, it is not involved in antibiotic resistance and stress responses, it is dispensable for metabolic pathway regulations and no phenotypes were linked to its deletion (Bohn et al., 2007; Geisinger et al., 2006; Huntzinger et al., 2005). Even if Hfq seems to be dispensable for riboregulation by sRNAs in low G+C Gram-positive bacteria (e.g. Firmicutes) (Jousselin et al., 2009), other aspects have to be taken into account. First, it has been shown that in methicillin-resistant staphylococcal strain (MRSA), Hfq largely contributes to stress resistance and pathogenicity (Liu *et al.*, 2010), suggesting a strain-dependent function of this protein. Second, Hfq homologues are found in several species belonging to Firmicutes division (Sun et al., 2002; Valentin-Hansen et al., 2004) with high conservation of the amino acids of the proximal and distal faces, which bind to sRNA and mRNA, respectively (Sun et al., 2002). Interestingly, another region of Hfq has been shown to be essential for the annealing activity, *i.e.* the Arginine-rich rim region (Panja et al., 2013). The ability of increasing the rate of RNA base-pairings and of

stabilizing the sRNA–mRNA complex, depend on the number of Arginine residues in this region (Zheng et al., 2016). In *E. coli*, Hfq rim contains three arginines, in *B. subtilis* only one and in *S. aureus* none, explaining why the protein does not mediate the annealing.

EcoS1 is an RNA chaperone protein which is able to promote strand displacement (Rajkowitsch and Schroeder, 2007). It binds numerous mRNAs to induce structural rearrangements and to facilitate the binding of the ribosome (Duval et al., 2013b). This activity is primarily carried out by its first four domains (d1 to d4) (Duval et al., 2017). Except d1, all the other domains are present in *SauS1*. Is *SauS1* able to bind RNAs outside the ribosome context? Which are the RNA partners of *SauS1*? Does *SauS1* interact with other protein partners? Could *SauS1* also participate to the sRNA-dependent regulation? Does *SauS1* protect sRNA from degradation or help them to promote annealing to the target RNAs? The second aim of my thesis was to address the *SauS1* regulatory functions expanding our investigation beyond its possible translation roles. Its impact on sRNA-dependent regulations has been particularly studied.

II.2. Main experimental strategies

The transcriptomic analysis obtained from the first part of my thesis has provided some indications on different roles of *SauS1* in *S. aureus* RNA metabolism. In order to understand which complexes involve *SauS1* and which RNAs are direct targets, different *in vivo* and *in vitro* approaches have been used.

- A strain carrying a flag-tagged version of the *rpsA* gene constructed by Isabelle Caldelari has been used to perform co-immunoprecipitation (Co-IP) assays. RNA-seq and LC/MSMS analyses of the purified complexes identified the *in vivo* targets of *SauS1*.
- Several RNAs specifically co-immunoprecipitated with *SauS1* have been validated *in vitro* using gel retardation assays.
- The possible effect of *SauS1* on sRNA-target RNAs interaction has been monitored using gel-retardation assays, and the annealing activity of *SauS1* has been followed by FRET analysis.
- The localization of *SauS1* on several sRNA targets has been checked by footprinting experiments. However, taken into account the transient and dynamic interaction occurring between the chaperone protein and its target

RNAs, we have introduced a crosslinking step to stabilize the ribonucleoprotein particle (RNP).

III. Summary of the main experimental strategies




Figure 11 Schematic representation of the experimental approaches that have been used to address the roles of *SauS1* in *S. aureus*.

Results

I. Result I: translation functions of *SauS1*

The first aim of my PhD project deals with the characterization of the functional impact of *SauS1* on the initiation of translation of specific structured mRNAs.

Because I showed that *SauS1* is not strictly a ribosomal protein (review in (Khusainov et al., 2016), see introduction), our approach for understanding its biological functions was first based on the characterization of its *in vivo* partners. Rip-Seq assays using chromosomally flag tagged *SauS1* were carried out to co-purify the RNA targets that were further identified by sequencing analysis. Interestingly, among the enriched RNAs, we found several RNA classes including mRNAs, regulatory RNAs (sRNAs, riboswitches) and some tRNAs. Using gel retardation assays, I have validated the specificity of the complex formation. To gain information about the molecular mechanism of action of *SauS1* on its target RNAs, I have also performed footprinting assays, and FRET experiments to monitor its chaperone activity on a model system.

Among the mRNAs that were co-IP with *SauS1*, we identified the operon *apsm1-4* encoding four PSM, which is particularly well structured. Comparative transcriptomic analysis of the wild-type and $\Delta rpsA$ strains shows down-regulation of several mRNAs, and of the operon *apsm1-4*. We made the hypothesis that the deletion of *SauS1* caused defects in the translation of the mRNA followed by degradation. Interestingly, many of the identified target mRNAs are involved in virulence and they adopt structures in their 5' untranslated regions that could modulate the accessibility of the 30S ribosomal subunit. In this manuscript, we have analyzed in details the mechanism of action of S1 on the operon *apsm1-4*. We first demonstrate that *SauS1* has a major positive impact on the formation of the simplified 30SIC (toeprintings assays) involving the *psm* mRNA, the initiator tRNA and the 30S subunits. Moreover, *in vivo* experiments using polysome profiles coupled with Northern blot experiment have demonstrated the central role of *SauS1* in the initial step of translation of these peptides.

In this work, I have also benefited from the expertise and the collaboration of several team members. I. Caldelari made the two introns insertion mutants of *rpsA* gene and a strain in which *SauS1* carries a flag-tag at its C-terminal domain and performed the purification of the RNAs for the CoIP experiment. Moreover, she has performed the Northern blot to monitor the expression profile of *rpsA* mRNA in various staphylococcal

strains, and to measure the half-life of the *psm* mRNA in the wild-type and mutant $\Delta rpsA$ strains. Lucas Herrgott has monitored the *in vivo* translation of the *psm* and *hu* mRNAs using polysome profiles followed by Northern blot analysis. Iskander Khusainov has prepared the *S. aureus* 30S ribosomal subunit, which was used for structural studies.

I. Result I: translation functions of *SauS1* (manuscript ready for submission)

***Staphylococcus aureus* S1 activates translation initiation of PSM α toxins and stimulates the production of several other secreted virulence factors**

Marena A.¹, Herrgott L.¹, Khusainov I.¹, Kuhn L.², Romby P.¹, Caldelari I.^{1*} and Marzi S.^{1*}

¹Université de Strasbourg, CNRS, Architecture et Réactivité de l'ARN, UPR9002, F-67000 Strasbourg, France

²Plateforme Protéomique Strasbourg-Esplanade FRC 1589, Université de Strasbourg, Centre National de la Recherche Scientifique, F-67000, France.

*To whom correspondence should be addressed. Tel: 33 (0) 388417051 (S.M.); 33(0) 388417068 (P.R.); Fax: 33(0) 3886022188; Email: s.marzi@ibmc-cnrs.unistra.fr
i.caldelari@ibmc-cnrs.unistra.fr

22 **ABSTRACT (155 words)**

23 *Staphylococcus aureus* is a formidable human pathogen that uses secreted cytolytic factors
24 to injure immune cells and promote infection of its host. Of these proteins, the PSM family of
25 pore-forming toxins play critical roles in *S. aureus* pathogenesis. The regulatory mechanisms
26 governing the expression of these toxins are incompletely defined. Whole-genome
27 transcriptomics, *S. aureus* exoprotein proteomics, and translation analyses revealed that
28 ribosomal protein S1 (*SauS1*), which is not associated with the ribosome, influences the
29 expression and production of exotoxins (PSMs, α -haemolysin, δ -haemolysin and γ -
30 haemolysins) and exoenzymes (proteases and lipases). We could demonstrate that *SauS1*
31 specifically promotes translation initiation of the *apsm* 1-4 operon by binding its highly
32 structured mRNA. We propose that the presence of structures at the RBS of different toxins
33 requires additional translation activators, which could be either sRNA or S1 protein. *SauS1*
34 belongs to a new class of RNA chaperones that play key roles in the regulation of translation
35 in *S. aureus*.

36

37

38 INTRODUCTION

39 *Staphylococcus aureus* is a low G+C content Gram-positive bacterium, which is a major
40 human opportunistic pathogen, causing a large spectrum of infections (e.g.(Lowy, 1998).
41 Persistent colonization of human nasals with *S. aureus* has been observed for approximately
42 30% of the population, which are also more susceptible to develop an infection (Wertheim et
43 al., 2005). During the colonization and infection processes, *S. aureus* often reprograms its
44 lifestyle in response to many environmental variations including amino acid and carbon
45 source limitation, iron depletion, decreased pH, and oxidative stress. Many studies have
46 shown that the bacteria sequentially synchronize the expression of genes encoding surface
47 proteins involved in adhesion and defense against the host immune system and, later,
48 numerous toxins (α -, β - and δ - hemolysins, P-V leukocidins, enterotoxins, exfoliative toxins,
49 Toxic Shock Syndrome toxin and PSM peptides) and enzymes (coagulases, lipases,
50 hyaluronidases, staphylokinases, nucleases) are secreted to disrupt host cells and tissues,
51 facilitating the spread of the infection (Thammavongsa et al., 2015). The production of these
52 virulence factors requires physiological adjustments for energy conservation and a fine
53 coordination with its metabolism (Somerville and Proctor, 2009). Responsible for these
54 adaptive responses are multiple interconnected regulatory networks, built on Two
55 Component Systems, sigma factors, transcriptional regulatory proteins (Ibarra et al., 2013)
56 and small non-coding RNAs (sRNAs) (e.g., for reviews (Felden et al., 2011; Tomasini et al.,
57 2014)).

58 A recognized master regulator of *S. aureus* virulence is the regulatory RNAIII encoded by
59 the *agr* system (Janzon and Arvidson, 1990; Novick et al., 1993). The *agr* system senses the
60 cellular density and triggers the transition from production of surface-bound proteins
61 (adhesion mode) to the secretion of soluble exotoxins and degradative enzymes
62 (dissemination mode) (Geisinger et al., 2009; Novick and Geisinger, 2008; Tomasini et al.,
63 2014). The switch is mainly promoted by the ability of RNAIII to enhance or repress the
64 translation of target mRNAs through the formation of basepairing interactions. Both
65 activation and repression influence the structural context of the Ribosome Binding Sites
66 (RBS) of the target mRNAs and their ability to be efficiently recognized by *S. aureus* 30S
67 ribosomal subunits. For instance, the 5' region of RNAIII binds to the leader region of *hla*
68 mRNA encoding α -haemolysin, to prevent the formation of an inhibitory structure involving
69 the Shine and Dalgarno (SD) sequence (Morfeldt et al., 1995). On the other hand, the 3'
70 domain of RNAIII contains four C-rich sequence motifs located in unpaired regions (Benito et
71 al., 2000), which directly base-pairs with the SD sequences of target mRNAs preventing
72 ribosome binding and the formation of the initiation complexes. These mRNAs encode for
73 virulence factors expressed at the cell surface (protein A, coagulase, SA1000, Sbi), and the

74 transcriptional repressor of toxins, Rot (Boisset et al., 2007; Chabelskaya et al., 2014;
75 Chevalier et al., 2010; Geisinger et al., 2006; Huntzinger et al., 2005). Through the inhibition
76 of Rot translation, RNAIII indirectly activates the transcription of exotoxins.

77 Besides RNAIII, the response regulatory protein AgrA also contributes to the *agr* regulon by
78 affecting the expression of numerous metabolic enzymes and by activating the membrane-
79 injuring toxins Phenol Soluble Modulines, PSM α and PSM β , as well as *hld* a third PSM
80 encoded by RNAIII (Queck et al., 2008). The translation of PSM α and δ -haemolysin (Hld) is
81 nevertheless delayed. Even if the onset of PSM α production is anticipated by 2 h compared
82 to δ -haemolysin (Vuong et al., 2004), only a small amount of peptide is produced and a real
83 activation takes place later, at the same time as δ -haemolysin, α -haemolysin and several
84 exoprotein production (Balaban and Novick, 1995; Li et al., 2010; Vandenesch et al., 1991;
85 Vuong et al., 2004). Thus, an exceptional temporal control correlates the expression of *hla*,
86 *psm-a* and *hld*, which could not be simply explained by the intervention of RNAIII and AgrA,
87 the two effectors of the quorum sensing system. It has been proposed that an unknown
88 translational factor should be responsible for the delay in δ -haemolysin and PSM α
89 production (Balaban and Novick, 1995; Li et al., 2010; Vandenesch et al., 1991; Vuong et al.,
90 2004).

91 In bacteria, changes in translation efficiency are correlated with specific mRNA features,
92 including structures responding to the intracellular concentration of metabolites
93 (riboswitches), to pH changes (fermentation...), temperature, or to the binding of regulatory
94 proteins or sRNAs (Duval et al., 2015; Romby, 2007; Wagner and Romby, 2015). Opening of
95 mRNA structures on the 30S ribosomal subunit is a slow process operated in Gram-negative
96 and in high G+C content Gram-positive bacteria, by ribosomal protein S1 (Duval et al., 2013).
97 S1 is an RNA chaperone composed by six OB-fold domains bearing distinct functions.
98 Domain 1 was shown to be responsible for ribosome anchoring through specific binding with
99 r-protein S2 (Byrgazov et al., 2015; Byrgazov et al., 2012; Duval et al., 2013). Phylogenetic
100 studies have indicated that S1 from low G+C Gram-positive bacteria, such as *B. subtilis* and
101 *S. aureus*, would not contain the ribosome binding domain (Salah et al., 2009). Indeed, after
102 purification of *S. aureus* 30S and 70S ribosomes, only traces of r-protein S1 were observed
103 by mass spectrometry analysis, suggesting that the protein is not tightly associated with the
104 ribosome (Khusainov et al., 2016; Khusainov et al., 2017). It was previously demonstrated
105 that *B. subtilis* S1 plays no major role in translation and is not an essential protein (Farwell et
106 al., 1992; Juhas et al., 2014; Vellanoweth and Rabinowitz, 1992). It was thus proposed that
107 firmicutes obviate the need of S1 acting on the 30S because the majority of mRNAs carry
108 short 5' UTRs with strong SD sequences (Omotajo et al., 2015). However, in *S. aureus*,

109 mRNAs carrying long 5' or 3' UTRs have been reported (Anderson et al., 2006; Lasa et al.,
110 2011; Ruiz de los Mozos et al., 2013). They include mRNAs encoding virulence factors,
111 various transcriptional regulators, and metabolic enzymes. We have recently analyzed *in*
112 *vitro* the ability of *S. aureus* 30S subunits to form initiation complexes using various *S.*
113 *aureus* mRNA substrates, in which the SD was either located in unpaired and flexible
114 regions, or sequestered into hairpins. *S. aureus* 30S, as the *E. coli* S1-depleted 30S, could
115 not recognize structured mRNAs (Khusainov et al., 2016) suggesting that a translation
116 activator would be necessary to translate structured mRNAs.

117 Here, we show that *S. aureus* S1 (*SauS1*) which is expressed in late-exponential phase, is
118 not a ribosomal protein. *SauS1* is not essential for the growth in rich medium *in vitro* but is
119 required for the correct coordination of virulence factors, by affecting the production of
120 exotoxins (PSMs, α -haemolysin, δ -haemolysin and γ -haemolysins) and exoenzymes
121 (proteases and lipases). Moreover, we demonstrate that *SauS1* can directly bind the highly
122 structured *α psm1-4* mRNA operon, promoting translation initiation of its four peptides. We
123 propose that the presence of structures at the RBS of different toxins requires additional
124 translation activators, which could be either sRNA or S1 protein. The translational functions
125 of *SauS1* are not broad, but rather specific to structured mRNAs in order to facilitate their
126 recruitment on the ribosome.

127

128 MATERIAL AND METHODS

129 Strains, plasmids and growth conditions

130 *S. aureus* strains, plasmids and PCR primers used in this study are listed in **Table S1**. *E. coli*
131 *strain* DC10B (Monk et al., 2012) was used as a host strain for plasmid construction.
132 Plasmids extracted from *E. coli* DC10B can be used directly for *S. aureus* electroporation. *E.*
133 *coli* strain was cultivated in Luria-Bertani (LB) medium (1% peptone, 0.5% yeast extract, 1%
134 NaCl) supplemented with ampicillin (100 μ g/ml) when necessary. LB-agar plates (with or
135 without ampicillin) were also used for growth on solid medium. *S. aureus* strains were grown
136 in Brain-Heart Infusion (BHI) medium (Sigma-Aldrich) supplemented with erythromycin (10
137 μ g/ml) when necessary. Blood-agar (VWR Chemicals) and BHI plates (with or without
138 erythromycin) were used for growth on solid medium.

139 Plasmids were prepared from transformed *E. coli* pellets using the Nucleospin Plasmid kit
140 (Macherey-Nagel). Transformation of both *E. coli* and *S. aureus* strains was performed by
141 electroporation (Bio-Rad Gene Pulser). The plasmid for *rpsA* complementation was prepared
142 using pCN51 as template vector (Charpentier et al., 2004). Synthesis of PCR products was
143 performed using Phusion Polymerase (Thermoscientific). To remove the cadmium inducible

144 promoter, pCN51 was digested by *SphI/PstI*. The P1-*rpsA* promoter region was amplified by
145 PCR and cloned into pCN51 following *SphI/PstI* digestion, forming pCN51::*rpsA*.

146 **Northern blot**

147 Total RNAs were prepared from different volumes of *S. aureus* HG001, HG001, RN6390 and
148 Mu50 cultures taken at 2, 4 and 6 h of growth. After centrifugation, bacterial pellets were
149 resuspended in RNA Pro Solution (MP Biomedicals). Lysis was performed with FastPrep
150 and the RNA purification followed strictly the procedure described for the FastRNA Pro Blue
151 Kit (MP Biomedicals). Electrophoresis of total RNAs (10 µg) was performed on 1% agarose
152 gel containing 20 mM guanidium thiocyanate. After migration, RNAs were vacuum
153 transferred on nitrocellulose membrane. Hybridization with specific digoxigenin (DIG)-
154 labelled probes complementary to *rpsA* sequence followed by luminescent detection was
155 carried out as described previously (Boisset et al., 2007). Hybridization with DNA
156 radioactively labelled probes complementary to *psm* and 5S sequences have been detected
157 by autoradiography film exposition.

158 **Western blot**

159 *S. aureus* BCJ100-*SauS1*-flag culture (100 ml) have been growth in BHI at 37°C and
160 samples were taken at 2, 3, 4, 5 and 6 h. A total of 1 OD for each of them was pelleted by
161 centrifugation and suspended in Laemmli SDS PAGE loading buffer. Total proteins have
162 been separated on 12% SDS-PAGE polyacrylamide gel and transferred on western blot
163 PVDF membranes (Biorad) using trans-blot turbo transfer system (Biorad) setted on low
164 molecular weight proteins for 5 min. The membrane was incubated for 1 h (or overnight) in
165 blocking solution (4,8% of milk in TBS-Tween20 (Sigma Aldrich)). The membrane was
166 washed and incubated with anti-flag antibody (Sigma) at a 1:2500 dilution in TBS-Tween20
167 for 1 h at 20°C under continuous agitation. The membrane was then washed 3 times for 10
168 min with TBS-Tween20 and further incubated with goat anti-mouse IgG (H+C) HRP antibody
169 (Biorad) diluted 1:2500 in TBS-Tween20 for 1 h at 20°C under continuous agitation. The
170 membrane was then washed and the result detected using detection reagent GE Healthcare
171 (Amersham, western blotting detection reagents).

172 **Mutagenesis of the *rspA* gene**

173 Three different mutants have been constructed to abolish *SauS1* production in the HG001
174 strain. A complete deletion mutant ($\Delta rpsA$) has been obtained by allelic replacement
175 according to Boisset et al. (2007). Alternatively, transposon introns containing several stop
176 codons were inserted at position 111 after the AUG start codon (*rpsA111::LtrB*) or at position
177 1029 close to the last domain of S1 (*rpsA1029::LtrB*) according to (Kiedrowski et al., 2011)
178 using the primers described in **Table S1**. The deletion of *rpsA* gene and the insertion of the
179 intron were followed by Northern blot analysis (data do not shown). Mass-spectrometry
180 analysis has confirmed the absence of *SauS1* in all the three strains.

181 **RNA preparation and transcriptomics analysis**

182 *S. aureus* HG001 wild-type (WT) and $\Delta rpsA$ mutant strains were grown in 50 ml BHI medium
183 to an OD_{600nm} of 5 (6h of culture at 37°C), immediately chilled on ice, and then pelleted by
184 centrifugation (3750 rpm, 15 min, 4°C). Lysis was performed with FastPrep and the RNA
185 purification followed strictly the procedure described for the FastRNA Pro Blue Kit (MP
186 Biomedicals). DNase I (0.1 U/ μ l) treatment was performed 1h at 37°C. The reactions
187 mixtures were then purified by phenol/chloroform/isoamylalcohol and subsequent ethanol
188 precipitation. RNA pellets were re-suspended in sterile milliQ water. RNA quality and
189 quantity assessments were performed on Agilent Nano Chip on the Bioanalyzer 2100. The
190 RNAs for total transcriptomics were then treated to deplete abundant rRNAs, and the cDNA
191 libraries were performed using the Random Hexamer approach and sequenced with Illumina
192 Mi-seq using a V4 chemistry sequencing kit (Illumina). Each RNA-seq was performed in
193 duplicates. The standard protocol used is the “TruSeq Stranded mRNA” which is based on
194 the TruSeq Illumina kit. It preserves the information about the orientation of the transcripts
195 and produces reads of 150 nts, which map on the complementary strand. The reads were
196 then processed to remove adapter sequences and poor quality reads by Trimmomatic
197 (Bolger et al., 2014), then they were converted to the FASTQ format with FASTQ Groomer
198 (Blankenberg et al., 2010), and were aligned on the HG001 genome (Caldelari et al., 2017)
199 using BOWTIE2 (Langmead et al., 2009). Finally, the number of reads mapping to each
200 annotated feature has been counted with HTSeq (Anders et al., 2015) using the interception
201 non-empty protocol. All processing steps were performed using the Galaxy platform (Afgan
202 et al., 2016). To estimate the enrichment values for the differential expression analysis for
203 the transcriptomic experiment, we used DEseq2 (Varet et al., 2016). The statistical analysis
204 process includes data normalization, graphical exploration of raw and normalized data, test
205 for differential expression for each feature between the conditions, raw p-value adjustment,
206 and export of lists of features having a significant differential expression (threshold p-
207 value=0.05; fold change threshold=2) between the conditions.

208 **Preparation of RNAs for *in vitro* experiments**

209 Transcription of full *psm* operon, *spa*, *mgrA* and RNAIII was performed using linearized
210 pUC18 vectors (Romilly et al., 2014) or PCR fragments containing the T7 promoter (See
211 **Table S1**). The RNAs were *in vitro* transcribed using T7 RNA polymerase, and purified using
212 a 6% polyacrylamide-8 M urea gel electrophoresis. After elution with 0.5 M ammonium
213 acetate pH 6.5 containing 1 mM EDTA, the RNAs were precipitated in cold absolute ethanol,
214 washed with 85% ethanol and vacuum-dried. The labelling of the 5' end of dephosphorylated
215 RNAs (*psm*, RNAIII) and DNA oligonucleotides were performed with T4 polynucleotide
216 kinase (Fermentas) and [γ ³²P] ATP as previously described (Boisset et al., 2007). Before
217 use, cold or labelled RNAs were renatured by incubation at 90°C for 1 min in 20 mM Tris-

218 HCl pH 7.5, cooled 1 min on ice, and incubated 10 min at 20°C in ToeP+ buffer (20 mM Tris-
219 HCl pH 7.5, 10 mM MgCl₂, 60 mM KCl, 1 mM DTT).

220 **SauS1 cloning and purification**

221 *SauS1* coding sequence with an His(6)-tag and a TEV cleavage site at the N-terminus
222 (Table S1) was cloned into the pQE30 vector (Quiagen), then transformed into *E. coli* M15.
223 Expression and purification of *SauS1* was done as described in (Duval et al., 2013) with the
224 following modifications. After the first Ni-NTA chromatography, the fractions containing
225 *SauS1*, were dialyzed in Buffer Q (20 mM Tris-HCl pH 7.5, 2 mM MgCl₂, 40 mM NH₄Cl, 1
226 mM EDTA, 6 mM β-mercaptoethanol), concentrated to 25 mg/ml and the N-terminal His-tag
227 enzymatically removed using Tev protease (Protean) digestion following the manufacture
228 protocol. The cleaved tag and the His-tagged Tev have been then removed by a second Ni-
229 NTA chromatography to isolate not retained *SauS1*. Finally, *SauS1* was purified on a mono
230 Q column. The protein was dialyzed and stored at -20°C in the storage buffer (20 mM Tris
231 HCl pH 7.5, 2 mM MgCl₂, 100 mM NH₄Cl, 1 mM EDTA, 1 mM DTT, 10% glycerol).

232 **Differential proteomics for cytoplasmic and secreted proteins**

233 Triplicate protein extracts from supernatant or cytoplasm of HG001 (WT) and $\Delta rpsA$ mutant
234 strain both transformed with the empty pCN51 plasmid, and the $\Delta rpsA$ mutant strain
235 complemented with a plasmid expressing *SauS1* (pCN51::*rpsA*), were analyzed in separate
236 LC/MS experiments. MS/MS spectra numbers were compared for each protein. Total protein
237 extracts were prepared as follows: 1.5 ml of a *S. aureus* culture (OD_{600nm} = 5) was
238 centrifuged and the pellet resuspended in 150 μl of Lysis buffer P (10 mM Tris pH 7.5, 20
239 mM NaCl, 1 mM EDTA, 5 mM MgCl₂) in the presence of 50 μg/ml lysostaphin, 15 μl of
240 protease inhibitor cocktail (Thermo Fischer Scientific), 2 μl DNase 10 U/μl (Roche), 2 μl
241 RNase 500 μg/ml (Roche) and incubated for 30 min at 37°C. Then, 1 ml Trizol Reagent (Life
242 Technologies) was used according to the manufacturer's protocol. The final protein phases
243 were then precipitated in ice-cold acetone at least for 2h at -20°C. Secreted proteins were
244 prepared as follows: supernatants of cultures were filtered through a 0.22 μm membrane
245 and precipitated with 5 volumes of 0.1 M ammonium acetate in methanol. To quantify protein
246 extracts by Bradford assay, air-dried protein pellets were resuspended in 2D buffer (7 M
247 urea, 2 M thiourea, 4% Chaps, 25 mM Tris-HCl pH 8) for total extracts or Triton buffer (1%
248 triton x100, 50 mM NaCl, 50 mM Tris-HCl pH 8) for secreted proteins. Proteins (5 μg) were
249 precipitated with methanol/0.1 M ammonium acetate, reduced and alkylated (5 mM DTT, 10
250 mM iodoacetamide), and digested overnight with 1/25 (W/W) of trypsin. The peptide
251 mixtures (1 μg /sample) were analyzed using a NanoLC-2DPlus system coupled to a
252 TripleTOF 5600 mass spectrometer (ABSciex), as previously described (Tomasini et al.,
253 2017). Protein identifications were assigned using Mascot algorithm (version 2.5, Matrix

254 Science, London, UK) through ProlineStudio 1.2 package (<http://proline.profiroteomic.fr/>).
255 Data were searched against the *S. aureus* HG001 genome (Caldelari et al., 2017). Peptide
256 modifications allowed during the search were: N-acetyl (protein), carbamidomethylation (C)
257 and oxidation (M). Mass tolerances in MS and MS/MS were set to 20 ppm and 0.5 Da,
258 respectively. Two trypsin missed cleavages sites were allowed. After the import of the
259 Mascot data files, proteins were validated on Mascot pretty rank equal to 1.1% FDR (False
260 Discovery Rate), on peptide spectrum matches (PSM) based on PSM score, and 1% FDR
261 on protein sets on protein set score. A Spectral Counting quantitative strategy was applied
262 on the Mascot identification summaries. To evaluate the reproducibility, a statistical Student
263 t-test was applied to this experiment.

264 ***psm* operon half-life determination**

265 Bacterial cultures were grown to an OD₆₀₀ of 3. They were then treated with rifampicin (final
266 concentration of 500 µg/ml) to abrogate transcription. RNA samples were collected at
267 indicated time points and quantified by northern blot analysis with ImageQuant TL software
268 (GE Healthcare Life Sciences).

269 **Polysome profiling coupled to Northern blot analysis**

270 WT and $\Delta rpsA$ mutant strains (transformed with the empty pCN51 plasmid for control) and
271 the same mutant strain complemented with the pCN51::*rpsA* plasmid expressing S1 (**Table**
272 **S1**) were cultured in BHI medium at 37°C for 4h (OD₆₀₀ of 4). Chloramphenicol was added to
273 the cultures to have 5 mM of final concentration. After two minutes, the cells have been
274 pelleted by centrifugation (15 minutes at 4°C), resuspended in 500 µl of Lysis buffer R (20
275 mM Tris pH 7.5, 100 mM NH₄Cl, 10 mM MgCl₂, 0.1 % Nonidet p-40, 0.4 % Triton X-100, 1
276 mM Chloramphenicol, 100 U/ml DNaseI) and disrupted with the FastPrep apparatus (MP
277 Biomedicals). 40 K OD₂₆₀ of cell lysates were loaded on sucrose gradient (5% - 50%) and
278 separated on Biocomp instrument. The RNA was extracted from the fractions using acid
279 phenol at 65°C and then precipitated. Northern blot analysis was performed using 1 µg of
280 RNA.

281 **Toe-printing assays**

282 The preparation of *S. aureus* 30S subunits, the formation of a simplified translational
283 initiation complex with mRNA, and the extension inhibition conditions were performed as
284 previously described (Fechter et al., 2009) with slight modifications in the buffer used to
285 dissociate *Sau*70S into subunits (10 mM HEPES-KOH pH 7.5, 100 mM NH₄Cl, 1 mM
286 Mg(OAc)₂, 1 mM DTT). Increasing concentrations of either *Sau*S1 were used to monitor its
287 effects on the formation of the initiation complex with *psm* operon, *spa*, *mgrA* and RNAIII.
288 Prior to toeprinting assay, *Sau*30S subunits were chilled on ice for 10 min then incubated at
289 37°C for 15 min in ToeP+ buffer. In parallel, mRNA (0,5 pmol) was annealed to a 5' end-

290 labeled oligonucleotide (50000 cps), heated at 90°C for 1 min, cooled on ice for 1 min and
291 incubated at RT°C for 10 min in ToeP+ buffer. *SauS1* was pre-incubated in ToeP+ buffer for
292 15 min at 37°C prior to use. 30SIC were constituted at 37°C for 15 min in the presence of
293 the mRNA annealed to the labelled primer and *Sau30S* (0,25; 0,5; 0,75; 1 pmole) pre-
294 incubated or not with 1.5 excess of *SauS1*. The tRNAi (20 pmoles) was then added and the
295 complexes were formed for 5 min at 37°C. Primer extension reactions were subsequently
296 performed by adding 2 units of AMV-RT at 37°C for 30 min. Reactions were stopped by
297 phenol extraction followed with ethanol precipitation, and samples were loaded on 10%
298 urea-PAGE. Quantification of the toe-printing signals present on the autoradiography was
299 done with ImageQuant TL software (GE Healthcare Life Sciences).

300 **Gel filtration**

301 *Sau30S* were reactivated at 37°C for 10 min and incubated in Buffer G (50 mM KCl, 10 mM
302 NH₄Cl, 10 mM MgCl₂, 10 mM Tris HCl pH 7.5, 1 mM DTT) with *SauS1* with or without *psm*
303 mRNA. Previously, *SauS1* was centrifuged for 1h at 4°C at 13000 rpm in order to remove
304 aggregates, new concentration was measured and the protein re-activated in Buffer G at
305 37°C for 10 min. 250 pmoles of *SauS1* were incubated with 25 pmoles of *Sau30S* ribosomal
306 subunit, for 10 min at 37°C in Buffer G, in a total volume of 50 µl. The mix was then
307 centrifuged at 4°C for 10 min at 4200 rpm and the supernatant was loaded on size exclusion
308 column (GE Healthcare Superose TM 6 Increase 3.2 /300). The eluted peaks for *Sau30S*
309 and the free protein have been then analysed by quantitative LC/MSMS to determine
310 stoichiometric ratios between *SauS1* and other ribosomal proteins.

311 **Gel retardation assays**

312 Radiolabelled purified *psm* operon and RNAIII (50000 cps/sample, concentration < 1 pM)
313 were renaturated as described above. For each experiment, increasing concentrations of
314 purified *SauS1* (100-900 nM) were added to the 5' end labelled *psm* or RNAIII in a total
315 volume of 10 µl containing the ToeP+ buffer. Complex formation was performed at 37°C
316 during 15 min. After incubation, 10 µl of glycerol blue was added and the samples were
317 loaded on a 10% PAGE under non denaturing conditions (1h, 300 V, 4°C).

318

319 **RESULTS**


320 ***SauS1* has an atypical expression profile if compared to other r-proteins**

321 In bacteria, the synthesis of the r-proteins is coordinated to the transcription of the ribosomal
322 RNA, which is regulated according to environmental changes and to the different phases of
323 bacterial growth (Kaczanowska and Ryden-Aulin, 2007; Kjeldgaard et al., 1958; Nomura,
324 1999; Nomura et al., 1984; Wagner, 1994). Ribosomes need to be quickly assembled, thus
325 r-RNA and r-proteins accumulate already in the lag and early exponential growth phases

326 (Condon et al., 1995; Rolfe et al., 2012). New ribosomes are also rapidly synthesized to react
327 to ribosome-directed antibiotics challenges (Wenzel and Bandow, 2011). *SauS1*, encoded
328 by *rpsA* gene, has nevertheless a peculiar expression profile. For instance, in response to
329 linezolid stress, *SauS1* is not produced when the other r-proteins are rapidly upregulated
330 (Bonn et al., 2016). We have first monitored the levels of *rpsA* transcript at different stages of
331 bacterial growth in BHI medium by Northern blot (**Figure 12**). The experiment was carried
332 out with *S. aureus* HG001 strain, a derivative of RN1 (NCT8325) strain with restored *rbsU*
333 (Herbert et al., 2010). The data showed that the *rpsA* mRNA has two distinct isoforms with a
334 different pattern of expression. The shorter transcript appears to be constitutively expressed,
335 while the long transcript starts to be expressed at the late exponential phase of growth after
336 3 h ($OD_{600} \sim 2$) and accumulates at the stationary phase (**Figure 12B**). A similar transcription
337 pattern could be observed in other *S. aureus* strains, indicating a conserved mechanism of
338 transcription regulation (**Figure 12D**). The transcripts possibly originate from two different
339 Transcription Start Sites (TSS), as evidenced by aligning raw data from (Koch et al., 2014)
340 on our genome (**Figure 12E**).

341 We have also monitored in parallel the levels of the protein *SauS1* using Western
342 blot analysis (**Figure 12C**). In this experiment, we have introduced into the chromosome of *S.*
343 *aureus* HG001 a 3xflag tag peptide sequence at the C-terminus of *SauS1*. After purification
344 of the total protein extracts, the *SauS1* protein was detected using an anti-flag antibody.
345 Surprisingly, the data showed that the protein levels do not correspond to the pattern of the
346 mRNA since the protein can only be detected after 3h of growth.

347 Taken together these data showed that the expression of *SauS1* is regulated during
348 the growth phase of the bacteria.



349

350 **Figure 12: *S. aureus rpsA* expression profile.** A. Growth curve of HG001 strain in BHI
 351 medium and time points at which cells were harvested for Northern blot and Western blot
 352 analyses. B. Northern blot analysis of *rpsA* mRNA detected at different time points of the
 353 growth (2h, 3h, 4h, 5h, and 6h). The two transcripts (short and long) are noted on the side of
 354 the gel. A short product has been visualized after 5h of growth, which most likely
 355 corresponded to a degradation product. C. Western blot analysis on *SauS1* detected at
 356 different time points of the growth (2h, 3h, 4h, 5h, and 6h). D. Northern blot analysis of
 357 *rpsA* mRNA in different *S. aureus* strains (RN1, RN6390 and Mu50). E. Organization of *rpsA*
 358 locus and possible transcription units (dataset SRR949025 obtained by (Koch et al., 2014)
 359 realigned on the HG001 genome and visualized by IGV (Thorvaldsdottir et al., 2013)). P1
 360 and P2 indicated putative Transcription Start Sites (TSS) from different promoters.
 361

362 ***SauS1* has significant effect on the virulon of *S. aureus* as revealed by comparative**
 363 **transcriptomics and proteomics**

364 We have then investigated the impact of *SauS1* on *S. aureus* total transcriptome (Table S1)
 365 by comparing the RNAs expressed from HG001 (WT) and the isogenic $\Delta rpsA$ mutant strains.
 366 Total RNAs were extracted from WT and $\Delta rpsA$ strains grown to $OD_{600} \sim 5$ (6h) in BHI at
 367 37°C. Under these conditions, *SauS1* is abundant in the WT (Figure 12C). The extracted
 368 RNAs were then used for library preparation and sequencing. The data were analyzed and
 369 visualized using Galaxy (Afgan et al., 2016) and the Integrative Genomics Viewer (IGV)
 370 browser, respectively (Thorvaldsdottir et al., 2013). A detailed protocol for the bioinformatics
 371 analysis is provided in Material and Methods. Briefly, we aligned the sequencing reads onto

372 HG001 genome (Caldelari et al., 2017), counted per feature and normalized. The data were
373 reproduced in two independent experiments.

374 Rather unexpectedly, the differential expression analysis revealed changes in a small
375 number of mRNAs. Among the 2565 annotated mRNAs, only 47 genes are up- and 55 are
376 down-regulated by at least a factor of 2 (**Tables S2 and S3**). Interestingly, more than 35% of
377 down-regulated mRNAs encoded virulence factors, with the *sspABC* and *apsm1-4* operons
378 being the less abundant mRNAs in Δ *rsaA* strain. The non-coding transcriptome showed
379 more extensive variations (**Supplementary excel file S1**). Indeed, the majority of tRNAs
380 and half of the annotated sRNAs showed significant decreased levels in the Δ *rpsA* strain
381 such as the quorum-sensing induced RNAIII and 6S RNA (**Table S4**). In addition, the yields
382 of cis-acting regulatory elements such as riboswitches, and T-boxes were also diminished in
383 Δ *rsaA* strain (**Table S4**).

384 Quantitative differential proteomic and transcriptomic analyses were carried out on
385 total RNA and cytosolic and secreted proteins, prepared from the WT and Δ *rpsA* mutant
386 strains and the same mutant strain complemented with a plasmid expressing S1. The WT
387 and Δ *rpsA* mutant strains were also transformed with the pCN51 plasmid for control (**Table**
388 **S1**). Bacterial growth was performed in BHI medium for 6h. Triplicates experiments have
389 been analyzed by LC/MSMS (**Tables S5, S6**). The differential spectral count analysis nicely
390 correlates with the observed effects on the mRNAs encoding virulence factors (**Table 2**). Of
391 the 79 classified virulence factors, 23 of them are less abundant in the Δ *rpsA* strain. A
392 classification analysis of these factors further evidenced a clear perturbation in the proteins
393 and/or mRNA levels for exoenzymes (serine and cysteine proteases and lipases) and of
394 membrane pore forming toxins, including the four α PMS peptides and the α - δ - and γ -
395 hemolysins (**Table 2**).

396 These data strongly suggested that S1 altered significantly the virulon. Because the
397 levels of several sRNAs and of RNAIII were enhanced in strain expressing S1, some of the
398 effects primarily on proteases might be indirect. However, this is not the case of α -*psm* and
399 β -*psm* operons, which are transcribed by AgrA (Queck et al., 2008), whose level is not
400 affected by SauS1 (**Supplementary excel file S1**). Therefore, we proposed that S1 might
401 regulate the translation of the *psm* operon, and belongs to the class of post-transcriptional
402 regulatory protein.

| id | gene | product | classification | Transcriptomics $\Delta rpsA$ /WT | | Proteomics $\Delta rpsA$ /WT | | Secretomics $\Delta rpsA$ /WT | | Secretomics $\Delta rpsA$ /comp | |
|-------------|-----------------------------|---------------------------------------------------------------------|---------------------------------|-----------------------------------|----------|------------------------------|----------|-------------------------------|----------|---------------------------------|----------|
| | | | | FoldChange | pvalue | FoldChange | pvalue | FoldChange | pvalue | FoldChange | pvalue |
| HG001_00899 | sspA | Glutaryl endopeptidase | Exoenzyme, Serine protease | 0.10 | 2,48E-55 | too few peptides | | 0.17 | 0.16390 | 0.03 | 1,44E-06 |
| HG001_03280 | psm-a4 | 4 psm peptide | Toxin, Pore-forming | 0.17 | 2,20E-32 | n.d. | | n.d. | | n.d. | |
| HG001_03282 | psm-a2 | 2 psm peptide | Toxin, Pore-forming | 0.29 | 1,68E-16 | n.d. | | n.d. | | n.d. | |
| HG001_01009 | hly | Alpha-hemolysin | Toxin, Pore-forming | 0.31 | 2,80E-07 | 0.23 | 0.02739 | 0.39 | 0.02908 | 0.12 | 1,90E-19 |
| HG001_00898 | sspB | Staphopain B | Exoenzyme, Cysteine protease | 0.32 | 1,28E-11 | 0.36 | 0.03388 | SI only | 3,32E-03 | COMET only | 3,19E-14 |
| HG001_02345 | 65 kDa membrane protein Eap | | Exoenzyme, C (L0036) | 0.33 | 8,93E-13 | SI only | 0.00309 | 0.29 | 0.02929 | 2.00 | |
| HG001_00897 | sspC | Staphostatin B | Exoenzyme, Cysteine protease | 0.33 | 3,16E-07 | n.d. | | n.d. | | n.d. | |
| HG001_02058 | hld | Delta-hemolysin | Toxin, Pore-forming | 0.35 | 9,33E-10 | n.d. | | n.d. | | n.d. | |
| HG001_01006 | scn_2 | Staphylococcal complement inhibitor | Immune evasion | 0.39 | 1,47E-04 | n.d. | | n.d. | | n.d. | |
| HG001_02456 | sbi | Immunoglobulin-binding protein | Immune evasion | 0.39 | 3,02E-06 | n.d. | | 0.77 | 0.61590 | 1.00 | 0.39520 |
| HG001_01023 | psm-b2 | 2 beta pm peptide | Adherence | 0.39 | 2,92E-10 | SI only | 0.23790 | n.d. | | n.d. | |
| HG001_03283 | psm-a1 | 1 alpha pm peptide | Toxin, Pore-forming | 0.41 | 4,79E-05 | n.d. | | n.d. | | n.d. | |
| HG001_00264 | lip2 | Lipase 2 | Exoenzyme, Lipase | 0.43 | 2,06E-09 | 0.25 | 1,74E-09 | 0.47 | 0.05042 | 0.18 | 3,06E-19 |
| HG001_02459 | HlgB | Gamma-hemolysin component B | Toxin, Pore-forming | 0.46 | 8,94E-05 | n.d. | | 0.11 | 0.04432 | 0.02 | 5,34E-09 |
| HG001_01971 | - | 65 kDa membrane protein Eap | Adherence | 0.46 | 5,37E-04 | n.d. | | n.d. | | n.d. | |
| HG001_01943 | sspP | Staphopain A | Exoenzyme, Cysteine protease | 0.47 | 1,95E-04 | 0.43 | 0.19580 | 0.42 | 0.44860 | 0.04 | 2,35E-20 |
| HG001_01005 | fib_2 | Fibrinogen-binding protein | Immune evasion, Adherence | 0.47 | 1,23E-03 | n.d. | | 1.37 | 0.01020 | 2.17 | 7,70E-04 |
| HG001_02458 | HlgC | Gamma-hemolysin component C | Toxin, Pore-forming | 0.48 | 3,27E-04 | n.d. | | 1.10 | 0.19490 | 0.37 | 0.07451 |
| HG001_02709 | lipA_2 | Lipase 1 | Exoenzyme, Lipase | 0.56 | 3,18E-03 | 0.38 | 0.59470 | 0.75 | 0.33850 | 0.52 | 0.04707 |
| HG001_03281 | psm-a3 | 3 alpha pm peptide | Toxin, Pore-forming | 0.57 | 8,89E-05 | n.d. | | n.d. | | n.d. | |
| HG001_00978 | isdA | Iron-regulated surface determinant protein A | Iron uptake, Heme uptake | 0.57 | 0.00757 | n.d. | | 0.76 | 0.34240 | 0.71 | 0.76880 |
| HG001_02044 | - | putative leukocidin-like protein 2 | Toxin, Pore-forming | 0.60 | 0.01068 | n.d. | | n.d. | | n.d. | |
| HG001_01340 | ebp5 | Elastin-binding protein Ebp5 | Adherence | 0.63 | 0.00097 | 0.79 | 0.34790 | 1.00 | 0.21290 | 1.27 | 0.12920 |
| HG001_02538 | fibA_1 | Fibrinectin-binding protein A | Adherence | 0.63 | 0.45381 | n.d. | | 1.00 | 0.63420 | 2.00 | 0.36280 |
| HG001_01974 | scn_3 | Staphylococcal complement inhibitor | Immune evasion | 0.68 | 0.03382 | SI only | 0.04091 | 0.63 | 0.98870 | 0.63 | 0.89640 |
| HG001_02043 | - | putative leukocidin-like protein 1 | Toxin, Pore-forming | 0.69 | 0.05932 | 0.70 | 0.64810 | 0.43 | 0.58700 | 0.21 | 0.04609 |
| HG001_01978 | sak | Staphylokinase | Plasminogen activator | 0.69 | 0.05998 | n.d. | | n.d. | | n.d. | |
| HG001_01976 | chp | Chemotaxis inhibitory protein | Immune evasion | 0.71 | 0.22727 | n.d. | | 1.00 | 0.41380 | 0.86 | 0.68490 |
| HG001_02707 | icaB | Poly-beta-1,2C6-N-acetyl-D-glucosamine N-deacetylase | Adherence | 0.71 | 0.23161 | n.d. | | n.d. | | n.d. | |
| HG001_02539 | fibA_2 | Fibrinectin-binding protein A | Adherence | 0.71 | 0.06276 | n.d. | | n.d. | | n.d. | |
| HG001_02559 | cifB | Clumping factor B | Immune evasion | 0.71 | 0.03383 | n.d. | | 1.63 | 0.03239 | 0.85 | 0.87440 |
| HG001_00172 | scn_1 | Staphylococcal complement inhibitor | Immune evasion | 0.72 | 0.22543 | n.d. | | n.d. | | n.d. | |
| HG001_01972 | esp | 65 kDa membrane protein Eap | Adherence | 0.72 | 0.06984 | n.d. | | n.d. | | n.d. | |
| HG001_00728 | cifA | Clumping factor A | Immune evasion | 0.73 | 0.02679 | 0.83 | 0.65790 | 0.79 | 0.56450 | 1.57 | 0.09078 |
| HG001_00977 | isdB | Iron-regulated surface determinant protein B | Iron uptake, Heme uptake | 0.74 | 0.27830 | n.d. | | n.d. | | n.d. | |
| HG001_01752 | lukDv | Leucotoxin LukDv | Toxin, Pore-forming | 0.74 | 0.26637 | n.d. | | n.d. | | n.d. | |
| HG001_02708 | icaC | poly-beta-1,2C6-N-acetyl-D-glucosamine export protein | Adherence | 0.74 | 0.30381 | n.d. | | n.d. | | n.d. | |
| HG001_01002 | fib_1 | Fibrinogen-binding protein | Immune evasion, Adherence | 0.74 | 0.27907 | ArpsA only | 0.24020 | 0.38 | 0.35330 | 1.25 | 0.37010 |
| HG001_00981 | isdE | High-affinity heme uptake system protein | Iron uptake, Heme uptake | 0.75 | 0.29359 | n.d. | | n.d. | | n.d. | |
| HG001_02706 | icaD | Poly-beta-1,2C6-N-acetyl-D-glucosamine synthesis protein | Adherence | 0.78 | 0.39029 | n.d. | | n.d. | | n.d. | |
| HG001_00767 | hlyC | Hemolysin C | Allows resistance to high Mg++ | 0.79 | 0.17686 | n.d. | | n.d. | | n.d. | |
| HG001_00234 | esxB | Virulence factor EsxB | Type VII secretion system | 0.79 | 0.34392 | n.d. | | n.d. | | n.d. | |
| HG001_01753 | lukEv | Leucotoxin LukEv | Toxin, Pore-forming | 0.79 | 0.41746 | n.d. | | n.d. | | n.d. | |
| HG001_00979 | isdC | Iron-regulated surface determinant protein C | Iron uptake, Heme uptake | 0.80 | 0.43470 | n.d. | | n.d. | | n.d. | |
| HG001_01973 | hly_1 | Phospholipase C | Toxin, Hydrolase | 0.82 | 0.47461 | n.d. | | n.d. | | n.d. | |
| HG001_00233 | esxA | hypothetical protein | Type VII secretion system | 0.83 | 0.40875 | n.d. | | n.d. | | n.d. | |
| HG001_00980 | isdD | hypothetical protein | Iron uptake, Heme uptake | 0.84 | 0.51617 | n.d. | | n.d. | | n.d. | |
| HG001_00231 | essB | putative membrane protein essB | Type VII secretion system | 0.84 | 0.43664 | n.d. | | n.d. | | n.d. | |
| HG001_00984 | isdG | Heme oxygenase (staphylobilin-producing) 1 | Iron uptake, Heme uptake | 0.85 | 0.57256 | n.d. | | n.d. | | n.d. | |
| HG001_02705 | icaA | Poly-beta-1,2C6-N-acetyl-D-glucosamine synthase | Adherence | 0.85 | 0.58631 | n.d. | | n.d. | | n.d. | |
| HG001_02576 | aur | Zinc metalloproteinase aureolysin | Exoenzyme, Zinc metalloprotease | 0.87 | 0.43983 | n.d. | | n.d. | | n.d. | |
| HG001_00217 | esxA | Virulence factor EsxA | Type VII secretion system | 0.89 | 0.50433 | 1.37 | 0.49980 | n.d. | | n.d. | |
| HG001_00102 | YwqE_1 | Tyrosine-protein phosphatase YwqE | Antiphagocytosis | 0.90 | 0.50249 | SI only | 0.09507 | n.d. | | n.d. | |
| HG001_01022 | psm-b1 | 1 beta pm peptide | Adherence | 0.905 | 0.50906 | 1.00 | 0.99450 | n.d. | | n.d. | |
| HG001_00729 | VWbp | Staphylocoagulase | Exoenzyme | 0.92 | 0.76399 | n.d. | | n.d. | | n.d. | |
| HG001_00230 | yukD | YukD | Type VII secretion system | 0.92 | 0.77518 | n.d. | | n.d. | | n.d. | |
| HG001_02242 | hlySA | Hyaluronate lyase | Exoenzyme, Spreading factor | 0.92 | 0.73210 | n.d. | | n.d. | | n.d. | |
| HG001_00101 | YwqD_1 | Tyrosine-protein kinase YwqD | Antiphagocytosis | 0.95 | 0.72346 | 0.84 | 0.40500 | n.d. | | n.d. | |
| HG001_00112 | epsL | putative sugar transferase EpsL | Antiphagocytosis | 0.95 | 0.72866 | n.d. | | n.d. | | n.d. | |
| HG001_00983 | srtB | Sortase family protein | Iron uptake, Heme uptake | 0.95 | 0.85382 | n.d. | | n.d. | | n.d. | |
| HG001_00219 | essA | Firmicute eSAT-6 protein secretion system EssA | Type VII secretion system | 0.97 | 0.98057 | n.d. | | n.d. | | n.d. | |
| HG001_00982 | isdF | heme-iron transport system permease | Iron uptake, Heme uptake | 0.98 | 0.93990 | n.d. | | n.d. | | n.d. | |
| HG001_00113 | gpfE | UDP-glucose 4-epimerase | Antiphagocytosis | 0.99 | 0.94326 | n.d. | | n.d. | | n.d. | |
| HG001_00232 | eccCa1 | ESK-1 secretion system protein EccCa1 | Type VII secretion system | 0.99 | 0.95368 | too few peptides | | n.d. | | n.d. | |
| HG001_02042 | Hly_2 | Phospholipase C | Toxin, Hydrolase | 0.99 | 0.95750 | n.d. | | n.d. | | n.d. | |
| HG001_02457 | HlgA | Gamma-hemolysin component A | Toxin, Pore-forming | 1.01 | 0.98451 | n.d. | | n.d. | | n.d. | |
| HG001_00493 | isdI | Serine-aspartate repeat-containing protein D | Adherence, MSCRAMMs | 1.03 | 0.89302 | too few peptides | | 0.73 | 0.45960 | 3.27 | 1,70E-04 |
| HG001_00115 | mnaA_1 | UDP-N-acetylglucosamine 2-epimerase | Antiphagocytosis | 1.07 | 0.86886 | 1.76 | 0.28740 | n.d. | | n.d. | |
| HG001_00104 | capD | UDP-glucose 4-epimerase | Antiphagocytosis | 1.08 | 0.68071 | Del-S1 only | 0.09371 | n.d. | | n.d. | |
| HG001_00105 | fdl | GDP-L-Fucose synthase | Antiphagocytosis | 1.11 | 0.48166 | Del-S1 only | 0.00667 | n.d. | | n.d. | |
| HG001_02704 | icaR | Biofilm operon icaADBC HFH-type negative transcriptional regulator | Adherence | 1.17 | 0.39326 | 0.76 | 0.73090 | n.d. | | n.d. | |
| HG001_00228 | esaA | Secretion accessory protein EsaA/YueB @ Bacteriophage SPP1 receptor | Type VII secretion system | 1.18 | 0.36029 | n.d. | | n.d. | | n.d. | |
| HG001_00100 | cap8A_1 | Capsular polysaccharide type 8 biosynthesis | Antiphagocytosis | 1.19 | 0.25569 | 0.43 | 0.55600 | n.d. | | n.d. | |
| HG001_00106 | wbpI | UDP-2,2C3-diacetamido-2,2C3-dideoxy-D-glucuronate 2-epimerase | Antiphagocytosis | 1.19 | 0.27180 | 1.00 | 0.98980 | n.d. | | n.d. | |
| HG001_00027 | yfjM_1 | Trifunctional nucleotide phosphoesterase | Immune evasion | 1.25 | 0.15295 | SI only | 0.10650 | 1.25 | 0.29720 | 1.67 | 0.21470 |
| HG001_00114 | wbpA | UDP-N-acetyl-D-glucosamine 6-dehydratase | Antiphagocytosis | 1.27 | 0.14709 | 0.65 | 0.51870 | n.d. | | n.d. | |
| HG001_00111 | cap5L | putative glycosyl transferase | Antiphagocytosis | 1.29 | 0.10239 | n.d. | | n.d. | | n.d. | |
| HG001_00103 | pgfI | UDP-N-acetyl-alpha-D-glucosamine C6 dehydratase | Antiphagocytosis | 1.33 | 0.16077 | n.d. | | n.d. | | n.d. | |
| HG001_00060 | spa | Immunoglobulin G-binding protein A | Immune evasion, Adherence | 1.35 | 0.07927 | n.d. | | 0.86 | 0.05719 | 5.00 | 2,02E-11 |

402

403

404

405

406

407

408

409

410

411

412

413


Table 2: Differential transcriptomics and proteomics analysis of virulence factors expression in $\Delta rpsA$. Fold change ($\Delta rpsA$ /WT) and p-values were calculated for the transcriptomics analysis by DESeq2 using shrinkage estimation for dispersions and fold changes (Varet et al., 2016), for the proteomics by the R-Studio software. Fold change estimations and p-values have p-values<0.005 (high significance), when highlighted by dark-grey boxes they have p-values>0.001; light-grey boxes indicate 0.005>p-values>0.001.

SauS1 protects *psm* mRNA operon against *in vivo* degradation.

Due to the structural resemblance of *SauS1* to the ribosomal protein *EcoS1*, we make the hypothesis that the protein would regulate the translation initiation process of the *psm* operon. Indeed, in Gram-positive bacteria, stabilization of mRNAs can be due to the binding

414 of the ribosome or of key factors close to their 5' ends (Condon, 2003). To test whether the
 415 decreased level of *psm* mRNA (0.17; **Table 2**) in the $\Delta rpsA$ strain could be due to a more
 416 rapid turnover, we have analysed its stability by measuring the kinetics of its degradation
 417 after rifampicin treatment, an antibiotic which prevents initiation of new transcripts by binding
 418 to the β subunit of RNA polymerase (Campbell et al., 2001). Rifampicin was added to WT
 419 and the mutant *rpsA111::LtrB* strains grown in BHI to $OD_{600}=3$ (4h), when *psm* started to
 420 accumulate (**Figure S1**). The *psm* mRNA was detected by Northern blot using total RNAs
 421 extracted after 2, 4, 8, 15, 30, 45 and 60 min (**Figure 13A**). Quantification, normalization and
 422 interpolation of the data by linear regression in logarithmic scale, showed that the *psm*
 423 transcript is highly stable, with a half-life of 77.02 min in the WT strain. In contrast to the
 424 majority of the transcripts (90%), which have half-lives shorter than 5 min (Roberts et al.,
 425 2006), this operon is one of the most stable transcript. In the mutant strain, the *psm* half-life
 426 appears to be significantly shorter and was decreased to 46.52 min (**Figure 13B**).

427 Therefore, these data showed that SauS1 has a significant effect on the stabilization
 428 of the *psm* operon, in agreement with the transcriptomics and proteomics analysis.



429
 430 **Figure 13. *psm* mRNA stability.** A. Northern blot analysis of the *psm* transcript in WT and
 431 *rpsA111::LtrB*. Cells were growth at 37°C in BHI and treated with rifampicin at 4h. Total RNA
 432 was extracted after 2, 4, 8, 15, 30, 45 and 60 min. *psm* mRNA and 5S rRNA were probed
 433 with specific oligonucleotides (**Table S1**). B. After quantification of the Northern blot signals
 434 and normalization of each point to the corresponding 5S signals, the % of remaining *psm*
 435 mRNA has been plotted to calculate *psm* half-lives in the two strains. $T_{1/2}$ HG001 (WT) is
 436 77.02 min, while in absence of *SauS1*, $T_{1/2}$ *rpsA111::LtrB* decreases to 46.52 min.


437

438 Polysome occupancy of *psm* mRNA is higher in presence of *SauS1*

439 Because the effect of S1 on the mRNA stability can be the result of an enhanced translation,
 440 we have analyzed the mRNA distribution using polysome profile analysis coupled with
 441 Northern blot experiments. The experiments were done on WT and mutant $\Delta rpsA$ strains
 442 grown in BHI at 37°C until mid-exponential phase ($OD_{600}=4$). Translation was then stopped
 443 by adding chloramphenicol to the cultures and the cells were rapidly harvested by
 444 centrifugation. After cell lysis, polysomes have been separated *via* ultracentrifugation on a 5-
 445 50% sucrose gradient. The RNA was extracted from each fraction and Northern blot was
 446 done using specific oligonucleotides to detect *psm*, *hu* mRNAs and 16S rRNA. Quantification

447 and normalization on the 16S rRNA level have revealed huge differences on the amount of
 448 *psm* mRNA recruited in the polysomes in the two strains (**Figure 14AB**). In the absence of
 449 *SauS1*, much less mRNA (0.23 fold change $\Delta rpsA/WT$) is engaged on the ribosomes to be
 450 translated compared to WT strain. Moreover, we could show that translation activation by
 451 *SauS1* is specific for *psm* mRNA. Indeed, the translation of *hu* mRNA does not depend on
 452 *SauS1* and its polysome occupancy does not significantly vary (1.27 fold). Because in both
 453 WT and mutant $\Delta rpsA$ strain, we did not detect the free mRNA in the fractions of low density
 454 (**Figure 14AB**), we could not exclude that the observed differences in the polysome fractions
 455 reflect the variation in *psm* mRNA levels. However, one cannot exclude that the free *psm*
 456 transcript, which is not protected by the ribosomes, is also rapidly degraded.

457 These data showed that the S1-dependent stabilization of the *psm* mRNA might
 458 result from an enhanced translatability.



459

460 **Figure 14. Effects of *SauS1* on the translation of *psm* and *hu* mRNAs by polysome**
 461 **profile coupled with Northern blot analysis.** WT and $\Delta rpsA$ strains (A and B, respectively)
 462 were cultured in BHI at 37°C until $OD_{600}=4$, translation was stopped with chloramphenicol
 463 and polysomes fractionated on a 5-50% sucrose gradient. The RNA was extracted from
 464 each fraction and Northern blot was done using specific oligonucleotides to detect *psm*, and
 465 *hu* mRNAs, and 16S rRNA. L= cellular lysate. The 16S rRNA in the L line was used for the
 466 normalization.


467

468 ***SauS1* specifically promotes ribosome binding on *psm* mRNA**

469 Toe-printing assays (Hartz et al., 1988) were used to decipher the effect of *SauS1* on the
 470 formation of the ternary initiation complex formed in the presence of *psm* mRNA, the initiator
 471 tRNA and the *Sau30S* subunit (**Figure 15**). We have verified that *SauS1* was not bound to
 472 the 30S. A toe-print is observed at position +16 (+1 is the adenine of the start codon) if the

473 mRNA occupies the decoding channel stabilized by the codon-anticodon interaction with the
 474 initiator tRNA. The *psm* operon contains four coding regions (CDS) and is predicted to be
 475 highly structured (**Figure S2**). In this structure, the four RBS are hindered into stable hairpin
 476 structures. **Figure 15A** shows that, without *SauS1* the toe-prints at the four RBSs are very
 477 weak. Even at the highest *Sau30S* concentration, they are barely detectable or above the
 478 noise with the exception of the first toe-print suggestion that the ribosome better recognized
 479 the first RBS. However, much stronger toe-print signals could be observed in the presence
 480 of the purified *SauS1* at the four translation initiation sites. *SauS1* stimulatory effect seems to
 481 be more pronounced for the 4th RBS, followed by the 2nd, while it is less marked for the 1st
 482 and the 3rd. Because the toeprint at the 1st RBS was too close to the full extended product to
 483 be quantified, we have repeated the experiment and used a different RT primer (**Table S1**)
 484 to uniquely detect this signal (**Figure 15B**). Quantification has been obtained from three
 485 independent experiments to establish the K_d using non-linear fitting of a single exponential
 486 between the plotted values. The calculated K_d for 30S binding are 0.13 and 0.03 μM for the
 487 *Sau30S* and *Sau30S+S1*, respectively. Thus *SauS1* helps the 30S to recruit *psm* mRNA
 488 increasing its affinity by a factor of ~4.

489 The observed *in vitro* stimulatory effect of *SauS1* on the formation of the initiation
 490 complexes with the *psm* operon is also compatible with the better recruitment of the *psm*
 491 transcript on polysomes (**Figure 14**) in the WT strain rather than in the mutant $\Delta rpsA$ strain.



492

493 **Figure 15. Toeprinting assays to monitor the effect of *SauS1* on the translation**
494 **initiation complex formation with *psm* mRNA.** (A) Effect of *SauS1* on the formation of
495 initiation complex using *psm* mRNA and an oligonucleotide that anneals at the 3' end of the
496 mRNA. When present, *SauS1* was pre-incubated with the ribosome at a constant 1.6 molar
497 ratio. Lane 1: incubation control of mRNA ; Lane 2: incubation control of mRNA with 30S
498 subunits ; Lanes 3, 4, 5 and 6: formation of the initiation complex containing mRNA,
499 increasing concentration of 30S (25, 50, 100, 200 nM) and fMet-tRNA. Lane7: incubation
500 control of mRNA with purified *SauS1*. Lane 8: incubation control of mRNA, 30S and *SauS1*.
501 Lanes 9, 10, 11 and 12: formation of initiation complex in presence of *SauS1* and increasing
502 concentrations of 30S (25, 50, 100, 200 nM). Lanes U, A, G, C: sequencing ladders. The
503 toe-printing signals at position +16 are indicated by arrows. (B) Toe-printing done with an
504 oligonucleotide annealing close to the 5' end to better visualize the 1st RBS of the *psm*
505 mRNA. Same legend as in the panel A. (C) Quantification of the toe-printing using
506 ImageQuanTL software (GE Healthcare). Signals were normalized according to the total
507 amount of radioactivity (full-length extension and +16 product bands).

508 In order to assess if the activity of *SauS1* is specifically linked to the alleviation of translation
509 repression mediated by cis-acting mRNA structures, we tested by toe-printing one more
510 natural *S. aureus. spa* mRNA, which harbours distinct structural features. A short 5' UTR
511 containing a strong SD sequence exposed in a hairpin loop, and an unpaired AU rich
512 sequence downstream the start codon which has low propensity of forming stable structures
513 (predicted $\Delta G = -2.7$ kcal/mol) (**Figure S3 and S4**). We have previously shown that *E. coli*
514 ribosomes, containing or not S1, are able to form initiation complexes with *spa* mRNA
515 (Khusainov et al., 2016). As shown in **Figure S3**, *SauS1* enhances only very weakly the
516 formation of the translation initiation complex on *spa* mRNA.

517

518 ***SauS1* stimulates *psm* translation initiation by binding directly to the mRNA**


519 To further investigate the mechanism by which *SauS1* stimulates translation of the *psm*
520 mRNA, we checked its ability to interact with the 30S ribosome. Mass spectrometry analyses
521 of purified *S. aureus* 70S and 30S have shown only traces of *SauS1* (Khusainov et al., 2016;
522 Khusainov et al., 2017). This could have been resulted from dissociation occurring during
523 ribosome purification or could be due to its inability to bind the ribosome. To address this
524 question we forced a possible interaction by incubating large excess of *SauS1* with *Sau30S*.
525 Gel filtration chromatography (GFC) was used to purify the complex, which has been
526 analyzed by LC/MSMS to determine the protein content (**Figure 16A**). The chromatogram,
527 following the absorbance of the 30S at 280 nm, shows a single peak where all 30S r-proteins
528 have been found except *SauS1* (**Table S7**), which was eluted at a later time. This data
529 indicates that *SauS1* does not interact with the 30S. The same experiment was then
530 performed in the presence of *psm* mRNA (**Figure 16B**). The obtained absorbance profile
531 resembles strictly the previous one, while the spectral count analysis of the fractions

532 indicates the presence of *SauS1* on the 30S at a level compatible with the other r-proteins
533 (Table S7).

534 We then analyzed whether *SauS1* binds directly to *psm* mRNA using gel retardation
535 assays (Figure 16C). *In vitro* 5' end-labelled *psm* was incubated with increasing
536 concentrations of *SauS1*. The data showed that *SauS1* is able to form two distinct
537 complexes with *psm* mRNA possibly indicating that two *SauS1* molecules are able to bind to
538 the mRNA with different affinity (between 100-200 nM and around 300 nM). To finally prove
539 that the activation mechanism relies on the formation of *SauS1-psm* complex, a new toe-
540 printing assay was done on *psm* mRNA pre-incubated with *SauS1* before the addition of the
541 30S and the initiator tRNA (Figure S5). A strong enhancement of the initiation complex
542 formation on the 1st CDS could be observed even at a low concentration of *SauS1* (100 nM).

543 Taken together, these data revealed that *SauS1* is not a ribosomal protein but
544 activates *psm* translation through a direct binding with *psm* mRNA, possibly at multiple sites.
545 The presence of inhibitory structures on *psm* RBSs would suggest a possible remodeling of
546 the RNA structure upon *SauS1* interaction, which would liberate their SD sequences to
547 facilitate the 30S recruitment.

548



549

550 **Figure 16. *SauS1* activates translation of *psm* by direct binding to the mRNA.** A.
551 Chromatogram of the gel filtration (Superose TM 6 Increase 3.2/300) for the *Sau30S+SauS1*
552 complex (green profile) indicating the peak for the *Sau30S* and the peak for *SauS1* (blue
553 profile) observed by spectral counts analysis of the fractions. B. As for panel A. with the sole
554 exception that *psm* mRNA has been added to the complex. *SauS1* spectral counts in the
555 different fractions have been normalized to the total *SauS1* counts obtained in each of the
556 two experiments. Peaks in panel A and B could be directly compared. C. Gel retardation
557 assays to monitor *SauS1* binding to *psm* mRNA. The 5' end-labelled *psm* mRNA was
558 incubated with increasing concentrations (nM) of *SauS1*. Two complexes could be detected.
559 The positions of the complexes and of the free *psm* are indicated by arrows.

560

561

562 DISCUSSION

563 In bacteria, the main determinant for mRNA recruitment on the 30S is the SD sequence
564 which base-pairs with the 3' end of the 16S rRNA in the center of the 30S platform, a
565 positively charged ring shape environment made by several key r-proteins (S1, S2, S7, S11,

566 S18 and S21)(Duval et al., 2015; Simonetti et al., 2009). Among these r-proteins, the largest
567 r-protein S1 confers to the *E. coli* 30S the ability to recognize any type of mRNAs (e.g.,(Boni
568 et al., 1991; Duval et al., 2013; Sorensen et al., 1998; Tzareva et al., 1994)). Particularly, S1
569 has been shown to increase the affinity of weak SD containing mRNAs, and to confer an
570 RNA chaperone activity to the 30S that is essential to unfold different structures promoting
571 mRNA accommodation into the decoding channel. In *E. coli*, the essential activity of S1 is
572 linked to its N-terminal OB-fold domain, which directly interacts with the 30S (Byrgazov et al.,
573 2015; Byrgazov et al., 2012; Duval et al., 2013). A phylogenetic study revealed that S1 from
574 Gram-negative bacteria and high G+C content Gram-positive bacteria (i.e., actinobacteria)
575 share similar domain organization containing at least the first four OB-fold domains that
576 retained full 30S and RNA binding capacity, and the RNA chaperone activity (Duval et al.,
577 2013; Duval et al., 2017; Salah et al., 2009). In contrast, S1 from low G+C content Gram-
578 positive bacteria (firmicutes), contained only four OB-fold domains (Salah et al., 2009). A
579 specific domain alignment analysis, strongly suggested that *SauS1* organization is most
580 likely d3-d2-d3-d4, and does not carry the domain required for ribosome binding
581 **(Supplementary Figure S6).**


582 Here, we show that *SauS1* is not an essential protein as it was demonstrated for
583 other Gram-positive bacteria (e.g. in *B. subtilis* (Kobayashi et al., 2003), and in *S.*
584 *pneumoniae* (Song et al., 2005)), and is not a ribosomal protein since we did not observe any
585 detectable interaction with the 30S and the 70S ribosomes. Despite its non-ribosomal
586 localization, we provide the first example of translation activation involving S1 in the major
587 bacterial pathogen *S. aureus*. Specifically, we show that *SauS1* strongly and specifically
588 activates the translation of the structured *psm* operon mRNA. Our data suggest that *SauS1*
589 plays multiple functions in gene regulation: (i) the protein facilitates the ribosome binding to
590 *psm* mRNA operon at the initiation step of protein synthesis; (ii) *SauS1* is present on
591 polysomes only through its interaction with *psm* mRNA; (ii) transcriptomics and proteomics
592 analysis revealed that *SauS1* is also an important regulator of exotoxin production, and
593 might be a partner of sRNA-mediated regulation.

594 Although previous experiments suggested that S1 homologues had different
595 properties and functions in Enterobacteriaceae and in low G-C Gram-positive bacteria, we
596 show here that *SauS1* still exerts an important function in translation disconnected from the
597 ribosome. The lack of the N-terminal domain most likely coincides with the fact that many
598 mRNAs in low G-C Gram-positive bacteria contains strong SD sequences. Although
599 additional experiments will be required to assess the molecular mechanism of S1-dependent
600 activation of *psm* translation, we propose that *SauS1* has evolved as a translational regulator
601 and RNA chaperone protein, in a way reminiscent to the cold shock protein CspA in *E. coli*
602 (Giuliodori et al., 2010). Indeed, the *psm* operon is predicted to be a highly structured RNA in

603 which the four SD and the coding sequences are sequestered into hairpin motifs. These
604 hairpins are connected through unpaired A/U rich regions (**Figure S2**), which are known to
605 be ideal binding sites for *E. coli* S1 (Boni et al., 1991; Duval et al., 2013). Band shift
606 experiments revealed that several proteins bind to *psm* transcript with low or medium
607 affinities (from 100 to 300 nM). . These data suggested that *SauS1* forms dynamic
608 complexes with RNA and most probably acts as an RNA chaperone to remodel the RNA
609 structure, which becomes competent for translation. Another example of a structured RNA
610 encoded *psm* is RNAIII, which contained several long-range interactions bringing in close
611 proximity its 5' and 3' non coding regions (Benito et al., 2000). Noteworthy, it has been
612 shown that the translation of the PSM delta-hemolysin and the activation of many exotoxins
613 are delayed after the transcription of RNAIII, and this delay was abolished if the 3' non
614 coding region of RNAIII is deleted (Balaban and Novick, 1995). It is tempting to propose that
615 *SauS1* might help to promote the RNAIII conformational switch allowing the recruitment of
616 the ribosome on *hld* RBS.

617 What could be the rationale of the *SauS1* regulation? The transcription of *rpsA* is
618 regulated upon cell growth and its synthesis enhances strongly at the late exponential level.
619 The functional significance for the existence of the two transcripts awaits for more
620 experimental data. Nevertheless, the accumulation of S1 at the late exponential level
621 corresponded to the expression pattern of the longest of the two transcripts (**Figure 12**).
622 Intriguingly, this expression pattern follows the synthesis of the quorum sensing system
623 RNAIII and of many exotoxins, for which the expression was found downregulated in the
624 mutant *rpsA* (**Table 2**). These exotoxins include the PSMs (α -PSM, β -PSM, Hld), the
625 endopeptidases SspAB, the fibronectin binding proteins (FnbA and FnbB), and hemolysins
626 (Hla, Hld, HlgB and HlgC). The PSMs are short, amphipathic α -helical peptides, which play
627 key roles in virulence by promoting lysis of neutrophils, and contributing to the dissemination
628 of biofilm-associated infection (reviewed in Otto, 2013). In contrast to many exotoxins, the
629 transcription of PSM is strictly dependent on the *agr* quorum sensing system. A recent study
630 revealed that SarA is required for the PSM synthesis as well as other exotoxins contributing
631 to the acute phase of *S. aureus* osteomyelitis (Loughran et al., 2016) but this regulatory
632 event could be the result of the SarA-dependent activation of AgrA transcription (Loughran et
633 al., 2016; Queck et al., 2008). Interestingly, the expression of *rpsA* is also drastically reduced
634 in different *sarA* mutant strains (Loughran et al., 2016; Roberts et al., 2006). Because SarA
635 is strongly induced during the transition from late exponential phase to stationary phase
636 (Manna et al., 1998), it might be responsible for the coordination of *rpsA* transcription with
637 that of *psm*. The strict regulation of PSMs expression under both the quorum sensing control
638 and *SauS1* might be necessary for the concerted action during acute infection, when they

639 are produced to promote dissemination and tissue lysis. Since they contribute to biofilm
 640 detachment/dissemination (Kong et al., 2006; Periasamy et al., 2012; Tsompanidou et al.,
 641 2011), an early induction could expose *S. aureus* to the host immune system before a critical
 642 mass could have been attained. In that regard, it is worth to notice that *SauS1* could also
 643 regulate the translation of the *sspABC* operon, coding endopeptidases important for immune
 644 suppression and infection dissemination (Imamura et al., 2005; Jusko et al., 2014;
 645 Ohbayashi et al., 2011). Their expression is *agr*-dependent, probably mediated by Rot, as
 646 inactivation of *rot* in an *agr* mutant resulted in upregulation of *sspABC* mRNA levels (Said-
 647 Salim et al., 2003). Rot levels are not changed in our $\Delta rpsA$ mutant (**Supplementary excel**
 648 **file S1**), leaving open the possibility that *SauS1* would also enhance their translation.
 649 Nevertheless, many other regulators have been described, like σ^B , SarA, MgrA, SaeRS,
 650 SarV, SarR, SarS, SrrAB and ArlRS (Bischoff et al., 2004; Cheung et al., 2001; Fournier et
 651 al., 2001; Luong et al., 2003; Manna et al., 2004; Novick and Jiang, 2003). Given the
 652 complexity of *sspABC* regulation, assessing the impact of *SauS1* would require individual
 653 analysis on the different pathways. Noteworthy, the RBSs of *sspA* and *sspB* are predicted to
 654 be embedded into inhibitory structures that would require the chaperone activity of *SauS1* for
 655 active translation (**Figure S4**). A similar situation could be shared by other virulence genes,
 656 such as the immune evasion protein *sbi*, which shows structured RBS (**Figure S4**) and a
 657 decreased level despite the strong *SauS1*-dependent reduction of the levels of the two
 658 translational repressor RNAs, SprD and RNAIII (Chabelskaya et al., 2014). Taken together,
 659 S1 adds another layer of regulation to modulate the expression of virulence factors (**Figure**
 660 **17**).



661

662 **Figure 17. Impact of *SauS1* on the regulatory circuits involved in virulence gene**
663 **expression.** Only parts of the regulatory circuits taken from the literature have been
664 represented. SarA might induce *rpsA* transcription coordinating *SauS1* expression with the
665 transcription of RNAIII which is also under the control of the quorum sensing system (*agr*)
666 *via* the activation of the transcription factor AgrA. *SauS1* activates the translation of PSM α
667 peptides and possibly also Ssp proteins, Sbi and δ -hemolysin (*hld*). The feedforward loop
668 motif involving RNAIII, the transcriptional regulator Rot and the circuits controlled by RsaA,
669 SprD and RsaE are also represented. The transcriptional regulatory proteins are in blue, the
670 regulatory RNAs are in red and the target proteins are in purple, *SauS1* is green. Values
671 reported on the sides of each gene represent their fold changes in the $\Delta rpsA$ mutant, as
672 transcripts (upper values) or proteins (lower values). The transcriptional regulation is shown
673 by black line, sRNA regulation is shown by red line while *SauS1* translation regulation is
674 shown with green lines. Arrows correspond to activation while bars correspond to repression.
675 Regulations shown by dotted lines await experimental validation.

676

677 Interestingly, the production of toxins and exoenzymes was reported to be
678 specifically perturbed by sub-inhibitory concentration of linezolid antibiotic (Coyle et al., 2003;
679 Diep et al., 2012; Dumitrescu et al., 2007; Gemmell and Ford, 2002; Otto et al., 2013).
680 Linezolid targets the A site of the ribosome and blocks peptide bond formation (Wilson et al.,
681 2008). At sub-inhibitory concentration, it promotes the synthesis of new ribosomal proteins to
682 make more ribosomes (Bonn et al., 2016). However, under these conditions, *SauS1* is no
683 more synthesized, thus producing a situation similar to the mutant $\Delta rpsA$ strain. It is possible
684 that the specific effect of linezolid on the synthesis of virulence factors is linked to the
685 incapacity of the newly synthesized ribosome to recognize the structured mRNAs encoded
686 these toxins and exoenzymes.

687 Finally, the yields of several sRNAs appear to be significantly reduced in $\Delta rpsA$ strain.
688 Such a phenotype has been largely demonstrated in Enterobacteriaceae for the RNA
689 chaperone Hfq (Cui et al., 2013; Sonnleitner et al., 2006; Updegrove et al., 2016; Vogel and
690 Luisi, 2011) and for ProQ (Smirnov et al., 2016; Smirnov et al., 2017). These two proteins
691 are key co-factors helping the sRNAs to regulate the expression of mRNAs at the post-
692 transcriptional level. Mutations in *hfq* also decrease virulence in several pathogens (for
693 review, see (Vogel and Papenfort, 2006)). In contrast to this, the function of Hfq in low G+C
694 Gram-positive bacteria is still unclear and controversial (Bouloc and Repoila, 2016), and
695 there is no ProQ equivalent in *S. aureus* (Attaiech et al., 2017; Olejniczak and Storz, 2017).
696 In *S. aureus*, Hfq binds to RNAs, but it neither enhances the recognition between antisense
697 RNAs and their target mRNAs (Zheng et al., 2016) nor the stability of sRNAs (Boisset et al.,
698 2007; Preis et al., 2009). Furthermore, no major phenotypes were linked to its deletion in *S.*

699 *aureus* (Bohn et al., 2007). By acting on the stability of several sRNAs, such as RNAIII,
700 RsaE, RsaA, and SprD, known to bind mRNAs and to affect their translation (reviewed in
701 (Felden et al., 2011; Mandin and Guillier, 2013; Tomasini et al., 2014), *SauS1* might be a
702 key partner of sRNA regulation. Some of the observed deregulations in the mutant $\Delta rpsA$
703 strain might be indirect. For instance, the *hla* reduced expression could be explained by less
704 amount of the translational activator RNAIII (Morfeldt et al., 1995), and the enhanced levels
705 of the pleiotropic regulatory protein MgrA might be due to a decreased level of its main
706 repressor RsaA (Romilly et al., 2014).

707 This work shows that *SauS1* belongs to a new class of RNA chaperones that play
708 key roles in the regulation of translation in *S. aureus* and most probably in Gram-positive
709 bacteria. Our current study provides some hints for further investigation of the molecular
710 functions and mechanisms of *SauS1* in gene regulation.

711

712 **ACKNOWLEDGEMENT**

713 We are grateful to Anne-Catherine Helfer for her help in the toe-printing assay on the RNAIII,
714 to Javier Rol for the RNAIII band-shift experiment and to Philippe Hammann for his
715 assistance with mass spectrometry analysis (IBMC proteomic platform).

716

717 **FUNDING**

718 This work was supported by the Centre National de la Recherche Scientifique (CNRS) to
719 [P.R.], by the ANR agency (ANR RIBOSTAPH) [P.R.] and has been published under the
720 framework of the LABEX: ANR-10-LABX-0036 NETRNA to [P.R.], a funding from the state
721 managed by the French National Research Agency as part of the investments for the future
722 program. In addition, the LABEX NetRNA granted the mass spectrometry instrumentation.

723

724 **REFERENCES**
725

- 726 Afgan, E., Baker, D., van den Beek, M., Blankenberg, D., Bouvier, D., Cech, M., Chilton, J.,
727 Clements, D., Coraor, N., Eberhard, C., *et al.* (2016). The Galaxy platform for accessible,
728 reproducible and collaborative biomedical analyses: 2016 update. *Nucleic Acids Res* *44*,
729 W3-W10.
- 730 Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq--a Python framework to work with high-
731 throughput sequencing data. *Bioinformatics* (Oxford, England) *31*, 166-169.
- 732 Anderson, K.L., Roberts, C., Disz, T., Vonstein, V., Hwang, K., Overbeek, R., Olson, P.D.,
733 Projan, S.J., and Dunman, P.M. (2006). Characterization of the *Staphylococcus aureus* heat
734 shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA
735 turnover. *Journal of bacteriology* *188*, 6739-6756.
- 736 Attaiech, L., Glover, J.N., and Charpentier, X. (2017). RNA Chaperones Step Out of Hfq's
737 Shadow. *Trends in microbiology* *25*, 247-249.
- 738 Balaban, N., and Novick, R.P. (1995). Translation of RNAIII, the *Staphylococcus aureus* agr
739 regulatory RNA molecule, can be activated by a 3'-end deletion. *FEMS microbiology letters*
740 *133*, 155-161.
- 741 Benito, Y., Kolb, F.A., Romby, P., Lina, G., Etienne, J., and Vandenesch, F. (2000). Probing
742 the structure of RNAIII, the *Staphylococcus aureus* agr regulatory RNA, and identification of
743 the RNA domain involved in repression of protein A expression. *RNA* (New York, NY) *6*,
744 668-679.
- 745 Bischoff, M., Dunman, P., Kormanec, J., Macapagal, D., Murphy, E., Mounts, W., Berger-
746 Bachi, B., and Projan, S. (2004). Microarray-based analysis of the *Staphylococcus aureus*
747 sigmaB regulon. *Journal of bacteriology* *186*, 4085-4099.
- 748 Blankenberg, D., Gordon, A., Von Kuster, G., Coraor, N., Taylor, J., and Nekrutenko, A.
749 (2010). Manipulation of FASTQ data with Galaxy. *Bioinformatics* (Oxford, England) *26*,
750 1783-1785.
- 751 Bohn, C., Rigoulay, C., and Bouloc, P. (2007). No detectable effect of RNA-binding protein
752 Hfq absence in *Staphylococcus aureus*. *BMC Microbiol* *7*, 10.
- 753 Boisset, S., Geissmann, T., Huntzinger, E., Fechter, P., Bendridi, N., Possedko, M.,
754 Chevalier, C., Helfer, A.C., Benito, Y., Jacquier, A., *et al.* (2007). *Staphylococcus aureus*
755 RNAIII coordinately represses the synthesis of virulence factors and the transcription
756 regulator Rot by an antisense mechanism. *Genes & development* *21*, 1353-1366.
- 757 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina
758 sequence data. *Bioinformatics* (Oxford, England) *30*, 2114-2120.
- 759 Boni, I.V., Isaeva, D.M., Musychenko, M.L., and Tzareva, N.V. (1991). Ribosome-
760 messenger recognition: mRNA target sites for ribosomal protein S1. *Nucleic Acids Res* *19*,
761 155-162.
- 762 Bonn, F., Pane-Farre, J., Schluter, R., Schaffer, M., Fuchs, S., Bernhardt, J., Riedel, K., Otto,
763 A., Volker, U., van Dijl, J.M., *et al.* (2016). Global analysis of the impact of linezolid onto
764 virulence factor production in *S. aureus* USA300. *International journal of medical*
765 *microbiology : IJMM* *306*, 131-140.
- 766 Bouloc, P., and Repoila, F. (2016). Fresh layers of RNA-mediated regulation in Gram-
767 positive bacteria. *Current opinion in microbiology* *30*, 30-35.
- 768 Byrgazov, K., Grishkovskaya, I., Arenz, S., Coudeville, N., Temmel, H., Wilson, D.N.,
769 Djinovic-Carugo, K., and Moll, I. (2015). Structural basis for the interaction of protein S1 with
770 the *Escherichia coli* ribosome. *Nucleic Acids Res* *43*, 661-673.
- 771 Byrgazov, K., Manoharadas, S., Kaberdina, A.C., Vesper, O., and Moll, I. (2012). Direct
772 interaction of the N-terminal domain of ribosomal protein S1 with protein S2 in *Escherichia*
773 *coli*. *PLoS one* *7*, e32702.
- 774 Caldelari, I., Chane-Woon-Ming, B., Noirot, C., Moreau, K., Romby, P., Gaspin, C., and
775 Marzi, S. (2017). Complete Genome Sequence and Annotation of the *Staphylococcus*
776 *aureus* Strain HG001. *Genome announcements* *5*.

777 Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst,
778 S.A. (2001). Structural mechanism for rifampicin inhibition of bacterial rna polymerase. *Cell*
779 *104*, 901-912.

780 Chabelskaya, S., Bordeau, V., and Felden, B. (2014). Dual RNA regulatory control of a
781 *Staphylococcus aureus* virulence factor. *Nucleic Acids Res* *42*, 4847-4858.

782 Charpentier, E., Anton, A.I., Barry, P., Alfonso, B., Fang, Y., and Novick, R.P. (2004). Novel
783 cassette-based shuttle vector system for gram-positive bacteria. *Applied and environmental*
784 *microbiology* *70*, 6076-6085.

785 Cheung, A.L., Schmidt, K., Bateman, B., and Manna, A.C. (2001). SarS, a SarA homolog
786 repressible by agr, is an activator of protein A synthesis in *Staphylococcus aureus*. *Infection*
787 *and immunity* *69*, 2448-2455.

788 Chevalier, C., Boisset, S., Romilly, C., Masquida, B., Fechter, P., Geissmann, T.,
789 Vandenesch, F., and Romby, P. (2010). *Staphylococcus aureus* RNAIII binds to two distant
790 regions of coa mRNA to arrest translation and promote mRNA degradation. *PLoS pathogens*
791 *6*, e1000809.

792 Condon, C. (2003). RNA processing and degradation in *Bacillus subtilis*. *Microbiology and*
793 *molecular biology reviews* : MMBR *67*, 157-174, table of contents.

794 Condon, C., Squires, C., and Squires, C.L. (1995). Control of rRNA transcription in
795 *Escherichia coli*. *Microbiological reviews* *59*, 623-645.

796 Coyle, E.A., Cha, R., and Rybak, M.J. (2003). Influences of linezolid, penicillin, and
797 clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release.
798 *Antimicrobial agents and chemotherapy* *47*, 1752-1755.

799 Cui, M., Wang, T., Xu, J., Ke, Y., Du, X., Yuan, X., Wang, Z., Gong, C., Zhuang, Y., Lei, S.,
800 *et al.* (2013). Impact of Hfq on global gene expression and intracellular survival in *Brucella*
801 *melitensis*. *PloS one* *8*, e71933.

802 Diep, B.A., Equils, O., Huang, D.B., and Gladue, R. (2012). Linezolid effects on bacterial
803 toxin production and host immune response: review of the evidence. *Current therapeutic*
804 *research, clinical and experimental* *73*, 86-102.

805 Dumitrescu, O., Boisset, S., Badiou, C., Bes, M., Benito, Y., Reverdy, M.E., Vandenesch, F.,
806 Etienne, J., and Lina, G. (2007). Effect of antibiotics on *Staphylococcus aureus* producing
807 Panton-Valentine leukocidin. *Antimicrobial agents and chemotherapy* *51*, 1515-1519.

808 Duval, M., Korepanov, A., Fuchsbaauer, O., Fechter, P., Haller, A., Fabbretti, A., Choulier, L.,
809 Micura, R., Klaholz, B.P., Romby, P., *et al.* (2013). *Escherichia coli* ribosomal protein S1
810 unfolds structured mRNAs onto the ribosome for active translation initiation. *PLoS biology* *11*,
811 e1001731.

812 Duval, M., Marena, A., Chevalier, C., and Marzi, S. (2017). Site-Directed Chemical Probing
813 to map transient RNA/protein interactions. *Methods (San Diego, Calif)* *117*, 48-58.

814 Duval, M., Simonetti, A., Caldelari, I., and Marzi, S. (2015). Multiple ways to regulate
815 translation initiation in bacteria: Mechanisms, regulatory circuits, dynamics. *Biochimie* *114*,
816 18-29.

817 Farwell, M.A., Roberts, M.W., and Rabinowitz, J.C. (1992). The effect of ribosomal protein
818 S1 from *Escherichia coli* and *Micrococcus luteus* on protein synthesis in vitro by *E. coli* and
819 *Bacillus subtilis*. *Molecular microbiology* *6*, 3375-3383.

820 Fechter, P., Chevalier, C., Yusupova, G., Yusupov, M., Romby, P., and Marzi, S. (2009).
821 Ribosomal initiation complexes probed by toeprinting and effect of trans-acting translational
822 regulators in bacteria. *Methods in molecular biology (Clifton, NJ)* *540*, 247-263.

823 Felden, B., Vandenesch, F., Boulloc, P., and Romby, P. (2011). The *Staphylococcus aureus*
824 RNome and its commitment to virulence. *PLoS pathogens* *7*, e1002006.

825 Fournier, B., Klier, A., and Rapoport, G. (2001). The two-component system ArlS-ArlR is a
826 regulator of virulence gene expression in *Staphylococcus aureus*. *Molecular microbiology* *41*,
827 247-261.

828 Geisinger, E., Adhikari, R.P., Jin, R., Ross, H.F., and Novick, R.P. (2006). Inhibition of rot
829 translation by RNAIII, a key feature of agr function. *Molecular microbiology* *61*, 1038-1048.

830 Geisinger, E., Muir, T.W., and Novick, R.P. (2009). agr receptor mutants reveal distinct
831 modes of inhibition by staphylococcal autoinducing peptides. *Proceedings of the National*
832 *Academy of Sciences of the United States of America* *106*, 1216-1221.

833 Gemmell, C.G., and Ford, C.W. (2002). Virulence factor expression by Gram-positive cocci
834 exposed to subinhibitory concentrations of linezolid. *The Journal of antimicrobial*
835 *chemotherapy* *50*, 665-672.

836 Giuliodori, A.M., Di Pietro, F., Marzi, S., Masquida, B., Wagner, R., Romby, P., Gualerzi,
837 C.O., and Pon, C.L. (2010). The cspA mRNA is a thermosensor that modulates translation of
838 the cold-shock protein CspA. *Molecular cell* *37*, 21-33.

839 Hartz, D., McPheeters, D.S., Traut, R., and Gold, L. (1988). Extension inhibition analysis of
840 translation initiation complexes. *Methods Enzymol* *164*, 419-425.

841 Herbert, S., Ziebandt, A.K., Ohlsen, K., Schafer, T., Hecker, M., Albrecht, D., Novick, R., and
842 Gotz, F. (2010). Repair of global regulators in *Staphylococcus aureus* 8325 and comparative
843 analysis with other clinical isolates. *Infection and immunity* *78*, 2877-2889.

844 Huntzinger, E., Boisset, S., Saveanu, C., Benito, Y., Geissmann, T., Namane, A., Lina, G.,
845 Etienne, J., Ehresmann, B., Ehresmann, C., *et al.* (2005). *Staphylococcus aureus* RNAIII
846 and the endoribonuclease III coordinately regulate spa gene expression. *The EMBO journal*
847 *24*, 824-835.

848 Ibarra, J.A., Perez-Rueda, E., Carroll, R.K., and Shaw, L.N. (2013). Global analysis of
849 transcriptional regulators in *Staphylococcus aureus*. *BMC genomics* *14*, 126.

850 Imamura, T., Tanase, S., Szmyd, G., Kozik, A., Travis, J., and Potempa, J. (2005). Induction
851 of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases
852 from *Staphylococcus aureus*. *The Journal of experimental medicine* *201*, 1669-1676.

853 Janzon, L., and Arvidson, S. (1990). The role of the delta-lysin gene (hld) in the regulation of
854 virulence genes by the accessory gene regulator (agr) in *Staphylococcus aureus*. *The*
855 *EMBO journal* *9*, 1391-1399.

856 Juhas, M., Reuss, D.R., Zhu, B., and Commichau, F.M. (2014). *Bacillus subtilis* and
857 *Escherichia coli* essential genes and minimal cell factories after one decade of genome
858 engineering. *Microbiology (Reading, England)* *160*, 2341-2351.

859 Jusko, M., Potempa, J., Kantyka, T., Bielecka, E., Miller, H.K., Kalinska, M., Dubin, G.,
860 Garred, P., Shaw, L.N., and Blom, A.M. (2014). Staphylococcal proteases aid in evasion of
861 the human complement system. *Journal of innate immunity* *6*, 31-46.

862 Kaczanowska, M., and Ryden-Aulin, M. (2007). Ribosome biogenesis and the translation
863 process in *Escherichia coli*. *Microbiology and molecular biology reviews : MMBR* *71*, 477-
864 494.

865 Khusainov, I., Marena, A., Cerciati, M., Fechter, P., Hashem, Y., Marzi, S., Romby, P.,
866 Yusupova, G., and Yusupov, M. (2016). [A glimpse on *Staphylococcus aureus* translation
867 machinery and its control]. *Molekuliarnaia biologii* *50*, 549-557.

868 Khusainov, I., Vicens, Q., Bochler, A., Grosse, F., Myasnikov, A., Menetret, J.F., Chicher, J.,
869 Marzi, S., Romby, P., Yusupova, G., *et al.* (2017). Structure of the 70S ribosome from
870 human pathogen *Staphylococcus aureus*. *Nucleic Acids Res* *45*, 1026.

871 Kiedrowski, M.R., Kavanaugh, J.S., Malone, C.L., Mootz, J.M., Voyich, J.M., Smeltzer, M.S.,
872 Bayles, K.W., and Horswill, A.R. (2011). Nuclease modulates biofilm formation in
873 community-associated methicillin-resistant *Staphylococcus aureus*. *PloS one* *6*, e26714.

874 Kjeldgaard, N.O., Maaloe, O., and Schaechter, M. (1958). The transition between different
875 physiological states during balanced growth of *Salmonella typhimurium*. *Journal of general*
876 *microbiology* *19*, 607-616.

877 Kobayashi, K., Ehrlich, S.D., Albertini, A., Amati, G., Andersen, K.K., Arnaud, M., Asai, K.,
878 Ashikaga, S., Aymerich, S., Bessieres, P., *et al.* (2003). Essential *Bacillus subtilis* genes.
879 *Proceedings of the National Academy of Sciences of the United States of America* *100*,
880 4678-4683.

881 Koch, G., Yepes, A., Forstner, K.U., Wermser, C., Stengel, S.T., Modamio, J., Ohlsen, K.,
882 Foster, K.R., and Lopez, D. (2014). Evolution of resistance to a last-resort antibiotic in
883 *Staphylococcus aureus* via bacterial competition. *Cell* *158*, 1060-1071.

884 Kong, K.F., Vuong, C., and Otto, M. (2006). Staphylococcus quorum sensing in biofilm
885 formation and infection. *International journal of medical microbiology : IJMM* 296, 133-139.

886 Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-
887 efficient alignment of short DNA sequences to the human genome. *Genome biology* 10, R25.

888 Lasa, I., Toledo-Arana, A., Dobin, A., Villanueva, M., de los Mozos, I.R., Vergara-Irigaray, M.,
889 Segura, V., Fagegaltier, D., Penades, J.R., Valle, J., *et al.* (2011). Genome-wide antisense
890 transcription drives mRNA processing in bacteria. *Proceedings of the National Academy of*
891 *Sciences of the United States of America* 108, 20172-20177.

892 Li, M., Cheung, G.Y., Hu, J., Wang, D., Joo, H.S., Deleo, F.R., and Otto, M. (2010).
893 Comparative analysis of virulence and toxin expression of global community-associated
894 methicillin-resistant *Staphylococcus aureus* strains. *The Journal of infectious diseases* 202,
895 1866-1876.

896 Loughran, A.J., Gaddy, D., Beenken, K.E., Meeker, D.G., Morello, R., Zhao, H., Byrum, S.D.,
897 Tackett, A.J., Cassat, J.E., and Smeltzer, M.S. (2016). Impact of sarA and Phenol-Soluble
898 Modulins on the Pathogenesis of Osteomyelitis in Diverse Clinical Isolates of
899 *Staphylococcus aureus*. *Infection and immunity* 84, 2586-2594.

900 Lowy, F.D. (1998). *Staphylococcus aureus* infections. *The New England journal of medicine*
901 339, 520-532.

902 Luong, T.T., Newell, S.W., and Lee, C.Y. (2003). Mgr, a novel global regulator in
903 *Staphylococcus aureus*. *Journal of bacteriology* 185, 3703-3710.

904 Mandin, P., and Guillier, M. (2013). Expanding control in bacteria: interplay between small
905 RNAs and transcriptional regulators to control gene expression. *Current opinion in*
906 *microbiology* 16, 125-132.

907 Manna, A.C., Bayer, M.G., and Cheung, A.L. (1998). Transcriptional analysis of different
908 promoters in the sar locus in *Staphylococcus aureus*. *Journal of bacteriology* 180, 3828-
909 3836.

910 Manna, A.C., Ingavale, S.S., Maloney, M., van Wamel, W., and Cheung, A.L. (2004).
911 Identification of sarV (SA2062), a new transcriptional regulator, is repressed by SarA and
912 MgrA (SA0641) and involved in the regulation of autolysis in *Staphylococcus aureus*. *Journal*
913 *of bacteriology* 186, 5267-5280.

914 Monk, I.R., Shah, I.M., Xu, M., Tan, M.W., and Foster, T.J. (2012). Transforming the
915 untransformable: application of direct transformation to manipulate genetically
916 *Staphylococcus aureus* and *Staphylococcus epidermidis*. *mBio* 3.

917 Morfeldt, E., Taylor, D., von Gabain, A., and Arvidson, S. (1995). Activation of alpha-toxin
918 translation in *Staphylococcus aureus* by the trans-encoded antisense RNA, RNAIII. *The*
919 *EMBO journal* 14, 4569-4577.

920 Nomura, M. (1999). Regulation of ribosome biosynthesis in *Escherichia coli* and
921 *Saccharomyces cerevisiae*: diversity and common principles. *Journal of bacteriology* 181,
922 6857-6864.

923 Nomura, M., Gourse, R., and Baughman, G. (1984). Regulation of the synthesis of
924 ribosomes and ribosomal components. *Annual review of biochemistry* 53, 75-117.

925 Novick, R.P., and Geisinger, E. (2008). Quorum sensing in staphylococci. *Annual review of*
926 *genetics* 42, 541-564.

927 Novick, R.P., and Jiang, D. (2003). The staphylococcal saeRS system coordinates
928 environmental signals with agr quorum sensing. *Microbiology (Reading, England)* 149, 2709-
929 2717.

930 Novick, R.P., Ross, H.F., Projan, S.J., Kornblum, J., Kreiswirth, B., and Moghazeh, S. (1993).
931 Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule.
932 *The EMBO journal* 12, 3967-3975.

933 Ohbayashi, T., Irie, A., Murakami, Y., Nowak, M., Potempa, J., Nishimura, Y., Shinohara, M.,
934 and Imamura, T. (2011). Degradation of fibrinogen and collagen by staphopains, cysteine
935 proteases released from *Staphylococcus aureus*. *Microbiology (Reading, England)* 157, 786-
936 792.

937 Olejniczak, M., and Storz, G. (2017). ProQ/FinO-domain proteins: another ubiquitous family
938 of RNA matchmakers? *Molecular microbiology* 104, 905-915.

939 Omotajo, D., Tate, T., Cho, H., and Choudhary, M. (2015). Distribution and diversity of
940 ribosome binding sites in prokaryotic genomes. *BMC genomics* 16, 604.

941 Otto, M.P., Martin, E., Badiou, C., Lebrun, S., Bes, M., Vandenesch, F., Etienne, J., Lina, G.,
942 and Dumitrescu, O. (2013). Effects of subinhibitory concentrations of antibiotics on virulence
943 factor expression by community-acquired methicillin-resistant *Staphylococcus aureus*. *The*
944 *Journal of antimicrobial chemotherapy* 68, 1524-1532.

945 Periasamy, S., Joo, H.S., Duong, A.C., Bach, T.H., Tan, V.Y., Chatterjee, S.S., Cheung,
946 G.Y., and Otto, M. (2012). How *Staphylococcus aureus* biofilms develop their characteristic
947 structure. *Proceedings of the National Academy of Sciences of the United States of America*
948 109, 1281-1286.

949 Preis, H., Eckart, R.A., Gudipati, R.K., Heidrich, N., and Brantl, S. (2009). CodY activates
950 transcription of a small RNA in *Bacillus subtilis*. *Journal of bacteriology* 191, 5446-5457.

951 Queck, S.Y., Jameson-Lee, M., Villaruz, A.E., Bach, T.H., Khan, B.A., Sturdevant, D.E.,
952 Ricklefs, S.M., Li, M., and Otto, M. (2008). RNAIII-independent target gene control by the
953 agr quorum-sensing system: insight into the evolution of virulence regulation in
954 *Staphylococcus aureus*. *Molecular cell* 32, 150-158.

955 Roberts, C., Anderson, K.L., Murphy, E., Projan, S.J., Mounts, W., Hurlburt, B., Smeltzer, M.,
956 Overbeek, R., Disz, T., and Dunman, P.M. (2006). Characterizing the effect of the
957 *Staphylococcus aureus* virulence factor regulator, SarA, on log-phase mRNA half-lives.
958 *Journal of bacteriology* 188, 2593-2603.

959 Rolfe, M.D., Rice, C.J., Lucchini, S., Pin, C., Thompson, A., Cameron, A.D., Alston, M.,
960 Stringer, M.F., Betts, R.P., Baranyi, J., *et al.* (2012). Lag phase is a distinct growth phase
961 that prepares bacteria for exponential growth and involves transient metal accumulation.
962 *Journal of bacteriology* 194, 686-701.

963 Romby, P., and Springer, M. (2007). Translational control in prokaryotes. In *Translational*
964 *control in biology and medicine*, M.B. Mathews, Sonenberg, N., and Hershey, J. W. B., ed.
965 (Cold Spring Harbour: Cold Spring Harbour Laboratory Press), pp. 803-827.

966 Romilly, C., Lays, C., Tomasini, A., Caldelari, I., Benito, Y., Hammann, P., Geissmann, T.,
967 Boisset, S., Romby, P., and Vandenesch, F. (2014). A non-coding RNA promotes bacterial
968 persistence and decreases virulence by regulating a regulator in *Staphylococcus aureus*.
969 *PLoS pathogens* 10, e1003979.

970 Ruiz de los Mozos, I., Vergara-Irigaray, M., Segura, V., Villanueva, M., Bitarte, N.,
971 Saramago, M., Domingues, S., Arraiano, C.M., Fechter, P., Romby, P., *et al.* (2013). Base
972 pairing interaction between 5'- and 3'-UTRs controls *icaR* mRNA translation in
973 *Staphylococcus aureus*. *PLoS genetics* 9, e1004001.

974 Said-Salim, B., Dunman, P.M., McAleese, F.M., Macapagal, D., Murphy, E., McNamara, P.J.,
975 Arvidson, S., Foster, T.J., Projan, S.J., and Kreiswirth, B.N. (2003). Global regulation of
976 *Staphylococcus aureus* genes by Rot. *Journal of bacteriology* 185, 610-619.

977 Salah, P., Bisaglia, M., Aliprandi, P., Uzan, M., Sizun, C., and Bontems, F. (2009). Probing
978 the relationship between Gram-negative and Gram-positive S1 proteins by sequence
979 analysis. *Nucleic Acids Res* 37, 5578-5588.

980 Simonetti, A., Marzi, S., Jenner, L., Myasnikov, A., Romby, P., Yusupova, G., Klaholz, B.P.,
981 and Yusupov, M. (2009). A structural view of translation initiation in bacteria. *Cellular and*
982 *molecular life sciences : CMLS* 66, 423-436.

983 Smirnov, A., Forstner, K.U., Holmqvist, E., Otto, A., Gunster, R., Becher, D., Reinhardt, R.,
984 and Vogel, J. (2016). Grad-seq guides the discovery of ProQ as a major small RNA-binding
985 protein. *Proceedings of the National Academy of Sciences of the United States of America*
986 113, 11591-11596.

987 Smirnov, A., Wang, C., Drewry, L.L., and Vogel, J. (2017). Molecular mechanism of mRNA
988 repression in trans by a ProQ-dependent small RNA. *The EMBO journal* 36, 1029-1045.

989 Somerville, G.A., and Proctor, R.A. (2009). At the crossroads of bacterial metabolism and
990 virulence factor synthesis in *Staphylococci*. *Microbiology and molecular biology reviews :*
991 *MMBR* 73, 233-248.

992 Song, J.H., Ko, K.S., Lee, J.Y., Baek, J.Y., Oh, W.S., Yoon, H.S., Jeong, J.Y., and Chun, J.
993 (2005). Identification of essential genes in *Streptococcus pneumoniae* by allelic replacement
994 mutagenesis. *Molecules and cells* *19*, 365-374.

995 Sonnleitner, E., Schuster, M., Sorger-Domenigg, T., Greenberg, E.P., and Blasi, U. (2006).
996 Hfq-dependent alterations of the transcriptome profile and effects on quorum sensing in
997 *Pseudomonas aeruginosa*. *Molecular microbiology* *59*, 1542-1558.

998 Sorensen, M.A., Fricke, J., and Pedersen, S. (1998). Ribosomal protein S1 is required for
999 translation of most, if not all, natural mRNAs in *Escherichia coli* in vivo. *J Mol Biol* *280*, 561-
1000 569.

1001 Thammavongsa, V., Kim, H.K., Missiakas, D., and Schneewind, O. (2015). Staphylococcal
1002 manipulation of host immune responses. *Nature reviews Microbiology* *13*, 529-543.

1003 Thorvaldsdottir, H., Robinson, J.T., and Mesirov, J.P. (2013). Integrative Genomics Viewer
1004 (IGV): high-performance genomics data visualization and exploration. *Briefings in*
1005 *bioinformatics* *14*, 178-192.

1006 Tomasini, A., Francois, P., Howden, B.P., Fechter, P., Romby, P., and Caldelari, I. (2014).
1007 The importance of regulatory RNAs in *Staphylococcus aureus*. *Infection, genetics and*
1008 *evolution : journal of molecular epidemiology and evolutionary genetics in infectious*
1009 *diseases* *21*, 616-626.

1010 Tomasini, A., Moreau, K., Chicher, J., Geissmann, T., Vandenesch, F., Romby, P., Marzi, S.,
1011 and Caldelari, I. (2017). The RNA targetome of *Staphylococcus aureus* non-coding RNA
1012 RsaA: impact on cell surface properties and defense mechanisms. *Nucleic Acids Res.*

1013 Tsompanidou, E., Sibbald, M.J., Chlebowicz, M.A., Dreisbach, A., Back, J.W., van Dijl, J.M.,
1014 Buist, G., and Denham, E.L. (2011). Requirement of the *agr* locus for colony spreading of
1015 *Staphylococcus aureus*. *Journal of bacteriology* *193*, 1267-1272.

1016 Tzareva, N.V., Makhno, V.I., and Boni, I.V. (1994). Ribosome-messenger recognition in the
1017 absence of the Shine-Dalgarno interactions. *FEBS letters* *337*, 189-194.

1018 Updegrave, T.B., Zhang, A., and Storz, G. (2016). Hfq: the flexible RNA matchmaker.
1019 *Current opinion in microbiology* *30*, 133-138.

1020 Vandenesch, F., Kornblum, J., and Novick, R.P. (1991). A temporal signal, independent of
1021 *agr*, is required for *hla* but not *spa* transcription in *Staphylococcus aureus*. *Journal of*
1022 *bacteriology* *173*, 6313-6320.

1023 Varet, H., Brillet-Gueguen, L., Coppee, J.Y., and Dillies, M.A. (2016). SARTools: A DESeq2-
1024 and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data.
1025 *PLoS one* *11*, e0157022.

1026 Vellanoweth, R.L., and Rabinowitz, J.C. (1992). The influence of ribosome-binding-site
1027 elements on translational efficiency in *Bacillus subtilis* and *Escherichia coli* in vivo. *Molecular*
1028 *microbiology* *6*, 1105-1114.

1029 Vogel, J., and Luisi, B.F. (2011). Hfq and its constellation of RNA. *Nature reviews*
1030 *Microbiology* *9*, 578-589.

1031 Vogel, J., and Papenfort, K. (2006). Small non-coding RNAs and the bacterial outer
1032 membrane. *Current opinion in microbiology* *9*, 605-611.

1033 Vuong, C., Durr, M., Carmody, A.B., Peschel, A., Klebanoff, S.J., and Otto, M. (2004).
1034 Regulated expression of pathogen-associated molecular pattern molecules in
1035 *Staphylococcus epidermidis*: quorum-sensing determines pro-inflammatory capacity and
1036 production of phenol-soluble modulins. *Cellular microbiology* *6*, 753-759.

1037 Wagner, E.G., and Romby, P. (2015). Small RNAs in bacteria and archaea: who they are,
1038 what they do, and how they do it. *Advances in genetics* *90*, 133-208.

1039 Wagner, R. (1994). The regulation of ribosomal RNA synthesis and bacterial cell growth.
1040 *Archives of microbiology* *161*, 100-109.

1041 Wenzel, M., and Bandow, J.E. (2011). Proteomic signatures in antibiotic research.
1042 *Proteomics* *11*, 3256-3268.

1043 Wertheim, H.F., Melles, D.C., Vos, M.C., van Leeuwen, W., van Belkum, A., Verbrugh, H.A.,
1044 and Nouwen, J.L. (2005). The role of nasal carriage in *Staphylococcus aureus* infections.
1045 *The Lancet Infectious diseases* *5*, 751-762.

1046 Wilson, D.N., Schluenzen, F., Harms, J.M., Starosta, A.L., Connell, S.R., and Fucini, P.
1047 (2008). The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and
1048 effect tRNA positioning. *Proceedings of the National Academy of Sciences of the United*
1049 *States of America* *105*, 13339-13344.

1050 Zheng, A., Panja, S., and Woodson, S.A. (2016). Arginine Patch Predicts the RNA
1051 Annealing Activity of Hfq from Gram-Negative and Gram-Positive Bacteria. *J Mol Biol* *428*,
1052 2259-2264.

1053

1054


1 **SUPPLEMENTARY MATERIALS AND METHODS**

2


3 **SUPPLEMENTARY FIGURES**

4

5 **Figure S1: Northern blot analysis of *psm* expression.** (A) HG001 and *rpsA111::LtrB*
6 strains were growth in BHI medium at 37°C, cells were harvested and RNA extracted at pre-
7 (2h), mid- (4h) and post- exponential (6h) phases. The Northern blot was performed with
8 specific oligonucleotide complementary to *psm* mRNA. In the *SauS1* mutant strain, much
9 less *psm* signal could be detected. (B) The membrane was colored using ethidium bromide
10 to visualize the rRNAs. Quantification and normalization against total RNAs revealed that the
11 *psm* operon is 4.6 fold less abundant in the mutant than in the WT strain.




30 **Figure S2: Secondary structure of *psm* mRNA.** The secondary structure has been
31 predicted with the Mfold server (Zuker, 2003). The *psm* operon contained four open reading
32 frames encoding PSM1-4. The Ribosome Binding Site are shaded in light-blue. The four toe-
33 printing signals are marked at +16 position by arrows.




34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Figure S3. Toeprinting assays to monitor the effect of *SauS1* on the translation**
 53 **initiation complex formation with *spa* mRNA.** (A) Effect of *SauS1* on the formation of
 54 initiation complex using *spa* mRNA. When present, *SauS1* was pre-incubated with the
 55 ribosome at a constant 1.6 molar ratio. Lane 1: incubation control of mRNA ; Lane 2:
 56 incubation control of mRNA with 30S subunits ; Lanes 3, 4, 5 and 6: formation of the
 57 initiation complex containing mRNA, increasing concentration of 30S (25, 50, 100, 200 nM)
 58 and fMet-tRNA. Lane 7: incubation control of mRNA with purified *SauS1*. Lane 8: incubation
 59 control of mRNA, 30S and *SauS1*. Lanes 9, 10, 11 and 12: formation of initiation complex in
 60 presence of *SauS1* and increasing concentrations of 30S (25, 50, 100, 200 nM). Lanes U, A,
 61 G, C: sequencing ladders. The toe-printing signals at position +16 are indicated by arrows.
 62 (B) Scheme for the secondary structure of the RBS and beginning of coding region of *spa*
 63 mRNA..
 64




65
66

67 **Figure S4: Predicted secondary structures for different Ribosome Binding Sites (RBS)**
 68 **of mRNAs encoding virulence factors.** Secondary structures have been predicted with the
 69 Mfold server (Zuker, 2003). For *sspA*, *sspB*, *sbi*, *hld* mRNAs, RBSs show structures
 70 sequestering their SDs.
 71



72
 73
 74
 75
 76
 77
 78
 79
 80

81 **Figure S5: Toe-print with *psm* mRNA pre-incubated with *SauS1*.** Effect of *SauS1* on the
 82 formation of initiation ribosomal complex on *psm* mRNA. *SauS1-psm* complex has been
 83 formed with increasing concentrations of *SauS1*. Lane 1 : control incubation of mRNA ; lane
 84 2 : mRNA in the presence of 30S ribosomal subunits; lane 3 : formation of the ribosomal
 85 initiation complex containing mRNA, the 30S subunits, and tRNA_i ; lane 4: mRNA incubated
 86 with 30S and *SauS1* (400 nM); lanes 5 to 8 : formation of the ribosomal initiation complex in
 87 the presence of increasing concentrations of *SauS1* : 100, 200, 400 nM. Lanes U, A, G, C :
 88 sequencing ladders. The toe-printing signal at the position +16 is indicated by an arrow.
 89




90
 91
 92
 93

94 **Figure S6: Domains alignment score matrix on *EcoS1* domains to determine *SauS1***
95 **domain organization.**

Alignment scores matrix for domain similarity

| Alignments | EcoS1_d1 | EcoS1_d2 | EcoS1_d3 | EcoS1_d4 | EcoS1_d5 | EcoS1_d6 |
|------------|-------------|--------------|--------------|--------------|--------------|--------------|
| SauS1_d1 | Score: 58.5 | Score: 47.5 | Score: 94.5 | Score: 72.5 | Score: 79.0 | Score: 80.0 |
| SauS1_d2 | Score: 37.0 | Score: 129.0 | Score: 49.5 | Score: 40.0 | Score: 51.5 | Score: 73.0 |
| SauS1_d3 | Score: 32.0 | Score: 32.0 | Score: 193.0 | Score: 142.5 | Score: 139.5 | Score: 108.5 |
| SauS1_d4 | Score: 32.0 | Score: 57.0 | Score: 147.5 | Score: 153.5 | Score: 116.0 | Score: 110.0 |



96
97
98
99
100
101
102
103
104
105
106
107
108
109

110 SUPPLEMENTARY TABLES

111

112 Table S1: Plasmids, strains and oligos

| List of oligos | | |
|-----------------------------------------|--------------------------------|---------------------------------------------------------------------------------|
| NAME | USAGE | Sequences are 5' end to 3' end |
| Oligo spa | Toeprinting spa | TTT GCA GGT GTT ACG CC |
| Oligo PSM 3' 4 CDS | Toeprinting PSM | CTG AGA ATT TTA AGT ATT CAA TTC GC |
| Oligo PSM 5' only 1' CDS | Toeprinting PSM | CIT TGT TTG TTA TGA AAT CIT ATT TACC |
| Oligo T7 FW <i>psm</i> | PCR and in vitro transcription | ATT ACG AAT TCA ATA CGA CTC ACT ATA GGG ACT CAT AAG CAA AGG AGG TAA TCT TAA |
| Oligo RW <i>psm</i> | PCR and in vitro transcription | TAG AGG ATC CAG TAC TGC CAC CAT CCC TAT TGG TAT AGT GGC C |
| <i>hu</i> | Northern blot | Tomasini et al., 2017 |
| <i>psm</i> | Northern Blot | CCC ATG TGA AAG ACC TCC TTT GTT TGT TAT GAA ATC TTA TTT AC |
| 5S | Northern Blot | Tomasini A. et al., 2017 |
| 16S | Northern Blot | CTTGTGCGGGTCCCCGTC |
| <i>rpsA</i> PCR T7 FW | Northern Blot | TAA TAC GAC TCA CTA TAG GGG TCT ATC AAT AGA TTT AAT |
| <i>rpsA</i> PCR RW | Northern Blot | AAA GCA GTT GAA CAA GAA GAA |
| RNAlII | Northern Blot | Benito et al., 2000 |
| Upstream <i>rpsA</i> FW | Δ rpsA | CTG ATC GGA TCC AGC AGA TGA TGC AGT GAC AT |
| Upstream <i>rpsA</i> RW | Δ rpsA | CAT CIT GTT TGC CTC CIT ATA CA |
| Downstream <i>rpsA</i> FW | Δ rpsA | TGT ATA AGG AGG CAA ACA AGA TGT TTA ATA TTT AAT AGT CAA CT |
| Downstream <i>rpsA</i> RW | Δ rpsA | GAG TCA GGA TCC GAA TAG AAA TCA TAC ACG TCT |
| Deletion <i>rpsA</i> FW | Verification Δ rpsA | CTG ATC GGA TCC AGC AGA TGA TGC AGT GAC AT |
| Deletion <i>rpsA</i> RW | Verification Δ rpsA | GAG TCA TTA TAG TTT AAG A TTTTT AAG |
| Complementation of Δ rpsA FW | Δ rpsA | TTT GCA TGC ATT CCA AAA ATA ATT CAT |
| Complementation of Δ rpsA RW | Δ rpsA | AAC TGC AGT TAT AGT TTA AGA TTT TT |
| SauS1 cloning His(6x) TEV FW | Cloning | AAA AAA GCA TGC GAA AAC CTG TAT TTT TCA GAT GACTGA AGA ATT CAA TGA ATC A |
| SauS1 cloning RW | Cloning | GCT AAT TAA GCT TTT ATT ATA GTT TAA G |
| SauS1 intron mutant at position 1089 RW | Mutation <i>rpsA</i> | AAA AAA GCT TAT AAT TAT CCT TAA ATG ACA GAG TAG TGC GCC CAG ATA GGG TG |
| SauS1 intron mutant at position 1089 FW | Mutation <i>rpsA</i> | CAG ATT GTA CAA ATG TGG TGA TAA CAG ATA AGT CAG AGT ATC TAA CIT ACC TTT CIT TGT |
| SauS1 intron mutant at position 404 FW | Mutation <i>rpsA</i> | TGA ACG CAA GTT TCT AAT TTC GAT TTC ATT TCG ATA GAG GAA AGT GTC T |
| SauS1 intron mutant at position 404 RW | Mutation <i>rpsA</i> | AAA AAAA GCT TAT AAT TAT CCT TAA CAA TCG GCG ATG TGC GCC CAG ATA GGG TG |

113

| Strains | Description |
|-------------------------------------|------------------------------------------------------------------------------------------|
| <i>E. coli</i> strains | |
| <i>E. coli</i> DC10B | Used for cloning of plasmids which can be directly transformed in <i>S. aureus</i> cells |
| <i>S. aureus</i> strains | |
| HG001 | Derivative of 8325-4, <i>rsbU</i> -restored RN1, <i>agr</i> positive |
| RN6390 | Mutated in <i>rsbU</i> that results in a phenotype resembling that of <i>sigB</i> mutant |
| Mu50 | Strain with vancomycin-intermediate resistance |
| BCJ100 | Flag-tag at the C-terminus of <i>rpsA</i> gene |
| HG001 Δ rpsA | Deletion of <i>rpsA</i> gene for allelic replacement using pMAD vector |
| HG001 pCN51:: <i>rpsA</i> | Δ rpsA complemented strain |
| HG001 <i>rpsA</i> 111:: <i>LtrB</i> | <i>rpsA</i> insertion mutant 1 |
| RN1 <i>rpsA</i> 1029:: <i>LtrB</i> | <i>rpsA</i> insertion mutant 2 |
| Plasmids | |
| pUCN51 | Shuttle vector |
| pUC18 | Shuttle vector |
| pMAD | Thermosensitive origine of replication, constitutively expressed <i>bgaB</i> gene |

114

115

116

117 **Table S2: mRNAs UP regulated in *ΔrpsA***

| mRNAs UP regulated in <i>ΔrpsA</i> | | | | | |
|------------------------------------|---------------|-----------|----------------------------------------------------------------|------------|----------|
| id | gene | uniprotKB | product | FoldChange | pvalue |
| HG001_02434 | <i>narG</i> | P09152 | Respiratory nitrate reductase 1 alpha chain | 7,907 | 6,47E-17 |
| HG001_02438 | <i>sirB</i> | O34632 | Sirohydrochlorin ferrochelata | 5,676 | 3,13E-13 |
| HG001_02437 | <i>nasD</i> | P42435 | Nitrite reductase %5BNAD%28P%29H%5D | 4,982 | 5,93E-11 |
| HG001_00607 | <i>sarX</i> | Q2G0D1 | HTH-type transcriptional regulator SarX | 4,959 | 2,55E-10 |
| HG001_01334 | <i>gpsA</i> | P64191 | Glycerol-3-phosphate dehydrogenase %5BNAD%28P%29%2B%5D | 4,438 | 4,83E-23 |
| HG001_01691 | <i>ribE</i> | P16440 | Riboflavin synthase | 4,379 | 7,96E-23 |
| HG001_01335 | <i>der_2</i> | P64060 | GTPase Der | 3,102 | 3,97E-13 |
| HG001_02295 | - | - | hypothetical protein | 3,084 | 5,73E-06 |
| HG001_01152 | <i>glpD</i> | Q7A5V7 | Aerobic glycerol-3-phosphate dehydrogenase | 2,994 | 2,33E-13 |
| HG001_01690 | <i>ribBA</i> | Q99TA0 | Riboflavin biosynthesis protein RibBA | 2,927 | 5,99E-11 |
| HG001_02649 | <i>betA</i> | P60337 | Oxygen-dependent choline dehydrogenase | 2,758 | 9,79E-09 |
| HG001_01689 | <i>ribH</i> | P99141 | 6%2C7-dimethyl-8-ribityllumazine synthase | 2,573 | 4,93E-10 |
| HG001_02424 | <i>narT</i> | O33854 | putative nitrate transporter NarT | 2,51 | 0,001146 |
| HG001_00927 | <i>ykoE</i> | O34738 | Putative HMP/thiamine permease protein YkoE | 2,509 | 4,75E-07 |
| HG001_01571 | - | - | hypothetical protein | 2,468 | 1,24E-05 |
| HG001_02436 | <i>nasE</i> | P42436 | Assimilatory nitrite reductase %5BNAD%28P%29H%5D small subunit | 2,462 | 0,001334 |
| HG001_00780 | <i>patA_1</i> | O25526 | Peptidoglycan O-acetyltransferase | 2,423 | 1,92E-08 |
| HG001_01692 | <i>ribD</i> | P17618 | Riboflavin biosynthesis protein RibD | 2,352 | 9,84E-07 |
| HG001_01142 | <i>korB</i> | O53181 | 2-oxoglutarate oxidoreductase subunit KorB | 2,347 | 8,19E-06 |
| HG001_02290 | <i>pbuG</i> | O34987 | Guanine/hypoxanthine permease PbuG | 2,316 | 9,80E-07 |
| HG001_00527 | - | - | hypothetical protein | 2,295 | 1,20E-05 |
| HG001_01306 | - | - | hypothetical protein | 2,274 | 1,71E-08 |
| HG001_02433 | <i>narH</i> | P11349 | Respiratory nitrate reductase 1 beta chain | 2,258 | 0,000768 |
| HG001_01670 | - | - | Phosphotransferase enzyme family protein | 2,243 | 1,38E-05 |
| HG001_02112 | - | - | hypothetical protein | 2,235 | 1,42E-05 |
| HG001_01705 | - | - | hypothetical protein | 2,227 | 0,00216 |
| HG001_02268 | <i>rplO</i> | P0A0F6 | 50S ribosomal protein L15 | 2,217 | 2,11E-05 |
| HG001_01501 | <i>mtaB_2</i> | P54462 | Threonylcarbamoyladenosine tRNA methyltransferase MtaB | 2,182 | 0,000671 |
| HG001_02097 | <i>mazE</i> | P0C7B4 | Antitoxin MazE | 2,178 | 1,78E-05 |
| HG001_02520 | - | - | hypothetical protein | 2,176 | 1,07E-05 |
| HG001_01018 | - | - | hypothetical protein | 2,15 | 0,000593 |
| HG001_01654 | <i>acsA_1</i> | P39062 | Acetyl-coenzyme A synthetase | 2,145 | 7,02E-08 |
| HG001_00739 | - | - | hypothetical protein | 2,145 | 0,000662 |
| HG001_01212 | <i>plsY</i> | Q45064 | Glycerol-3-phosphate acyltransferase | 2,14 | 0,001328 |
| HG001_01633 | <i>tpx</i> | P99146 | putative thiol peroxidase | 2,135 | 2,06E-06 |
| HG001_01082 | <i>fabG</i> | P99093 | 3-oxoacyl-%5Bacyl-carrier-protein%5D reductase FabG | 2,097 | 4,03E-06 |
| HG001_01218 | <i>mprF</i> | Q2G2M2 | Phosphatidylglycerol lysyltransferase | 2,095 | 3,33E-07 |
| HG001_00741 | - | - | hypothetical protein | 2,095 | 5,84E-05 |
| HG001_01141 | <i>korA</i> | O53182 | 2-oxoglutarate oxidoreductase subunit KorA | 2,084 | 4,87E-05 |
| HG001_00604 | <i>sle1_2</i> | Q7A7E0 | N-acetylmuramoyl-L-alanine amidase sle1 | 2,066 | 2,63E-06 |
| HG001_00946 | <i>pdhD</i> | P99084 | Dihydrolipoyl dehydrogenase | 2,049 | 7,24E-06 |
| HG001_01150 | <i>glpF</i> | P18156 | Glycerol uptake facilitator protein | 2,039 | 9,83E-05 |
| HG001_02048 | <i>ktrB_2</i> | O32081 | Ktr system potassium uptake protein B | 2,037 | 0,000973 |
| HG001_02435 | <i>nasF</i> | P42437 | Uroporphyrinogen-III C-methyltransferase | 2,037 | 0,003747 |
| HG001_00625 | <i>mgrA</i> | P0C1S0 | HTH-type transcriptional regulator MgrA | 2,035 | 6,72E-06 |
| HG001_00411 | - | - | hypothetical protein | 2,024 | 0,0012 |
| HG001_02325 | <i>ureC</i> | P67404 | Urease subunit alpha | 2,014 | 6,68E-06 |

118

119

120 **Table S3: mRNAs DOWN regulated in *ΔrpsA***

| mRNAs DOWN regulated in <i>ΔrpsA</i> | | | | | |
|--------------------------------------|---------------|-----------|--------------------------------------------------------------|------------|----------|
| id | gene | uniprotKB | product | FoldChange | pvalue |
| HG001_01336 | <i>rpsA_1</i> | Q7A5J0 | 30S ribosomal protein S1 | 0,042 | 5,20E-82 |
| HG001_00899 | <i>sspA</i> | POC1U8 | Glutamyl endopeptidase | 0,099 | 2,48E-55 |
| HG001_03280 | <i>psm-4</i> | - | 4 psm peptide | 0,166 | 2,20E-32 |
| HG001_01548 | - | - | hypothetical protein | 0,224 | 1,24E-25 |
| HG001_03282 | <i>psm-2</i> | - | 2 psm peptide | 0,286 | 1,68E-16 |
| HG001_01009 | <i>hly</i> | Q2G1X0 | Alpha-hemolysin | 0,312 | 2,80E-07 |
| HG001_00711 | - | - | hypothetical protein | 0,317 | 6,43E-15 |
| HG001_02124 | <i>ssb_2</i> | P37455 | Single-stranded DNA-binding protein <i>ssb</i> | 0,319 | 2,05E-10 |
| HG001_00898 | <i>sspB</i> | Q2FZL3 | Staphopain B | 0,324 | 1,26E-11 |
| HG001_02245 | - | A6QIG2 | 65 kDa membrane protein <i>Eap</i> | 0,326 | 8,93E-13 |
| HG001_00897 | <i>sspC</i> | Q7A189 | Staphostatin B | 0,333 | 3,16E-07 |
| HG001_01874 | - | - | hypothetical protein | 0,341 | 9,05E-05 |
| HG001_01463 | <i>aroK_2</i> | O67925 | Shikimate kinase | 0,35 | 2,01E-10 |
| HG001_02058 | <i>hld</i> | POC1V1 | Delta-hemolysin | 0,35 | 9,33E-10 |
| HG001_00735 | - | - | hypothetical protein | 0,367 | 5,38E-07 |
| HG001_01006 | <i>scn_2</i> | Q6GFB4 | Staphylococcal complement inhibitor | 0,386 | 0,000147 |
| HG001_02456 | <i>sbi</i> | Q2FVK5 | Immunoglobulin-binding protein <i>sbi</i> | 0,389 | 3,02E-06 |
| HG001_01023 | - | P11699 | Antibacterial protein 3 | 0,39 | 2,92E-10 |
| HG001_02683 | - | Q2G222 | N-acetylmuramoyl-L-alanine amidase domain-containing protein | 0,396 | 2,54E-10 |
| HG001_01877 | - | - | hypothetical protein | 0,409 | 0,001013 |
| HG001_03283 | <i>psm-1</i> | - | 1 psm peptide | 0,412 | 4,78E-06 |
| HG001_00326 | <i>tcyP</i> | P54596 | L-cystine uptake protein <i>TcyP</i> | 0,415 | 2,63E-08 |
| HG001_00958 | - | - | hypothetical protein | 0,415 | 2,94E-06 |
| HG001_02584 | - | - | hypothetical protein | 0,416 | 0,000209 |
| HG001_02745 | <i>cspLA</i> | P0A355 | Cold shock-like protein <i>CspLA</i> | 0,417 | 1,08E-06 |
| HG001_00647 | - | - | Electron transfer DM13 | 0,424 | 1,91E-06 |
| HG001_00866 | - | - | hypothetical protein | 0,425 | 0,00016 |
| HG001_02279 | <i>rpmC</i> | P66173 | 50S ribosomal protein L29 | 0,426 | 5,55E-05 |
| HG001_01065 | - | - | TM2 domain protein | 0,428 | 3,04E-05 |
| HG001_00264 | <i>lip2</i> | P10335 | Lipase 2 | 0,431 | 2,00E-09 |
| HG001_02492 | <i>pnbA</i> | P37967 | Para-nitrobenzyl esterase | 0,431 | 5,31E-09 |
| HG001_02454 | <i>gpmA_2</i> | P99153 | 2%2C3-bisphosphoglycerate-dependent phosphoglycerate mutase | 0,435 | 5,35E-08 |
| HG001_01595 | <i>rplT</i> | P66108 | 50S ribosomal protein L20 | 0,45 | 6,19E-06 |
| HG001_01890 | - | - | hypothetical protein | 0,452 | 0,000418 |
| HG001_01261 | <i>cspA_2</i> | Q7A2R8 | Cold shock protein <i>CspA</i> | 0,453 | 1,57E-07 |
| HG001_00258 | <i>sglT</i> | P96169 | Sodium/glucose cotransporter | 0,453 | 1,03E-05 |
| HG001_01456 | - | - | hypothetical protein | 0,453 | 0,004245 |
| HG001_02459 | <i>hlgB</i> | P0A077 | Gamma-hemolysin component B | 0,455 | 8,94E-05 |
| HG001_00609 | - | - | hypothetical protein | 0,458 | 3,35E-05 |
| HG001_01899 | - | - | hypothetical protein | 0,459 | 0,000744 |
| HG001_02626 | - | - | hypothetical protein | 0,46 | 0,000162 |
| HG001_01057 | - | - | hypothetical protein | 0,46 | 0,000181 |
| HG001_01971 | - | A6QIG2 | 65 kDa membrane protein <i>Eap</i> | 0,462 | 0,000537 |
| HG001_02001 | - | - | HNH endonuclease | 0,465 | 0,004861 |
| HG001_02664 | - | - | hypothetical protein | 0,466 | 2,45E-05 |
| HG001_01943 | <i>sspP</i> | Q2G2R8 | Staphopain A | 0,468 | 0,000195 |
| HG001_01005 | <i>fib_2</i> | A6QG59 | Fibrinogen-binding protein | 0,469 | 0,001234 |
| HG001_00976 | <i>rpmF</i> | P66210 | 50S ribosomal protein L32 | 0,473 | 6,83E-06 |
| HG001_02635 | <i>panD</i> | Q2FV23 | Aspartate 1-decarboxylase | 0,476 | 0,001569 |
| HG001_02458 | <i>hlgC</i> | Q2FVK2 | Gamma-hemolysin component C | 0,478 | 0,000327 |
| HG001_00415 | <i>spoVG</i> | Q7A7B5 | Putative septation protein <i>SpoVG</i> | 0,483 | 2,51E-07 |
| HG001_02678 | - | - | hypothetical protein | 0,491 | 0,000331 |
| HG001_01897 | - | - | hypothetical protein | 0,491 | 0,003621 |
| HG001_01884 | - | - | Helix-turn-helix domain protein | 0,493 | 0,004261 |

121

Table S4: non coding RNAs variations in *ΔrpsA*

| non coding RNAs variations in <i>ΔrpsA</i> | | | | | | | |
|--------------------------------------------|-------------------|--------------|----------|----------------------------------|-------------------|--------------|----------|
| tRNAs variations in <i>ΔrpsA</i> | | | | sRNAs variations in <i>ΔrpsA</i> | | | |
| id | product | F.C. | pvalue | id | product | F.C. | pvalue |
| HG001_00441 | tRNA-Arg(acg) | 0,024 | 1,08E-39 | HG001_00584 | RsaD | 0,115 | 1,61E-13 |
| HG001_01760 | tRNA-His(gtg) | 0,025 | 1,74E-61 | HG001_01553 | 6S | 0,143 | 1,77E-12 |
| HG001_01802 | tRNA-Tyr(gta) | 0,037 | 3,23E-94 | HG001_02756 | RsaG | 0,16 | 2,20E-11 |
| HG001_01814 | tRNA-Arg(acg) | 0,038 | 2,54E-29 | HG001_02347 | RsaOG | 0,204 | 1,30E-31 |
| HG001_01815 | tRNA-Leu(taa) | 0,04 | 1,30E-35 | HG001_01975 | SprD | 0,215 | 7,11E-09 |
| HG001_00440 | tRNA-Leu(taa) | 0,041 | 2,53E-29 | HG001_00847 | RsaE | 0,234 | 4,80E-05 |
| HG001_02195 | tRNA-Tyr(gta) | 0,041 | 3,71E-88 | HG001_02057 | RNAIII | 0,363 | 5,71E-09 |
| HG001_01817 | tRNA-Leu(tag) | 0,042 | 2,60E-53 | HG001_01981 | rli28 | 0,418 | 0,00018 |
| HG001_01800 | tRNA-His(gtg) | 0,043 | 4,49E-30 | HG001_00880 | rli28 | 0,458 | 0,00244 |
| HG001_01809 | tRNA-Ser(tga) | 0,043 | 6,97E-31 | HG001_02466 | RsaJ | 0,558 | 0,10163 |
| HG001_02089 | tRNA-Leu(gag) | 0,044 | 3,99E-32 | HG001_02470 | RsaJ | 0,623 | 0,13983 |
| HG001_01021 | tRNA-Arg(tct) | 0,048 | 4,63E-39 | HG001_02554 | fstAT | 0,658 | 0,24125 |
| HG001_02197 | tRNA-Glu(ttc) | 0,048 | 9,96E-23 | HG001_00516 | RsaA | 0,676 | 0,09411 |
| HG001_01757 | tRNA-Glu(ttc) | 0,049 | 1,10E-21 | HG001_01652 | RsaB | 0,703 | 0,30954 |
| HG001_02201 | tRNA-Ile(gat) | 0,05 | 1,35E-31 | HG001_01125 | rliD | 0,732 | 0,38281 |
| HG001_01813 | tRNA-Pro(tgg) | 0,062 | 4,62E-18 | HG001_02471 | fstAT | 0,768 | 0,41632 |
| HG001_01818 | tRNA-Lys(ttt) | 0,071 | 3,49E-18 | HG001_00710 | RsaH | 0,832 | 0,59711 |
| HG001_00442 | tRNA-Pro(tgg) | 0,071 | 5,38E-16 | HG001_02469 | RsaJ | 0,931 | 0,77697 |
| HG001_02193 | tRNA-Lys(ttt) | 0,076 | 1,82E-15 | HG001_01716 | STnc490k | 0,977 | 0,90181 |
| HG001_00020 | tRNA-Glu(ttc) | 0,08 | 2,43E-14 | HG001_00848 | RsaF | 0,989 | 0,96155 |
| HG001_00438 | tRNA-Lys(ttt) | 0,08 | 3,46E-14 | HG001_00569 | RsaC | 1,037 | 0,89814 |
| HG001_00385 | tRNA-Ser(tga) | 0,084 | 1,85E-18 | HG001_02176 | rli28 | 1,092 | 0,59565 |
| HG001_01807 | tRNA-Ser(tga) | 0,09 | 1,28E-16 | HG001_01732 | fstAT | 1,265 | 0,51022 |
| HG001_01823 | tRNA-Ala(tgc) | 0,093 | 4,79E-17 | | | | |
| HG001_01763 | tRNA-Met(cat) | 0,098 | 6,82E-15 | | | | |
| HG001_01806 | tRNA-Met(cat) | 0,104 | 1,44E-13 | | | | |
| HG001_01798 | tRNA-Cys(gca) | 0,11 | 3,47E-12 | | | | |
| HG001_02088 | tRNA-Gly(tcc) | 0,12 | 3,00E-10 | | | | |
| HG001_01797 | tRNA-Gly(tcc) | 0,158 | 9,56E-08 | | | | |
| HG001_01756 | tRNA-Ser(gga) | 0,171 | 3,25E-07 | | | | |
| HG001_00437 | tRNA-Thr(tgt) | 0,187 | 2,79E-06 | | | | |
| HG001_02194 | tRNA-Gln(ttg) | 0,197 | 5,57E-06 | | | | |
| HG001_01810 | tRNA-Met(cat) | 0,197 | 4,53E-06 | | | | |
| HG001_01803 | tRNA-Thr(tgt) | 0,232 | 4,02E-05 | | | | |
| HG001_02196 | tRNA-Val(ttc) | 0,247 | 9,06E-05 | | | | |
| HG001_01799 | tRNA-Gln(ttg) | 0,265 | 0,000182 | | | | |
| HG001_01819 | tRNA-Thr(tgt) | 0,285 | 0,000359 | | | | |
| HG001_01804 | tRNA-Phe(gaa) | 0,291 | 0,000442 | | | | |
| HG001_01796 | tRNA-Gly(tcc) | 0,298 | 0,000695 | | | | |
| HG001_00436 | tRNA-Val(ttc) | 0,304 | 0,000723 | | | | |
| HG001_01808 | tRNA-Asp(gtc) | 0,325 | 0,0013 | | | | |
| HG001_00443 | tRNA-Ala(tgc) | 0,341 | 0,002103 | | | | |
| HG001_01805 | tRNA-Asp(gtc) | 0,344 | 0,002053 | | | | |
| HG001_01820 | tRNA-Val(tac) | 0,356 | 0,002877 | | | | |
| HG001_01812 | tRNA-Ala(tgc) | 0,364 | 0,003576 | | | | |
| HG001_01762 | tRNA-Asp(gtc) | 0,411 | 0,008131 | | | | |
| HG001_00021 | tRNA-Asp(gtc) | 0,416 | 0,008908 | | | | |
| HG001_01761 | tRNA-Phe(gaa) | 0,438 | 0,012357 | | | | |
| HG001_01811 | tRNA-Met(cat) | 0,441 | 0,013319 | | | | |
| HG001_01758 | tRNA-Asn(gtt) | 0,445 | 0,016241 | | | | |
| HG001_00874 | tRNA-Asn(gtt) | 0,458 | 0,019652 | | | | |
| HG001_02198 | tRNA-Asn(gtt) | 0,469 | 0,022848 | | | | |
| HG001_00873 | tRNA-Ser(gct) | 0,478 | 0,020962 | | | | |
| HG001_01824 | tRNA-Ile(gat) | 0,485 | 0,023908 | | | | |
| HG001_01816 | tRNA-Gly(gcc) | 0,523 | 0,042309 | | | | |
| HG001_01795 | tRNA-Gly(tcc) | 0,568 | 0,071387 | | | | |
| HG001_00439 | tRNA-Gly(gcc) | 0,576 | 0,070428 | | | | |
| HG001_01801 | tRNA-Trp(cca) | 0,62 | 0,102456 | | | | |
| HG001_00707 | tRNA-Arg(ccg) | 0,652 | 0,127072 | | | | |
| HG001_01794 | tRNA-Leu(caa) | 0,655 | 0,131339 | | | | |
| HG001_01759 | tRNA-Gly(tcc) | 0,747 | 0,236529 | | | | |
| HG001_02310 | tRNA-Gln(ttg) | 3,493 | 4,00E-06 | | | | |
| riboswitches variations in <i>ΔrpsA</i> | | | | | | | |
| id | product | F.C. | pvalue | id | product | F.C. | pvalue |
| HG001_00755 | SAM metN2 | 0,238 | 8,98E-18 | HG001_01043 | T-box ileS | 0,333 | 3,54E-06 |
| HG001_01345 | FMN ribU | 0,338 | 1,09E-13 | HG001_01598 | L20_leader | 0,343 | 7,03E-05 |
| HG001_01680 | T-box leuS | 0,414 | 1,81E-07 | HG001_01225 | T-box trpE | 0,436 | 0,0012 |
| HG001_01581 | T-box vsIS | 0,555 | 0,01325 | HG001_01462 | Glycine gcvT | 0,62 | 0,10996 |
| HG001_01600 | Lysine lysP_2 | 0,645 | 0,14845 | HG001_00303 | T-box metI | 0,669 | 0,02351 |
| HG001_02363 | SAM mleN_2 | 0,71 | 0,03617 | HG001_02363 | SAM mleN_2 | 0,71 | 0,03617 |
| HG001_00458 | T-box cysE | 0,714 | 0,05277 | HG001_01542 | T-box alaS | 0,728 | 0,28617 |
| HG001_00986 | T-box pheS | 0,78 | 0,20049 | HG001_00986 | T-box pheS | 0,78 | 0,20049 |
| HG001_01713 | SAM metK | 0,815 | 0,31446 | HG001_01251 | Lysine lysC | 0,831 | 0,29448 |
| HG001_01226 | T-box trpE | 0,874 | 0,68588 | HG001_00013 | SAM metX | 0,894 | 0,64935 |
| HG001_00013 | SAM metX | 0,894 | 0,64935 | HG001_02122 | TPP tenA | 1,019 | 0,90794 |
| HG001_00009 | T-box serS | 1,163 | 0,59618 | HG001_01649 | T-box tyrS | 1,219 | 0,45625 |
| HG001_02182 | glmS | 1,575 | 0,09555 | HG001_01602 | T-box thrS | 1,813 | 0,03484 |
| HG001_00469 | L10_leader | 1,904 | 0,01479 | HG001_02255 | L13_leader | 2,137 | 0,00139 |
| HG001_01556 | T-box hisS | 2,192 | 0,00063 | HG001_01693 | FMN ribDEBAH | 2,476 | 4,48E-09 |
| HG001_00330 | Purine | 4,508 | 9,44E-09 | HG001_00928 | TPP ykoE | 4,66 | 2,94E-07 |
| other ncRNAs variations in <i>ΔrpsA</i> | | | | | | | |
| id | product | F.C. | pvalue | id | product | F.C. | pvalue |
| HG001_00723 | tmRNA SsrA | 0,971 | 0,81765 | HG001_00389 | SRP | 1,538 | 0,00063 |
| HG001_01304 | RNaseP | 5,95 | 5,06E-14 | | | | |

Table S5: Differential Proteomics analysis of Δ rp*sA* and WT HG001Proteomics Analysis: UP in Δ rp*sA***DelS1-enriched proteins (2 MS instruments):**

| accession | gene | uniprotKB | product | TT5600+ | | Q-Exactive+ | |
|-------------|--------|-----------|----------------------------------------------|---------|---------------------------|-------------|---------------------------|
| | | | | p.value | Δ rp <i>sA</i> /S1 | p.value | Δ rp <i>sA</i> /S1 |
| HG001_01335 | der_2 | P64060 | GTPase Der | 0,00000 | 2,65 | 0,00000 | 2,37 |
| HG001_02129 | atpC | P63665 | ATP synthase epsilon chain | 0,00060 | Del-S1 only | 0,03239 | 2,08 |
| HG001_01334 | gpsA | P64191 | Glycerol-3-phosphate dehydrogenase [NAD(P)+] | 0,00000 | 9,70 | 0,00049 | 2,06 |
| HG001_00637 | glcR | P94591 | HTH-type transcriptional repressor GlcR | 0,08621 | Del-S1 only | 0,09671 | Del-S1 only |
| HG001_00607 | sarX | Q2G0D1 | HTH-type transcriptional regulator SarX | 0,08621 | Del-S1 only | 0,15060 | 2,86 |
| HG001_01147 | mutS_1 | Q931S8 | DNA mismatch repair protein MutS | 0,08621 | Del-S1 only | 0,15750 | 2,00 |
| HG001_00120 | - | - | hypothetical protein | 0,25670 | 2,00 | 0,15060 | 2,86 |

DelS1-enriched proteins (1 MS instrument):

| accession | gene | uniprotKB | product | TT5600+ | | Q-Exactive+ | |
|-------------|--------|-----------|--------------------------------------------------------|---------|---------------------------|-------------|---------------------------|
| | | | | p.value | Δ rp <i>sA</i> /S1 | p.value | Δ rp <i>sA</i> /S1 |
| HG001_00105 | fcl | - | GDP-L-fucose synthase | 0,00667 | Del-S1 only | | |
| HG001_00232 | eccCa1 | O69735 | ESX-1 secretion system protein EccCa1 | 0,08621 | Del-S1 only | | |
| HG001_01132 | phbB | P14697 | Acetoacetyl-CoA reductase | 0,22510 | Del-S1 only | | |
| HG001_00655 | kipl_1 | P60495 | Kinase A inhibitor | | | 0,00863 | Del-S1 only |
| HG001_01415 | - | - | hypothetical protein | | | 0,01882 | Del-S1 only |
| HG001_02379 | yhal | P64592 | Inner membrane protein Yhal | | | 0,02601 | 3,31 |
| HG001_01416 | srrB | Q5HFT1 | Sensor protein SrrB | | | 0,02895 | 4,29 |
| HG001_00108 | - | - | hypothetical protein | | | 0,02895 | 4,29 |
| HG001_01547 | limB_2 | Q9EUT9 | Limonene 1%2C2-monoxygenase | | | 0,04192 | Del-S1 only |
| HG001_00576 | tagH_1 | Q7A713 | Teichoic acids export ATP-binding protein TagH | | | 0,04192 | Del-S1 only |
| HG001_01351 | - | - | hypothetical protein | | | 0,04192 | Del-S1 only |
| HG001_02421 | - | - | hypothetical protein | | | 0,04192 | Del-S1 only |
| HG001_02447 | - | - | hypothetical protein | | | 0,04192 | Del-S1 only |
| HG001_02474 | - | - | hypothetical protein | | | 0,04192 | Del-S1 only |
| HG001_02114 | csor_2 | O32222 | Copper-sensing transcriptional repressor CsoR | | | 0,04192 | Del-S1 only |
| HG001_00294 | ytrB_1 | O34641 | ABC transporter ATP-binding protein YtrB | | | 0,04192 | Del-S1 only |
| HG001_02106 | kdpD | P21865 | Sensor protein KdpD | | | 0,04748 | 6,67 |
| HG001_00170 | pflA | Q7A7X5 | Pyruvate formate-lyase-activating enzyme | | | 0,07836 | 3,00 |
| HG001_02387 | - | - | hypothetical protein | | | 0,07836 | 3,00 |
| HG001_01063 | priA | P17888 | Primosomal protein N' | | | 0,08815 | 3,29 |
| HG001_01064 | - | - | hypothetical protein | | | 0,08948 | 5,67 |
| HG001_02143 | ywlC_2 | P39153 | Threonylcarbamoyl-AMP synthase | | | 0,08948 | 5,67 |
| HG001_00392 | - | - | Acetyltransferase (GNAT) family protein | | | 0,09671 | Del-S1 only |
| HG001_00104 | capD | Q9ZD15 | UDP-glucose 4-epimerase | | | 0,09671 | Del-S1 only |
| HG001_02446 | bdbD | O32218 | Disulfide bond formation protein D precursor | | | 0,09671 | Del-S1 only |
| HG001_00066 | ala | - | Alanine dehydrogenase | | | 0,09671 | Del-S1 only |
| HG001_01030 | ftsL | - | Cell division protein FtsL | | | 0,09671 | Del-S1 only |
| HG001_00055 | - | B9E972 | Oleate hydratase | | | 0,09671 | Del-S1 only |
| HG001_02187 | ebh_3 | Q2FYJ6 | Extracellular matrix-binding protein ebh precursor | | | 0,09671 | Del-S1 only |
| HG001_02392 | tcaA | A6QJJ7 | Membrane-associated protein TcaA | | | 0,09671 | Del-S1 only |
| HG001_01734 | - | - | hypothetical protein | | | 0,09671 | Del-S1 only |
| HG001_02252 | - | - | hypothetical protein | | | 0,09671 | Del-S1 only |
| HG001_01908 | - | - | hypothetical protein | | | 0,09671 | Del-S1 only |
| HG001_01962 | - | - | hypothetical protein | | | 0,09671 | Del-S1 only |
| HG001_00493 | sdrD | Q2G0L4 | Serine-aspartate repeat-containing protein D precursor | | | 0,09671 | Del-S1 only |
| HG001_01198 | - | - | Cysteine-rich secretory protein family protein | | | 0,09671 | Del-S1 only |
| HG001_02241 | adhR | O06008 | HTH-type transcriptional regulator AdhR | | | 0,09671 | Del-S1 only |
| HG001_01150 | glpF | P18156 | Glycerol uptake facilitator protein | | | 0,09671 | Del-S1 only |
| HG001_00791 | ydil | P77781 | Esterase Ydil | | | 0,09671 | Del-S1 only |
| HG001_00219 | lytM_2 | O33599 | Glycyl-glycine endopeptidase LytM precursor | | | 0,12740 | 2,70 |
| HG001_01216 | glcT | O33618 | GlcA/glcB genes antiterminator | | | 0,12740 | 2,70 |
| HG001_01197 | guaC | P60563 | GMP reductase | | | 0,12740 | 2,70 |
| HG001_00954 | - | - | hypothetical protein | | | 0,15060 | 2,86 |
| HG001_00451 | ctsR | Q7A799 | Transcriptional regulator CtsR | | | 0,15060 | 2,86 |
| HG001_02123 | sceD | Q2FWF8 | putative transglycosylase SceD precursor | | | 0,16370 | 2,31 |
| HG001_01669 | trmB | P67500 | tRNA (guanine-N(7)-)-methyltransferase | | | 0,16730 | 4,33 |
| HG001_00488 | dgk | P37530 | Deoxyguanosine kinase | | | 0,16730 | 4,33 |
| HG001_01316 | - | Q7A5K4 | hypothetical protein | | | 0,16730 | 4,33 |
| HG001_02380 | - | - | Putative 3-methyladenine DNA glycosylase | | | 0,24020 | Del-S1 only |

| | | | | | |
|-------------|---------|--------|---------------------------------------------------------|---------|-------------|
| HG001_01769 | - | - | Bacterial ABC transporter protein EcsB | 0,24020 | Del-S1 only |
| HG001_00513 | yhdG_1 | O07576 | putative amino acid permease YhdG | 0,24020 | Del-S1 only |
| HG001_02600 | dapL | A0LEA5 | LL-diaminopimelate aminotransferase | 0,24020 | Del-S1 only |
| HG001_02362 | mleN_2 | P54571 | Malate-2H(+)/Na(+)-lactate antiporter | 0,24020 | Del-S1 only |
| HG001_00684 | dosC | P0AA89 | Diguanylate cyclase DosC | 0,24020 | Del-S1 only |
| HG001_01066 | def1 | Q819U0 | Peptide deformylase 1 | 0,24020 | Del-S1 only |
| HG001_00424 | divIC | P37471 | Cell division protein DivIC | 0,24020 | Del-S1 only |
| HG001_02634 | cocE | Q9L9D7 | Cocaine esterase | 0,24020 | Del-S1 only |
| HG001_00256 | psuG | P33025 | Pseudouridine-5'-phosphate glycosidase | 0,24020 | Del-S1 only |
| HG001_00052 | yxeP_1 | P54955 | putative hydrolase YxeP | 0,24020 | Del-S1 only |
| HG001_02116 | - | - | putative hydrolase | 0,24020 | Del-S1 only |
| HG001_02157 | coaW | Q6G7I0 | Type II pantothenate kinase | 0,24020 | Del-S1 only |
| HG001_01625 | - | Q8XIQ9 | Cobalt-dependent inorganic pyrophosphatase | 0,24020 | Del-S1 only |
| HG001_01721 | menE | P63526 | 2-succinylbenzoate--CoA ligase | 0,24020 | Del-S1 only |
| HG001_00047 | - | Q2G1Q1 | putative lipoprotein precursor | 0,24020 | Del-S1 only |
| HG001_01218 | mprF | Q2G2M2 | Phosphatidylglycerol lysyltransferase | 0,24020 | Del-S1 only |
| HG001_00305 | ykuT | O34897 | putative MscS family protein YkuT | 0,24020 | Del-S1 only |
| HG001_00575 | tagA | Q7A714 | Putative N-acetylmannosaminyltransferase | 0,24020 | Del-S1 only |
| HG001_01220 | msrR | Q99Q02 | Regulatory protein MsrR | 0,24020 | Del-S1 only |
| HG001_00361 | - | - | hypothetical protein | 0,24020 | Del-S1 only |
| HG001_01593 | - | - | hypothetical protein | 0,24020 | Del-S1 only |
| HG001_00592 | - | - | hypothetical protein | 0,24020 | Del-S1 only |
| HG001_01668 | ytnP | O34760 | putative quorum-quenching lactonase YtnP | 0,24020 | Del-S1 only |
| HG001_01149 | - | - | Glycerol-3-phosphate responsive antiterminator | 0,24020 | Del-S1 only |
| HG001_00406 | rsml | P67087 | Ribosomal RNA small subunit methyltransferase I | 0,24020 | Del-S1 only |
| HG001_00706 | whiA | A0QWV9 | Putative sporulation transcription regulator WhiA | 0,24020 | Del-S1 only |
| HG001_02090 | - | - | Protein SprT-like protein | 0,24020 | Del-S1 only |
| HG001_02560 | catE_2 | P54721 | Catechol-2%2C3-dioxygenase | 0,24020 | Del-S1 only |
| HG001_00802 | yug_2 | P80870 | General stress protein 13 | 0,24020 | Del-S1 only |
| HG001_01227 | trpE | P20580 | Anthranilate synthase component 1 | 0,24020 | Del-S1 only |
| HG001_02216 | iucA_2 | Q47316 | N(2)-citryl-N(6)-acetyl-N(6)-hydroxylysine synthase | 0,24020 | Del-S1 only |
| HG001_02075 | tsaE | O05515 | tRNA threonylcarbamoyladenine biosynthesis protein TsaE | 0,24020 | Del-S1 only |
| HG001_01433 | malR | P0A4T2 | HTH-type transcriptional regulator MalR | 0,24020 | Del-S1 only |
| HG001_00204 | lytR_1 | P60611 | Sensory transduction protein LytR | 0,24020 | Del-S1 only |
| HG001_01770 | ecsA | P55339 | ABC-type transporter ATP-binding protein EcsA | 0,24020 | Del-S1 only |
| HG001_02440 | nirC | P0AC26 | Nitrite transporter NirC | 0,24020 | Del-S1 only |
| HG001_01002 | fib_1 | A6QG59 | Fibrinogen-binding protein precursor | 0,24020 | Del-S1 only |
| HG001_01289 | - | Q931R7 | hypothetical protein | 0,24020 | Del-S1 only |
| HG001_00827 | - | A6QIG2 | 65 kDa membrane protein precursor | 0,24020 | Del-S1 only |
| HG001_02498 | relJ | P65067 | Antitoxin RelJ | 0,25280 | 2,43 |
| HG001_01912 | - | P44886 | putative acyl-CoA thioester hydrolase | 0,30950 | 3,33 |
| HG001_01078 | recG | P64325 | ATP-dependent DNA helicase RecG | 0,30950 | 3,33 |
| HG001_00630 | phrB | P00914 | Deoxyribodipyrimidine photo-lyase | 0,30950 | 3,33 |
| HG001_01011 | - | - | hypothetical protein | 0,30950 | 3,33 |
| HG001_02428 | nreC | Q7WZY4 | Oxygen regulatory protein NreC | 0,30950 | 3,33 |
| HG001_02323 | ureA | Q4A0J3 | Urease subunit gamma | 0,30950 | 3,33 |
| HG001_01697 | arsC2 | P0DKS7 | Arsenate-myocthiol transferase ArsC2 | 0,30950 | 3,33 |
| HG001_01640 | ugpQ_2 | P10908 | Glycerophosphoryl diester phosphodiesterase | 0,56390 | 2,33 |
| HG001_01341 | recQ_2 | P15043 | ATP-dependent DNA helicase RecQ | 0,56390 | 2,33 |
| HG001_00806 | glpQ1_1 | P96236 | putative glycerophosphoryl diester phosphodiesterase 1 | 0,56390 | 2,33 |
| HG001_01190 | thrB_2 | Q8Y4A6 | Homoserine kinase | 0,56390 | 2,33 |
| HG001_02521 | - | Q99RE8 | putative lipoprotein precursor | 0,56390 | 2,33 |
| HG001_00026 | yycJ | C0SP91 | Putative metallo-hydrolase YycJ | 0,56390 | 2,33 |
| HG001_01831 | - | Q99T13 | Putative multidrug export ATP-binding/permease protein | 0,56390 | 2,33 |
| HG001_01599 | lysP_2 | P25737 | Lysine-specific permease | 0,56390 | 2,33 |
| HG001_02404 | lctP_2 | P55910 | L-lactate permease | 0,56390 | 2,33 |
| HG001_00769 | - | - | hypothetical protein | 0,56390 | 2,33 |
| HG001_01145 | - | - | hypothetical protein | 0,56390 | 2,33 |
| HG001_00724 | - | - | hypothetical protein | 0,56390 | 2,33 |
| HG001_00402 | - | - | hypothetical protein | 0,56390 | 2,33 |
| HG001_02597 | copA | Q2FV64 | Copper-exporting P-type ATPase A | 0,56390 | 2,33 |
| HG001_01275 | arlR | P0C000 | Response regulator ArlR | 0,56390 | 2,33 |

126

127

128

| | | | | | |
|-------------|---------|--------|-------------------------------------------------------------|---------|------|
| HG001_02338 | ssaA2_3 | Q7A423 | Staphylococcal secretory antigen ssaA2 precursor | 0,56390 | 2,33 |
| HG001_02429 | nreB | Q7WZY5 | Oxygen sensor histidine kinase NreB | 0,56390 | 2,33 |
| HG001_02423 | - | P80485 | Acid shock protein | 0,56390 | 2,33 |
| HG001_00036 | dus_2 | P67717 | putative tRNA-dihydrouridine synthase | 0,56390 | 2,33 |
| HG001_00041 | - | - | hypothetical protein | 0,56390 | 2,33 |
| HG001_00555 | pip | P46541 | Proline iminopeptidase | 0,56390 | 2,33 |
| HG001_00319 | gpmA_1 | Q1MMY4 | 2%2C3-bisphosphoglycerate-dependent phosphoglycerate mutase | 0,24850 | 2,08 |
| HG001_02125 | - | - | hypothetical protein | 0,24850 | 2,08 |
| HG001_02732 | yfIS | O34726 | Putative malate transporter YfIS | 0,31760 | 2,00 |

DelS1-enriched proteins (same global trend):

| accession | gene | uniprotKB | product |
|-------------|--------|-----------|------------------------------------------------------------|
| HG001_00783 | nfuA | P63020 | Fe/S biogenesis protein NfuA |
| HG001_01439 | - | - | hypothetical protein |
| HG001_00865 | murE_1 | Q2FZP6 | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase |
| HG001_01237 | - | - | hypothetical protein |
| HG001_01199 | lexA_1 | P31080 | LexA repressor |
| HG001_01140 | - | - | Calcineurin-like phosphoesterase |
| HG001_02210 | - | - | hypothetical protein |
| HG001_01075 | rpmB | P23374 | 50S ribosomal protein L28 |
| HG001_02658 | cysJ | O32214 | Sulfite reductase [NADPH] flavoprotein alpha-component |
| HG001_02179 | ywpJ_2 | P94592 | Putative phosphatase YwpJ |
| HG001_02537 | gtaB | Q7A3J9 | UTP--glucose-1-phosphate uridylyltransferase |
| HG001_01457 | lipM | P54511 | Octanoyltransferase LipM |
| HG001_02519 | - | - | hypothetical protein |
| HG001_01946 | - | - | hypothetical protein |
| HG001_01552 | tcdA | Q46927 | tRNA threonylcarbamoyladenosine dehydratase |
| HG001_01444 | recN | P05824 | DNA repair protein RecN |
| HG001_00975 | - | - | hypothetical protein |
| HG001_01284 | msrA2 | P0A086 | Peptide methionine sulfoxide reductase MsrA 2 |
| HG001_02325 | ureC | P67404 | Urease subunit alpha |
| HG001_01213 | parE | P66939 | DNA topoisomerase 4 subunit B |
| HG001_00543 | - | - | YwhD family protein |
| HG001_00453 | - | P65205 | Putative ATP:guanido phosphotransferase |
| HG001_01071 | prkC | A6QGCO | Serine/threonine-protein kinase PrkC |
| HG001_00640 | nagA | O34450 | N-acetylglucosamine-6-phosphate deacetylase |
| HG001_01565 | queA | P65951 | S-adenosylmethionine:tRNA ribosyltransferase-isomerase |
| HG001_00375 | metQ_1 | P31728 | putative D-methionine-binding lipoprotein MetQ precursor |
| HG001_01561 | recJ | P21893 | Single-stranded-DNA-specific exonuclease RecJ |
| HG001_01094 | rbgA | O31743 | Ribosome biogenesis GTPase A |
| HG001_00317 | - | - | hypothetical protein |
| HG001_01632 | - | - | N-6 DNA Methylase |
| HG001_02372 | lyrA | Q7A3Z2 | Lysostaphin resistance protein A |
| HG001_01280 | - | Q7A5M9 | putative CtpA-like serine protease |
| HG001_00926 | ykoD_1 | O34362 | Putative HMP/thiamine import ATP-binding protein YkoD |
| HG001_00211 | rbsK | P0A9J6 | Ribokinase |
| HG001_02736 | nhoA | Q00267 | N-hydroxyarylamine O-acetyltransferase |
| HG001_01788 | trmL | P0AGJ7 | tRNA (cytidine(34)-2'-O)-methyltransferase |
| HG001_00472 | rsmC | P39406 | Ribosomal RNA small subunit methyltransferase C |
| HG001_00520 | galK_1 | - | Galactokinase |
| HG001_01827 | ghrB_2 | P37666 | Glyoxylate/hydroxypyruvate reductase B |
| HG001_01104 | hslV | P65797 | ATP-dependent protease subunit HslV |
| HG001_02449 | tcyC_2 | P39456 | L-cystine import ATP-binding protein TcyC |
| HG001_01300 | der_1 | - | GTPase Der |
| HG001_01641 | - | - | OsmC-like protein |
| HG001_02629 | pyrD | P0A7E1 | Dihydroorotate dehydrogenase (quinone) |

| TT5600+ | | Q-Exactive+ | |
|---------|-------------|-------------|----------|
| p.value | ArpsA /S1 | p.value | ArpsA/S1 |
| 0,00060 | Del-S1 only | 0,41020 | 1,59 |
| 0,00296 | Del-S1 only | 0,51770 | 1,26 |
| 0,00003 | Del-S1 only | 0,45480 | 1,20 |
| 0,00060 | Del-S1 only | 0,98660 | 1,00 |
| 0,00296 | Del-S1 only | 0,84250 | 0,94 |
| 0,00012 | Del-S1 only | 0,72340 | 0,90 |
| 0,00000 | 2,08 | 0,00000 | 1,68 |
| 0,00195 | 2,73 | 0,51230 | 1,14 |
| 0,00031 | 5,15 | 0,91510 | 1,04 |
| 0,00323 | 4,70 | 0,60280 | 0,88 |
| 0,00323 | 4,70 | 0,63810 | 0,88 |
| 0,00667 | Del-S1 only | 0,23040 | 1,27 |
| 0,00667 | Del-S1 only | 0,80640 | 1,17 |
| 0,00667 | Del-S1 only | 0,98610 | 1,00 |
| 0,00667 | Del-S1 only | 0,98910 | 1,00 |
| 0,00667 | Del-S1 only | 0,53960 | 0,84 |
| 0,01525 | Del-S1 only | 0,36860 | 1,77 |
| 0,01525 | Del-S1 only | 0,48320 | 1,70 |
| 0,01525 | Del-S1 only | 0,25690 | 1,39 |
| 0,01525 | Del-S1 only | 0,69860 | 1,12 |
| 0,01525 | Del-S1 only | 0,83010 | 1,10 |
| 0,01525 | Del-S1 only | 0,48110 | 0,73 |
| 0,03561 | Del-S1 only | 0,50490 | 1,26 |
| 0,03561 | Del-S1 only | 0,70910 | 0,88 |
| 0,03561 | Del-S1 only | 0,77190 | 0,87 |
| 0,08621 | Del-S1 only | 0,41020 | 1,59 |
| 0,08621 | Del-S1 only | 0,74640 | 1,31 |
| 0,08621 | Del-S1 only | 0,76830 | 1,11 |
| 0,08621 | Del-S1 only | 0,86720 | 1,06 |
| 0,08621 | Del-S1 only | 0,88170 | 1,05 |
| 0,08621 | Del-S1 only | 0,99450 | 1,00 |
| 0,08621 | Del-S1 only | 0,82810 | 0,93 |
| 0,08621 | Del-S1 only | 0,62670 | 0,82 |
| 0,08621 | Del-S1 only | 0,29300 | 0,70 |
| 0,22510 | Del-S1 only | 0,41450 | 1,86 |
| 0,22510 | Del-S1 only | 0,25470 | 1,74 |
| 0,22510 | Del-S1 only | 0,41020 | 1,59 |
| 0,22510 | Del-S1 only | 0,69530 | 1,16 |
| 0,22510 | Del-S1 only | 0,98720 | 1,00 |
| 0,22510 | Del-S1 only | 0,99610 | 1,00 |
| 0,22510 | Del-S1 only | 0,82810 | 0,93 |
| 0,22510 | Del-S1 only | 0,84640 | 0,93 |
| 0,22510 | Del-S1 only | 0,82200 | 0,93 |
| 0,22510 | Del-S1 only | 0,70910 | 0,88 |

129

130

131

| | | | | | | | |
|-------------|--------|--------|----------------------------------------------------------------------|---------|-------------|---------|------|
| HG001_01144 | miaB | Q7A5W3 | (Dimethylallyl)adenosine tRNA methylthiotransferase MiaB | 0,22510 | Del-S1 only | 0,57660 | 0,82 |
| HG001_02226 | - | P99173 | Zinc-type alcohol dehydrogenase-like protein | 0,22510 | Del-S1 only | 0,33100 | 0,74 |
| HG001_02649 | betA | P60337 | Oxygen-dependent choline dehydrogenase | 0,22510 | Del-S1 only | 0,64810 | 0,70 |
| HG001_02499 | yehR | P33354 | putative lipoprotein YehR precursor | 0,22510 | Del-S1 only | 0,27880 | 0,68 |
| HG001_01343 | - | P10245 | Ferredoxin | 0,22510 | Del-S1 only | 0,51870 | 0,65 |
| HG001_00433 | folK | P43777 | 2-amino-4-hydroxy-6-hydroxymethylidihydropteridine pyrophosphokinase | 0,22510 | Del-S1 only | 0,47120 | 0,59 |
| HG001_01606 | gapA2 | P99067 | Glyceraldehyde-3-phosphate dehydrogenase 2 | 0,00663 | 2,13 | 0,16050 | 1,32 |
| HG001_00539 | yhdN_1 | P80874 | General stress protein 69 | 0,01041 | 4,00 | 0,58980 | 1,23 |
| HG001_01915 | ptpA | P0C5D2 | Low molecular weight protein-tyrosine-phosphatase PtpA | 0,01584 | 2,08 | 0,42150 | 0,78 |
| HG001_01123 | ribF | P0AG40 | Riboflavin biosynthesis protein RibF | 0,03224 | 3,30 | 0,98070 | 1,00 |
| HG001_01050 | pyrP | P39766 | Uracil permease | 0,03607 | 6,67 | 0,69830 | 0,77 |
| HG001_01129 | phnF | P16684 | putative transcriptional regulator PhnF | 0,03647 | 3,86 | 0,83010 | 1,10 |
| HG001_01666 | pepA_2 | Q48677 | Glutamyl aminopeptidase | 0,04946 | 2,00 | 0,66670 | 0,92 |
| HG001_01331 | ubiE | P67062 | Demethylmenaquinone methyltransferase | 0,07097 | 2,15 | 0,55140 | 0,80 |
| HG001_00619 | yvdD | O06986 | LOG family protein YvdD | 0,07113 | 5,67 | 0,52230 | 0,82 |
| HG001_02518 | - | Q99RF5 | putative oxidoreductase | 0,07437 | 2,54 | 0,70360 | 0,92 |
| HG001_02371 | hutG | P99158 | Formimidoylglutamase | 0,08317 | 2,04 | 0,63040 | 1,13 |
| HG001_01115 | polC_1 | P63982 | DNA polymerase III PolC-type | 0,11810 | 2,86 | 0,85860 | 0,96 |
| HG001_00291 | - | - | hypothetical protein | 0,13910 | 4,33 | 0,71170 | 1,30 |
| HG001_01646 | plsC | O07584 | 1-acyl-sn-glycerol-3-phosphate acyltransferase | 0,13910 | 4,33 | 0,98980 | 1,00 |
| HG001_01485 | sigA | P0A018 | RNA polymerase sigma factor SigA | 0,15750 | 2,30 | 0,97530 | 1,00 |
| HG001_00854 | ppnK | P65777 | putative inorganic polyphosphate/ATP-NAD kinase | 0,19030 | 2,08 | 0,30750 | 0,66 |
| HG001_02598 | copZ | Q7A3E5 | Copper chaperone CopZ | 0,51260 | 2,33 | 0,35120 | 1,61 |
| HG001_01321 | - | - | Putative neutral zinc metallopeptidase | 0,51260 | 2,33 | 0,85490 | 1,08 |
| HG001_02146 | tdk | P65231 | Thymidine kinase | 0,78870 | 0,77 | 0,01676 | 4,00 |
| HG001_01432 | malL | P29094 | Oligo-1%2C6-glucosidase | 0,55480 | 1,14 | 0,10580 | 2,54 |
| HG001_00927 | ykoE | O34738 | Putative HMP/thiamine permease protein YkoE | 0,72230 | 0,70 | 0,25280 | 2,43 |
| HG001_01130 | - | - | Peptidase M16 inactive domain protein | 0,83510 | 0,76 | 0,15750 | 2,00 |

132

133

134

135

Proteomics Analysis: DOWN in $\Delta rpsA$ **S1-enriched proteins (2 MS instruments):**

| accession | gene | uniprotKB | product | TT5600+ | | Q-Exactive+ | |
|-------------|--------|-----------|---------------------------------------------------------|---------|-------------------|-------------|-------------------|
| | | | | p.value | $\Delta rpsA$ /S1 | p.value | $\Delta rpsA$ /S1 |
| HG001_01336 | rpsA_1 | Q7A5J0 | 30S ribosomal protein S1 | 0,00000 | S1 only | 0,00000 | S1 only |
| HG001_02674 | arcA | P63554 | Arginine deiminase | 0,00000 | S1 only | 0,00004 | S1 only |
| HG001_02245 | - | A6QIG2 | 65 kDa membrane protein precursor Eap | 0,00061 | S1 only | 0,00009 | S1 only |
| HG001_00423 | hslR | P0ACG8 | Heat shock protein 15 | 0,00252 | S1 only | 0,04840 | 0,26 |
| HG001_02673 | arcB | P65602 | Ornithine carbamoyltransferase%2C catabolic | 0,00252 | S1 only | 0,02019 | 0,40 |
| HG001_00175 | fadN | O32178 | putative 3-hydroxyacyl-CoA dehydrogenase | 0,00000 | 0,11 | 0,00104 | 0,50 |
| HG001_02492 | pnbA | P37967 | Para-nitrobenzyl esterase | 0,00515 | S1 only | 0,14530 | 0,35 |
| HG001_00177 | lcfB | O07610 | Long-chain-fatty-acid--CoA ligase | 0,02237 | S1 only | 0,00153 | 0,43 |
| HG001_01918 | vraR | Q7A4R9 | Response regulator protein VraR | 0,10320 | 0,43 | 0,02070 | 0,43 |
| HG001_02514 | ahpD | - | Alkyl hydroperoxide reductase AhpD | 0,34660 | 0,30 | 0,03668 | 0,40 |
| HG001_02045 | dapE | Q99SN6 | putative succinyl-diaminopimelate desuccinylase | 0,05977 | 0,33 | 0,06735 | 0,43 |
| HG001_00016 | nrnA_1 | Q5SM25 | Bifunctional oligoribonuclease and PAP phosphatase NrnA | 0,10630 | S1 only | 0,14530 | 0,35 |
| HG001_02159 | - | - | hypothetical protein | 0,19430 | 0,23 | 0,14920 | 0,50 |

S1-enriched proteins (1 MS instrument):

| accession | gene | uniprotKB | product | TT5600+ | | Q-Exactive+ | |
|-------------|--------|-----------|-----------------------------------------------------------------|---------|-------------------|-------------|-------------------|
| | | | | p.value | $\Delta rpsA$ /S1 | p.value | $\Delta rpsA$ /S1 |
| HG001_00398 | speA | P21885 | Arginine decarboxylase | 0,01066 | S1 only | | |
| HG001_00027 | yfkN_1 | O34313 | Trifunctional nucleotide phosphoesterase protein YfkN precursor | 0,10630 | S1 only | | |
| HG001_02685 | - | - | hypothetical protein | 0,25340 | S1 only | | |
| HG001_01939 | pcrA | Q53727 | ATP-dependent DNA helicase PcrA | | | 0,00004 | S1 only |
| HG001_02544 | ywaC | P39583 | GTP pyrophosphokinase YwaC | | | 0,00001 | 0,10 |
| HG001_00277 | slyA_1 | - | Transcriptional regulator SlyA | | | 0,00084 | S1 only |
| HG001_00636 | ybaK | P0AAR3 | Cys-tRNA(Pro)/Cys-tRNA(Cys) deacylase YbaK | | | 0,00179 | S1 only |
| HG001_00140 | - | - | hypothetical protein | | | 0,00384 | S1 only |
| HG001_01192 | - | - | hypothetical protein | | | 0,00831 | S1 only |
| HG001_02103 | kdpC | P94606 | Potassium-transporting ATPase C chain | | | 0,01824 | S1 only |
| HG001_00949 | potA | Q7A679 | Spermidine/putrescine import ATP-binding protein PotA | | | 0,01824 | S1 only |
| HG001_02436 | nasE | P42436 | Assimilatory nitrite reductase [NAD(P)H] small subunit | | | 0,01824 | S1 only |
| HG001_01466 | - | - | hypothetical protein | | | 0,01824 | S1 only |
| HG001_01557 | lytC | Q02114 | N-acetylmuramoyl-L-alanine amidase LytC precursor | | | 0,04092 | S1 only |
| HG001_01974 | scn_3 | Q2FWV6 | Staphylococcal complement inhibitor precursor | | | 0,04092 | S1 only |
| HG001_02671 | arcC2 | P99069 | Carbamate kinase 2 | | | 0,04092 | S1 only |
| HG001_01723 | yokF | O32001 | SPBc2 prophage-derived endonuclease YokF precursor | | | 0,04092 | S1 only |
| HG001_02694 | - | - | Flavin reductase like domain protein | | | 0,04092 | S1 only |
| HG001_02558 | mhqR | O31672 | HTH-type transcriptional regulator MhqR | | | 0,04092 | S1 only |
| HG001_00141 | murQ | Q45582 | N-acetylmuramic acid 6-phosphate etherase | | | 0,09507 | S1 only |
| HG001_00793 | mnhG1 | P60698 | Na(+)/H(+) antiporter subunit G1 | | | 0,09507 | S1 only |
| HG001_00127 | - | P33160 | Formate dehydrogenase | | | 0,09507 | S1 only |
| HG001_01670 | - | - | Phosphotransferase enzyme family protein | | | 0,09507 | S1 only |
| HG001_02258 | ecfA2 | Q7A471 | Energy-coupling factor transporter ATP-binding protein EcfA2 | | | 0,09507 | S1 only |
| HG001_01642 | - | P16421 | Soluble hydrogenase 42 kDa subunit | | | 0,09507 | S1 only |
| HG001_00048 | - | Q2G1Q0 | putative lipoprotein precursor | | | 0,09507 | S1 only |
| HG001_02305 | mobA | P65405 | putative molybdenum cofactor guanylyltransferase | | | 0,09507 | S1 only |
| HG001_00262 | nanE | P65517 | Putative N-acetylmannosamine-6-phosphate 2-epimerase | | | 0,09507 | S1 only |
| HG001_00094 | yfkN_2 | O34313 | Trifunctional nucleotide phosphoesterase protein YfkN precursor | | | 0,09507 | S1 only |
| HG001_00102 | ywqE_1 | P96717 | Tyrosine-protein phosphatase YwqE | | | 0,09507 | S1 only |
| HG001_00403 | - | Q99WB7 | Initiation-control protein YabA | | | 0,09507 | S1 only |
| HG001_00968 | - | - | hypothetical protein | | | 0,09507 | S1 only |
| HG001_01664 | - | - | hypothetical protein | | | 0,09507 | S1 only |
| HG001_00126 | - | - | hypothetical protein | | | 0,09507 | S1 only |
| HG001_01832 | - | - | hypothetical protein | | | 0,09507 | S1 only |

| | | | | | |
|-------------|---------|--------|-----------------------------------------------------------------------|---------|---------|
| HG001_00378 | nudC | - | NADH pyrophosphatase | 0,09507 | S1 only |
| HG001_02079 | ilvC | P37253 | Ketol-acid reductoisomerase | 0,09507 | S1 only |
| HG001_02583 | ssaA2_4 | Q7A423 | Staphylococcal secretory antigen ssaA2 precursor | 0,09507 | S1 only |
| HG001_01614 | citZ | P39120 | Citrate synthase 2 | 0,09507 | S1 only |
| HG001_02150 | yodB | O34844 | HTH-type transcriptional regulator YodB | 0,09507 | S1 only |
| HG001_01968 | ytrA | O34712 | HTH-type transcriptional repressor YtrA PmtR | 0,09507 | S1 only |
| HG001_01239 | oppD_3 | P24136 | Oligopeptide transport ATP-binding protein OppD | 0,09507 | S1 only |
| HG001_02661 | yxdL | P42423 | ABC transporter ATP-binding protein YxdL | 0,09507 | S1 only |
| HG001_01494 | ybeY | O67367 | Endoribonuclease YbeY | 0,09507 | S1 only |
| HG001_00494 | tagE_1 | P13484 | putative poly(glycerol-phosphate) alpha-glucosyltransferase | 0,09507 | S1 only |
| HG001_01944 | - | - | Staphostatin A | 0,23790 | S1 only |
| HG001_00178 | ydiF | Q8X5X6 | Acetate CoA-transferase YdiF | 0,23790 | S1 only |
| HG001_01520 | aroE | Q5HNV1 | Shikimate dehydrogenase | 0,23790 | S1 only |
| HG001_01643 | serA | P0A544 | D-3-phosphoglycerate dehydrogenase | 0,23790 | S1 only |
| HG001_02614 | - | - | Glyoxalase-like domain protein | 0,23790 | S1 only |
| HG001_01133 | - | - | ACT domain protein | 0,23790 | S1 only |
| HG001_01318 | cca | Q7SIB1 | CCA-adding enzyme | 0,23790 | S1 only |
| HG001_01079 | fapR | O34835 | Transcription factor FapR | 0,23790 | S1 only |
| HG001_01964 | - | - | ABC-2 family transporter protein PmtD | 0,23790 | S1 only |
| HG001_01782 | liaS | O32198 | Sensor histidine kinase LiaS | 0,23790 | S1 only |
| HG001_00163 | - | - | Xylose isomerase-like TIM barrel | 0,23790 | S1 only |
| HG001_01153 | - | - | lysophospholipase L2 | 0,23790 | S1 only |
| HG001_00259 | nanA | Q2G160 | N-acetylneuraminatase lyase | 0,23790 | S1 only |
| HG001_00299 | metE | P65342 | 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase | 0,23790 | S1 only |
| HG001_00282 | luxA | P07740 | Alkanal monooxygenase alpha chain | 0,23790 | S1 only |
| HG001_01949 | nos | P0A004 | Nitric oxide synthase oxygenase | 0,23790 | S1 only |
| HG001_00952 | potD | P0AFK9 | Spermidine/putrescine-binding periplasmic protein precursor | 0,23790 | S1 only |
| HG001_02236 | lacR | P67744 | Lactose phosphotransferase system repressor | 0,23790 | S1 only |
| HG001_01486 | dnaG | P63964 | DNA primase | 0,23790 | S1 only |
| HG001_01473 | gluP | P54493 | Rhomboid protease GluP | 0,23790 | S1 only |
| HG001_01023 | - | P11699 | Antibacterial protein 3 | 0,23790 | S1 only |
| HG001_01919 | vraS | Q99S27 | Sensor protein VraS | 0,23790 | S1 only |
| HG001_02228 | - | - | hypothetical protein | 0,23790 | S1 only |
| HG001_01837 | - | - | hypothetical protein | 0,23790 | S1 only |
| HG001_00075 | - | - | hypothetical protein | 0,23790 | S1 only |
| HG001_00223 | - | - | hypothetical protein | 0,23790 | S1 only |
| HG001_00651 | queC | O31675 | 7-cyano-7-deazaguanine synthase | 0,23790 | S1 only |
| HG001_01967 | ytrB_2 | O34641 | ABC transporter ATP-binding protein YtrB PmtA | 0,23790 | S1 only |
| HG001_00336 | - | - | PemK-like protein | 0,23790 | S1 only |
| HG001_00129 | grsB | P0C064 | Gramicidin S synthase 2 | 0,00221 | 0,44 |
| HG001_02693 | sraP | Q2FUW1 | Serine-rich adhesin for platelets precursor | 0,00251 | 0,39 |
| HG001_00142 | - | Q7A804 | PTS system EIIBC component | 0,01570 | 0,37 |
| HG001_02607 | oatA_2 | Q7A3D6 | O-acetyltransferase OatA | 0,02422 | 0,30 |
| HG001_01009 | hly | Q2G1X0 | Alpha-hemolysin precursor | 0,02739 | 0,23 |
| HG001_00898 | sspB | Q2FZL3 | Staphopain B precursor | 0,03388 | 0,36 |
| HG001_00463 | - | - | YacP-like NYN domain protein | 0,04484 | 0,30 |
| HG001_02691 | - | - | hypothetical protein | 0,04484 | 0,30 |
| HG001_00579 | tagX | Q7A711 | Putative glycosyltransferase TagX | 0,04840 | 0,26 |
| HG001_01551 | rarA | P0AAZ4 | Replication-associated recombination protein A | 0,06735 | 0,43 |
| HG001_02442 | - | - | hypothetical protein | 0,08449 | 0,30 |
| HG001_01118 | - | - | hypothetical protein | 0,08449 | 0,30 |
| HG001_00368 | est_1 | Q06174 | Carboxylesterase | 0,08449 | 0,30 |
| HG001_02405 | - | - | CDP-Glycerol:Poly(glycerophosphate) glycerophosphotransferase | 0,08649 | 0,18 |
| HG001_01590 | engB | P64071 | putative GTP-binding protein EngB | 0,08649 | 0,18 |
| HG001_01860 | - | - | Phage major tail protein 2 | 0,08649 | 0,18 |
| HG001_00326 | tcyP | P54596 | L-cystine uptake protein TcyP | 0,10110 | 0,47 |
| HG001_00650 | queD | O31676 | 6-carboxy-5%2C6%2C7%2C8-tetrahydropterin synthase | 0,12190 | 0,37 |
| HG001_00161 | ycjS_1 | P77503 | putative oxidoreductase YcjS | 0,14530 | 0,35 |
| HG001_01724 | - | - | Telomeric repeat-binding factor 2 | 0,14530 | 0,35 |
| HG001_02592 | ydfJ | P96687 | Membrane protein YdfJ | 0,15650 | 0,43 |
| HG001_00594 | aes | Q8ZRA1 | Acetyl esterase | 0,16280 | 0,23 |

139

140

141

| | | | | | |
|-------------|---------|--------|------------------------------------------------------------|---------|------|
| HG001_01943 | sspP | Q2G2R8 | Staphopain A precursor | 0,19580 | 0,43 |
| HG001_00542 | - | - | HD domain protein | 0,19580 | 0,43 |
| HG001_01608 | mutM | O50606 | Formamidopyrimidine-DNA glycosylase | 0,19580 | 0,43 |
| HG001_02507 | nikA | P33590 | Nickel-binding periplasmic protein precursor | 0,19580 | 0,43 |
| HG001_00044 | recD | - | RecBCD enzyme subunit RecD | 0,24550 | 0,41 |
| HG001_01764 | ydeN | P96671 | Putative hydrolase YdeN | 0,24550 | 0,41 |
| HG001_00179 | - | - | hypothetical protein | 0,24550 | 0,41 |
| HG001_01488 | ccpN | O34994 | Transcriptional repressor CcpN | 0,24550 | 0,41 |
| HG001_00024 | yycH | Q794W0 | Two-component system YycF/YycG regulatory protein YycH | 0,24550 | 0,41 |
| HG001_00298 | kynB | - | Kynurenine formamidase | 0,30320 | 0,30 |
| HG001_00412 | ispE | P65178 | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | 0,30320 | 0,30 |
| HG001_00904 | yjcF | O31628 | putative N-acetyltransferase YjcF | 0,30320 | 0,30 |
| HG001_00742 | pspB | D3DFP8 | Putative phosphoserine phosphatase 2 | 0,30320 | 0,30 |
| HG001_01916 | - | - | hypothetical protein | 0,30320 | 0,30 |
| HG001_01605 | nrdR | P0A8D0 | Transcriptional repressor NrdR | 0,30320 | 0,30 |
| HG001_00028 | rlmH | P0C1V0 | Ribosomal RNA large subunit methyltransferase H | 0,30320 | 0,30 |
| HG001_02173 | czrA | O31844 | HTH-type transcriptional repressor CzrA | 0,30320 | 0,30 |
| HG001_00656 | kipA_1 | Q7WY77 | KipI antagonist | 0,23900 | 0,48 |
| HG001_00008 | hutH | P64416 | Histidine ammonia-lyase | 0,30780 | 0,50 |
| HG001_02601 | crtN | Q7A3E2 | Dehydrosqualene desaturase | 0,30780 | 0,50 |
| HG001_02581 | cynR_2 | P27111 | HTH-type transcriptional regulator CynR | 0,30780 | 0,50 |
| HG001_00973 | coaD | P63820 | Phosphopantetheine adenylyltransferase | 0,55600 | 0,43 |
| HG001_00787 | erpA | P45344 | Iron-sulfur cluster insertion protein ErpA | 0,55600 | 0,43 |
| HG001_01330 | hepT | P31114 | Heptaprenyl diphosphate synthase component 2 | 0,55600 | 0,43 |
| HG001_00712 | cggR | O32253 | Central glycolytic genes regulator | 0,55600 | 0,43 |
| HG001_00730 | ssp | A6QF98 | Extracellular matrix protein-binding protein emp precursor | 0,55600 | 0,43 |
| HG001_00363 | yicC_1 | P94400 | Putative metal chaperone YicC | 0,55600 | 0,43 |
| HG001_02185 | mtlF | P17876 | Mannitol-specific phosphotransferase enzyme IIA component | 0,55600 | 0,43 |
| HG001_00100 | cap8A_1 | P72367 | Capsular polysaccharide type 8 biosynthesis protein cap8A | 0,55600 | 0,43 |
| HG001_01309 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_01302 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_00037 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_02300 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_00819 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_00511 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_00029 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_00247 | - | - | hypothetical protein | 0,55600 | 0,43 |
| HG001_00492 | sdrC | Q7A781 | Serine-aspartate repeat-containing protein C precursor | 0,55600 | 0,43 |
| HG001_00285 | ydaF | P96579 | Putative ribosomal N-acetyltransferase YdaF | 0,55600 | 0,43 |
| HG001_02575 | - | - | Thioredoxin | 0,55600 | 0,43 |
| HG001_01911 | queE_2 | - | 7-carboxy-7-deazaguanine synthase | 0,55600 | 0,43 |

S1-enriched proteins (same global trend):

| accession | gene | uniprotKB | product | TT5600+ | | Q-Exactive+ | |
|-------------|--------|-----------|-------------------------------------------------------------|---------|------------------|-------------|------------------|
| | | | | p.value | $\Delta rpsA/S1$ | p.value | $\Delta rpsA/S1$ |
| HG001_00118 | aldA | Q7A825 | Putative aldehyde dehydrogenase AldA | 0,00124 | S1 only | 0,08007 | 0,57 |
| HG001_01498 | - | - | hypothetical protein | 0,00015 | S1 only | 0,75420 | 0,85 |
| HG001_00501 | hxlB | P42404 | 3-hexulose-6-phosphate isomerase | 0,00002 | S1 only | 0,98910 | 1,00 |
| HG001_00449 | pdxT | Q7A7A1 | Glutamine amidotransferase subunit PdxT | 0,00061 | S1 only | 0,25210 | 0,69 |
| HG001_01496 | - | - | hypothetical protein | 0,00061 | S1 only | 0,31900 | 0,73 |
| HG001_01332 | - | - | Heptaprenyl diphosphate synthase (HEPPP synthase) subunit 1 | 0,00252 | S1 only | 0,60700 | 0,77 |
| HG001_01662 | sftA | C0SP86 | DNA translocase SftA | 0,00252 | S1 only | 0,51090 | 0,86 |
| HG001_00758 | metQ_2 | O32167 | Methionine-binding lipoprotein MetQ precursor | 0,00252 | S1 only | 0,86930 | 0,95 |
| HG001_00264 | lip2 | P10335 | Lipase 2 precursor | 0,00000 | 0,25 | 0,00448 | 0,71 |
| HG001_02315 | modA | P45323 | Molybdate-binding periplasmic protein precursor | 0,00001 | 0,11 | 0,07118 | 0,70 |
| HG001_00924 | purD | P65896 | Phosphoribosylamine-glycine ligase | 0,00004 | 0,38 | 0,00286 | 0,61 |
| HG001_00789 | pepA_1 | O86436 | Cytosol aminopeptidase | 0,00006 | 0,25 | 0,21480 | 0,76 |

142

143

144

| | | | | | | | |
|-------------|--------|--------|--------------------------------------------------------------------------------------------------------------------|---------|---------|---------|------|
| HG001_02298 | femX | Q2FVZ4 | Lipid II:glycine glycytransferase | 0,00063 | 0,16 | 0,13970 | 0,77 |
| HG001_00139 | ptsG_1 | Q7A807 | PTS system glucose-specific EIICBA component | 0,00148 | 0,26 | 0,63630 | 0,91 |
| HG001_02330 | sarR | Q7A425 | HTH-type transcriptional regulator SarR | 0,00149 | 0,35 | 0,33180 | 0,78 |
| HG001_00582 | bmrA | O06967 | Multidrug resistance ABC transporter ATP-binding/permease protein BmrA | 0,00186 | 0,18 | 0,29630 | 0,77 |
| HG001_00274 | - | - | PTS system ascorbate-specific transporter subunits IICB | 0,00186 | 0,18 | 0,17150 | 0,53 |
| HG001_01285 | - | P67370 | DegV domain-containing protein | 0,00215 | 0,21 | 0,79540 | 0,95 |
| HG001_02186 | mtlD | P99140 | Mannitol-1-phosphate 5-dehydrogenase | 0,00278 | 0,41 | 0,76220 | 1,08 |
| HG001_00697 | uvrA | P63383 | UvrABC system protein A | 0,00515 | S1 only | 0,70990 | 0,92 |
| HG001_02752 | mnmE | Q8YN91 | tRNA modification GTPase MnmE | 0,02237 | S1 only | 0,68190 | 0,85 |
| HG001_00774 | - | - | hypothetical protein | 0,01066 | S1 only | 0,51870 | 0,65 |
| HG001_01495 | ybeZ | P0A9K3 | PhoH-like protein | 0,02237 | S1 only | 0,13690 | 0,54 |
| HG001_00704 | aroK_1 | - | Shikimate kinase | 0,02237 | S1 only | 0,98780 | 1,00 |
| HG001_01178 | cls_1 | P63801 | Cardiolipin synthase | 0,02237 | S1 only | 0,30820 | 0,61 |
| HG001_02615 | azoB | Q8KU07 | NAD(P)H azoreductase | 0,04792 | S1 only | 0,19250 | 0,57 |
| HG001_01624 | nrnA_2 | O34600 | Bifunctional oligoribonuclease and PAP phosphatase NrnA | 0,04792 | S1 only | 0,10910 | 0,63 |
| HG001_00061 | sarS | Q7A872 | HTH-type transcriptional regulator SarS | 0,04792 | S1 only | 0,38600 | 0,75 |
| HG001_01411 | - | - | hypothetical protein | 0,04792 | S1 only | 0,53670 | 0,79 |
| HG001_01445 | argR_1 | P63580 | Arginine repressor | 0,04792 | S1 only | 0,42270 | 0,82 |
| HG001_01673 | - | - | hypothetical protein | 0,04792 | S1 only | 0,82810 | 0,93 |
| HG001_01203 | - | - | hypothetical protein | 0,04792 | S1 only | 0,84250 | 0,94 |
| HG001_01278 | murG | P65482 | UDP-N-acetylglucosamine-N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase | 0,04792 | S1 only | 0,86550 | 0,96 |
| HG001_01059 | - | - | hypothetical protein | 0,04792 | S1 only | 0,88170 | 1,05 |
| HG001_00413 | purR | P37551 | Pur operon repressor | 0,10630 | S1 only | 0,13670 | 0,59 |
| HG001_01579 | fgs | P15925 | Folypolyglutamate synthase | 0,10630 | S1 only | 0,47120 | 0,59 |
| HG001_02574 | lipR_2 | O53301 | Putative acetyl-hydrolase LipR precursor | 0,10630 | S1 only | 0,60700 | 0,77 |
| HG001_02529 | pgcA | Q2FVC1 | Phosphoglucomutase | 0,10630 | S1 only | 0,56460 | 0,81 |
| HG001_01412 | - | - | hypothetical protein | 0,10630 | S1 only | 0,75420 | 0,85 |
| HG001_01265 | - | P60108 | TelA-like protein | 0,10630 | S1 only | 0,70090 | 0,89 |
| HG001_02356 | - | Q9X0Y1 | Phosphorylated carbohydrates phosphatase | 0,10630 | S1 only | 0,85300 | 0,95 |
| HG001_01068 | rsmB | P36929 | Ribosomal RNA small subunit methyltransferase B | 0,10630 | S1 only | 0,98910 | 1,00 |
| HG001_01020 | - | - | hypothetical protein | 0,10630 | S1 only | 0,99140 | 1,00 |
| HG001_01408 | dnaQ | P03007 | DNA polymerase III subunit epsilon | 0,10630 | S1 only | 0,99330 | 1,00 |
| HG001_02619 | - | - | Amidohydrolase | 0,10630 | S1 only | 0,89970 | 1,05 |
| HG001_00692 | prfB | Q7A6R4 | Peptide chain release factor 2 | 0,10630 | S1 only | 0,80050 | 1,08 |
| HG001_00886 | tagE_3 | P13484 | putative poly(glycerol-phosphate) alpha-glucosyltransferase | 0,25340 | S1 only | 0,16990 | 0,58 |
| HG001_01523 | mtnN | Q7A5B0 | 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase | 0,25340 | S1 only | 0,68190 | 0,85 |
| HG001_00721 | rnr | P21499 | Ribonuclease R | 0,25340 | S1 only | 0,98320 | 1,00 |
| HG001_01311 | ponA | P39793 | Penicillin-binding protein 1A/1B | 0,00377 | 0,45 | 0,09972 | 0,77 |
| HG001_01249 | cvfB | Q2FYF3 | Conserved virulence factor B | 0,00680 | 0,46 | 0,02650 | 0,54 |
| HG001_01088 | ffn | P37105 | Signal recognition particle protein | 0,01330 | 0,19 | 0,38230 | 0,78 |
| HG001_00486 | ppaX | Q9JMQ2 | Pyrophosphatase PpaX | 0,02233 | 0,39 | 0,40170 | 0,82 |
| HG001_02168 | - | - | EVE domain protein | 0,02456 | 0,25 | 0,27290 | 0,75 |
| HG001_00491 | azoI | Q50H63 | FMN-dependent NADPH-azoreductase | 0,03968 | 0,43 | 0,87110 | 0,97 |
| HG001_02709 | lipA_2 | Q2FUU5 | Lipase 1 precursor | 0,04208 | 0,38 | 0,59470 | 0,90 |
| HG001_01016 | arcC1 | Q7A627 | Carbamate kinase 1 | 0,05934 | 0,15 | 0,67060 | 0,86 |
| HG001_02098 | alr1 | Q5HED1 | Alanine racemase 1 | 0,05977 | 0,33 | 0,31430 | 0,75 |
| HG001_02361 | - | - | hypothetical protein | 0,06469 | 0,30 | 0,89320 | 1,04 |
| HG001_01558 | dtd | P0A026 | D-tyrosyl-tRNA(Tyr) deacylase | 0,07066 | 0,40 | 0,98270 | 1,00 |
| HG001_00553 | - | - | hypothetical protein | 0,07066 | 0,40 | 0,12110 | 0,59 |
| HG001_00017 | rplI | P66318 | 50S ribosomal protein L9 | 0,11110 | 0,30 | 0,87110 | 0,97 |
| HG001_01938 | ligA | Q9AIU7 | DNA ligase | 0,11110 | 0,30 | 0,61750 | 0,92 |
| HG001_00155 | azoR | Q99X11 | FMN-dependent NADH-azoreductase | 0,11110 | 0,30 | 0,68110 | 0,91 |
| HG001_02064 | scrB | P13394 | Sucrose-6-phosphate hydrolase | 0,14000 | 0,39 | 0,82380 | 1,07 |
| HG001_01324 | - | - | tetratricopeptide repeat protein | 0,19430 | 0,23 | 0,85300 | 0,95 |
| HG001_01678 | glpE_2 | - | Thiosulfate sulfurtransferase GlpE | 0,24910 | 0,43 | 0,69860 | 1,12 |
| HG001_00064 | yfiY | O31567 | putative siderophore-binding lipoprotein YfiY precursor | 0,24910 | 0,43 | 0,55510 | 0,86 |
| HG001_00197 | tagF | P13485 | CDP-glycerol:poly(glycerophosphate) glycerophosphotransferase | 0,24910 | 0,43 | 0,45320 | 0,75 |
| HG001_02680 | manP | O31645 | PTS system mannose-specific EIIBCA component | 0,29660 | 0,41 | 0,37250 | 0,75 |

145

146

147

| | | | | | | | |
|-------------|--------|--------|--------------------------------------------------------|---------|------|---------|------|
| HG001_01259 | lysA | P0A5M4 | Diaminopimelate decarboxylase | 0,34660 | 0,30 | 0,83950 | 1,12 |
| HG001_00914 | purE | Q9WYS7 | N5-carboxyaminoimidazole ribonucleotide mutase | 0,01649 | 0,45 | 0,17530 | 0,73 |
| HG001_02208 | - | Q7A4A4 | putative uridylyltransferase | 0,04776 | 0,46 | 0,44240 | 0,88 |
| HG001_01965 | yxjF_3 | P94374 | putative ABC transporter ATP-binding protein YxjF PmtC | 0,00390 | 0,48 | 0,08067 | 0,71 |
| HG001_00176 | acdA | P45867 | Acyl-CoA dehydrogenase | 0,00054 | 0,48 | 0,01163 | 0,63 |
| HG001_00400 | - | - | hypothetical protein | 0,17600 | 0,46 | 0,81500 | 0,89 |
| HG001_01434 | - | - | Glyoxalase-like domain protein | 0,07661 | 0,50 | 0,43370 | 0,85 |
| HG001_02585 | mvaA | P13702 | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 0,21050 | 0,50 | 0,38960 | 0,82 |
| HG001_01073 | rpe | P74061 | Ribulose-phosphate 3-epimerase | 0,35440 | 1,86 | 0,55600 | 0,43 |
| HG001_00818 | yidA | P0A8Y5 | Sugar phosphatase YidA | 0,93450 | 0,90 | 0,08234 | 0,43 |
| HG001_01826 | perR | Q2G282 | Peroxide-responsive repressor PerR | 0,62460 | 1,30 | 0,08449 | 0,30 |
| HG001_01491 | era | P64085 | GTPase Era | 0,95280 | 1,00 | 0,16280 | 0,23 |

148
149
150
151

Table S7: Spectral count analysis of gel filtration fraction

LEGEND:

| | |
|----------------------------------|-----------------|
| # spectra (BASIC Spectral Count) | = 1 spectrum |
| # spectra (BASIC Spectral Count) | = 2-5 spectra |
| # spectra (BASIC Spectral Count) | = 6-10 spectra |
| # spectra (BASIC Spectral Count) | = 11-30 spectra |
| # spectra (BASIC Spectral Count) | >= 31 spectra |

Samples 36/39/42/45 min: 1µg injected (The Spectral Count values are comparable)
 Samples 48 min: whole sample injected

Total number of proteins & protein of interest (S1):

| Elution Time (min.) | BASIC Spectral Count | | | | | BASIC Spectral Count | | | | |
|-------------------------------------------------------------------|----------------------|----|----|------|----|----------------------|-----|-----|------|----|
| | 36 | 39 | 42 | 45 | 48 | 36 | 39 | 42 | 45 | 48 |
| | 22 | 31 | 24 | 25 | 0 | 35 | 35 | 21 | 26 | 14 |
| | BASIC Spectral Count | | | | | BASIC Spectral Count | | | | |
| | 36 | 39 | 42 | 45 | 48 | 36 | 39 | 42 | 45 | 48 |
| HG001_01336 gene_rpsA_1 30S ribosomal protein S1 | | 1 | 76 | 1475 | | 189 | 62 | 50 | 1633 | 4 |
| | BASIC Spectral Count | | | | | BASIC Spectral Count | | | | |
| | 36 | 39 | 42 | 45 | 48 | 36 | 39 | 42 | 45 | 48 |
| HG001_02281 gene_rpsC 30S ribosomal protein S3 | 24 | 82 | 59 | 57 | | 37 | 104 | 80 | 51 | 1 |
| HG001_02283 gene_rpsS 30S ribosomal protein S19 | 17 | 49 | 90 | 34 | | 33 | 52 | 97 | 37 | |
| HG001_01639 gene_rpsD 30S ribosomal protein S4 | 14 | 67 | 43 | 39 | | 28 | 85 | 48 | 49 | 1 |
| HG001_00309 gene_rpsF 30S ribosomal protein S6 | 11 | 45 | 31 | 39 | | 24 | 46 | 44 | 33 | |
| HG001_00476 gene_rpsL 30S ribosomal protein S12 | 26 | 65 | 63 | 25 | | 43 | 73 | 133 | 40 | 3 |
| HG001_01510 gene_rpsT 30S ribosomal protein S20 | 26 | 75 | 94 | 28 | | 58 | 74 | 119 | 38 | |
| HG001_02270 gene_rpsE 30S ribosomal protein S5 | 22 | 54 | 34 | 17 | | 34 | 64 | 100 | 28 | |
| HG001_02263 gene_rpsM 30S ribosomal protein S13 | 26 | 91 | 33 | 14 | | 37 | 104 | 57 | 22 | |
| HG001_00477 gene_rpsG 30S ribosomal protein S7 | 14 | 41 | 51 | 19 | | 15 | 57 | 34 | 31 | |
| HG001_01107 gene_rpsJ 30S ribosomal protein S2 | 15 | 64 | 24 | 30 | | 24 | 77 | 57 | 36 | |
| HG001_02262 gene_rpsK 30S ribosomal protein S11 | 25 | 64 | 30 | 23 | | 25 | 66 | 57 | 15 | |
| HG001_02273 gene_rpsH 30S ribosomal protein S8 | 15 | 49 | 23 | 15 | | 15 | 44 | 34 | 18 | |
| HG001_02288 gene_rpsI 30S ribosomal protein S10 | 14 | 55 | 28 | 4 | | 10 | 45 | 45 | 5 | |
| HG001_00311 gene_rpsR 30S ribosomal protein S18 | 12 | 29 | 14 | 8 | | 21 | 39 | 28 | 7 | |
| HG001_02253 gene_rpsL 30S ribosomal protein S9 | 9 | 15 | 11 | 14 | | 4 | 31 | 24 | 14 | |
| HG001_02278 gene_rpsQ 30S ribosomal protein S17 | 5 | 33 | 42 | 7 | | 23 | 21 | 52 | 7 | |
| HG001_01089 gene_rpsP 30S ribosomal protein S16 | 3 | 30 | 5 | 15 | | 7 | 32 | 20 | 26 | 2 |
| HG001_02274 gene_rpsN1 30S ribosomal protein S14 | 5 | 5 | 8 | 1 | | 5 | 2 | 18 | 3 | |
| HG001_01196 gene_rpsN2 Alternate 30S ribosomal protein S14 | 1 | 2 | 2 | 1 | | 1 | 2 | 1 | 1 | |
| HG001_00830 gene_fabF 3-oxoacyl-[acyl-carrier-protein] synthase 2 | 1 | | | | | | | | | 2 |
| HG001_00717 gene_eno Enolase | 1 | | | | | | | | | 1 |
| HG001_00713 gene_gapA1 Glyceraldehyde-3-phosphate dehydrogenase 1 | 1 | | | | | | | | | 1 |
| HG001_01124 gene_rpsO 30S ribosomal protein S15 | | 16 | 11 | 18 | | 10 | 26 | 18 | 13 | 1 |
| HG001_02271 gene_rplR 50S ribosomal protein L18 | | 2 | 1 | 1 | | 2 | 1 | | 2 | |
| HG001_00976 gene_rpmF 50S ribosomal protein L32 | | 2 | 1 | | | 1 | | | 1 | |
| HG001_02284 gene_rplB 50S ribosomal protein L2 | | 2 | | 1 | | 2 | 1 | | 2 | |
| HG001_01499 gene_rpsU 30S ribosomal protein S21 | | 1 | 1 | | | | 1 | | | |
| HG001_01075 gene_rpmB 50S ribosomal protein L28 | | 1 | | 1 | | 5 | 1 | | | |
| HG001_01595 gene_rplT 50S ribosomal protein L20 | | 1 | | | | 2 | 1 | | | |
| HG001_02269 gene_rpmD 50S ribosomal protein L30 | | 1 | | | | 1 | 2 | | | |
| HG001_02254 gene_rplM 50S ribosomal protein L13 | | 1 | | | | 1 | 1 | | | |
| HG001_02260 gene_rplQ 50S ribosomal protein L17 | | 1 | | | | 1 | | | | |
| HG001_01597 gene_infC Translation initiation factor IF-3 | | 1 | | | | | | | | |
| HG001_02287 gene_rplC 50S ribosomal protein L3 | | | | 1 | | | | | | |
| HG001_02282 gene_rplV 50S ribosomal protein L22 | | | | | | 3 | 3 | | | |
| HG001_02280 gene_rplP 50S ribosomal protein L16 | | | | | | 1 | 1 | | | |
| HG001_02286 gene_rplD 50S ribosomal protein L4 | | | | | | 1 | | | | 1 |
| HG001_01092 gene_rplS 50S ribosomal protein L19 | | | | | | 1 | | | | |
| HG001_02275 gene_rplE 50S ribosomal protein L5 | | | | | | 1 | | | | |
| HG001_02277 gene_rplN 50S ribosomal protein L14 | | | | | | 1 | | | | |
| HG001_02285 gene_rplW 50S ribosomal protein L23 | | | | | | | 1 | | 1 | |
| HG001_02279 gene_rpmC 50S ribosomal protein L29 | | | | | | | 1 | | | |
| HG001_00722 gene_smpB SsrA-binding protein | | | | | | | 1 | | | |
| HG001_01572 gene_rplU 50S ribosomal protein L21 | | | | | | | 1 | | | |
| HG001_02276 gene_rplX 50S ribosomal protein L24 | | | | | | | 1 | | | |
| HG001_00425 gene_yug1_1 General stress protein 13 | | | | | | | | | 1 | |
| HG001_00479 gene_tuf Elongation factor Tu | | | | | | | | | | 12 |
| HG001_01618 gene_pyk Pyruvate kinase | | | | | | | | | | 1 |
| HG001_00473 gene_rpoB DNA-directed RNA polymerase subunit beta | | | | | | | | | | 1 |
| HG001_01963 gene_NONE hypothetical protein | | | | | | | | | | 1 |

155 **References**

156

157 Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic*
158 *Acids Res* 31, 3406-3415.

159

160

II. Result II: *SauS1* is an RNA chaperone involved in different steps of sRNA-dependent regulation and of RNA metabolism in *S. aureus*

In the previous section, I have described how *SauS1* affected the production of late expressed virulence factors (exotoxins and exoenzymes) and showed how it promoted the translation initiation of the highly structured *apsm1-4* mRNA. The transcriptomic and proteomics studies have also revealed other possible roles for this protein in stabilizing sRNAs or helping the correct folding of complicated RNA structures, like the riboswitches (see §I. Result I, “DISCUSSION” of the manuscript “*Staphylococcus aureus* S1 activates translation initiation of PSM α toxins and stimulates the production of several other secreted virulence factors”). This second section will focus on study of the possible extra translational functions of *SauS1*.

II.1. *SauS1* helps translation initiation of structured mRNAs

In order to assess if the activity of *SauS1* is linked to the alleviation of translation repression mediated by cis-acting mRNA structures, besides the *apsm1-4* we tested by toe-printing one more natural *S. aureus* mRNA harbouring distinct structural features. *mgrA* mRNA carries structured 5' UTR in which the SD sequence is hidden in a double-strand region (Romilly et al., 2014; Gupta et al., 2015). We have previously shown that *E. coli* ribosomes, containing S1, are able to form initiation complexes with *mgrA* mRNAs (Khusainov et al., 2016). This efficient recognition, was linked to the presence of *EcoS1* because S1-depleted *E. coli* ribosome, were not able to efficiently recognize *mgrA* mRNA, while mRNA binding was restored using S1-depleted 30S saturated with purified *EcoS1* added in trans (Khusainov et al., 2016). Moreover, we had demonstrated that *Sau30S*, similarly to S1-depleted *Eco30S*, could recognize only the unstructured *spa* mRNA. As shown in **Figure 18**, *SauS1* enhances the formation of the initiation complex at low concentration of 30S.




Figure 18. Toeprinting assays to monitor the effect of *SauS1* on the translation initiation complex formation with *mgrA* mRNA. (A) Effect of *SauS1* on the formation of initiation complex using *mgrA* mRNA. When present, *SauS1* was pre-incubated with the ribosome at a constant 1.6 molar ratio. Lane 1: incubation control of mRNA ; Lane 2: incubation control of mRNA with 30S subunits ; Lanes 3, 4, 5 and 6: formation of the initiation complex containing mRNA, increasing concentration of 30S (25, 50, 100, 200 nM) and fMet-tRNA. Lane7: incubation control of mRNA with purified *SauS1*. Lane 8: incubation control of mRNA, 30S and *SauS1*. Lanes 9, 10, 11 and 12: formation of initiation complex in presence of *SauS1* and increasing concentrations of 30S (25, 50, 100, 200 nM). Lanes U, A, G, C: sequencing ladders. The toeprinting signals at position +16 are indicated by arrows. (B) Scheme for the secondary structure of the RBS and beginning of coding region of *mgrA* mRNA.

II.2. Phenotypic characterization of *rpsA* mutants

To elucidate how *SauS1* is impacting the physiology of *S. aureus*, the three previously obtained mutants strains were analyzed for phenotypic alterations under different stress conditions. Two mutant strains resulted from introns insertion, one located immediately after the AUG codon (*rpsA111::LtrB*) and the second close to the stop codon (*rpsA1029::LtrB*) of the *rpsA*, while the third strain corresponded to a deletion of the gene per allelic replacement ($\Delta rpsA$).

I first demonstrated that the three mutant strains grow similarly in normal laboratory conditions (e.g. rich medium at 37°C) in agreement with a previous study showing that *S. aureus rpsA* gene is not essential (Chaudhuri et al., 2009). I have then compared the growth rates of the mutant and WT (HG001) strains under various stresses. Because the expression of the virulence factors is modulated by metabolic changes and stress responses, I have analyzed whether *SauS1* might also be required for other adaptive processes. **Figure 19** shows growth curves in BHI (Brain Heart Infusion) at different pH, during cold and heat shocks, or in NZM minimal medium supplemented with glucose. No differences could be observed between the HG001 and the three mutants strains in BHI at 37°C (**Figures 19A and B**). Nutrient starvation conditions (NZM minimal medium supplemented with glucose) did not affect the specific growth of the WT and the mutant *rpsA111::LtrB* or *rpsA1029::LtrB* strains (**Figure 19C**) although we observed a reduced duplication time when compared with the growth in rich media.

An acid shock (pH 5) was also tested (**Figure 19D**). The main reason why this stress was selected is because in the host body, infecting microorganisms frequently face acidity e.g. in the stomach, the phagolysosomes (Jensen and Bainton, 1973) and in the oral cavity and for the presence of fermentation products from other co-colonizing anaerobic bacteria. It was also shown that mild acidic stress altered the expression of a large set of virulence factors (Weinrick et al., 2004), which most likely illustrate the ability of the bacteria to adapt to particular tissue sites of the host. The acidic stress has been applied when bacteria reached $OD_{600}=1$. A drastic arrest of the growth could be observed which was even more sudden for the *rpsA111::LtrB* and *rpsA1029::LtrB* strains than the WT (HG001).




Figure 19. Bacterial growth under different stress conditions. Samples were taken each 30 min through the time course of six hours to check the optical density at OD_{600nm}. A. BHI growth at 37°C for WT (HG001) and the insertion mutants *rpsA111* ::LtrB and *rpsA1029* ::LtrB. B. BHI growth at 37°C for WT (HG001) and the $\Delta rpsA$ strain. C. Growth curves in NZM minimum media supplemented with glucose. D. Acidic stress. Growth in BHI 37°C was allowed to proceed until OD_{600nm}=1 was reached. E. The bacteria were exposed to pH 5. E. The cells were grown at 37°C in rich media and at OD_{600nm}=1 and then they were placed at 15°C. F. The bacteria were exposed to pH 5. E. The cells were grown at 37°C in rich media and at OD_{600nm}=1 and then they were placed at 42°C.

Bacterial cold shock response has been largely studied in *E. coli* and *Bacillus subtilis* (Brandi et al., 1994; Graumann and Marahiel, 1996; Graumann et al., 1996; Jones and Inouye, 1994). Exposition to cold induces the synthesis of specific set of cold-shock proteins able to help microorganisms to overcome the damaging effects of rapidly reduced temperatures on transcription and translation (Brandi et al., 1994; Giangrossi et al., 2007; Giuliadori et al., 2007; Giuliadori et al., 2004; Giuliadori et al., 2010; Gualerzi et al., 2003). These proteins are presumed to function as RNA chaperones preventing the formation of secondary structures in RNAs thereby facilitating translation at low temperature (Yamanaka et al., 1998). The common protein fold (cold shock domain CSD) of the cold shock proteins such as *E. coli* CspA is very similar to the OB-fold S1 domain. As I described above (“Introduction”), the domains of *EcoS1* are not functionally equivalent and it has been shown that the deletion of domains 5 and 6 at the C-terminal region of *EcoS1* (*rpsA* Δ 56) does not affect the general translation, but causes a cold

sensitive phenotype ((Duval et al., 2013b). and unpublished data from the lab). The cold-sensitive phenotype could be due to an impaired ability to unfold RNA structures stabilized at low temperature. The fact that mutations could affect the chaperone activity preferentially at low temperatures is not so surprising. Indeed, *EcoS1* does not need energy like an RNA helicase, and therefore at the permissive temperature, the thermal energy may help the protein to melt RNA secondary structures. Surprisingly, **Figure 19E** shows no difference in the behavior of the different strains subjected to cold shock. It has to be noted though that no slow down or temporary arrest of the growth was observed for any of the strains.

The bacterial heat shock response has been also extensively studied in several Gram-positive and Gram-negative bacteria (Bukau, 1993; Chuang and Blattner, 1993; Cowing et al., 1985). Upon shifts to higher temperature, the cells start to induce the expression of numerous heat-shock proteins (HSPs). Many of them are molecular chaperones including DnaK and GroEL and ATP-dependent proteases such as Lon and ClpAP that are essential to overcome protein denaturation (Barrios et al., 1994; Wild et al., 1996; Yura et al., 1993). In *P. putida*, exposure to high temperatures has been shown to downregulate *rpsA* (Ito et al., 2014). Since the unrestricted synthesis of thermolabile proteins can potentially lead the cell to danger, *P. putida* might arrest the de novo protein synthesis of non-HSPs reducing S1 level upon exposure to high temperatures. However, as evidenced in **Figure 19F**, no significant effects were produced when the WT and mutant strains were exposed to elevated (42°C) temperatures.

Although we did not monitor all the phenotypes with the three mutant strains, our data nevertheless suggested that mutations or the deletion of the gene had very similar effects, and that S1 had little effect on cell growth. These data suggest that S1 is not a ribosomal component and support the idea that *SauS1* is a regulatory protein.

II.3. *SauS1* and its constellation of RNAs. RIP-seq (co-immunoprecipitation and RNA-seq) analysis

As mentioned above, *SauS1* is able to modulate the translation of PSM α peptides by direct binding to the *apsm1-4* operon. Other mRNAs have been also postulated to be potential target of *SauS1*, which *in vitro* seems to modulate the translation of other

structured mRNAs (e.g. *mgrA*) while not affecting unstructured one (e.g. *spa*). Moreover, several sRNAs have been found to be downregulated in the $\Delta rpsA$ strain. To characterize the repertoire of RNA targets, we have performed RIP-seq analysis (co-immunoprecipitation and RNA-seq) using the *SauS1*-3X flag-tagged strain, which allow us to detect the synthesis of *SauS1* during bacterial growth (Figure 1 of the manuscript). We also performed RIP-seq on the WT (HG001) strain as the negative control. The experiments were done in triplicates. Bacterial growth was performed in BHI medium for 6 h where *SauS1* is sufficiently abundant. After immunoprecipitation with the anti-flag agarose beads and washing to remove unspecific binders, the sample was extracted with acidic phenol and then by chloroform-isoamyl alcohol. RNA was precipitated with ethanol, treated with DNase I, extracted with phenol, precipitated and prepared for sequencing. In parallel, we have performed a transcriptomic analysis from total RNA extracts prepared from the wild-type strain and the *SauS1* flagged strain to gain some indication on the expression levels of the mRNAs. This analysis has revealed no major changes in the corresponding transcriptomes including *rpsA* levels in the two strains (1.26 fold). The data were analyzed and visualized using Galaxy (Afgan et al., 2016) and the Integrative Genomics Viewer (IGV) browser, respectively (Thorvaldsdottir et al., 2013). A detailed protocol for the bioinformatics analysis is provided in Material and Methods. Briefly, we aligned the sequencing reads onto HG001 genome (Caldelari et al., 2017), counted per feature, and normalized. We have estimated the enrichment of putative targets by comparing the number of reads obtained from the RNA immunoprecipitated with the flag-tagged S1 and the non tagged (WT) S1 as control. **Table 3** and **Table 4** show the best hits divided into mRNAs and other classes of RNAs (sRNAs, riboswitches, tRNAs...), respectively.

RIP-seq of *Sau* S1. Co-immuno precipitated mRNAs

| Virulence factors | | | | |
|-------------------|-----------|-----------------------------------------------------------|------------|----------|
| id | gene | product | Enrichment | pvalue |
| HG001_02059 | agrB | Accessory gene regulator protein B | 14,108 | 1,03E-08 |
| HG001_02755 | psm_locus | psm α operon | 13,228 | 2,09E-08 |
| HG001_02245 | - | 65 kDa membrane protein precursor Eap | 12,192 | 9,09E-08 |
| HG001_00728 | clfA | Clumping factor A precursor | 5,556 | 0,00011 |
| HG001_00113 | galE | UDP-glucose 4-epimerase | 5,301 | 0,00021 |
| HG001_00100 | cap8A_1 | Capsular polysaccharide type 8 biosynthesis protein cap8A | 3,998 | 0,0012 |
| HG001_01022 | - | psm β 1 | 3,98 | 0,00206 |
| HG001_00899 | sspA | Glutamyl endopeptidase precursor | 3,974 | 0,00139 |
| HG001_00227 | esxA | Virulence factor EsxA | 3,787 | 0,00184 |
| HG001_00556 | sarA | Transcriptional regulator SarA | 3,372 | 0,00457 |
| Other mRNAs | | | | |
| id | gene | product | Enrichment | pvalue |
| HG001_01747 | - | Thermophilic serine proteinase | 20,53 | 4,20E-12 |
| HG001_02647 | hmoB | Heme-degrading monooxygenase HmoB | 9,433 | 3,30E-07 |
| HG001_00560 | xerD_2 | Tyrosine recombinase XerD | 8,288 | 3,32E-06 |
| HG001_01665 | ytpP | Thioredoxin-like protein YtpP | 8,243 | 1,48E-06 |
| HG001_02406 | - | putative lipoprotein precursor | 7,815 | 1,83E-05 |
| HG001_00733 | - | cspA | 7,447 | 2,40E-06 |
| HG001_02161 | luxS | S-ribosylhomocysteine lyase | 6,734 | 1,38E-05 |
| HG001_02543 | zntR | HTH-type transcriptional regulator ZntR | 6,58 | 8,53E-05 |
| HG001_02609 | isaA | putative transglycosylase IsaA precursor | 6,375 | 1,10E-05 |
| HG001_01549 | - | CsbD-like protein | 6,189 | 6,98E-05 |
| HG001_02222 | - | Alkaline shock protein 23 | 6,095 | 6,76E-05 |
| HG001_02418 | ydaG | General stress protein 26 | 5,946 | 0,00011 |
| HG001_01065 | - | TM2 domain protein | 5,924 | 0,00017 |
| HG001_00759 | - | CsbD-like protein | 5,663 | 0,00062 |
| HG001_00087 | deoC1 | Deoxyribose-phosphate aldolase 1 | 5,502 | 0,00012 |
| HG001_02655 | nrdD | Anaerobic ribonucleoside-triphosphate reductase | 5,237 | 8,47E-05 |
| HG001_00214 | degA | HTH-type transcriptional regulator DegA | 5,222 | 0,00023 |
| HG001_02644 | fda | Fructose-bisphosphate aldolase class 1 | 5,124 | 0,00047 |
| HG001_02628 | - | Fructosamine kinase | 5,111 | 0,00021 |
| HG001_00131 | yagU | Inner membrane protein YagU | 5,066 | 0,00013 |
| HG001_01336 | rpsA_1 | 30S ribosomal protein S1 | 5,018 | 0,0005 |
| HG001_01127 | - | Ribonuclease J 2 | 4,93 | 0,00019 |

Table 3: List of mRNAs sequenced by RIP-seq using *Sau*S1-flag immunoprecipitation. Fold change (IP-S1flag/IP-S1) correspond to enrichment values and together with p-values were calculated for by DESeq2 using shrinkage estimation for dispersions and fold changes (Varet et al., 2016).

Interestingly, among the best enrichments obtained for mRNAs, we have found the α *psm* operon, which was previously experimentally validated (Figure 5C of the manuscript). *Sau*S1 protein was also co-purified with other mRNAs encoding virulence factors and of two main regulators of virulence (*agr*, *sarA*; **Table 3**).

RIP-seq of *SauS1*. Co-immuno precipitated RNAs

| sRNAs | | | | | | | | |
|------------------------|------|--------------------|------------|----------|------------------|----------|----------------------------|--|
| id | gene | product | Enrichment | pvalue | $\Delta rpsA/WT$ | pvalue | Binding (Kd ^a) | |
| HG001_02347 | - | RsaI | 70,443 | 6,16E-19 | 0,204 | 1,30E-31 | ~ 500 nM | |
| HG001_01553 | - | 6S | 63,163 | 4,87E-22 | 0,143 | 1,77E-12 | n.d. | |
| HG001_00710 | - | RsaH | 20,371 | 2,88E-09 | 0,832 | 0,59711 | ~ 100 nM | |
| HG001_00584 | - | RsaD | 19,601 | 4,32E-09 | 0,115 | 1,61E-13 | n.d. | |
| HG001_00848 | - | RsaE | 9,727 | 9,48E-06 | 0,234 | 4,80E-05 | > 1 μ M | |
| HG001_02057 | - | RNAIII | 3,885 | 0,00438 | 0,363 | 5,71E-09 | ~ 200 nM | |
| HG001_00516 | - | RsaA | 3,846 | 0,00175 | 0,676 | 0,09411 | no binding | |
| HG001_02756 | - | RsaG | 2,556 | 0,04221 | 0,16 | 2,20E-11 | no binding | |
| New sRNAs ^b | | | | | | | | |
| id | gene | product | Enrichment | pvalue | $\Delta rpsA/WT$ | pvalue | Binding (Kd ^a) | |
| HG001_03138 | - | RsaOT | 18,167 | 3,71E-09 | | | | |
| HG001_03067 | - | SprX | 6,258 | 0,00045 | | | | |
| HG001_03009 | - | SprX2 | 6,016 | 0,00069 | | | | |
| HG001_02954 | - | RsaOF | 4,606 | 0,00119 | | | | |
| tRNAs | | | | | | | | |
| id | gene | product | Enrichment | pvalue | $\Delta rpsA/WT$ | pvalue | Binding (Kd ^a) | |
| HG001_00443 | - | tRNA-Ala(tgc) | 22,261 | 7,49E-11 | 0,341 | 0,0021 | n.d. | |
| HG001_01823 | - | tRNA-Ala(tgc) | 7,036 | 9,03E-05 | 0,093 | 4,79E-17 | n.d. | |
| HG001_02201 | - | tRNA-Ile(gat) | 5,841 | 8,04E-05 | 0,05 | 1,35E-31 | n.d. | |
| HG001_02088 | - | tRNA-Gly(tcc) | 3,67 | 0,01249 | 0,12 | 3,00E-10 | n.d. | |
| HG001_01816 | - | tRNA-Gly(gcc) | 3,439 | 0,0506 | 0,523 | 0,04231 | n.d. | |
| HG001_01812 | - | tRNA-Ala(tgc) | 3,36 | 0,03646 | 0,364 | 0,00358 | n.d. | |
| Riboswitches | | | | | | | | |
| id | gene | product | Enrichment | pvalue | $\Delta rpsA/WT$ | pvalue | Binding (Kd ^a) | |
| HG001_01602 | - | T-box | 5,569 | 7,82E-05 | 1,813 | 0,03484 | n.d. | |
| HG001_01693 | - | FMN Riboswitch | 5,544 | 7,12E-05 | 2,476 | 4,48E-09 | n.d. | |
| HG001_01462 | - | Glycine Riboswitch | 5,121 | 0,00079 | 0,62 | 0,10996 | n.d. | |
| HG001_00986 | - | T-box | 4,22 | 0,00162 | 0,78 | 0,20049 | n.d. | |
| HG001_02363 | - | SAM Riboswitch | 3,894 | 0,00756 | 0,71 | 0,03617 | n.d. | |
| HG001_01542 | - | T-box | 3,554 | 0,00509 | 0,728 | 0,28617 | n.d. | |

Table 4: List of sRNAs, tRNAs and other *cis*-acting non coding RNAs (riboswitches) sequenced by RIP-seq using *SauS1*-flag immunoprecipitation. Fold change (IP-S1flag/IP-S1) correspond to enrichment values and together with p-values were calculated for by DESeq2 using shrinkage estimation for dispersions and fold changes (Varet et al., 2016). For the sake of simplicity also the corresponding differences in RNA levels observed by the transcriptomic analysis (see § Result I) is reported with the corresponding p-values. ^aThe last column refers to apparent Kds obtained by the gel-shift experiments (§ Result II; II.4.). ^bNew sRNAs are sRNAs newly incorporated into the annotation file (Caldelari et al., 2017).

Several sRNAs have been found together with *SauS1* (**Table 4**). The most enriched is the sRNA RsaI (70,4 enrichment). RsaI level was also strongly decreased in the $\Delta rpsA$ mutant strain (0,2 **Table 4**). Interestingly, the yields of many co-IP sRNAs were also found less abundant in $\Delta rpsA$ mutant strain. Like RsaI, RsaD (0,11), RsaG (0,16), RsaE (0,23), RNAIII (0,36) and RsaA (0,68) might be stabilized by the binding with *SauS1*. Such a correlation was also found for the co-IP tRNAs (**Table 4**).

These data suggested that *SauS1* binds to many of the co-IP RNAs, and by doing so, might activate the translation of some mRNAs and stabilize other RNAs.

II.4. *SauS1* forms stable complexes with various sRNAs but does not interact with all of them

Based on the RIP-seq data, we first analyzed whether *SauS1* directly binds to different sRNA candidates using gel retardation assays (**Figure 20**). In vitro 5' end-labeled RsaI, RsaH, RsaG, RsaA, RsaE, and RNAIII were incubated with increasing concentrations of purified *SauS1*. The data show that the protein directly binds to RsaH (**Fig. 20A**, K_d 100 nM), RsaI (**Fig. 20B**, K_d 500 nM), RNAIII (**Fig. 20D**, K_d 200 nM). In contrast, no significant interaction was observed for RsaE (**Fig. 20C**, $> 1 \mu\text{M}$), RsaG (**Fig. 20E**), and RsaA (**Fig. 20F**). The apparent K_d for the different sRNAs is also included in **Table 4**.

Taken together, the gel retardation assays showed that many of the co-IP sRNAs are direct binders of *SauS1*. For those, which do not directly interact, their presence in the list could be explained by the formation of multi-partner complexes. *SauS1* could thus interact with a specific RNA or protein which in turn could establish other interaction with other RNAs.




Figure 20. Gel retardation assays to monitor *SauS1* binding to several sRNAs. Experiments were performed on complexes formed with the 5' end-labeled RsaH (A), RsaI (B), RsaE (C), RNAIII (D), RsaG (E) and RsaA (F) in presence of increasing concentrations of *SauS1* as marked on the figure.

II.5. *SauS1* forms a ternary complex with RsaI and RsaG

The gel retardation analysis has shown a direct binding of *SauS1* to RsaI while no detectable interaction was observed with RsaG, even with high concentrations of protein (up to 3.5 μM, data do not shown). RsaG belongs to the class of sRNA, which contain a C-rich sequence motif (UCCC) as the seed sequence to interact with the SD sequence of target mRNAs (Geissmann et al., 2009a). RsaI is characterized by several conserved stretches of nucleotides including a long unpaired region rich in uridines and adenines and two G-rich tracts (**Figure 21**). MS2-affinity purification approach coupled to RNA sequencing (MAPS) (Lalaouna and Masse, 2015; Tomasini et al., 2017), used to identify

the targetomes of both RsaI and RsaG, have shown that the two sRNAs are interacting *in vivo* (Delphine Bronesky and Emma Desgranges unpublished results). The predicted interaction site would involve one of the C-rich motif of RsaG and one G-rich region of RsaI (Figure 21).




Figure 21 Predicted interaction between RsaG and RsaI. A. Predicted base-pairings between C-rich motif of RsaG and G-rich tract of RsaI carried out using IntaRNA program (Mann et al., 2017). B. Secondary structures of RsaG and RsaI. The sequences involved in their interaction are highlighted by red circles and connected by an arrow. (DG= -9,5 kcal/mol).

I then checked the possibility that a ternary complex could form between *SauS1*, RsaI and RsaG by gel-retardation assays. Increasing concentrations of cold RsaG were incubated with constant amount of 5' end-labeled RsaI in the presence and in the absence of *SauS1* (1 μ M). The results showed that, although RsaI and RsaG are able to interact (apparent K_d = 50 nM), the addition of *SauS1* drastically enhances their binding affinity as shown in **Figure 22** (apparent K_d = 6,25 nM). *SauS1* is thus able to interact with RsaI to facilitate its binding to RsaG leading to the formation of a highly stable ternary complex both *in vitro* and *in vivo*.




Figure 22: Gel retardation assays to follow the formation of ternary complex SauS1-RsaI-RsaG. The assay was performed on complexes formed with the 5' end-labeled RsaI, increasing concentration of cold RsaG (marked on the figure) in the presence and in the absence of SauS1 (1 μ M). Lanes C1 and C2 are control lanes with RsaI and RsaI-SauS1, respectively. The binary (RsaI-RsaG and RsaI-SauS1) and ternary (SauS1-RsaI-RsaG) complexes are indicated by arrows. The observed SauS1-RsaI-RsaG complex could explain the RIP-seq data.

II.6. RsaI binding site for RsaG is hindered into a pseudoknot structure

RsaI has been proposed to fold in a stable pseudoknot structure involving its highly conserved regulatory regions, the G-rich tract and the long single-stranded region (Marchais et al., 2010). This G-rich motif is supposed to bind to RsaG, and recent works have shown that the two conserved regions of RsaI are required for the recognition of target RNAs (Delphine Bronesky unpublished results). The pseudoknot structure would be thus incompatible with the regulatory functions of RsaI. This opens the following question: Is SauS1 able to help the RsaI targeting process by promoting pseudoknot remodeling?

In order to probe RsaI structure, I have performed SHAPE (Rice et al., 2014) and structure mapping using different RNases and lead (II) (Fechter et al., 2016). As an RNA folds into a defined tertiary structure, specific set of nucleotides are expected to be constrained in base-pairing interactions, while unpaired nucleotides remains exposed and flexible. SHAPE is based on the chemical modification of the ribose 2'-hydroxyl position which appears to be strongly dependent on the nucleotide flexibility (Steen et al., 2011). Hence, flexible nucleotides preferentially adopt conformations that react with a hydroxyl-selective chemical to form a 2'-O-adduct while basepaired nucleotides are unreactive. This method was particularly well appropriate to map long-range interactions such as the pseudoknot structure motif (Figure 23).




Figure 23: SHAPE reactivity. In panel A is represented a generic RNA helix where the 2'-hydroxyl groups, accessible for chemical modification, are represented as blue spheres, while the aromatic bases are in green. All the nucleotides have the same level of reactivity to chemical compound. In panel B, is shown the reactivity of nucleotides in a pseudoknot structure. The increasing reactivity of 2'-OH is indicated by different colors, from constrained and unreactive (black), to not very reactive (orange) and completely accessible nucleotides (red). The figure was adapted from (Weeks, 2015).

Double-stranded or stacked regions were tested with RNase V1, and unpaired guanine residues with RNase T1. I also used lead (II) that cleaves preferentially interhelical and loop regions, with high sensitivity for flexible regions (**Figure 24A**). Modified sites or cleaved nucleotides were detected as stops of primer extension reactions using reverse transcriptase. Our data were in agreement with the secondary structure model (**Figure 24B**) and is compatible with the presence of a pseudoknot interaction. Based on the data, a 3D structure has been built with RNAComposer (Popenda et al., 2012) (**Figure 24C**).




Figure 24: Results of the probing experiments. (A). Autoradiographs of enzymatic hydrolysis. Lanes 1 and 2: incubations controls. Lanes 3, 4 and 5: increasing concentration of RNase V1. The red square show the regions involved in the pseudoknot formation; Lanes 6, 7 and 8: increasing concentration of RNase T1; Lanes 9, 10 and 11, increasing concentration of RNase T2. Lanes T and L: RNase T1 in denaturing condition and formamide ladders, respectively. Lanes 15 and 16: Lead (II)-induced cleavage (B). Summary of the probing experiments reported on the secondary structural model of RsaI pseudoknot. T1 induced cuts are represented by red arrows. The reactivity of guanine residues to the V1 cuts are represented by blue triangles. The intensity of the cuts is given from weak to strong cleavages. Lead (II) induced cleavages are represented by purple circles. (C). 3D structure of RsaI pseudoknot obtained by RNAComposer. The interaction occurring between the G-rich track and the U-rich motifs, involved in the pseudoknot folding are highlighted by red circles on the structures in B and C.

II.7. Probing the interaction between RsaI and RsaG by footprinting experiments

In order to identify the sequence-specific contacts of RsaG and RsaI and to better clarify the mechanisms of action of *SauS1*, I have performed footprinting experiments using RNases V1 and T1, and lead (II)-induced cleavages. The results, summarized in **Figure 25**, support the prediction that the G-rich tract of RsaI, which is engaged in the pseudoknot structure, interacts with RsaG. Indeed the major RsaG-induced protections were located at the G-tract motif which is not exposed to RNase T1 cuts.

We thus propose that *SauS1* would bind to RsaI to promote the melting of the pseudoknot and to facilitate its interaction with RsaG. I have tried to localize the

footprint of *SauS1* on *RsaI* using enzymes and lead II). However, no signature for *SauS1* could be detected most probably due to the dynamic nature of the RNP. This is a typical RNA chaperone behavior (Duval et al., 2017).




Figure 25. Footprinting assays for RsaG on RsaI. 3'-end labeled *RsaI* alone (first part of the autoradiography) or in the presence of cold *RsaG*, was treated with RNases T1, V1 and lead (II). Lane 1: incubation control (*RsaI*); Lanes 2 and 3: *RsaI* with and without RNase T1, respectively; Lanes 4 and 5: *RsaI* with and without RNase T1, respectively; Lanes 6 and 7: *RsaI* with and without lead (II), respectively. Lane 8: incubation control (*RsaI* + *RsaG*). Lane 9 and 10: *RsaI*+ *RsaG* with and without RNase T1, respectively; Lanes 11 and 12: *RsaI* + *RsaG* with and without RNase V1, respectively; lanes 13 and 14: *RsaI* + *RsaG* with and without lead (II), respectively. Sequence ladder identifying position of guanines, is shown in the last line.

II.8. Characterization of RNA annealing and strand displacement activities of S1 by FRET experiments

Chaperone proteins could act in two reactions: the RNA annealing and the dissociation of RNA duplexes (Rajkowitsch and Schroeder, 2007). In order to dissect the chaperone activity of *SauS1*, we used Fluorescence Resonance Energy Transfer (FRET) assay using the protocol proposed by Rajkowitsch and Schroeder in 2007 (Rajkowitsch and Schroeder, 2007). Briefly, for the experiment, we used two different fluorophore-labeled RNA oligonucleotides that are fully complementary. The assay was divided in two main phases (**Figure 26**). During the first step, we have followed the kinetic of annealing of

the two complementary oligonucleotides in the presence or in the absence of *SauS1*. In the second step, we have injected an excess of a cold competitor oligonucleotide to monitor the strand displacement (**Figure 20**).




Figure 26: RNA chaperone proteins are basically active in two reactions. RNA annealing and strand displacement. The chaperone activity could be followed by FRET assay. (I.) Annealing of two fluorophore-labeled RNAs completely self-complementary gives a FRET signal that is reduced upon RNA chaperone facilitating strand displacement with a cold competitor RNA (II).

Our data shown that in contrast to *E. coli* S1, *SauS1* enhances the rate of annealing five fold (**Figure 27A**) while it is not involved in the strand displacement reaction (**Figure 27B**).




Figure 27: We used Fluorescence-based assays to monitor the chaperone activity of *SauS1* in two reactions, annealing and strand displacement. In the phase I. the two fluorophore-labeled oligonucleotides were mixed in a microplate reader in the absence /presence of S1. The donor (Cy3) and acceptor (Cy5) fluorescence emission, were registered each second. The FRET index was estimated and normalized at t 180 s. The annealing of two oligonucleotides, is enhanced five times by the presence of S1 (A) while no effect of S1 was monitored on the strand displacement during the phase II (B).

Discussions and Perspectives

I. *Staphylococcus aureus* S1 as translational activator. Further considerations

I.1. General discussion

In the manuscript (Results, §I) “*Staphylococcus aureus* S1 activates translation initiation of PSM α toxins and stimulates the production of several other secreted virulence factors”, we have demonstrated that *SauS1* is not associated to the ribosome, but is required for translation initiation of α -*psm* mRNA coding for Phenol Soluble Modulines of type α . Moreover, it affects the production of many other exotoxins (α -haemolysin, δ -haemolysin and γ -haemolysins) and exoenzymes (proteases and lipases). We have proposed that, by direct binding to the mRNAs, it could remove inhibitory structures at the RBS to allow the correct 30S-mRNA interactions to take place. Our differential transcriptomics analysis has provided indications on the mRNAs which would require *SauS1* to be translated and protected from degradation. With the RIP-seq experiments (Results, §II.3; **Table 3** and **Table 4**), we could detect *in vivo* the whole set of mRNAs interacting with *SauS1*. The two datasets are well correlated, providing a detailed picture of the regulatory network coordinated by *SauS1*.

First, α -*psm* operon was found as one of the best target of *SauS1* (Results, §II.3; **Table 3**). In addition, the RNAlII transcript coding for another PSM peptide (*hld*) with stable structure at its RBS (Benito et al., 2000) is also downregulated in the Δ *rpsA* strain, is enriched in the RIP-seq (Results, §II.3; **Table 4**), and directly binds to *SauS1* (Results, **Figure 20D**). The third *psm* locus coding for two PSM β peptides is also downregulated in Δ *rpsA* (**Table 2**, Results, §I). PSM β 1, co-immunoprecipitated with *SauS1* (Results, §II.3; **Table 3**) has strong and inaccessible Shine and Dalgarno sequence, suggesting possible needed of *SauS1* to be expressed, while the second peptides PSM β 2, results to be less structured (**Figure 28**). Although experimental validation is needed to demonstrate the *hld* and *psm* β translation activation by *SauS1*, it is tempting to propose that the three PSM coding genes would be coordinated both at transcriptional level by AgrA (Queck et al., 2008) and at translational level by *SauS1*. Because their mRNAs are highly structured, there is a risk that the efficiency of translation might be different from one operon to the other.




Figure 28 Secondary structure model of PSM β operon. The PSM β operon codes for two peptides 44 amino acids long. PSM β 1 has strong SD sequence constrained in a stable double strand region while the SD of PSM β 2 is more accessible. Yellow and green nucleotides correspond to the SD sequences and the initiation codons, respectively. In light blue the ribosome binding sites. The position +16 is indicated by red arrows

Hence, the role of *SauS1* would add another layer of regulation allowing an efficient synthesis of PSM peptides at a very similar level. In favor of this hypothesis is the fact that the expression pattern of *SauS1* follows the expression of RNAlII and of the *psm* mRNAs. This fine coordination of the PSMs under both the quorum sensing control and *SauS1* might be necessary for the concerted action during acute infection, when they are produced to promote dissemination and tissue lysis. Since they contribute to biofilm detachment/dissemination (Kong et al., 2006; Periasamy et al., 2012; Tsompanidou et al., 2011), an early induction could expose *S. aureus* to the host immune system before a critical mass could have been attained. In that regard, it is worth to notice that *SauS1* could also regulate the translation of the *sspABC* operon, coding endopeptidases important for immune suppression and infection dissemination (Imamura et al., 2005; Jusko et al., 2014; Ohbayashi et al., 2011). Indeed, the expression of the *sspABC* operon is strongly affected by the absence of S1 and which the RNA is among the best enriched RIP-seq targets (**Table 3**).

The differential transcriptomics and RIP-seq experiments also revealed other virulence factors as candidates for translation activation by *SauS1*. Among them the gene HG001_02245 coding for the Extracellular Adherence Protein (Eap) involved in adherence and internalization (Hagggar et al., 2003; Palma et al., 1999). Its mRNA interacts with *SauS1* (enrichment 12,2), and both the Eap protein (0,29 in the secretome) and its mRNA (0,33) levels are highly perturbed in the $\Delta rpsA$ strain. Also the Clumping factor *clfA*, which binds to fibrinogen to inhibit phagocytosis (Higgins et al., 2006), shares the same situation, although milder effects on the mRNA and protein levels have been detected.

Finally, two regulatory genes directly linked to virulence were found in the RIP-seq list, *agrB* and *sarA* mRNAs. *AgrB* is the membrane protease responsible for the release of the autoinducing peptide AIP, which is the quorum sensing signal. Its mRNA level does not change in the $\Delta rpsA$ strain. The significance of the possible interaction with *SauS1* is not clear, but since this membrane protein is detected with difficulty in *S. aureus* proteomics analyses, we cannot rule out the possibility that S1 could play a role in its translation. In that respect, the mRNA presented a short 5'UTR with a potential large hairpin motif where the SD is engaged in base-pairings. The other gene, *sarA*, is the transcription factor potentially responsible for the simultaneous expression of both *rpsA* and *psm* transcripts (see "DISCUSSION" of the manuscript). Its level is slightly increased in the $\Delta rpsA$ strain (1,44). The functional significance of this potential *sarA-SauS1* interaction awaits further experimental data.

1.2. Perspectives

To have a complete picture of the mRNAs, which are directly recruited by *SauS1* on the ribosome to be translated, ribosome profiling experiments would be an appropriate and sensitive method. Ribosome profiling approach is based on deep sequencing of ribosome-protected mRNA fragments (RPFs, usually around 30 nt). The distribution and abundance of RPF reads mapped on a given mRNA transcript reveal the locations and densities of ribosome occupation (Ingolia et al., 2009). This approach bridges the gap between global measurements of steady state mRNA and protein levels, providing a snapshot of active ribosomes in the bacteria at a specific time and under specific conditions of growth. Statistical analysis on the differential ribosome occupancy

between WT (HG001) and $\Delta rpsA$ would provide the extent of *SauS1*-dependent translational control at the genome-wide scale. Furthermore, by applying different stresses encountered during the infection (*i.e.*, oxidative and NO), it would be possible to define the contribution of the *SauS1*-mediated translational control in the regulatory circuits taking place in response to stress. Pilot experiments have been already performed (by Lucas Herrgott) to set up the conditions for optimizing cell lysis, chloramphenicol treatment to stall the elongated ribosomes on the mRNAs, nuclease digestion to recover RNA fragments protected by the ribosomes, separation of the ribosome bound mRNA fragments using sedimentation by centrifugation with a sucrose gradient, and purification of specific 25-35 nucleotides long RNA fragments before the analysis by high throughput sequencing.

Our data suggested that the *SauS1*-mRNA complexes are dynamic explaining why I did not manage to get the footprint of *SauS1* on *psm* mRNA using the classical enzymatic and chemical mapping. Therefore, it would be better to adapt the CLIP-seq (cross-linking immunoprecipitation and RNA-seq) approach (Jensen and Darnell, 2008) to *S. aureus*. In addition to the RIP-seq, the CLIP-seq involves a pre-treatment of the cells with UV irradiation to generate a covalent bond between RNA-protein complexes prior to the purification of RNP complexes by immunoprecipitation. RT arrest at crosslink sites during cDNA library preparation can then be used as a means of mapping the interaction sites. By combining the ribosome profiling data with the CliP-Seq, we will be able to define the interaction sites, and to gain knowledge on the regulatory mechanism at the molecular level. Our preliminary data showed that many of the mRNAs that are downregulated by *SauS1* carry hairpin structures with base-paired SD, and just downstream or upstream the hairpin is often present an unstructured AU rich sequence that could be appropriate for the recognition by the OB-fold domain.

Finally, to get mechanistic details on the translation activation by *SauS1* we could also try a more direct structural approach by analyzing ribosomal complexes using cryo-electro microscopy (cryo-EM). The gel filtration experiment (**Figure 16**; Results, §I) indicated that *SauS1* does not interact directly with the ribosome but together with *psm* mRNA can form a ternary complex. This complex is stable and pure (**Table S9**; Results, §I). Thus, it would be possible to get its structure by cryo-EM. In collaboration with Yaser Hashem (IBMC, Strasbourg), the laboratory contributed to the structure of the 70S

ribosome from *S. aureus* (Khusainov et al., 2017) and more ribosomal complexes are currently under investigation.

II. Involvement of *SauS1* in sRNAs stabilization

II.1. General discussion

SauS1 was co-immunoprecipitated with numerous sRNAs (6S RNA, RsaI, RsaH, RsaE, RsaD, RNAIII, RsaA and RsaG). With the sole exception of RsaH and RsaA, their levels of expression are severely affected in the $\Delta rspA$ strain (**Table 4**; Results, §II.3). The observed down-regulation of these genes in the mutant strain could be due a defect of their transcription or a more rapid degradation. In Enterobacteriaceae, different classes of sRNAs are stabilized through the binding of the chaperone protein Hfq (Cui et al., 2013; Gottesman, 2004; Masse et al., 2003; Sonnleitner et al., 2006; Updegrove et al., 2016; Vogel and Luisi, 2011) and for ProQ (Smirnov et al., 2016; Smirnov et al., 2017), and more recently of another class of RNA chaperone called ProQ (Attaiech et al., 2017; Smirnov et al., 2017). It has been proposed that Hfq binding stabilizes sRNAs through a variety of mechanisms, e.g., blocking the attack of RNase E in many sRNAs (Masse et al., 2003), protect the sRNAs from a 3'-exoribonuclease attack by binding to the polyU tails of their Rho-independent terminators (Kovach et al., 2014);(Otaka et al., 2011). In contrast to this behavior, in *S. aureus* Hfq has no effect on sRNA stability (Boisset et al., 2007; Preis et al., 2009) and there is no ProQ equivalent (Attaiech et al., 2017; Olejniczak and Storz, 2017). Furthermore, in *S. aureus*, Hfq does not seem to be important for the recognition between sRNAs acting through base-pairings with target mRNAs (Zheng et al., 2016) and no major phenotypes were linked to its deletion (Bohn et al., 2007). In fact, little is known on the function of RNA-binding protein in regulation and clearly the machineries associated with RNAs have evolved differently in Gram-positive and Gram-negative bacteria. However, several ribonucleases contributed to RNA regulation such as RNase III (Boisset et al., 2007; Lasa et al., 2011; Lioliou et al., 2012), RNase J1 (Linder et al., 2014), and RNase Y (Khemici et al., 2015; Marincola et al., 2012). Besides, it was shown that the CshA DEAD-Box helicase is important to control the degradation of the *agr* operon (Oun et al., 2013) most likely through the recruitment of the degradosome (Giraud et al., 2015). Finally, SarA was unexpectedly found as an important factor that controlled mRNA stability but the binding to RNA seems to be not specific (Morrison et

al., 2012). Up to now, no major success was obtained to identify specifically RNP involving regulatory RNAs (Zhang et al., 2015).

In our study, we could demonstrate that *SauS1* would be responsible for a protective effect on several sRNAs. What could be the mechanism? At this regard, almost of the sRNAs strongly enriched with *SauS1* carry U-rich tails at their 3', which could be an appropriate binding site for S1. In these lines, *RsaA*, which carries a weak Rho-independent terminator (Geissmann et al., 2009a), does not bind to *SauS1* (**Figure 20F**). Another possibility is that *SauS1* would recognize other regions on the sRNAs. Many identified sRNAs in *S. aureus*, carry C-rich regions (CRRs) predicted to interact with G-rich sequences such as SD elements in their mRNA targets. It was proposed that besides this role, the CRR could also be recognized as binding site for specific proteins, as it was demonstrated for CRR found in the 3' UTR of some mRNAs in eukaryotes (Durand et al., 2015; Makeyev and Liebhaber, 2002). The CLIP approach will be useful to map the *SauS1* binding site while further experiments would be necessary to clarify the stabilizing role of *SauS1*.

II.2. Perspectives

The stability of sRNAs in the *rpsA* mutant could be determined by measuring the kinetics of their degradation after rifampicin treatment (Campbell et al., 2001). Preliminary data have been already obtained by Delphine Bronesky on the stability of *RsaI*, the main target of S1. The experiment was done comparing WT (HG001) with the two intron insertion mutants of *rpsA* (*rpsA1111::LtrB* and *rpsA1029::LtrB*). Rifampicin was added to WT and the mutant strains grown in BHI to $OD_{600}=3$ (4h), when both *SauS1* and *RsaI* are present. *RsaI* was detected by Northern blot using total RNAs extracted after 2, 4, 8, 15, 30, 45 and 60 min (**Figure 29**). Quantification, normalization and interpolation of the data by linear regression in logarithmic scale, show an effect of *SauS1* on *RsaI* stability by factor of two, as shown in the **Figure 29**.




Figure 29: Stability of RsaI in different strains. After quantification of the Northern blot signals and normalization of each point to the corresponding 5S signals, the % of remaining *psm* mRNA has been plotted to calculate RsaI half-life in the three strains. $T_{1/2}$ HG001 (WT) is 50.23 min, while in absence of *SauS1*, $T_{1/2}$ *rpsA111::LtrB* and $T_{1/2}$ *rpsA1029::LtrB* decreased to 25.96 min and 27.51 min, respectively.

To determine the mechanism by which *SauS1* recognizes sRNAs to protect them from degradation, the CLIP-seq experiment proposed above could be used to get sRNA interaction sites. Moreover, a mutagenesis analysis of those sites would be necessary to confirm their importance in *SauS1* recognition. At this regard, two mutants of RsaI have been obtained by Delphine Bronesky in the laboratory. RsaI regulatory regions (G-rich tract and UC-rich sequence, **Figure 24**) have been deleted separately or in combination and these RsaI variants could be used to analyze their ability to bind *SauS1* using gel retardation assays.

III. Involvement of *SauS1* in sRNA-target recognition

III.1. General discussion

Among the sRNAs isolated in complex with the protein, RsaI is the most enriched RNA. We have demonstrated that RsaI directly interacts with *SauS1* using gel retardation assays (**Figure 20B**; Results, §II). The works of Delphine Bronesky and Emma Desgranges in our laboratory have clarified the role of RsaI. Briefly, MS2-affinity purification approach coupled to RNA sequencing (MAPS) (Lalaouna and Masse, 2015; Tomasini et al., 2017) has allowed the characterization of its targetome. RsaG is its major sRNA target and it was demonstrated to synergically work with RsaI for the regulation of glucose metabolism. The two non-coding RNAs are expressed during the late exponential phase of bacterial growth, when *SauS1* is well expressed too. Both of them negatively respond to the presence of free glucose in the media (D glucose) while the expression of RsaG is enhanced by glucose 6 phosphate (G 6P). RsaI is a bifunctional

molecule able to simultaneously bind more than one target RNA throughout two different conserved regions: a G-rich tract and UC rich sequences. By footprinting experiments, I could show that the G-rich region of RsaI is responsible for the recognition of RsaG (**Figure 25**; Results, §II) while the UC rich sequence is required for the binding of many mRNA targets (D. Bronesky and E. Desgranges). Nevertheless, the predicted secondary model of RsaI (Marchais et al., 2010) and structure probing experiments (**Figure 24**; Results, §II), have evidenced that this G-rich could be constrained in a pseudoknot structure. Indeed, our preliminary probing experiments have shown that on one hand, the nucleotides of the UC rich region of RsaI are highly reactive to SHAPE, indicating a single strand conformation, but at the same time these nucleotides are also subjected to RNase V1 cuts, specific for double stranded region. On the other hand, the G rich motif is cleaved by RNase T1 (specific for unpaired G), while these nucleotides are poorly cleaved by Pb(II) induced cleavages and less reactive to SHAPE. Such mixed behavior is typical of the co-existence of multiple structures at the equilibrium and might be the signature of the presence of a pseudoknot. In fact, thermodynamic analysis has shown that an equilibrium between pseudoknot structure and alternative hairpin loop conformation existed (Philippe et al., 1990). The inaccessibility of the RsaI regulatory sequences makes necessary the action of a trans-acting factor able to unfold and remodel the secondary structure of RsaI, thus allowing target binding. RsaI and RsaG are able to interact even in the absence of *SauS1* (apparent $K_d= 50$ nM), while the addition of *SauS1* largely promotes the ability of RsaI to recognize RsaG (apparent $K_d= 6,25$ nM). Even if *SauS1* interacts only with RsaI, a ternary complex could be evidenced (**Figure30**).




Figure 30 : Gel retardation assays to follow the formation of ternary complex *SauS1*-*RsaI*-*RsaG*. 5' end-labeled *RsaI* was incubated with increasing concentration of cold *RsaG* in the presence and in the absence of *SauS1* used at 1 μ M. Lanes C1 and C2 are control lanes with *RsaI* and *RsaI*-*SauS1*, respectively. The binary (*RsaI*-*RsaG* and *RsaI*-*SauS1*) and ternary (*SauS1*-*RsaI*-*RsaG*) complexes are indicated by arrows.

In Enterobacteria, the Sm protein Hfq binds to sRNAs and facilitates their base-pairing with mRNA targets. The mechanism by which it stimulates the annealing has been demonstrated by several structural works and mutagenesis analyses. Hfq from *Escherichia coli* and other Enterobacteriaceae form a compact hexamer that presents two structurally non-equivalent surfaces for RNA recognition: the proximal face, which interacts preferentially with uridine-rich sequences of sRNA and the distal face, favoring the binding of the target RNAs (Schumacher et al., 2002; Link et al., 2009; Sauer and Weichenrieder, 2011) (**Figure 31A**). In addition to the distal and proximal faces, the torus-shaped (or donut) of the Hfq hexamer bears an arginine patch sequence motif called rim that has recently been identified as a surface contributing to the annealing of both RNAs (Sauer et al., 2012; Zhang et al., 2013; (Zheng et al., 2016)). In *S. aureus*, Hfq does not accomplish this function because of the absence of this conserved rim motif of the hexamer (Panja S. et al, 2013(Zheng et al., 2016)). For instance, studies carried out on *S. aureus* RNAlIIII/*spa* mRNA model system have shown that Hfq neither form a ternary complex nor promote their annealing although it specifically binds to RNAlIIII and *spa* mRNA *in vitro*. Furthermore, Hfq did not affect the stability of RNAlIIII and *spa* mRNA *in vivo* (Eric Huntzinger et al., 2005). Therefore Hfq has probably evolved other functions in Gram-positive bacteria that are not yet determined.

Instead, in this work, we have demonstrated the ability of *SauS1* to promote base-pairing between short RNA molecules while the protein is not able to perform the strand displacement reaction (Figure 13). Differently from Hfq, *SauS1* does not interact with both RNAs (only RsaI, not RsaG) but is able to promote the formation of ternary complexes and stimulate RsaI-RsaG base pairings (**Figure 31B**). Based on the probing experiment, we proposed that this annealing activity is indirect and resulted from the remodeling of the RsaI secondary structure, i.e. melting of the pseudoknot, which would render accessible the regulatory regions of RsaI. A model is presented in **Figure 31**.




Figure 31. Hypothetical models of the sRNA/mRNA interacting with EcoHfq or SauS1. Figure adapted from (Dimastrogiovanni et al., 2014). A. EcoHfq model represented by six spheres, from which the disordered C-terminal tails extend radially. sRNA (RydC pseudoknot model; orange) sits on the proximal face of Hfq, with the 3' end U-rich tail interacting with the central channel. The two double strands conferring the pseudoknot structure to RydC are indicated as S I and S II. The target mRNA (*cfa*, depicted in yellow) associates with the distal face of Hfq, and it is proposed to form a duplex with the 5' end seed region of RydC that is recognized by the circumferential rim of Hfq. B. *SauS1* model represented by 4 spheres for its four domains colored according to Supplementary Figure S5 of the manuscript. The sRNA (orange) binds directly to *SauS1* and prepare it for interaction with its target (mRNA or another sRNA as for the RsaI-RsaG case; yellow). The ternary complex thus forms via RNA-RNA base pairing

III.2. Perspectives

The annealing activity of *SauS1* could be further investigated by *in vitro* biophysical experiments. The thermodynamics of *SauS1*-RsaI-RsaG complex formation could be obtained by ITC (Isothermal Titration Calorimetry). ITC is a quantitative technique that can determine accurately the binding affinity (K_a), the enthalpy (ΔH) and entropy (ΔS) changes, and binding stoichiometry (n) of the interaction between two or more molecules in solution. In this way, we could for example understand whether RsaI pseudoknot is melted by *SauS1* before RsaG binding. Another approach could be the use of the SwitchSense apparatus. In this technique, binding kinetics and conformational changes can be monitored by the real time tracking of hydrodynamic friction difference in the motion of short DNA nanolevers upon ligand binding. RsaI could be linked to the DNA levers and RsaG binding in the presence of in the absence of *SauS1* could be monitored. Both ITC and SwitchSense are available in our Unit.

The effect of *SauS1* on the kinetics of sRNA target recognition could also be monitored *in vivo*. Vanderpool and Ha laboratories have recently developed a technique to visualize

by super-resolution imaging *in vivo* fluorescently labelled sRNA (SgrS) and mRNA (*ptsG*) in *E. coli* and to determine base-pairing kinetics using mathematical modeling (Fei et al., 2015). They could quantitatively examine the effect of Hfq, showing that in the Δhfq strain, the degradation rate of SgrS increased 20-fold, while the SgrS-*ptsG* mRNA association rate decreased only slightly. Similar experiments could be done to assess sRNA-target RNA couples in *S. aureus* WT or $\Delta rpsA$. In collaboration with Michaël Ryckelynck (IBMC, Strasbourg), we are developing single-cell analyses on *S. aureus* RNA regulations, using microfluidics lab-on Chip and the recently developed bright aptamer probes to visualize the sRNA (Autour et al., 2016).

IV. Involvement of *SauS1* in tRNA maturation

IV.I. General statement

Several tRNAs were isolated from the RIP-seq analysis. They all belong to a special class of tRNAs with chromosomally encoded CCA 3'-end. The secondary structure of the tRNAs is composed of three stem-loops (D, anticodon and T) and its 5'- and 3'-ends pair to form a fourth terminal stem, where the amino acid is attached. At the extremity of this stem a single strand region, the CCA sequence, mediates amino acid attachment occurring to the 2' or 3'-hydroxyl group of the 3' terminal A in the CCA-motif by the aminoacyl-tRNA synthetases (Meinzel *et al*, 1995; Giegé and Springer, 2016).

The presence of chromosomally encoded 3'-CCA, is not a universally conserved feature of tRNA genes. Indeed some bacteria like *E. coli*, have this sequence encoded in all tRNAs (Hartmann, 2009; Blattner, 1997), while other bacteria, such as *S. aureus*, lack the 3'-CCA in some of its tRNA genes. In these cases, the CCA-end is added post-transcriptionally like in eukaryotes by the tRNA-nucleotidyl transferase (Weiner, 2004; Xiong et al., 2006). When directly transcribed as in the *SauS1* interacting tRNAs, the CCA is a crucial signal required for the activation of alternative 3' maturation pathway of the tRNA primary transcript (Kirsebom and Svärd, 1994; Wegscheid and Hartmann, 2007). Indeed while the tRNA 5'-end processing is a largely conserved process catalyzed by the ubiquitous RNase P (Hartmann, 2009; Gopalan, 2007), the maturation of the 3'-end is a more complex mechanism and it varies according to the presence or not of the chromosomally encoded 3'-CCA (Hartmann et al., 2009; Marck et al., 1993). In *E. coli*, the tRNA processing is initiated by the endoribonuclease RNase E few nucleotides

downstream of the 3'-CCA sequence to generate pre-tRNAs with short or long 3' External Transcription Sequences (3'ETS) (Li and Deutcher, 2002). An AU-rich sequence in the proximity of the tRNA 3'-end (Li et al., 2005) is presumably recognized as a signal sequence during the endonucleolytic processing of the 3'-ETS. In contrast, Gram-positive bacteria lack the RNase E and the conserved AU-rich sequence is also not present in this region. In tRNAs, where RNase E cleaves further away from the 3'-CCA sequence, exoribonucleases like RNase II and PNPase initiate 3'-end maturation producing shorter 3' trailers which are then completely matured by the action of RNase PH and RNase T (Li and Deutscher, 1995, 1996). Alternative pre-tRNA 3' end maturation processes were observed in *B. subtilis* (**Figure 32**). Indeed, the tRNAs missing the CCA end, are processed at their 3' end by a single endoribonuclease, the RNase Z. After this primary step, the CCA is added by the tRNA nucleotidyl transferase (Pellegrini et al., 2003), an enzyme also involved in the repairing of damaged 3'CCA ends in mature tRNAs. In contrast, if the 3'-CCA is encoded, the pre-tRNAs are matured by the exonucleolytic action of RNase R, PNPase and RNase PH in a process similar to *E. coli* (Pellegrini et al., 2003; Wen et al., 2005).




Figure 32 Processing of 3' end CCA- encoded and 3' end CCA- less tRNAs. Vertical arrows on 5' leader of tRNA precursor represents the endoribonucleolytic cleavage carried out by the RNase P (A-B), while horizontal arrows on the 3' trailer represent the exoribonucleolytic trimming accomplished by RNase PH, PNPase RNase R (A) and RNaseZ (B). *SauS1* could be required for the exonucleolytic activity of one of the enzyme involved in the 3' end processing. Addition of CCA by tRNA nucleotidyl transferase is marked as "+CCA." The order of processing reactions is marked by numbers in parentheses.

By inspecting the reads distribution of the differential transcriptomic analysis at the loci of the immunoprecipitated tRNAs with the IGV browser (Thorvaldsdottir et al., 2013), an higher density could be observed at the 3'ETS in the $\Delta rpsA$ (**Figure 33**). We speculate a possible role of *SauS1* in assisting the exoribonucleolytic activity of one of the involved enzymes (RNase R, PNPase or RNase PH).




Figure 33. tRNA maturation defect in the $\Delta rpsA$ strain. Comparative analysis of reads accumulation between wild-type HG001 and the $\Delta rpsA$ strains. Here details of the HG001_00443 locus for the Ala-tRNA (tgc) that was isolated in complex with *SauS1*. The accumulation of reads at the 3'-ETS could indicate a defect of maturation.

Moreover, defects in tRNAs processing or incorrect folding, are linked to the formation of non-functional molecules that are subjected to quality control mechanisms (Li et al., 2002) and are often rapidly degraded. It has been proposed that this process takes place at the 3'-end via the polyadenylation made by the poly (A) polymerase (PAP) followed by the trimming of the adenines by RNase R and the PNPase (Zhongwei Li et al., 2002). The presence of non-matured tRNA species in the $\Delta rpsA$ would imply defects in the maturation process but also an unefficient clearance of the unprocessed pre-tRNA.

To understand which nucleases might require *SauS1* action, we have performed an immunoprecipitation experiment under the same conditions for the RIP-seq, but looking at which protein complexes would be co-purified with *SauS1* by LC/MSMS. Among the most enriched proteins, we have identified several ribosomal proteins and RNases, which are known to be part of the *S. aureus* degradosome (Giraud et al., 2015; Roux et al., 2011) (Table 5).

| Ribosome | | | | | | | | |
|----------------------|----------------------|--------------------------------------------------------------------------------------------------------|------------------------|--------|---------|---------|--------------|--|
| Name | Gene | Description | References | log2FC | p.value | adjp | -log10(adjp) | |
| Small subunit | | | | | | | | |
| bS16 | <i>rpsP</i> | Ribosomal protein bS16 | Khusainov et al., 2016 | 6,05 | 0,00005 | 0,00033 | 3,48 | |
| uS9 | <i>rpsI</i> | Ribosomal protein uS9 | Khusainov et al., 2016 | 5,77 | 0,00016 | 0,00092 | 3,04 | |
| uS4 | <i>rpsD</i> | Ribosomal protein uS4 | Khusainov et al., 2016 | 3,78 | 0,00042 | 0,00223 | 2,65 | |
| uS7 | <i>rpsG</i> | Ribosomal protein uS7 | Khusainov et al., 2016 | 3,61 | 0,00018 | 0,00098 | 3,01 | |
| uS17 | <i>rpsQ</i> | Ribosomal protein uS17 | Khusainov et al., 2016 | 3,57 | 0,00001 | 0,00005 | 4,27 | |
| uS13 | <i>rpsM</i> | Ribosomal protein uS13 | Khusainov et al., 2016 | 2,75 | 0,00122 | 0,00518 | 2,29 | |
| bS20 | <i>rpsT</i> | Ribosomal protein bS20 | Khusainov et al., 2016 | 2,34 | 0,00000 | 0,00000 | 5,48 | |
| Large subunit | | | | | | | | |
| uL23 | <i>rplW</i> | Ribosomal protein uL23 | Khusainov et al., 2016 | 5,05 | 0,00693 | 0,02407 | 1,62 | |
| bL9 | <i>rplL</i> | Ribosomal protein uL9 | Khusainov et al., 2016 | 5,04 | 0,00323 | 0,01264 | 1,90 | |
| uL29 | <i>rpmC</i> | Ribosomal protein uL29 | Khusainov et al., 2016 | 4,61 | 0,01046 | 0,03454 | 1,46 | |
| bL12 | <i>rplL</i> | Ribosomal protein uL12 | Khusainov et al., 2016 | 4,57 | 0,01313 | 0,04175 | 1,38 | |
| uL6 | <i>rplF</i> | Ribosomal protein uL6 | Khusainov et al., 2016 | 1,35 | 0,01614 | 0,04905 | 1,31 | |
| Degradosome | | | | | | | | |
| Name | Gene | Description | References | log2FC | p.value | adjp | -log10(adjp) | |
| RNJ1 | <i>rnjA</i> | Ribonuclease J 1 | Roux et al., 2011 | 8,86 | 0,00000 | 0,00000 | 10,84 | |
| RNJ2 | <i>rnjB</i> | Ribonuclease J 2 | Roux et al., 2011 | 8,71 | 0,00000 | 0,00000 | 10,31 | |
| PNP | <i>pnp</i> | PNPase | Roux et al., 2011 | 7,80 | 0,00001 | 0,00007 | 4,18 | |
| RNY | <i>rny</i> | Ribonuclease Y | Roux et al., 2011 | 5,78 | 0,00142 | 0,00597 | 2,22 | |
| Tex | <i>Tex</i> | Toxin Expression, structurally similar to Eukaryotic Spt6 involved in transcription and RNA maturation | | 5,75 | 0,00143 | 0,00597 | 2,22 | |
| PNP-like | <i>SAOUHSC_00483</i> | Sequence similarity with PNPase | | 4,67 | 0,01026 | 0,03422 | 1,47 | |
| CshA | <i>CshA</i> | DEAD-box ATP-dependent RNA helicase | Giraud et al., 2015 | 3,67 | 0,06397 | 0,14370 | 0,84 | |

Table 5. *In vivo* complexes involving *SauS1*. *SauS1* co-immunoprecipitation was performed under the same conditions as for the RIP-seq experiment (Results). The protein were extracted and analyzed by LC/MSMS. Two main cellular complexes have been found to co-purify with *S1*, the ribosome and the degradosome.

While RNase R and RNase PH do not seem to be associated with *SauS1*, PNPase was found to be the most enriched together with RNases J1 and J2. It is thus possible that *SauS1* helps PNPase in the processing of 3'ETS of tRNAs with encoded CCA. PNPase is arrested by stem-loop structures and it is tempting to propose that the chaperone activity of *SauS1* would help removing them to prepare the pre-tRNA substrate for efficient maturation. RNases J1 and J2 are 5'-3' exoribonucleases (and endonucleases as well (Hausmann et al., 2017)) involved in the 5' maturation of both the 16S rRNA and the RNase P. They could also perform initial cleavages, competing with ribosomes for the stability of *S. aureus* mRNAs (Linder et al., 2014). In our transcriptomic analysis, we have removed the rRNA (RiboZero depletion; Illumina) and therefore we cannot draw any conclusion about 16S rRNA processing. Nevertheless, a slight accumulation of reads

at the 5' of the RNase P RNA could be observed in the $\Delta rpsA$ strain (data not shown). Is *SauS1* helping exoribonucleases in their maturation activities? More experiment will be necessary to clarify this possible function.

Interestingly, the multiple functions of *SauS1* in translation and tRNA maturation, was also demonstrated for a protein largely conserved in wide variety of eukaryotes, named protein La. As *SauS1*, La protein is an RNA chaperone able to interact with different RNA molecules including precursor tRNAs, 5S rRNA, the signal recognition particle SRP (J.P Hendrick et al., 1981 - J Rinke, J.A Steitz, 1982 - J Rinke, J.A Steitz, 1985). The La proteins recognize their RNAs through a UUU_{OH} 3' sequence. Despite its best characterized function is to protect premature exoribonucleolytic digestion of tRNAs during their processing, La protein has been show to bind to several mRNAs affecting their translation (Christopher J Yoo¹, Sandra L Wolin, 1997).). A La-related protein LARP7 is also a component of the 7SK RNP assembly and as the La protein binds to a UUU sequence motif at the 3' end of the RNA (Market et al., 2008; Uchikawa et al., 2015).

IV.2. Perspectives

To confirm the 3'ETS maturation defect, Northern blot analysis using specific probes targeting the ETSs will be performed. Alternatively, RT-PCR experiments can be envisaged. Two-dimensional (denaturing and semi-denaturing conditions) electrophoresis on polyacrylamide gels (Suyama, 1986) could also be used for the separation of mature tRNAs from unprocessed transcripts. In the long term, mutant strains at specific genes encoding exoribonucleases will be constructed and studied to define the pre-tRNA processing pathway at the 3' end, and the role of *SauS1* in this pathway.

V. Involvement of *SauS1* in *cis-acting* regulatory elements

The most widespread example of RNA regulatory elements in bacteria are riboswitches, complex folded RNA domains located in the non-coding regions of mRNAs, that control gene expression by binding specific metabolites (cofactors, vitamins, amino acids, nucleotides, Mg²⁺, second messenger cyclic di-GMP). Simple riboswitches are composed of two regions: an aptamer, responsible for ligand binding and an expression platform,

located in the 5' UTR of the regulated mRNA and/or operon. Upon ligand binding to the aptamer domain, a structural rearrangement is promoted on the nearby platform. Regulation mediated by riboswitches can occur at the transcriptional and/or translational levels. Translational riboswitches act throughout the formation of secondary structures, which sequester the RBS or the SD sequences of target mRNAs. This regulatory mechanism is not widespread in *S. aureus*. The only example in *S. aureus* is given by the flavin mononucleotide (FMN) riboswitch that controls the expression of *ribU* (HG001_01344 in HG001), encoding a membrane riboflavin transporter. It has been proposed that in the absence of the ligand, the platform has a conformation competent for the mRNA translation, while the binding of FMN induces the formation of a hairpin structure which sequesters the SD sequence of the mRNA thus inhibiting its translation (Geissmann et al. 2009; Marchais et al. 2009; Abu-Qatouseh et al. 2010; Beaume et al. 2010; Bohn et al. 2010; Ten Broeke-Smits et al. 2010). In general, riboswitches work by forming Rho-dependent terminators to prematurely arrest the transcription of the downstream genes (Gusarov and Nudler 1999; Yarnell and Roberts, 1999). *S. aureus* FMN riboswitch (HG001_01693) which was specifically co-immunoprecipitated with *SauS1*, is a transcriptional riboswitch which controls the expression of genes involved in the biosynthesis and/or transport of riboflavin (vitamin B2). It has been shown that the binding of FMN to the aptamer of the *ribD* operon (*ribDEBAH* genes) induces the formation of an intrinsic transcription terminator thus blocking the synthesis of vitamin when it is not required (Pedrolli D. Biscaro, Suess B, 2015) (Serganov et al., 2009; Wickiser et al., 2005) (**Figure 34**).




Figure 34: FMN riboswitch controlling *ribD* operon. In *S. aureus* as well as in *B. subtilis*, the riboflavin genes are organized in a large operon. The 5' UTR of the corresponding mRNA contains a riboswitch (HG001_01693) that controls the expression of the whole operon. When the levels of FMN are sufficient, it binds to the riboswitch with the formation of a terminator at the platform region. Transcription is then halted and the genes necessary for the riboflavin production and transport are repressed.

Our transcriptomic analysis of the $\Delta rpsA$ strain has shown an up-regulation of the FMN riboswitch (2.5) as well of the genes that are under its control (*ribD* 2.3; *ribE* 4.4; *ribBA* 2.9; *ribH* 2.6). The whole operon is thus enhanced. This indicates that in the absence of *SauS1*, the Rho-independent terminator did not form efficiently otherwise the downstream gene of the *ribD* operon would have been repressed. It is possible that to form correctly, the terminator needs the action of *SauS1*. By binding specifically to the riboswitch region (RIP-seq data), *SauS1* might act as a helper protein to promote the switch between alternative conformers for efficient regulation.

Interestingly, other riboswitches seem to require *SauS1*. The Glycine riboswitch (HG001_01462) interacts with *SauS1*, its level is slightly less in the $\Delta rpsA$ (0.62 but with a bad p-value) while the regulated downstream operon *gcvT* is upregulated. Finally, also the T-box riboswitches for the aminoacyl tRNA synthetases ThrRS and AlaRS are enriched with *SauS1* as shown in the RIP-Seq, and the downstream corresponding genes are upregulated in the $\Delta rpsA$ mutant strain.

The CLIP-Seq approach and single-round *in vitro* transcription assays would be helpful to precisely define the role of *SauS1* in these processes (Choonee et al., 2007).

VI. General conclusion

Despite the fact that *SauS1* is not essential, we have demonstrated its crucial role in the correct coordination of different virulence factors.

First, we have shown that it acts as translational activator of PSM α peptides, even if not associated on the ribosome (**Figure 35**). *SauS1* could work as an RNA chaperone on its target mRNAs, removing inhibitory structures and increasing their ability to bind the ribosome and to present their AUG start codon for initiator tRNA interaction. We have also shown that the protein is involved in the production of several secreted virulence factors thus globally impacting *Staphylococcal* virulence.

In our study we have proposed the possible involvement of *SauS1* in RNA metabolism. Analysis of isolated S1-*in vivo* complexes has allowed the identification of several classes of RNA targets whose level of expression is affected in the $\Delta rpsA$ strain. By binding to sRNAs, not only *SauS1* could protect them from rapid degradation but also we have demonstrated, at least in one case, to promote the annealing between a sRNA and its target, probably by helping the RNA to get its functional conformation.

Comparative transcriptomic analysis has been found an up-regulation of the FMN riboswitch, *in vivo* isolated with *SauS1*, and of the genes under its control. We assume that in absence of the protein the formation of the terminator fails, thus allowing the expression of downstream genes.

Moreover we have proposed a link between *SauS1* and the degradosome. Indeed, in absence of the protein a defect of maturation and degradation of 3' end CCA- encoding tRNAs has been observed.

Taken together, my results highlight, a key RNA binding protein involved in gene expression regulation in *S. aureus*. Whether the action of *SauS1* in translation initiation as well as in regulatory mechanisms might be conserved in other Gram positive bacteria remained to be elucidated.




Figure 35: Summarized picture of regulatory networks coordinated by *SauS1*: AgrC activates AgrA in response of appropriate level of secreted AIP. The three *PSMs* locus are controlled both at transcriptional level by AgrA and at translational level by *SauS1*. SarA is responsible of the *rpsA* and *psm* transcript expression. Co-immunoprecipitation assay of a flag-tagged version of *SauS1* has allowed the identification of its *in vivo* targets including mRNAs, sRNAs, riboswitches and 3' end encoding CCA- tRNAs. All the identified targets are affected in the $\Delta rpsA$ strain. Examples of misregulation per each class of molecule are given in the yellow panel.

Materials and Methods

Media and growth of bacteria

Pre-cultures were started from glycerol stocks. *S. aureus* was grown in Brain Heart Infusion medium (Fluka, analytical) while *E. coli* in Luria-Bertani Broth Powder microbial growth medium (Sigma-Aldrich) supplemented if needed with antibiotics (100 mg/liter ampicillin and 100 mg/liter erythromycin), at 37 °C over night under constant agitation (300 rpm). The cultures were started at $OD_{600} = 0,02$ respecting 1:5 flask-culture volume ratio.

The tested stress conditions were applied at $OD_{600} = 1$ and then optical density was followed each 30 minutes until the end of bacterial growth.

Purification of SauS1

Single colony of *E. coli* M15, transformed with the pQE30 (Qiagen) plasmid carrying *SauS1*, was grown in LB medium supplemented with 100 mg/liter ampicillin and 100 mg/liter erythromycin at 37°C under constant agitation (300 rpm) over night. The pre-culture was inoculated in 1 L of fresh LB supplemented with appropriated antibiotics and incubated at 37 °C until $OD_{600nm} = 0.6$, when overexpression of the protein was induced using IPTG. An aliquot of 1 ml of culture was taken before the induction (BI) as control, centrifuged (2 min at 1000g, 4°C) and resuspended in 100 µL of protein loading buffer. 1, 2 and 3 hours after induction, aliquots of 1 ml each were taken as controls after induction (AI) and treated in the same way as BI. At the end of the growth the cells were pelleted by centrifugation (15 min at 4200rpm, 4 °C), washed with 10 mM Tris-HCl pH 7.5 and then resuspended in buffer A. Before sonication (120 V, 10 sec of sonication followed by 30 sec on ice, repeated at least 15 times), 3 µl of DNase (RNase free, Roche 10 U/ul), protease inhibitor cocktail 1X (Roche) and 35 mg lysozyme (Sigma), were added.

Sonication

Bacterial lysis was obtained for sonication (120 V, 10 sec of sonication followed by 30 sec on ice, repeated at least 15 times). In order to remove cellular debris, the sample was centrifuged at 4200 rpm for 30 min, 4 °C. The supernatant (S30) was recovered and an aliquot of 15 µl was taken for SDS-page analysis. The SDS-page gel was prepared at 12%.

First Ni-NTa column purification

The Ni-Nta agarose beads (Agarose, Qiagen) were washed using Qiagen protocol (<http://www.qiagen.com/literature/render.aspx?id=201426>) and then were resuspended in 8 ml of Buffer E. The S30 was incubated with the Ni-Nta beads for 1 hour at 4 °C under agitation. At the end of the incubation, the sample was loaded on Poly-prep chromatography column (Biorad). The flow-through (FT) was recovered in a falcon tube and the column was washed with 8 ml of Buffer E. The elution of *SauS1* fused with 6-Hys was obtained by using increasing concentration of imidazole (10 ml of imidazole at 20 mM, 50 mM and 100 mM). An aliquot from each fraction (10 µl of FT, 30 µl of wash, 20 mM, 50 mM and 100 mM supplemented with ½ of loading proteins buffer) was loaded on 12% SDS-PAGE gel.




Figure 36 Schematic summary of *SauS1* purification

Dialysis

The fractions containing *SauS1*, were dialyzed over night at 4 °C under agitation against

buffer Q. (Slide-A-Lyzer dialysis cassette, 3500 MWCO, 15 ml)

Protein concentration

Dialyzed protein was concentrated using M Centrifugal filter units 15 ml, 10K tubes. The centrifugation was performed for 25 minutes at 4200 rpm, 4 °C until the protein reached a final volume of 1 ml (25 mg/ml). *SauS1* was then enzymatically digested using 120 µl of Protean 10U Tev.

Second Ni-Nta column purification

The Ni-Nta agarose beads were washed as described above and then were resuspended in 8 ml of Buffer Q. The cleaved protein was incubated with the Ni-Nta beads for 1 hour at 4 °C under agitation. At the end of the incubation, the sample was loaded on Poly-prep chromatography column (Biorad). The flow-through (FT) was recovered in a falcon tube and then the column was washed with 8 ml of Buffer Q and treated with 10 ml of imidazole at 20 mM, 50 mM and 100 mM. An aliquot from each fraction (10 µl of FT, 30 µl of wash, 20 mM, 50 mM and 100 mM of imidazole, supplemented with ½ of loading proteins buffer) was loaded on 12% SDS-PAGE gel.

FPLC using anion exchange column

The fractions containing the cleaved protein (FT and wash) were centrifuged for 1 hour at 8000 rpm, 4 °C in order to pellet the cellular debris and eventually formed aggregates that could obstruct the anion exchange column (GE Healthcare). Before loading the sample, the column was washed with 5 vol of mQ water, 5 vol of buffer QB and 5 vol of buffer Q (all the buffer were filtered and degassed). Upon the injection of the sample, *SauS1* was eluted by gradient of HH_4Cl (from 40 mM to 1 M, buffer QB). The fraction identified on the MonoQ analysis, having an absorbance peak at 280 nm were analyzed by polyacrylamide-SDS gel 12%. The fraction containing pure protein, were pooled and dialyzed over night at 4 °C using storage buffer. As dialysis cassettes were used the Slide-A-Lyzer dialysis cassette, 3500 MWCO. The concentration of the protein was

estimated using the specific protein extinction coefficient ($\epsilon = 47565\text{M}^{-1}\text{cm}^{-1}$, www.expasy.ch). It has to be taken into account that *SauS1* does not contain any Trp and this could result in more than 10% error in the computed extinction coefficient. The purified protein was finally stored at $-20\text{ }^{\circ}\text{C}$ in 10% of glycerol.

Buffer A : Tris-HCl pH 7,5 20 mM, MgCl₂ 2 mM, KCl 60 mM, NH₄Cl 1 M, EDTA 10 mM, β mercaptoethanol 10 mM

Buffer E : Tris HCl pH 7,5 20 mM, MgCl₂ 2 mM, KCl 60 mM, NH₄Cl 1 M, imidazole 10 mM, β mercaptoethanol 10 mM

Buffer Q : Tris-HCl pH 7,5 20 mM, MgCl₂ 2 mM, NH₄Cl 40 mM, EDTA 1 mM, β mercaptoethanol 6 mM

Buffer QB : Tris-HCl pH 7,5 20 mM, MgCl₂ 2 mM, NH₄Cl 1 M, EDTA 1 mM, β mercaptoethanol 6 mM

Storage buffer : Tris-HCl pH 7,5 20 mM, NH₄Cl 40 mM, KCl 60 mM, TCEP 200 μM , glycerol 7 %

SDS-PAGE analysis

The SDS-PAGE gel is composed of two gels, the first of resolving and the second of running. Its concentration is depending on the size of the molecules that has to be analyzed (for *SauS1* 10 – 12%). Before loading on the gel, the samples were diluted in 1 vol of protein loading buffer and heated at $90\text{ }^{\circ}\text{C}$ for 3 min. The migration buffer was TGS 1X and the gel was runned at 80V until the end of the resolving part and then at 150 V until the end of the run.

Resolving gel : Tris HCl pH 6,8 80 mM, SDS 0,1%, 5% acrylamide, APS 0,1%, Temed 1/1000

Running gel : Tris HCl pH 8,8 500 mM, SDS 0,1%, 12% acrylamide, APS 0,1%, Temed 1/1000

Loading protein buffer : Tris-HCl pH 6,8 60 mM, Glycerol 25 %, SDS 2 %, β mercaptoethanol 5 % (0,7 M), bromophenol blue 0,1 %

TGS 1x : Tris 25 mM, glycine 200 mM, SDS 0,1%

Co-immunoprecipitation assays

Chromosomally flag-tagged *SauS1* and wild type BEJ100 strains were grown in BHI medium at 37°C, under constant agitation at late exponential phase. At the end of the growth, the cells were centrifuged for 10 min at max speed and the pellet was stored at -20 °C. Bacterial cell pellet was suspended in 2 mL of lysis buffer, transferred onto glass beads (provided by FastRNA Pro Blue Kit, Qbiogene) and processed in the FastPrep instrument (3645 s at a setting of 6.0). Samples were centrifuged at 13,000 rpm for 2 min. The supernatants were mixed with Anti-Flag M2 Affinity Gel (Sigma, A2220) and incubated at 4°C for 60 min. Then the beads were washed three times with TBS. Elution was made with 0.2 ml of 3X Flag Peptide (Sigma, F3290) prepared at the concentration recommended by the supplier. The sample was extracted with acidic phenol and then by chloroform-isoamyl alcohol. RNA was precipitated with ethanol, treated with DNase I, extracted with phenol and precipitated. The final RNA samples were dissolved in 50 ml of sterile water and lyophilized.

Deep-sequencing analysis

cDNA-seq libraries were constructed with RNA samples isolated from Co-IP experiments under late-exponential phase of growth of the Flag-tagged *SauS1* and wild-type BJ100. The resulting cDNA libraries were sequenced on a Roche 454 sequencer using FLX and Titanium chemistry. From the resulting cDNA reads, 5'-linker sequences and polyA-tails were clipped from the sequenced cDNA reads. Only reads of ≥ 18 nt were aligned to the reference genome, which was retrieved from the NCBI server (accession number of the chromosome: NC_002745.2; accession number of the plasmid: NC_003140.1), using the program segemehl. Based on the resulting mapping data, read coverage files were generated in the GR format representing the number of mapped reads per nucleotide. The GR files were visualized in combination with FASTA and GFF files of the genome using the Integrated Genome Browser (IGB) (Nicol JW *et al.*, 2009). Additionally, overlaps of mapped reads and gene annotation positions were identified and counted. The overlap between mapped read and a gene annotation had to be at least 10 nucleotides long to be taken into account. Each single overlap counting was normalized by the number of positions to which the overlapping read was mapped and the number

of annotations that overlap with the read. For instance, if reads map to multiple regions with exactly the same score (e.g. this is the case for reads that map to the different multiple copies of the rRNA genes), only a relative fraction of one read is counted instead of a count of one read. For example, if a read maps twice, each location gets a score of 0.5 reads. Moreover, if a read overlaps two annotations, each annotation gets a score of 0.5 reads.

Lysis buffer : 20 mM Tris HCl pH8 – 150 mM KCl – 1M MgCl₂ – 1 mM DTT.

Bandshift on polyacrylamide gel

The 5'-end labeled RNAs (50.000 cpm/line) and cold RNAs were denatured at 95 °C for 1 min, cooled on ice for 1 min and then renatured at 20 °C for 10 min in presence of 10 mM of MgCl₂. The protein was incubated in *SauS1* buffer 1X + for 15 min at 37 °C. The RNAs were incubated with increasing concentration of protein, except for the first tube used as RNA control and complex formation was performed at 37 °C for 15 min. After incubation, 1 vol of glycerol blue was added in each tube before the loading on acrylamide gel containing 1mM of MgCl₂ in TBE 1X. The gels were runned according to the size of the RNAs at 4°C at 300 V.

SauS1 buffer 10 X + : 200 mM Tris HCl 7.5, 600 mM KCl, 400 mM NH₄Cl, 30 mM DTT, 100 mM MgCl₂, 0.2mg/ml BSA.

Chemical probing of *S. aureus* RsaI

Chemical probing with BzCN was performed as in Helfer *et al.* 2013 with the exception that Vic and Ned fluorescent labeled oligonucleotides (**Tab5**) have been used. Separation of RT fragments has been done using ABI PRISM 31 30XI Genetic analyzer.

Enzymatic probing of RsaI

5' end-labeled RsaI (50 .000 cpm/line) was denatured in sterile water at 90°C for 1 min, cooled on ice for 2 min and briefly centrifuged. Native buffer 5X was added and the

samples are incubated at 20°C for 15 min for renaturation. 1µl of total tRNA 1 µg/µl was added to all samples. Enzymatic hydrolysis was performed by addition of 1 mL RNase as follows:

-RNase T1 10 min at 20°C

-RNase T2 10 min at 20°C

-RNase V1 5 min at 25°C

-Lead II 5 min at 20°C

0.3 M Na-acetate of pH 6.0 and cold ethanol were then added to all samples. After a vigorous mix, the samples are transferred in a dry ice-ethanol bath for 10 min. The samples are then precipitated, washed and dried and resuspended in 6 µL of urea blue.

RNase T1 ladder: labeled mRNA (25,000 cpm) is preincubated at 50°C for 5 min in 5 mL of the Buffer ΔT1 containing 1 mg total tRNA. Reaction is then performed at 50°C for 10 min in the presence of 1 mL of RNase T1 (0.5 U).

Alkaline ladder: labeled mRNA (100,000 cpm) is incubated at 90°C for 3 min in the presence of total tRNA (2 mg) in 5 mL of the Ladder Buffer.

Before loading, each sample was adjusted to contains the same amount of radioactivity (except for the ladder that should have twice more radioactivity). The samples were heated (except the RNase T1 and alkaline ladders) for 3 min at 90°C. The 12% acrylamide was prerun at 75 W for 30 min using 1× TBE as running buffer.

The samples were finally loaded on the gel, runned in TBE 1X for 2 hours at 75W.

Native buffer 5X: Hepes Na-OH pH 7.5 100mM – Mg²⁺ Acetate 25 mM - KCH₃COO 250 nM

Footprinting RsaI*/RsaG

5' end-labeled RsaI (50.000 cpm/line) and 1.25 µM of cold RsaG were denatured in sterile water at 90°C for 1 min, cooled on ice for 2 min and briefly centrifuged. Native buffer 5X was added and the samples are incubated at 20°C for 10 min for renaturation. The sample containing RsaI and the sample containing RsaG were mixed and incubated at 37 °C for 15 min. 6µl of total tRNA 1 µg/µl were added to all samples. Enzymatic hydrolysis was performed as described above.

0.3 M Na-acetate of pH 6.0 and cold ethanol were then added to all samples. After a vigorous mix, the samples are transferred in a dry ice-ethanol bath for 10 min. The samples are then precipitated, washed and dried and resuspended in 20 μ L of blue formamide .

RNase T1 ladder: labeled mRNA (25,000 cpm) is preincubated at 50°C for 5 min in 5 mL of the Buffer Δ T1 containing 1 mg total tRNA. Reaction is then performed at 50°C for 10 min in the presence of 1 mL of RNase T1 (0.5 U).

Alkaline ladder: labeled mRNA (100,000 cpm) is incubated at 90°C for 3 min in the presence of total tRNA (2 mg) in 5 mL of the Ladder Buffer.

Before loading, each sample was adjusted to contains the same amount of radioactivity (except for the ladder that should have twice more radioactivity). The samples were heated (except the RNase T1 and alkaline ladders) for 3 min at 90°C. The 12% acrylamide was prerun at 75 W for 30 min using 1 \times TBE as running buffer.

The samples were finally loaded on the gel, runned in TBE 1X for 2 hours at 75W.

FRET

Two fluorophore-tagged and self-complementary RNA 21mers were incubated in FRET buffer at 37°C. Annealing reaction was started by injection of 30 nM Cy3-21R+ into a cuvette containing an equal volume of 30 nM Cy3-21R- and (**Tab6**), where applicable, 6 μ M (final concentration) of the *SauS1* protein. The reaction was allowed to proceed for 120 sec, and with Cy3 excited, donor and acceptor dye fluorescence emissions were measured once every second at 37°C. Then non labeled competitor RNA (21R-) were injected to yield a 10-fold molar excess over the labeled strands, the mixture was rapidly mixed for 2 sec, and readings were taken for another 120 sec.

Buffer FRET : 50 mM Tris HCl pH 7.5 – 3 mM MgCl₂ – 1 mM DTT

Northern Blot

In vitro transcription of RNA-DIG probes

The Digoxigenin (DIG)-labeled RNA antisense probes were *in vitro* transcribed starting

from PCR template of the gene of interest. (The primer, complementary to the 3' end of the strand encoding for the target gene, carries the T7 promoter at its 5'). The transcription was performed using DIG-RNA labelling mix Kit, according to the manufacturer protocol (Roche 11277073910). The transcript was treated with DNase I (04716728001 10 U/ μ L) for 15 min at 37°C. The reaction was arrested by the addition of 17 mM EDTA and AcNa 0.3M. The RNA-DIG were then treated with phenol/chloroforme and chloroforme/alcool isoamylique, precipitated in absolute ethanol at 20°C for 2 hours, washed, dried and resuspended in 20 μ L of mQ water. Their size and integrity were verified on 1% agarose gel in presence of guanidium thiocyanate 20 mM and ethidium bromide (5% vol/vol), runned for 30 min at 135 V. The use of DIG-labeled probes was used to follow the expression profile of *rpsA* mRNA in different bacterial strains, while DNA-labeled probes were used for the detection of the *psm* mRNA.

Migration, transfer, hybridization and detection

Total RNA extracted at different point of bacterial growth, was loaded on 1% agarose gel, runned at 4 °C (120 V, 3h). The RNA was then transferred on a positively charged membrane (Hybond Dutscher RPN303B) by capillarity or by vacuum absorption and cross-linked on it. The membrane was pre-hybridized for 45 min at 68°C. 1 to 5 μ L of the RNA-DIG probe and the hybridation buffer, were heated for 5 min at 75°C, while the membrane hybridization was carried out at 68°C over night. The probe can be stored at -20°C, and could be reused for mounth. The membrane was washed twice for 5 min at room temperature for 5 min using wash buffer n°1 and than using the buffer n°2 for 15 min at 68°C. The membrane was than treated for 30 min with blocking buffer (Roche 11 096 176 001) diluted in 1X maleic acid buffer. 2 μ L of anti-DIG antibodies (Roche 11 093 274 910) were incubated to the membrane for 30 min at room temperature. The membrane is finally washed twice using maleic/tween solution for 15 min. The addition of bioluminescent CDP-star (Roche 70427821) substrate, has allowed the detection.

Hybridization buffer : Formamide 50%, SSC 5x, NaPO₄ pH 7 50 mM, blocking solution 2% (Roche 11 096 176 001 diluted in maleic acid pH 7,5 VWR 8.00380.1000), N-Lauroyl sarcosine 0,1% (Sigma L7414), SDS 7%

Wash buffer n°1 : 2x SSC, 0,1% SDS

Wash buffer n°2 : 0,2x SSC, 0,1% SDS

SSC 20 X : 3M NaCl, 300 mM Sodium Nitrate

30S ribosomal subunits purification

Purification of the 30S subunits from *S. aureus* was performed by dissociation of the 70S ribosomes. First, full 70S ribosomes were prepared as described in Khusainov et al., 2016b. The 70S ribosomes were diluted with buffer G until final concentration 6-8 mg/mL. The sample was dialyzed against 1 L of dissociation buffer for 2h. The solution was diluted in dissociation buffer until concentration 7 mg/mL, 500 μ L were layered onto 0 – 30% sucrose density gradients prepared in dissociation buffer and centrifuged at $58,357 \times g$ for 15 h using a Beckman SW28 rotor (Figure 1B). After fractionation the purity of each peak was analyzed by loading 0.03 AU₂₆₀ of each fraction on 1% agarose gel in TAE buffer. The fractions containing mostly 30S ribosomal subunit were pooled together and dialyzed twice for 2 h against 1 L of buffer G. Sample was then concentrated using Centricon MWCO 100K until 150 – 170 AU₂₆₀/mL. Aliquots of 6 μ L were flash frozen in liquid nitrogen and stored at -80 °C.

Buffer G: 10 mM Hepes-KOH pH 7.5, 50 mM KCl, 10 mM NH₄Cl, 10 mM Mg(OAc)₂

Dissociation buffer: 10 mM Hepes-KOH pH 7.5, 100 mM NH₄Cl, 1 mM Mg(OAc)₂, 1 mM DTT

Gel in TAE buffer: 40mM Tris, 20mM acetic acid, 1mM EDTA

Toeprinting assay

5' end Labeling of oligonucleotides

The DNA oligonucleotides were labeled using γ ³²P ATP -370 MBq/ml – 10 mci/ml. 1 μ L of oligonucleotides at 10 μ M, was mixed with 1 μ L of Buffer PNK 10X A (Fermentas), 1 μ L of T4 PNK 10U/ μ L enzyme (Fermentas) and 5 μ L of γ ATP. The reaction was carried out in a total volume of 10 μ L at 37 °C for 1 hour. The labeled oligonucleotides were then purified on Micro Bio-spin chromatography column (Biorad) according to the manufacture protocol. The level of radioactivity was measured using Multi-purpose Scintillator counter (Beckman).

Toeprinting

The toeprintings were carried out using radiolabeled oligonucleotides.

The formation of a simplified translational initiation complex (30SIC) was done using published procedure, Fechter *et al.* 2009.

Buffer toe (-) 5x : Tris-HCl pH 7,5 100 mM, NH₄Cl 300 mM, DTT 5 mM

Buffer toe(+) 5x : buffer toe (-) 5x , MgCl₂ 50 mM

Sequences preparation

For the preparation of sequences were used ddNTs. In each mix there were 0,3 μM of RNA and 200.000 cpm of radioactivity. The RNA was denatured at 90 °C for 1 min, cooled for 1 min on ice and incubated in AMV 1V commercial buffer. For instance, for the tube « U », 1 mM of dTTP, dCTP, dGTP, 0,25 mM of dATP and 2 mM of ddATP were mixed in presence of 0,8 U AMV (007S-1), in a total volume of 26 μL. The RT was performed at 37 °C for 30 min.

The RNA template is then destroyed with 0,25 M of KOH and 40 μL of destroy buffer. The sample were putted for 1 min at 90°C, followed by an incubation of 15 min at 37°C. 0,4 mM of acetic acid were added in order to adjust the pH, then the sample was precipitated, centrifuged, washed, dried and resuspended in 10 μL of urea blue. Before loading on the gel, the samples were putted 3 min at 90°C.

Destroy buffer : Tris HCl 50mM pH8, SDS 0,5%, EDTA 7,5mM

Table 6 List of plasmids

| Plasmid | Description |
|------------|-----------------------------------------|
| pUC18-RsaE | pUC18 expressing RsaE under T7 promoter |
| pUC18-RsaH | pUC18 expressing RsaH under T7 promoter |
| pUT7-RsaG | pUT7 expressing RsaG under T7 promoter |
| pCN51-RsaA | pCN51 expressing RsaA under T2 promoter |
| pQE30Xa | 6 X Hys-Tag plasmid |

Table 7 List of oligonucleotides

| NAME | USAGE | Sequences are 5' end to 3' end |
|-------------------------|----------------------|--------------------------------------------------------|
| Rsal Vic | Probing | AAA AAA ATC GGc TAG TCA CG |
| Rsal Ned | Probing | AAA AAA ATC GGC TAG TCA CG |
| <i>S. aureus</i> Rsal | PCR Amplification | Fw: TAA TAC GAC TCA CTA TAG TAA CAG GGG GAG CGA TTA |
| <i>S. aureus</i> Rsal | PCR Amplification | Rw: AAA AAA ATC GGC TAG TCA CG |
| Cy3 oligonucleotides | FRET | AUG CAC CGU AAA GC |
| CY5 oligonucleotides | FRET | GCU UUA CGG UGC UA |
| Cold compeitor | FRET | AUG CAC CGU AAA GC |

References

- Afgan, E., Baker, D., van den Beek, M., Blankenberg, D., Bouvier, D., Cech, M., Chilton, J., Clements, D., Coraor, N., Eberhard, C., *et al.* (2016). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. *Nucleic Acids Res* *44*, W3-W10.
- Allen, G.S., Zavialov, A., Gursky, R., Ehrenberg, M., and Frank, J. (2005). The cryo-EM structure of a translation initiation complex from *Escherichia coli*. *Cell* *121*, 703-712.
- Anderson, K.L., Roberts, C., Disz, T., Vonstein, V., Hwang, K., Overbeek, R., Olson, P.D., Projan, S.J., and Dunman, P.M. (2006). Characterization of the *Staphylococcus aureus* heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover. *Journal of bacteriology* *188*, 6739-6756.
- Antignac, A., Sieradzki, K., and Tomasz, A. (2007). Perturbation of cell wall synthesis suppresses autolysis in *Staphylococcus aureus*: evidence for coregulation of cell wall synthetic and hydrolytic enzymes. *Journal of bacteriology* *189*, 7573-7580.
- Arvidson, J., Lonnerholm, G., Tuvemo, T., Carlson, K., Lannering, B., and Lonnerholm, T. (2000). Prepubertal growth and growth hormone secretion in children after treatment for hematological malignancies, including autologous bone marrow transplantation. *Pediatric hematology and oncology* *17*, 285-297.
- Atkins, K.L., Burman, J.D., Chamberlain, E.S., Cooper, J.E., Poutrel, B., Bagby, S., Jenkins, A.T., Feil, E.J., and van den Elsen, J.M. (2008). *S. aureus* IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. *Molecular immunology* *45*, 1600-1611.
- Attaiech, L., Glover, J.N., and Charpentier, X. (2017). RNA Chaperones Step Out of Hfq's Shadow. *Trends in microbiology* *25*, 247-249.
- Autour, A., Westhof, E., and Ryckelynck, M. (2016). iSpinach: a fluorogenic RNA aptamer optimized for in vitro applications. *Nucleic Acids Res* *44*, 2491-2500.
- Barrios, C., Georgopoulos, C., Lambert, P.H., and Del Giudice, G. (1994). Heat shock proteins as carrier molecules: in vivo helper effect mediated by *Escherichia coli* GroEL and DnaK proteins requires cross-linking with antigen. *Clinical and experimental immunology* *98*, 229-233.
- Benito, Y., Kolb, F.A., Romby, P., Lina, G., Etienne, J., and Vandenesch, F. (2000). Probing the structure of RNAIII, the *Staphylococcus aureus* agr regulatory RNA, and identification of the RNA domain involved in repression of protein A expression. *RNA (New York, NY)* *6*, 668-679.
- Bergmann, S., and Hammerschmidt, S. (2007). Fibrinolysis and host response in bacterial infections. *Thrombosis and haemostasis* *98*, 512-520.
- Berube, B.J., and Bubeck-Wardenburg, J. (2013). *Staphylococcus aureus* alpha-toxin: nearly a century of intrigue. *Toxins* *5*, 1140-1166.
- Bhattacharya, S., Ploplis, V.A., and Castellino, F.J. (2012). Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. *Journal of biomedicine & biotechnology* *2012*, 482096.
- Bischoff, M., Dunman, P., Kormanec, J., Macapagal, D., Murphy, E., Mounts, W., Berger-Bachi, B., and Projan, S. (2004). Microarray-based analysis of the *Staphylococcus aureus* sigmaB regulon. *Journal of bacteriology* *186*, 4085-4099.
- Bischoff, M., Entenza, J.M., and Giachino, P. (2001). Influence of a functional sigB operon on the global regulators sar and agr in *Staphylococcus aureus*. *Journal of bacteriology* *183*, 5171-5179.

- Bohn, C., Rigoulay, C., and Bouloc, P. (2007). No detectable effect of RNA-binding protein Hfq absence in *Staphylococcus aureus*. *BMC Microbiol* 7, 10.
- Boisset, S., Geissmann, T., Huntzinger, E., Fechter, P., Bendridi, N., Possedko, M., Chevalier, C., Helfer, A.C., Benito, Y., Jacquier, A., *et al.* (2007). *Staphylococcus aureus* RNAIII coordinately represses the synthesis of virulence factors and the transcription regulator Rot by an antisense mechanism. *Genes & development* 21, 1353-1366.
- Bourgeois-Nicolaos, N., Lucet, J.C., Daubie, C., Benchaba, F., Rajguru, M., Ruimy, R., Andremont, A., and Armand-Lefevre, L. (2010). Maternal vaginal colonisation by *Staphylococcus aureus* and newborn acquisition at delivery. *Paediatric and perinatal epidemiology* 24, 488-491.
- Brandi, A., Pon, C.L., and Gualerzi, C.O. (1994). Interaction of the main cold shock protein CS7.4 (CspA) of *Escherichia coli* with the promoter region of *hns*. *Biochimie* 76, 1090-1098.
- Brennan, R.G., and Link, T.M. (2007). Hfq structure, function and ligand binding. *Current opinion in microbiology* 10, 125-133.
- Bronesky, D., Wu, Z., Marzi, S., Walter, P., Geissmann, T., Moreau, K., Vandenesch, F., Caldelari, I., and Romby, P. (2016). *Staphylococcus aureus* RNAIII and Its Regulon Link Quorum Sensing, Stress Responses, Metabolic Adaptation, and Regulation of Virulence Gene Expression. *Annual review of microbiology* 70, 299-316.
- Bukau, B. (1993). Regulation of the *Escherichia coli* heat-shock response. *Molecular microbiology* 9, 671-680.
- Burian, M., Rautenberg, M., Kohler, T., Fritz, M., Krismer, B., Unger, C., Hoffmann, W.H., Peschel, A., Wolz, C., and Goerke, C. (2010). Temporal expression of adhesion factors and activity of global regulators during establishment of *Staphylococcus aureus* nasal colonization. *The Journal of infectious diseases* 201, 1414-1421.
- Burmann, B.M., Schweimer, K., Luo, X., Wahl, M.C., Stitt, B.L., Gottesman, M.E., and Rosch, P. (2010). A NusE:NusG complex links transcription and translation. *Science (New York, NY)* 328, 501-504.
- Byrgazov, K., Grishkovskaya, I., Arenz, S., Coudevylle, N., Temmel, H., Wilson, D.N., Djinovic-Carugo, K., and Moll, I. (2015). Structural basis for the interaction of protein S1 with the *Escherichia coli* ribosome. *Nucleic Acids Res* 43, 661-673.
- Caldelari, I., Chane-Woon-Ming, B., Noirot, C., Moreau, K., Romby, P., Gaspin, C., and Marzi, S. (2017). Complete Genome Sequence and Annotation of the *Staphylococcus aureus* Strain HG001. *Genome announcements* 5.
- Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst, S.A. (2001). Structural mechanism for rifampicin inhibition of bacterial rna polymerase. *Cell* 104, 901-912.
- Campos, M., and Jacobs-Wagner, C. (2013). Cellular organization of the transfer of genetic information. *Current opinion in microbiology* 16, 171-176.
- Carter, A.P., Clemons, W.M., Jr., Brodersen, D.E., Morgan-Warren, R.J., Hartsch, T., Wimberly, B.T., and Ramakrishnan, V. (2001). Crystal structure of an initiation factor bound to the 30S ribosomal subunit. *Science (New York, NY)* 291, 498-501.
- Chambers, H.F., and Deleo, F.R. (2009). Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nature reviews Microbiology* 7, 629-641.
- Chan, P.F., and Foster, S.J. (1998). Role of SarA in virulence determinant production and environmental signal transduction in *Staphylococcus aureus*. *Journal of bacteriology* 180, 6232-6241.

- Chapman, M.R., Robinson, L.S., Pinkner, J.S., Roth, R., Heuser, J., Hammar, M., Normark, S., and Hultgren, S.J. (2002). Role of *Escherichia coli* curli operons in directing amyloid fiber formation. *Science (New York, NY)* 295, 851-855.
- Chatterjee, S.S., Chen, L., Joo, H.S., Cheung, G.Y., Kreiswirth, B.N., and Otto, M. (2011). Distribution and regulation of the mobile genetic element-encoded phenol-soluble modulins PSM-mec in methicillin-resistant *Staphylococcus aureus*. *PloS one* 6, e28781.
- Chatterjee, S.S., Joo, H.S., Duong, A.C., Dieringer, T.D., Tan, V.Y., Song, Y., Fischer, E.R., Cheung, G.Y., Li, M., and Otto, M. (2013). Essential *Staphylococcus aureus* toxin export system. *Nature medicine* 19, 364-367.
- Chatterjee, S.S., and Otto, M. (2013). How can *Staphylococcus aureus* phenol-soluble modulins be targeted to inhibit infection? *Future microbiology* 8, 693-696.
- Chaudhuri, R.R., Allen, A.G., Owen, P.J., Shalom, G., Stone, K., Harrison, M., Burgis, T.A., Lockyer, M., Garcia-Lara, J., Foster, S.J., *et al.* (2009). Comprehensive identification of essential *Staphylococcus aureus* genes using Transposon-Mediated Differential Hybridisation (TMDH). *BMC genomics* 10, 291.
- Chen, H., Bjercknes, M., Kumar, R., and Jay, E. (1994). Determination of the optimal aligned spacing between the Shine-Dalgarno sequence and the translation initiation codon of *Escherichia coli* mRNAs. *Nucleic Acids Res* 22, 4953-4957.
- Cheng, A.G., McAdow, M., Kim, H.K., Bae, T., Missiakas, D.M., and Schneewind, O. (2010). Contribution of coagulases towards *Staphylococcus aureus* disease and protective immunity. *PLoS pathogens* 6, e1001036.
- Chesney, P.J., Halsey, N.A., and Marcy, S.M. (1997). Treatment of bacterial infections. *The New England journal of medicine* 337, 793-794.
- Cheung, A.L., Bayer, A.S., Zhang, G., Gresham, H., and Xiong, Y.Q. (2004). Regulation of virulence determinants *in vitro* and *in vivo* in *Staphylococcus aureus*. *FEMS immunology and medical microbiology* 40, 1-9.
- Cheung, A.L., Eberhardt, K.J., Chung, E., Yeaman, M.R., Sullam, P.M., Ramos, M., and Bayer, A.S. (1994). Diminished virulence of a *sar- / agr-* mutant of *Staphylococcus aureus* in the rabbit model of endocarditis. *The Journal of clinical investigation* 94, 1815-1822.
- Cheung, A.L., Nishina, K.A., Trottonda, M.P., and Tamber, S. (2008). The SarA protein family of *Staphylococcus aureus*. *The international journal of biochemistry & cell biology* 40, 355-361.
- Cheung, A.L., Schmidt, K., Bateman, B., and Manna, A.C. (2001). SarS, a SarA homolog repressible by *agr*, is an activator of protein A synthesis in *Staphylococcus aureus*. *Infection and immunity* 69, 2448-2455.
- Cheung, G.Y., Joo, H.S., Chatterjee, S.S., and Otto, M. (2014). Phenol-soluble modulins--critical determinants of staphylococcal virulence. *FEMS microbiology reviews* 38, 698-719.
- Cheung, G.Y., Rigby, K., Wang, R., Queck, S.Y., Braughton, K.R., Whitney, A.R., Teintze, M., DeLeo, F.R., and Otto, M. (2010). *Staphylococcus epidermidis* strategies to avoid killing by human neutrophils. *PLoS pathogens* 6, e1001133.
- Chevalier, C., Boisset, S., Romilly, C., Masquida, B., Fechter, P., Geissmann, T., Vandenesch, F., and Romby, P. (2010). *Staphylococcus aureus* RNAlII binds to two distant regions of *coa* mRNA to arrest translation and promote mRNA degradation. *PLoS pathogens* 6, e1000809.
- Chuang, S.E., and Blattner, F.R. (1993). Characterization of twenty-six new heat shock genes of *Escherichia coli*. *Journal of bacteriology* 175, 5242-5252.

- Cogen, A.L., Yamasaki, K., Sanchez, K.M., Dorschner, R.A., Lai, Y., MacLeod, D.T., Torpey, J.W., Otto, M., Nizet, V., Kim, J.E., *et al.* (2010). Selective antimicrobial action is provided by phenol-soluble modulins derived from *Staphylococcus epidermidis*, a normal resident of the skin. *The Journal of investigative dermatology* 130, 192-200.
- Cowing, D.W., Bardwell, J.C., Craig, E.A., Woolford, C., Hendrix, R.W., and Gross, C.A. (1985). Consensus sequence for *Escherichia coli* heat shock gene promoters. *Proceedings of the National Academy of Sciences of the United States of America* 82, 2679-2683.
- Craven, R.R., Gao, X., Allen, I.C., Gris, D., Bubeck Wardenburg, J., McElvania-Tekippe, E., Ting, J.P., and Duncan, J.A. (2009). *Staphylococcus aureus* alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. *PloS one* 4, e7446.
- Cui, M., Wang, T., Xu, J., Ke, Y., Du, X., Yuan, X., Wang, Z., Gong, C., Zhuang, Y., Lei, S., *et al.* (2013). Impact of Hfq on global gene expression and intracellular survival in *Brucella melitensis*. *PloS one* 8, e71933.
- Das, H.K., Goldstein, A., and Lowney, L.I. (1967). Attachment of ribosomes to nascent messenger RNA in *Escherichia coli*. *J Mol Biol* 24, 231-245.
- DeDent, A.C., McAdow, M., and Schneewind, O. (2007). Distribution of protein A on the surface of *Staphylococcus aureus*. *Journal of bacteriology* 189, 4473-4484.
- DeLeo, F.R., Otto, M., Kreiswirth, B.N., and Chambers, H.F. (2010). Community-associated methicillin-resistant *Staphylococcus aureus*. *Lancet (London, England)* 375, 1557-1568.
- Deora, R., and Misra, T.K. (1996). Characterization of the primary sigma factor of *Staphylococcus aureus*. *J Biol Chem* 271, 21828-21834.
- Deora, R., Tseng, T., and Misra, T.K. (1997). Alternative transcription factor sigmaSB of *Staphylococcus aureus*: characterization and role in transcription of the global regulatory locus *σ*. *Journal of bacteriology* 179, 6355-6359.
- Dimastrogiovanni, D., Frohlich, K.S., Bandyra, K.J., Bruce, H.A., Hohensee, S., Vogel, J., and Luisi, B.F. (2014). Recognition of the small regulatory RNA RydC by the bacterial Hfq protein. *eLife* 3.
- Dinges, M.M., Orwin, P.M., and Schlievert, P.M. (2000). Exotoxins of *Staphylococcus aureus*. *Clinical microbiology reviews* 13, 16-34, table of contents.
- Drapeau, G.R. (1978). Role of metalloprotease in activation of the precursor of staphylococcal protease. *Journal of bacteriology* 136, 607-613.
- Draper, D.E., Pratt, C.W., and von Hippel, P.H. (1977). *Escherichia coli* ribosomal protein S1 has two polynucleotide binding sites. *Proceedings of the National Academy of Sciences of the United States of America* 74, 4786-4790.
- Draper, D.E., and von Hippel, P.H. (1979). Measurement of macromolecular equilibrium binding constants by a sucrose gradient band sedimentation method. Application to protein-nucleic acid interactions. *Biochemistry* 18, 753-760.
- Dueholm, M.S., Sondergaard, M.T., Nilsson, M., Christiansen, G., Stensballe, A., Overgaard, M.T., Givskov, M., Tolker-Nielsen, T., Otzen, D.E., and Nielsen, P.H. (2013). Expression of Fap amyloids in *Pseudomonas aeruginosa*, *P. fluorescens*, and *P. putida* results in aggregation and increased biofilm formation. *MicrobiologyOpen* 2, 365-382.
- Durand, S., Tomasini, A., Braun, F., Condon, C., and Romby, P. (2015). sRNA and mRNA turnover in Gram-positive bacteria. *FEMS microbiology reviews* 39, 316-330.

- Duval, M., Korepanov, A., Fuchsbauer, O., Fechter, P., Haller, A., Fabbretti, A., Choulier, L., Micura, R., Klaholz, B.P., and Romby, P. (2013a). Escherichia coli ribosomal protein S1 unfolds structured mRNAs onto the ribosome for active translation initiation. *PLoS biology* *11*, e1001731.
- Duval, M., Korepanov, A., Fuchsbauer, O., Fechter, P., Haller, A., Fabbretti, A., Choulier, L., Micura, R., Klaholz, B.P., Romby, P., *et al.* (2013b). Escherichia coli ribosomal protein S1 unfolds structured mRNAs onto the ribosome for active translation initiation. *PLoS biology* *11*, e1001731.
- Duval, M., Marena, A., Chevalier, C., and Marzi, S. (2017). Site-Directed Chemical Probing to map transient RNA/protein interactions. *Methods (San Diego, Calif)* *117*, 48-58.
- Entenza, J.M., Moreillon, P., Senn, M.M., Kormanec, J., Dunman, P.M., Berger-Bachi, B., Projan, S., and Bischoff, M. (2005). Role of sigmaB in the expression of Staphylococcus aureus cell wall adhesins ClfA and FnbA and contribution to infectivity in a rat model of experimental endocarditis. *Infection and immunity* *73*, 990-998.
- Essmann, F., Bantel, H., Totzke, G., Engels, I.H., Sinha, B., Schulze-Osthoff, K., and Janicke, R.U. (2003). Staphylococcus aureus alpha-toxin-induced cell death: predominant necrosis despite apoptotic caspase activation. *Cell death and differentiation* *10*, 1260-1272.
- Farwell, M.A., Roberts, M.W., and Rabinowitz, J.C. (1992). The effect of ribosomal protein S1 from Escherichia coli and Micrococcus luteus on protein synthesis in vitro by E. coli and Bacillus subtilis. *Molecular microbiology* *6*, 3375-3383.
- Fechter, P., Chevalier, C., Yusupova, G., Yusupov, M., Romby, P., and Marzi, S. (2009). Ribosomal initiation complexes probed by toeprinting and effect of trans-acting translational regulators in bacteria. *Methods in molecular biology (Clifton, NJ)* *540*, 247-263.
- Fechter, P., Parmentier, D., Wu, Z., Fuchsbauer, O., Romby, P., and Marzi, S. (2016). Traditional Chemical Mapping of RNA Structure In Vitro and In Vivo. *Methods in molecular biology (Clifton, NJ)* *1490*, 83-103.
- Fei, J., Singh, D., Zhang, Q., Park, S., Balasubramanian, D., Golding, I., Vanderpool, C.K., and Ha, T. (2015). RNA biochemistry. Determination of in vivo target search kinetics of regulatory noncoding RNA. *Science (New York, NY)* *347*, 1371-1374.
- Fitzgerald, C.J., Pranikoff, T.V., Ross, G.A., Mou, S., Givner, L.B., and Shetty, A.K. (2012). Purpura fulminans caused by community-associated methicillin-resistant Staphylococcus aureus. *The American journal of emergency medicine* *30*, 1013 e1011-1014.
- Foster, T.J. (2005). Immune evasion by staphylococci. *Nature reviews Microbiology* *3*, 948-958.
- Foster, T.J., Geoghegan, J.A., Ganesh, V.K., and Hook, M. (2014). Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. *Nature reviews Microbiology* *12*, 49-62.
- Friedrich, R., Panizzi, P., Fuentes-Prior, P., Richter, K., Verhamme, I., Anderson, P.J., Kawabata, S., Huber, R., Bode, W., and Bock, P.E. (2003). Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. *Nature* *425*, 535-539.
- Gao, J., and Stewart, G.C. (2004). Regulatory elements of the Staphylococcus aureus protein A (Spa) promoter. *Journal of bacteriology* *186*, 3738-3748.

- Geiger, T., Francois, P., Liebeke, M., Fraunholz, M., Goerke, C., Krismer, B., Schrenzel, J., Lalk, M., and Wolz, C. (2012). The stringent response of *Staphylococcus aureus* and its impact on survival after phagocytosis through the induction of intracellular PSMs expression. *PLoS pathogens* *8*, e1003016.
- Geiger, T., Goerke, C., Mainiero, M., Kraus, D., and Wolz, C. (2008). The virulence regulator Sae of *Staphylococcus aureus*: promoter activities and response to phagocytosis-related signals. *Journal of bacteriology* *190*, 3419-3428.
- Geisinger, E., Adhikari, R.P., Jin, R., Ross, H.F., and Novick, R.P. (2006). Inhibition of rot translation by RNAIII, a key feature of agr function. *Molecular microbiology* *61*, 1038-1048.
- Geissmann, T., Chevalier, C., Cros, M.J., Boisset, S., Fechter, P., Noirot, C., Schrenzel, J., Francois, P., Vandenesch, F., Gaspin, C., *et al.* (2009a). A search for small noncoding RNAs in *Staphylococcus aureus* reveals a conserved sequence motif for regulation. *Nucleic Acids Res* *37*, 7239-7257.
- Geissmann, T., Marzi, S., and Romby, P. (2009b). The role of mRNA structure in translational control in bacteria. *RNA Biol* *6*, 153-160.
- Ghuysen, J.M. (1994). Molecular structures of penicillin-binding proteins and beta-lactamases. *Trends in microbiology* *2*, 372-380.
- Giangrossi, M., Brandi, A., Giuliadori, A.M., Gualerzi, C.O., and Pon, C.L. (2007). Cold-shock-induced de novo transcription and translation of *infA* and role of IF1 during cold adaptation. *Molecular microbiology* *64*, 807-821.
- Giraud, C., Hausmann, S., Lemeille, S., Prados, J., Redder, P., and Linder, P. (2015). The C-terminal region of the RNA helicase CshA is required for the interaction with the degradosome and turnover of bulk RNA in the opportunistic pathogen *Staphylococcus aureus*. *RNA Biol* *12*, 658-674.
- Giraud, A.T., Cheung, A.L., and Nagel, R. (1997). The *sae* locus of *Staphylococcus aureus* controls exoprotein synthesis at the transcriptional level. *Archives of microbiology* *168*, 53-58.
- Giuliadori, A.M., Brandi, A., Giangrossi, M., Gualerzi, C.O., and Pon, C.L. (2007). Cold-stress-induced de novo expression of *infC* and role of IF3 in cold-shock translational bias. *RNA (New York, NY)* *13*, 1355-1365.
- Giuliadori, A.M., Brandi, A., Gualerzi, C.O., and Pon, C.L. (2004). Preferential translation of cold-shock mRNAs during cold adaptation. *RNA (New York, NY)* *10*, 265-276.
- Giuliadori, A.M., Di Pietro, F., Marzi, S., Masquida, B., Wagner, R., Romby, P., Gualerzi, C.O., and Pon, C.L. (2010). The *cspA* mRNA is a thermosensor that modulates translation of the cold-shock protein CspA. *Molecular cell* *37*, 21-33.
- Goerke, C., Fluckiger, U., Steinhuber, A., Bisanzio, V., Ulrich, M., Bischoff, M., Patti, J.M., and Wolz, C. (2005). Role of *Staphylococcus aureus* global regulators *sae* and *sigmaB* in virulence gene expression during device-related infection. *Infection and immunity* *73*, 3415-3421.
- Gold, L. (1988). Posttranscriptional regulatory mechanisms in *Escherichia coli*. *Annual review of biochemistry* *57*, 199-233.
- Gonzalez, C.D., Ledo, C., Gai, C., Garofalo, A., and Gomez, M.I. (2015). The Sbi Protein Contributes to *Staphylococcus aureus* Inflammatory Response during Systemic Infection. *PloS one* *10*, e0131879.
- Goodyear, C.S., and Silverman, G.J. (2004). Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America* *101*, 11392-11397.

- Gordon, R.J., and Lowy, F.D. (2008). Pathogenesis of methicillin-resistant *Staphylococcus aureus* infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 46 Suppl 5, S350-359.
- Gottesman, S. (2004). The small RNA regulators of *Escherichia coli*: roles and mechanisms*. *Annual review of microbiology* 58, 303-328.
- Graumann, P., and Marahiel, M.A. (1996). Some like it cold: response of microorganisms to cold shock. *Archives of microbiology* 166, 293-300.
- Graumann, P., Schroder, K., Schmid, R., and Marahiel, M.A. (1996). Cold shock stress-induced proteins in *Bacillus subtilis*. *Journal of bacteriology* 178, 4611-4619.
- Grigoriadou, C., Marzi, S., Pan, D., Gualerzi, C.O., and Cooperman, B.S. (2007). The translational fidelity function of IF3 during transition from the 30 S initiation complex to the 70 S initiation complex. *Journal of molecular biology* 373, 551-561.
- Gualerzi, C.O., Giuliodori, A.M., and Pon, C.L. (2003). Transcriptional and post-transcriptional control of cold-shock genes. *J Mol Biol* 331, 527-539.
- Hacker, J., Hochhut, B., Middendorf, B., Schneider, G., Buchrieser, C., Gottschalk, G., and Dobrindt, U. (2004). Pathogenomics of mobile genetic elements of toxigenic bacteria. *International journal of medical microbiology : IJMM* 293, 453-461.
- Haggar, A., Hussain, M., Lonnie, H., Herrmann, M., Norrby-Teglund, A., and Flock, J.I. (2003). Extracellular adherence protein from *Staphylococcus aureus* enhances internalization into eukaryotic cells. *Infection and immunity* 71, 2310-2317.
- Haggar, A., Shannon, O., Norrby-Teglund, A., and Flock, J.I. (2005). Dual effects of extracellular adherence protein from *Staphylococcus aureus* on peripheral blood mononuclear cells. *The Journal of infectious diseases* 192, 210-217.
- Hartleib, J., Kohler, N., Dickinson, R.B., Chhatwal, G.S., Sixma, J.J., Hartford, O.M., Foster, T.J., Peters, G., Kehrel, B.E., and Herrmann, M. (2000). Protein A is the von Willebrand factor binding protein on *Staphylococcus aureus*. *Blood* 96, 2149-2156.
- Hartz, D., Binkley, J., Hollingsworth, T., and Gold, L. (1990). Domains of initiator tRNA and initiation codon crucial for initiator tRNA selection by *Escherichia coli* IF3. *Genes & development* 4, 1790-1800.
- Hausmann, S., Guimaraes, V.A., Garcin, D., Baumann, N., Linder, P., and Redder, P. (2017). Both exo- and endo-nucleolytic activities of RNase J1 from *Staphylococcus aureus* are manganese dependent and active on triphosphorylated 5'-ends. *RNA Biol*, 1-13.
- Horsburgh, M.J., Aish, J.L., White, I.J., Shaw, L., Lithgow, J.K., and Foster, S.J. (2002). sigmaB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from *Staphylococcus aureus* 8325-4. *Journal of bacteriology* 184, 5457-5467.
- Hui, A., and de Boer, H.A. (1987). Specialized ribosome system: preferential translation of a single mRNA species by a subpopulation of mutated ribosomes in *Escherichia coli*. *Proceedings of the National Academy of Sciences of the United States of America* 84, 4762-4766.
- Huntzinger, E., Boisset, S., Saveanu, C., Benito, Y., Geissmann, T., Namane, A., Lina, G., Etienne, J., Ehresmann, B., Ehresmann, C., *et al.* (2005). *Staphylococcus aureus* RNAIII and the endoribonuclease III coordinately regulate spa gene expression. *The EMBO journal* 24, 824-835.
- Imamura, T., Tanase, S., Szmyd, G., Kozik, A., Travis, J., and Potempa, J. (2005). Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from *Staphylococcus aureus*. *The Journal of experimental medicine* 201, 1669-1676.

- Ingavale, S., van Wamel, W., Luong, T.T., Lee, C.Y., and Cheung, A.L. (2005). Rat/MgrA, a regulator of autolysis, is a regulator of virulence genes in *Staphylococcus aureus*. *Infection and immunity* 73, 1423-1431.
- Ingolia, N.T., Ghaemmaghami, S., Newman, J.R., and Weissman, J.S. (2009). Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. *Science (New York, NY)* 324, 218-223.
- Ishii, K., Adachi, T., Yasukawa, J., Suzuki, Y., Hamamoto, H., and Sekimizu, K. (2014). Induction of virulence gene expression in *Staphylococcus aureus* by pulmonary surfactant. *Infection and immunity* 82, 1500-1510.
- Ito, F., Tamiya, T., Ohtsu, I., Fujimura, M., and Fukumori, F. (2014). Genetic and phenotypic characterization of the heat shock response in *Pseudomonas putida*. *MicrobiologyOpen* 3, 922-936.
- Jacob, W.F., Santer, M., and Dahlberg, A.E. (1987). A single base change in the Shine-Dalgarno region of 16S rRNA of *Escherichia coli* affects translation of many proteins. *Proceedings of the National Academy of Sciences of the United States of America* 84, 4757-4761.
- Jensen, K.B., and Darnell, R.B. (2008). CLIP: crosslinking and immunoprecipitation of in vivo RNA targets of RNA-binding proteins. *Methods in molecular biology (Clifton, NJ)* 488, 85-98.
- Jensen, M.S., and Bainton, D.F. (1973). Temporal changes in pH within the phagocytic vacuole of the polymorphonuclear neutrophilic leukocyte. *The Journal of cell biology* 56, 379-388.
- Jin, T., Bokarewa, M., McIntyre, L., Tarkowski, A., Corey, G.R., Reller, L.B., and Fowler, V.G., Jr. (2003). Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient *Staphylococcus aureus* strains. *Journal of medical microbiology* 52, 919-923.
- Jones, P.G., and Inouye, M. (1994). The cold-shock response--a hot topic. *Molecular microbiology* 11, 811-818.
- Joo, H.S., Chatterjee, S.S., Villaruz, A.E., Dickey, S.W., Tan, V.Y., Chen, Y., Sturdevant, D.E., Ricklefs, S.M., and Otto, M. (2016). Mechanism of Gene Regulation by a *Staphylococcus aureus* Toxin. *mBio* 7.
- Joo, H.S., and Otto, M. (2016). Toxin-mediated gene regulatory mechanism in *Staphylococcus aureus*. *Microbial cell (Graz, Austria)* 4, 29-31.
- Jousselin, A., Metzinger, L., and Felden, B. (2009). On the facultative requirement of the bacterial RNA chaperone, Hfq. *Trends in microbiology* 17, 399-405.
- Juhas, M., Reuss, D.R., Zhu, B., and Commichau, F.M. (2014). *Bacillus subtilis* and *Escherichia coli* essential genes and minimal cell factories after one decade of genome engineering. *Microbiology (Reading, England)* 160, 2341-2351.
- Jusko, M., Potempa, J., Kantyka, T., Bielecka, E., Miller, H.K., Kalinska, M., Dubin, G., Garred, P., Shaw, L.N., and Blom, A.M. (2014). Staphylococcal proteases aid in evasion of the human complement system. *Journal of innate immunity* 6, 31-46.
- Kaito, C., Saito, Y., Ikuo, M., Omae, Y., Mao, H., Nagano, G., Fujiyuki, T., Numata, S., Han, X., Obata, K., *et al.* (2013). Mobile genetic element SCCmec-encoded psm-mec RNA suppresses translation of agrA and attenuates MRSA virulence. *PLoS pathogens* 9, e1003269.
- Kaito, C., Saito, Y., Nagano, G., Ikuo, M., Omae, Y., Hanada, Y., Han, X., Kuwahara-Arai, K., Hishinuma, T., Baba, T., *et al.* (2011). Transcription and translation products of the cytolysin gene psm-mec on the mobile genetic element SCCmec regulate *Staphylococcus aureus* virulence. *PLoS pathogens* 7, e1001267.

- Kaltschmidt, E., and Wittmann, H.G. (1970). Ribosomal proteins. XII. Number of proteins in small and large ribosomal subunits of *Escherichia coli* as determined by two-dimensional gel electrophoresis. *Proceedings of the National Academy of Sciences of the United States of America* *67*, 1276-1282.
- Kaneko, J., Ozawa, T., Tomita, T., and Kamio, Y. (1997). Sequential binding of Staphylococcal gamma-hemolysin to human erythrocytes and complex formation of the hemolysin on the cell surface. *Bioscience, biotechnology, and biochemistry* *61*, 846-851.
- Karlsson, A., Saravia-Otten, P., Tegmark, K., Morfeldt, E., and Arvidson, S. (2001). Decreased amounts of cell wall-associated protein A and fibronectin-binding proteins in *Staphylococcus aureus* sarA mutants due to up-regulation of extracellular proteases. *Infection and immunity* *69*, 4742-4748.
- Katunin, V.I., Semenov, Y.P., Makhno, V.I., and Kirillov, S.V. (1980). Comparative study of the interaction of polyuridylic acid with 30S subunits and 70S ribosomes of *Escherichia coli*. *Nucleic Acids Res* *8*, 403-421.
- Kennell, D., and Riezman, H. (1977). Transcription and translation initiation frequencies of the *Escherichia coli* lac operon. *J Mol Biol* *114*, 1-21.
- Kerrigan, S.W., Douglas, I., Wray, A., Heath, J., Byrne, M.F., Fitzgerald, D., and Cox, D. (2002). A role for glycoprotein Ib in *Streptococcus sanguis*-induced platelet aggregation. *Blood* *100*, 509-516.
- Khemici, V., Prados, J., Linder, P., and Redder, P. (2015). Decay-Initiating Endoribonucleolytic Cleavage by RNase Y Is Kept under Tight Control via Sequence Preference and Sub-cellular Localisation. *PLoS genetics* *11*, e1005577.
- Khusainov, I., Marenga, A., Cerciat, M., Fechter, P., Hashem, Y., Marzi, S., Romby, P., Yusupova, G., and Yusupov, M. (2016). [A glimpse on *Staphylococcus aureus* translation machinery and its control]. *Molekuliarnaia biologii* *50*, 549-557.
- Khusainov, I., Vicens, Q., Bochler, A., Grosse, F., Myasnikov, A., Menetret, J.F., Chicher, J., Marzi, S., Romby, P., Yusupova, G., *et al.* (2017). Structure of the 70S ribosome from human pathogen *Staphylococcus aureus*. *Nucleic Acids Res* *45*, 1026.
- Kluytmans, J., van Belkum, A., and Verbrugh, H. (1997). Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clinical microbiology reviews* *10*, 505-520.
- Komarova, A.V., Tchufistova, L.S., Dreyfus, M., and Boni, I.V. (2005). AU-rich sequences within 5' untranslated leaders enhance translation and stabilize mRNA in *Escherichia coli*. *Journal of bacteriology* *187*, 1344-1349.
- Kong, K.F., Vuong, C., and Otto, M. (2006). *Staphylococcus* quorum sensing in biofilm formation and infection. *International journal of medical microbiology : IJMM* *296*, 133-139.
- Kovach, A.R., Hoff, K.E., Canty, J.T., Orans, J., and Brennan, R.G. (2014). Recognition of U-rich RNA by Hfq from the Gram-positive pathogen *Listeria monocytogenes*. *RNA (New York, NY)* *20*, 1548-1559.
- Kroh, H.K., Panizzi, P., and Bock, P.E. (2009). Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. *Proceedings of the National Academy of Sciences of the United States of America* *106*, 7786-7791.
- Kwieceński, J., Josefsson, E., Mitchell, J., Higgins, J., Magnusson, M., Foster, T., Jin, T., and Bokarewa, M. (2010). Activation of plasminogen by staphylokinase reduces the severity of *Staphylococcus aureus* systemic infection. *The Journal of infectious diseases* *202*, 1041-1049.

- Laarman, A.J., Mijnheer, G., Mootz, J.M., van Rooijen, W.J., Ruyken, M., Malone, C.L., Heezius, E.C., Ward, R., Milligan, G., van Strijp, J.A., *et al.* (2012). Staphylococcus aureus Staphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. *The EMBO journal* *31*, 3607-3619.
- Lalaouna, D., and Masse, E. (2015). Identification of sRNA interacting with a transcript of interest using MS2-affinity purification coupled with RNA sequencing (MAPS) technology. *Genomics data* *5*, 136-138.
- Lasa, I., Toledo-Arana, A., Dobin, A., Villanueva, M., de los Mozos, I.R., Vergara-Irigaray, M., Segura, V., Fagegaltier, D., Penades, J.R., Valle, J., *et al.* (2011). Genome-wide antisense transcription drives mRNA processing in bacteria. *Proceedings of the National Academy of Sciences of the United States of America* *108*, 20172-20177.
- Lauber, M.A., Rappsilber, J., and Reilly, J.P. (2012). Dynamics of ribosomal protein S1 on a bacterial ribosome with cross-linking and mass spectrometry. *Molecular & cellular proteomics : MCP* *11*, 1965-1976.
- Liang, X., Yu, C., Sun, J., Liu, H., Landwehr, C., Holmes, D., and Ji, Y. (2006). Inactivation of a two-component signal transduction system, SaeRS, eliminates adherence and attenuates virulence of Staphylococcus aureus. *Infection and immunity* *74*, 4655-4665.
- Lin, Y.C., and Peterson, M.L. (2010). New insights into the prevention of staphylococcal infections and toxic shock syndrome. *Expert review of clinical pharmacology* *3*, 753-767.
- Linder, P., Lemeille, S., and Redder, P. (2014). Transcriptome-wide analyses of 5'-ends in RNase J mutants of a gram-positive pathogen reveal a role in RNA maturation, regulation and degradation. *PLoS genetics* *10*, e1004207.
- Lioliou, E., Sharma, C.M., Caldelari, I., Helfer, A.C., Fechter, P., Vandenesch, F., Vogel, J., and Romby, P. (2012). Global regulatory functions of the Staphylococcus aureus endoribonuclease III in gene expression. *PLoS genetics* *8*, e1002782.
- Liu, G.Y., Essex, A., Buchanan, J.T., Datta, V., Hoffman, H.M., Bastian, J.F., Fierer, J., and Nizet, V. (2005). Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. *The Journal of experimental medicine* *202*, 209-215.
- Liu, Q., Yeo, W.S., and Bae, T. (2016). The SaeRS Two-Component System of Staphylococcus aureus. *Genes* *7*.
- Loffler, B., Hussain, M., Grundmeier, M., Bruck, M., Holzinger, D., Varga, G., Roth, J., Kahl, B.C., Proctor, R.A., and Peters, G. (2010). Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. *PLoS pathogens* *6*, e1000715.
- Londei, P. (2005). Evolution of translational initiation: new insights from the archaea. *FEMS microbiology reviews* *29*, 185-200.
- Lowy, F.D. (2003). Antimicrobial resistance: the example of Staphylococcus aureus. *The Journal of clinical investigation* *111*, 1265-1273.
- Lu, T., Park, J.Y., Parnell, K., Fox, L.K., and McGuire, M.A. (2012). Characterization of fatty acid modifying enzyme activity in staphylococcal mastitis isolates and other bacteria. *BMC research notes* *5*, 323.
- Luong, T.T., Newell, S.W., and Lee, C.Y. (2003). Mgr, a novel global regulator in Staphylococcus aureus. *Journal of bacteriology* *185*, 3703-3710.
- Makeyev, A.V., and Liebhaber, S.A. (2002). The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. *RNA (New York, NY)* *8*, 265-278.

- Malachowa, N., Kohler, P.L., Schlievert, P.M., Chuang, O.N., Dunny, G.M., Kobayashi, S.D., Miedzobrodzki, J., Bohach, G.A., and Seo, K.S. (2011). Characterization of a *Staphylococcus aureus* surface virulence factor that promotes resistance to oxidative killing and infectious endocarditis. *Infection and immunity* 79, 342-352.
- Mann, M., Wright, P.R., and Backofen, R. (2017). IntaRNA 2.0: enhanced and customizable prediction of RNA-RNA interactions. *Nucleic Acids Res.*
- Manna, A., and Cheung, A.L. (2001). Characterization of *sarR*, a modulator of *sar* expression in *Staphylococcus aureus*. *Infection and immunity* 69, 885-896.
- Manna, A.C., Bayer, M.G., and Cheung, A.L. (1998). Transcriptional analysis of different promoters in the *sar* locus in *Staphylococcus aureus*. *Journal of bacteriology* 180, 3828-3836.
- Manna, A.C., and Cheung, A.L. (2006). Expression of *SarX*, a negative regulator of *agr* and exoprotein synthesis, is activated by *MgrA* in *Staphylococcus aureus*. *Journal of bacteriology* 188, 4288-4299.
- Marchais, A., Bohn, C., Bouloc, P., and Gautheret, D. (2010). *RsaOG*, a new staphylococcal family of highly transcribed non-coding RNA. *RNA Biol* 7, 116-119.
- Marincola, G., Schafer, T., Behler, J., Bernhardt, J., Ohlsen, K., Goerke, C., and Wolz, C. (2012). RNase Y of *Staphylococcus aureus* and its role in the activation of virulence genes. *Molecular microbiology* 85, 817-832.
- Markiewski, M.M., and Lambris, J.D. (2007). The role of complement in inflammatory diseases from behind the scenes into the spotlight. *The American journal of pathology* 171, 715-727.
- Martin, E., Cevik, C., and Nugent, K. (2012). The role of hypervirulent *Staphylococcus aureus* infections in the development of deep vein thrombosis. *Thrombosis research* 130, 302-308.
- Marzi, S., Fechter, P., Chevalier, C., Romby, P., and Geissmann, T. (2008a). RNA switches regulate initiation of translation in bacteria. *Biological chemistry* 389, 585-598.
- Marzi, S., Fechter, P., Chevalier, C., Romby, P., and Geissmann, T. (2008b). RNA switches regulate initiation of translation in bacteria. *Biological chemistry* 389, 585-598.
- Marzi, S., Myasnikov, A.G., Serganov, A., Ehresmann, C., Romby, P., Yusupov, M., and Klaholz, B.P. (2007). Structured mRNAs regulate translation initiation by binding to the platform of the ribosome. *Cell* 130, 1019-1031.
- Masse, E., Escorcía, F.E., and Gottesman, S. (2003). Coupled degradation of a small regulatory RNA and its mRNA targets in *Escherichia coli*. *Genes & development* 17, 2374-2383.
- McAdow, M., DeDent, A.C., Emolo, C., Cheng, A.G., Kreiswirth, B.N., Missiakas, D.M., and Schneewind, O. (2012). Coagulases as determinants of protective immune responses against *Staphylococcus aureus*. *Infection and immunity* 80, 3389-3398.
- McAleese, F.M., Walsh, E.J., Sieprawska, M., Potempa, J., and Foster, T.J. (2001). Loss of clumping factor B fibrinogen binding activity by *Staphylococcus aureus* involves cessation of transcription, shedding and cleavage by metalloprotease. *J Biol Chem* 276, 29969-29978.
- McCormick, J.K., Yarwood, J.M., and Schlievert, P.M. (2001). Toxic shock syndrome and bacterial superantigens: an update. *Annual review of microbiology* 55, 77-104.
- McGavin, M.J., Zahradka, C., Rice, K., and Scott, J.E. (1997). Modification of the *Staphylococcus aureus* fibronectin binding phenotype by V8 protease. *Infection and immunity* 65, 2621-2628.
- McNamara, P.J., Milligan-Monroe, K.C., Khalili, S., and Proctor, R.A. (2000). Identification, cloning, and initial characterization of *rot*, a locus encoding a regulator of virulence

- factor expression in *Staphylococcus aureus*. *Journal of bacteriology* *182*, 3197-3203.
- Mehdi, Q., and Yudkin, M.D. (1967). Coupling of transcription to translation in the induced synthesis of beta-galactosidase. *Biochim Biophys Acta* *149*, 288-290.
- Mertz, D., Frei, R., Jaussi, B., Tietz, A., Stebler, C., Fluckiger, U., and Widmer, A.F. (2007). Throat swabs are necessary to reliably detect carriers of *Staphylococcus aureus*. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* *45*, 475-477.
- Miller, H.K., Carroll, R.K., Burda, W.N., Krute, C.N., Davenport, J.E., and Shaw, L.N. (2012). The extracytoplasmic function sigma factor sigmaS protects against both intracellular and extracytoplasmic stresses in *Staphylococcus aureus*. *Journal of bacteriology* *194*, 4342-4354.
- Milon, P., Maracci, C., Filonava, L., Gualerzi, C.O., and Rodnina, M.V. (2012). Real-time assembly landscape of bacterial 30S translation initiation complex. *Nat Struct Mol Biol* *19*, 609-615.
- Montgomery, C.P., Boyle-Vavra, S., Adem, P.V., Lee, J.C., Husain, A.N., Clasen, J., and Daum, R.S. (2008). Comparison of virulence in community-associated methicillin-resistant *Staphylococcus aureus* pulsotypes USA300 and USA400 in a rat model of pneumonia. *The Journal of infectious diseases* *198*, 561-570.
- Morfeltdt, E., Taylor, D., von Gabain, A., and Arvidson, S. (1995). Activation of alpha-toxin translation in *Staphylococcus aureus* by the trans-encoded antisense RNA, RNAIII. *The EMBO journal* *14*, 4569-4577.
- Morikawa, K., Takemura, A.J., Inose, Y., Tsai, M., Nguyen Thi le, T., Ohta, T., and Msadek, T. (2012). Expression of a cryptic secondary sigma factor gene unveils natural competence for DNA transformation in *Staphylococcus aureus*. *PLoS pathogens* *8*, e1003003.
- Morrison, J.M., Anderson, K.L., Beenken, K.E., Smeltzer, M.S., and Dunman, P.M. (2012). The staphylococcal accessory regulator, SarA, is an RNA-binding protein that modulates the mRNA turnover properties of late-exponential and stationary phase *Staphylococcus aureus* cells. *Frontiers in cellular and infection microbiology* *2*, 26.
- Myasnikov, A.G., Marzi, S., Simonetti, A., Giuliodori, A.M., Gualerzi, C.O., Yusupova, G., Yusupov, M., and Klaholz, B.P. (2005). Conformational transition of initiation factor 2 from the GTP- to GDP-bound state visualized on the ribosome. *Nat Struct Mol Biol* *12*, 1145-1149.
- Nair, S.P., Bischoff, M., Senn, M.M., and Berger-Bachi, B. (2003). The sigma B regulon influences internalization of *Staphylococcus aureus* by osteoblasts. *Infection and immunity* *71*, 4167-4170.
- Nizet, V. (2007). Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. *The Journal of allergy and clinical immunology* *120*, 13-22.
- Novick, R.P., Christie, G.E., and Penades, J.R. (2010). The phage-related chromosomal islands of Gram-positive bacteria. *Nature reviews Microbiology* *8*, 541-551.
- Novick, R.P., and Geisinger, E. (2008). Quorum sensing in staphylococci. *Annual review of genetics* *42*, 541-564.
- Novick, R.P., and Jiang, D. (2003). The staphylococcal saeRS system coordinates environmental signals with agr quorum sensing. *Microbiology (Reading, England)* *149*, 2709-2717.
- Novick, R.P., and Ram, G. (2016). The Floating (Pathogenicity) Island: A Genomic Dessert. *Trends in genetics : TIG* *32*, 114-126.

- Novick, R.P., Ross, H.F., Projan, S.J., Kornblum, J., Kreiswirth, B., and Moghazeh, S. (1993). Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. *The EMBO journal* *12*, 3967-3975.
- Novick, R.P., and Subedi, A. (2007). The SaPIs: mobile pathogenicity islands of *Staphylococcus*. *Chemical immunology and allergy* *93*, 42-57.
- Ogston, A. (1881). Report upon Micro-Organisms in Surgical Diseases. *British medical journal* *1*, 369 b362-375.
- Ohbayashi, T., Irie, A., Murakami, Y., Nowak, M., Potempa, J., Nishimura, Y., Shinohara, M., and Imamura, T. (2011). Degradation of fibrinogen and collagen by staphopains, cysteine proteases released from *Staphylococcus aureus*. *Microbiology (Reading, England)* *157*, 786-792.
- Olejniczak, M., and Storz, G. (2017). ProQ/FinO-domain proteins: another ubiquitous family of RNA matchmakers? *Molecular microbiology* *104*, 905-915.
- Omotajo, D., Tate, T., Cho, H., and Choudhary, M. (2015). Distribution and diversity of ribosome binding sites in prokaryotic genomes. *BMC genomics* *16*, 604.
- Oogai, Y., Matsuo, M., Hashimoto, M., Kato, F., Sugai, M., and Komatsuzawa, H. (2011). Expression of virulence factors by *Staphylococcus aureus* grown in serum. *Applied and environmental microbiology* *77*, 8097-8105.
- Oscarsson, J., Tegmark-Wisell, K., and Arvidson, S. (2006). Coordinated and differential control of aureolysin (*aur*) and serine protease (*sspA*) transcription in *Staphylococcus aureus* by *sarA*, *rot* and *agr* (RNAIII). *International journal of medical microbiology : IJMM* *296*, 365-380.
- Otaka, H., Ishikawa, H., Morita, T., and Aiba, H. (2011). PolyU tail of rho-independent terminator of bacterial small RNAs is essential for Hfq action. *Proceedings of the National Academy of Sciences of the United States of America* *108*, 13059-13064.
- Otto, M. (2014). *Staphylococcus aureus* toxins. *Current opinion in microbiology* *17*, 32-37.
- Oun, S., Redder, P., Didier, J.P., Francois, P., Corvaglia, A.R., Buttazzoni, E., Giraud, C., Girard, M., Schrenzel, J., and Linder, P. (2013). The CshA DEAD-box RNA helicase is important for quorum sensing control in *Staphylococcus aureus*. *RNA Biol* *10*, 157-165.
- Palma, M., and Cheung, A.L. (2001). $\sigma(B)$ activity in *Staphylococcus aureus* is controlled by RsbU and an additional factor(s) during bacterial growth. *Infection and immunity* *69*, 7858-7865.
- Palma, M., Hagggar, A., and Flock, J.I. (1999). Adherence of *Staphylococcus aureus* is enhanced by an endogenous secreted protein with broad binding activity. *Journal of bacteriology* *181*, 2840-2845.
- Panja, S., Schu, D.J., and Woodson, S.A. (2013). Conserved arginines on the rim of Hfq catalyze base pair formation and exchange. *Nucleic Acids Res* *41*, 7536-7546.
- Parker, M.W., and Feil, S.C. (2005). Pore-forming protein toxins: from structure to function. *Progress in biophysics and molecular biology* *88*, 91-142.
- Parrillo, J.E. (1993). Pathogenetic mechanisms of septic shock. *The New England journal of medicine* *328*, 1471-1477.
- Periasamy, S., Joo, H.S., Duong, A.C., Bach, T.H., Tan, V.Y., Chatterjee, S.S., Cheung, G.Y., and Otto, M. (2012). How *Staphylococcus aureus* biofilms develop their characteristic structure. *Proceedings of the National Academy of Sciences of the United States of America* *109*, 1281-1286.

- Pestova, T.V., Lorsch, J.R., and Hellen, C.U.T. (2007). *The Mechanism of Translation Initiation in Eukaryotes*, Cold Spring Harbor edn (NY: Cold Spring Harbor Laboratory Press).
- Peton, V., Breyne, K., Rault, L., Demeyere, K., Berkova, N., Meyer, E., Even, S., and Le Loir, Y. (2016). Disruption of the sigS gene attenuates the local innate immune response to *Staphylococcus aureus* in a mouse mastitis model. *Veterinary microbiology* *186*, 44-51.
- Philippe, C., Portier, C., Mougél, M., Grunberg-Manago, M., Ebel, J.P., Ehresmann, B., and Ehresmann, C. (1990). Target site of *Escherichia coli* ribosomal protein S15 on its messenger RNA. Conformation and interaction with the protein. *J Mol Biol* *211*, 415-426.
- Piechowicz, L., Galin'ski, J., Garbacz, K., and Haras, K. (2010). Bacteriophage analysis of staphylokinase-negative *Staphylococcus aureus* strains isolated from people. *Journal of basic microbiology* *50*, 557-561.
- Piroth, L., Que, Y.A., Widmer, E., Panchaud, A., Piu, S., Entenza, J.M., and Moreillon, P. (2008). The fibrinogen- and fibronectin-binding domains of *Staphylococcus aureus* fibronectin-binding protein A synergistically promote endothelial invasion and experimental endocarditis. *Infection and immunity* *76*, 3824-3831.
- Popenda, M., Szachniuk, M., Antczak, M., Purzycka, K.J., Lukasiak, P., Bartol, N., Blazewicz, J., and Adamiak, R.W. (2012). Automated 3D structure composition for large RNAs. *Nucleic Acids Res* *40*, e112.
- Potempa, J., Dubin, A., Korzus, G., and Travis, J. (1988). Degradation of elastin by a cysteine proteinase from *Staphylococcus aureus*. *J Biol Chem* *263*, 2664-2667.
- Preis, H., Eckart, R.A., Gudipati, R.K., Heidrich, N., and Brantl, S. (2009). CodY activates transcription of a small RNA in *Bacillus subtilis*. *Journal of bacteriology* *191*, 5446-5457.
- Prokesova, L., Potuznikova, B., Potempa, J., Zikan, J., Radl, J., Hachova, L., Baran, K., Porwit-Bohr, Z., and John, C. (1992). Cleavage of human immunoglobulins by serine proteinase from *Staphylococcus aureus*. *Immunology letters* *31*, 259-265.
- Proshkin, S., Rahmouni, A.R., Mironov, A., and Nudler, E. (2010). Cooperation between translating ribosomes and RNA polymerase in transcription elongation. *Science (New York, NY)* *328*, 504-508.
- Qin, L., McCausland, J.W., Cheung, G.Y., and Otto, M. (2016). PSM-Mec-A Virulence Determinant that Connects Transcriptional Regulation, Virulence, and Antibiotic Resistance in *Staphylococci*. *Frontiers in microbiology* *7*, 1293.
- Que, Y.A., Haefliger, J.A., Piroth, L., Francois, P., Widmer, E., Entenza, J.M., Sinha, B., Herrmann, M., Francioli, P., Vaudaux, P., *et al.* (2005). Fibrinogen and fibronectin binding cooperate for valve infection and invasion in *Staphylococcus aureus* experimental endocarditis. *The Journal of experimental medicine* *201*, 1627-1635.
- Queck, S.Y., Jameson-Lee, M., Villaruz, A.E., Bach, T.H., Khan, B.A., Sturdevant, D.E., Ricklefs, S.M., Li, M., and Otto, M. (2008). RNAIII-independent target gene control by the agr quorum-sensing system: insight into the evolution of virulence regulation in *Staphylococcus aureus*. *Molecular cell* *32*, 150-158.
- Rachid, S., Cho, S., Ohlsen, K., Hacker, J., and Ziebuhr, W. (2000). Induction of *Staphylococcus epidermidis* biofilm formation by environmental factors: the possible involvement of the alternative transcription factor sigB. *Advances in experimental medicine and biology* *485*, 159-166.
- Rajkowitsch, L., and Schroeder, R. (2007). Dissecting RNA chaperone activity. *RNA (New York, NY)* *13*, 2053-2060.

- Reed, S.B., Wesson, C.A., Liou, L.E., Trumble, W.R., Schlievert, P.M., Bohach, G.A., and Bayles, K.W. (2001). Molecular characterization of a novel *Staphylococcus aureus* serine protease operon. *Infection and immunity* *69*, 1521-1527.
- Reingold, A.L., Hargrett, N.T., Dan, B.B., Shands, K.N., Strickland, B.Y., and Broome, C.V. (1982). Nonmenstrual toxic shock syndrome: a review of 130 cases. *Annals of internal medicine* *96*, 871-874.
- Rice, G.M., Busan, S., Karabiber, F., Favorov, O.V., and Weeks, K.M. (2014). SHAPE analysis of small RNAs and riboswitches. *Methods in enzymology* *549*, 165-187.
- Romby, P., and Springer, M. (2007). Translational control in prokaryotes. In *Translational control in biology and medicine*, M.B. Mathews, Sonenberg, N., and Hershey, J. W. B., ed. (Cold Spring Harbour: Cold Spring Harbour Laboratory Press), pp. 803-827.
- Romero, D., Aguilar, C., Losick, R., and Kolter, R. (2010). Amyloid fibers provide structural integrity to *Bacillus subtilis* biofilms. *Proceedings of the National Academy of Sciences of the United States of America* *107*, 2230-2234.
- Rooijackers, S.H., van Kessel, K.P., and van Strijp, J.A. (2005). Staphylococcal innate immune evasion. *Trends in microbiology* *13*, 596-601.
- Rosenbach, F.J. (1884). Mikro-Organismen bei den. In *Wund-Infektions-Krankheiten des Menschen*, J.F. Bergman, ed. (Wiesbaden, Germany), pp. 1-122.
- Roux, C.M., DeMuth, J.P., and Dunman, P.M. (2011). Characterization of components of the *Staphylococcus aureus* mRNA degradosome holoenzyme-like complex. *Journal of bacteriology* *193*, 5520-5526.
- Ruiz de los Mozos, I., Vergara-Irigaray, M., Segura, V., Villanueva, M., Bitarte, N., Saramago, M., Domingues, S., Arraiano, C.M., Fechter, P., Romby, P., *et al.* (2013). Base pairing interaction between 5'- and 3'-UTRs controls *icaR* mRNA translation in *Staphylococcus aureus*. *PLoS genetics* *9*, e1004001.
- Said-Salim, B., Dunman, P.M., McAleese, F.M., Macapagal, D., Murphy, E., McNamara, P.J., Arvidson, S., Foster, T.J., Projan, S.J., and Kreiswirth, B.N. (2003). Global regulation of *Staphylococcus aureus* genes by Rot. *Journal of bacteriology* *185*, 610-619.
- Salah, P., Bisaglia, M., Aliprandi, P., Uzan, M., Sizun, C., and Bontems, F. (2009). Probing the relationship between Gram-negative and Gram-positive S1 proteins by sequence analysis. *Nucleic Acids Res* *37*, 5578-5588.
- Salis, H.M., Mirsky, E.A., and Voigt, C.A. (2009). Automated design of synthetic ribosome binding sites to control protein expression. *Nature biotechnology* *27*, 946-950.
- Sanderson-Smith, M.L., De Oliveira, D.M., Ranson, M., and McArthur, J.D. (2012). Bacterial plasminogen receptors: mediators of a multifaceted relationship. *Journal of biomedicine & biotechnology* *2012*, 272148.
- Schuwirth, B.S., Borovinskaya, M.A., Hau, C.W., Zhang, W., Vila-Sanjurjo, A., Holton, J.M., and Cate, J.H. (2005). Structures of the bacterial ribosome at 3.5 Å resolution. *Science (New York, NY)* *310*, 827-834.
- Schwartz, K., Syed, A.K., Stephenson, R.E., Rickard, A.H., and Boles, B.R. (2012). Functional amyloids composed of phenol soluble modulins stabilize *Staphylococcus aureus* biofilms. *PLoS pathogens* *8*, e1002744.
- Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics (Oxford, England)* *30*, 2068-2069.
- Serganov, A., Huang, L., and Patel, D.J. (2009). Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. *Nature* *458*, 233-237.

- Shaw, L., Golonka, E., Potempa, J., and Foster, S.J. (2004). The role and regulation of the extracellular proteases of *Staphylococcus aureus*. *Microbiology (Reading, England)* *150*, 217-228.
- Shin, D.H., and Moldave, K. (1966). Effect of ribosomes on the biosynthesis of ribonucleic acid in vitro. *J Mol Biol* *21*, 231-245.
- Shine, J., and Dalgarno, L. (1974). The 3'-terminal sequence of *Escherichia coli* 16S ribosomal RNA: complementarity to nonsense triplets and ribosome binding sites. *Proc Natl Acad Sci U S A* *71*, 1342-1346.
- Sibbald, M.J., Ziebandt, A.K., Engelmann, S., Hecker, M., de Jong, A., Harmsen, H.J., Raangs, G.C., Stokroos, I., Arends, J.P., Dubois, J.Y., *et al.* (2006). Mapping the pathways to staphylococcal pathogenesis by comparative secretomics. *Microbiology and molecular biology reviews : MMBR* *70*, 755-788.
- Simonetti, A., Marzi, S., Fabbretti, A., Hazemann, I., Jenner, L., Urzhumtsev, A., Gualerzi, C.O., and Klaholz, B.P. (2013). Structure of the protein core of translation initiation factor 2 in apo, GTP-bound and GDP-bound forms. *Acta crystallographica Section D, Biological crystallography* *69*, 925-933.
- Simonetti, A., Marzi, S., Myasnikov, A.G., Fabbretti, A., Yusupov, M., Gualerzi, C.O., and Klaholz, B.P. (2008). Structure of the 30S translation initiation complex. *Nature* *455*, 416-420.
- Smirnov, A., Forstner, K.U., Holmqvist, E., Otto, A., Gunster, R., Becher, D., Reinhardt, R., and Vogel, J. (2016). Grad-seq guides the discovery of ProQ as a major small RNA-binding protein. *Proceedings of the National Academy of Sciences of the United States of America* *113*, 11591-11596.
- Smirnov, A., Wang, C., Drewry, L.L., and Vogel, J. (2017). Molecular mechanism of mRNA repression in trans by a ProQ-dependent small RNA. *The EMBO journal* *36*, 1029-1045.
- Smith, E.J., Corrigan, R.M., van der Sluis, T., Grundling, A., Speziale, P., Geoghegan, J.A., and Foster, T.J. (2012). The immune evasion protein Sbi of *Staphylococcus aureus* occurs both extracellularly and anchored to the cell envelope by binding lipoteichoic acid. *Molecular microbiology* *83*, 789-804.
- Smith, E.J., Visai, L., Kerrigan, S.W., Speziale, P., and Foster, T.J. (2011). The Sbi protein is a multifunctional immune evasion factor of *Staphylococcus aureus*. *Infection and immunity* *79*, 3801-3809.
- Sonnleitner, E., Schuster, M., Sorger-Domenigg, T., Greenberg, E.P., and Blasi, U. (2006). Hfq-dependent alterations of the transcriptome profile and effects on quorum sensing in *Pseudomonas aeruginosa*. *Molecular microbiology* *59*, 1542-1558.
- Steen, K.A., Siegfried, N.A., and Weeks, K.M. (2011). Selective 2'-hydroxyl acylation analyzed by protection from exoribonuclease (RNase-detected SHAPE) for direct analysis of covalent adducts and of nucleotide flexibility in RNA. *Nature protocols* *6*, 1683-1694.
- Stent, G.S. (1964). THE OPERON: ON ITS THIRD ANNIVERSARY. MODULATION OF TRANSFER RNA SPECIES CAN PROVIDE A WORKABLE MODEL OF AN OPERATOR-LESS OPERON. *Science (New York, NY)* *144*, 816-820.
- Storz, G., Vogel, J., and Wassarman, K.M. (2011). Regulation by small RNAs in bacteria: expanding frontiers. *Molecular cell* *43*, 880-891.
- Sun, X., Zhulin, I., and Wartell, R.M. (2002). Predicted structure and phyletic distribution of the RNA-binding protein Hfq. *Nucleic Acids Res* *30*, 3662-3671.

- Surewaard, B.G., Nijland, R., Spaan, A.N., Kruijtzter, J.A., de Haas, C.J., and van Strijp, J.A. (2012). Inactivation of staphylococcal phenol soluble modulins by serum lipoprotein particles. *PLoS pathogens* 8, e1002606.
- Suyama, Y. (1986). Two dimensional polyacrylamide gel electrophoresis analysis of *Tetrahymena* mitochondrial tRNA. *Current genetics* 10, 411-420.
- Tamber, S., and Cheung, A.L. (2009). SarZ promotes the expression of virulence factors and represses biofilm formation by modulating SarA and agr in *Staphylococcus aureus*. *Infection and immunity* 77, 419-428.
- Tao, L., Wu, X., and Sun, B. (2010). Alternative sigma factor sigmaH modulates prophage integration and excision in *Staphylococcus aureus*. *PLoS pathogens* 6, e1000888.
- Tayeb-Fligelman, E., and Landau, M. (2017). X-Ray Structural Study of Amyloid-Like Fibrils of Tau Peptides Bound to Small-Molecule Ligands. *Methods in molecular biology (Clifton, NJ)* 1523, 89-100.
- Thammavongsa, V., Kim, H.K., Missiakas, D., and Schneewind, O. (2015). Staphylococcal manipulation of host immune responses. *Nature reviews Microbiology* 13, 529-543.
- Thorvaldsdottir, H., Robinson, J.T., and Mesirov, J.P. (2013). Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Briefings in bioinformatics* 14, 178-192.
- Toapanta, F.R., and Ross, T.M. (2006). Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. *Immunologic research* 36, 197-210.
- Tomasini, A., Moreau, K., Chicher, J., Geissmann, T., Vandenesch, F., Romby, P., Marzi, S., and Caldelari, I. (2017). The RNA targetome of *Staphylococcus aureus* non-coding RNA RsaA: impact on cell surface properties and defense mechanisms. *Nucleic Acids Res.*
- Tsompanidou, E., Sibbald, M.J., Chlebowicz, M.A., Dreisbach, A., Back, J.W., van Dijl, J.M., Buist, G., and Denham, E.L. (2011). Requirement of the agr locus for colony spreading of *Staphylococcus aureus*. *Journal of bacteriology* 193, 1267-1272.
- Tsui, H.C., Leung, H.C., and Winkler, M.E. (1994). Characterization of broadly pleiotropic phenotypes caused by an hfq insertion mutation in *Escherichia coli* K-12. *Molecular microbiology* 13, 35-49.
- Updegrave, T.B., Zhang, A., and Storz, G. (2016). Hfq: the flexible RNA matchmaker. *Current opinion in microbiology* 30, 133-138.
- Valentin-Hansen, P., Eriksen, M., and Udesen, C. (2004). The bacterial Sm-like protein Hfq: a key player in RNA transactions. *Molecular microbiology* 51, 1525-1533.
- van Wamel, W.J., Rooijackers, S.H., Ruyken, M., van Kessel, K.P., and van Strijp, J.A. (2006). The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of *Staphylococcus aureus* are located on beta-hemolysin-converting bacteriophages. *Journal of bacteriology* 188, 1310-1315.
- Varet, H., Brillet-Gueguen, L., Coppee, J.Y., and Dillies, M.A. (2016). SARTools: A DESeq2- and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data. *PloS one* 11, e0157022.
- Vellanoweth, R.L., and Rabinowitz, J.C. (1992). The influence of ribosome-binding-site elements on translational efficiency in *Bacillus subtilis* and *Escherichia coli* in vivo. *Molecular microbiology* 6, 1105-1114.
- Vimberg, V., Tats, A., Remm, M., and Tenson, T. (2007). Translation initiation region sequence preferences in *Escherichia coli*. *BMC molecular biology* 8, 100.

- Vogel, J., and Luisi, B.F. (2011). Hfq and its constellation of RNA. *Nature reviews Microbiology* 9, 578-589.
- Wagner, E.G., and Romby, P. (2015). Small RNAs in bacteria and archaea: who they are, what they do, and how they do it. *Advances in genetics* 90, 133-208.
- Wang, R., Braughton, K.R., Kretschmer, D., Bach, T.H., Queck, S.Y., Li, M., Kennedy, A.D., Dorward, D.W., Klebanoff, S.J., Peschel, A., *et al.* (2007). Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. *Nature medicine* 13, 1510-1514.
- Weeks, K.M. (2015). Review toward all RNA structures, concisely. *Biopolymers* 103, 438-448.
- Weinrick, B., Dunman, P.M., McAleese, F., Murphy, E., Projan, S.J., Fang, Y., and Novick, R.P. (2004). Effect of mild acid on gene expression in *Staphylococcus aureus*. *Journal of bacteriology* 186, 8407-8423.
- Wertheim, H.F., Melles, D.C., Vos, M.C., van Leeuwen, W., van Belkum, A., Verbrugh, H.A., and Nouwen, J.L. (2005). The role of nasal carriage in *Staphylococcus aureus* infections. *The Lancet Infectious diseases* 5, 751-762.
- Wickiser, J.K., Winkler, W.C., Breaker, R.R., and Crothers, D.M. (2005). The speed of RNA transcription and metabolite binding kinetics operate an FMN riboswitch. *Molecular cell* 18, 49-60.
- Wild, J., Rossmeissl, P., Walter, W.A., and Gross, C.A. (1996). Involvement of the DnaK-DnaJ-GrpE chaperone team in protein secretion in *Escherichia coli*. *Journal of bacteriology* 178, 3608-3613.
- Wyatt, M.A., Wang, W., Roux, C.M., Beasley, F.C., Heinrichs, D.E., Dunman, P.M., and Magarvey, N.A. (2010). *Staphylococcus aureus* nonribosomal peptide secondary metabolites regulate virulence. *Science (New York, NY)* 329, 294-296.
- Xu, S.X., and McCormick, J.K. (2012). Staphylococcal superantigens in colonization and disease. *Frontiers in cellular and infection microbiology* 2, 52.
- Yamanaka, K., Fang, L., and Inouye, M. (1998). The CspA family in *Escherichia coli*: multiple gene duplication for stress adaptation. *Molecular microbiology* 27, 247-255.
- Yotis, W.W. (1963). ABSORPTION OF THE ANTIBACTERIAL SERUM FACTOR BY STAPHYLOCOCCI. *Journal of bacteriology* 85, 911-917.
- Yura, T., Nagai, H., and Mori, H. (1993). Regulation of the heat-shock response in bacteria. *Annual review of microbiology* 47, 321-350.
- Yusupov, M.M., Yusupova, G.Z., Baucom, A., Lieberman, K., Earnest, T.N., Cate, J.H., and Noller, H.F. (2001). Crystal structure of the ribosome at 5.5 Å resolution. *Science (New York, NY)* 292, 883-896.
- Yusupova, G., Jenner, L., Rees, B., Moras, D., and Yusupov, M. (2006). Structural basis for messenger RNA movement on the ribosome. *Nature* 444, 391-394.
- Zecconi, A., and Scali, F. (2013). *Staphylococcus aureus* virulence factors in evasion from innate immune defenses in human and animal diseases. *Immunology letters* 150, 12-22.
- Zhang, X., Zhu, Q., Tian, T., Zhao, C., Zang, J., Xue, T., and Sun, B. (2015). Identification of RNAPIII-binding proteins in *Staphylococcus aureus* using tethered RNAs and streptavidin aptamers based pull-down assay. *BMC Microbiol* 15, 102.
- Zheng, A., Panja, S., and Woodson, S.A. (2016). Arginine Patch Predicts the RNA Annealing Activity of Hfq from Gram-Negative and Gram-Positive Bacteria. *J Mol Biol* 428, 2259-2264.

Zielinska, A.K., Beenken, K.E., Joo, H.S., Mrak, L.N., Griffin, L.M., Luong, T.T., Lee, C.Y., Otto, M., Shaw, L.N., and Smeltzer, M.S. (2011). Defining the strain-dependent impact of the Staphylococcal accessory regulator (sarA) on the alpha-toxin phenotype of *Staphylococcus aureus*. *Journal of bacteriology* 193, 2948-2958.

Staphylococcus aureus protein S1, an RNA chaperone involved in translation initiation and sRNA regulation

Résumé

Bien que l'initiation de la traduction soit un processus conservé entre les bactéries, nous avons montré que le mécanisme par lequel les ARNm structurés sont reconnus et adaptés sur le ribosome diffère chez *Staphylococcus aureus*, un micro-organisme avec un bas taux de G+C et chez *Escherichia coli*. Une particularité du ribosome de *S. aureus* est l'absence de la protéine ribosomale S1, qui non seulement est plus courte que celle de *E. coli* mais qui possède également une organisation distincte des domaines. Mes expériences suggèrent que la protéine S1 (*SauS1*) favorise spécifiquement l'initiation de la traduction de l'opéron α -*psm* 1-4 en liant son ARNm hautement structuré. En outre, il influence aussi l'expression et la production de facteurs de virulence comme les exotoxines (α -haémolysine, δ -hémolysine et γ -hémolysine) et les exoenzymes (protéases et lipases). En plus de son rôle dans la traduction, *SauS1* pourrait être impliquée dans d'autres processus cellulaires tels que le métabolisme de l'ARN et la régulation par des ARN non-codants (ARNnc). Elle forme des complexes *in vivo* avec plusieurs ARNnc dont la stabilité serait affectée dans la souche délétée du gène *rpsA* codant S1. *SauS1* a donc une activité chaperonne favorisant la cinétique d'appariement entre deux molécules d'ARN et au moins dans un cas, elle stimule la reconnaissance entre un ARNnc et son ARN cible.

Ainsi, *SauS1* appartient à une nouvelle classe de chaperons d'ARN qui jouent un rôle clé dans la régulation du virulon de *S. aureus*.

Mots-clés:

S. aureus S1, traduction, ARNnc, régulation du virulon

Résumé en anglais

Even if translation initiation is a conserved process among bacteria, we have recently shown that low G+C content Gram-positive, such as *Staphylococcus aureus*, differ from *E. coli* on the mechanism by which structured mRNAs are recognized and adapted on the ribosome. One peculiarity of the *S. aureus* ribosome is the absence of ribosomal protein S1, which is shorter than *E. coli* S1 and has different domains organization. My work could demonstrate that *S. aureus* S1 (*SauS1*) specifically promotes translation initiation of the α -*psm* 1-4 operon by binding its highly structured mRNA. Moreover, it influences the expression and production of other exotoxins (α -haemolysin, δ -haemolysin and γ -haemolysins) and exoenzymes (proteases and lipases). Besides its role in translation, *SauS1* could be implicated in other cellular processes such as RNA maturation/degradation and sRNA-mediated regulation. It forms *in vivo* complexes with several sRNAs whose level is affected in a strain deleted of *rpsA* gene, coding for S1. Preliminary results show that *SauS1* has a chaperone activity promoting the kinetic of annealing of two model RNA molecules and at least in one case, we could demonstrate that it stimulates the recognition between a sRNA and its target RNA.

Taken together, *SauS1* belongs to a new class of RNA chaperones that play key roles in the regulation of *S. aureus* virulon.

Key words:

S. aureus S1, translation, sRNA, regulation of *S. aureus* virulon